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ABSTRACT
In chapter 1, an overview is given of sample preparation methods and analytical 
techniques in use today. Each one is discussed, and relevant examples are given.
In chapter 2, the development of a method for the HPLC analysis of taurine in human 
plasma using acetonitrile precipitation and pre-column derivatisation with fluorescamine 
is presented. This procedure was found to be faster and easier to use than previous taurine 
assays.
In chapter 3, the evaluation of novel aspirin derivatives as prodrugs for transdermal 
aspirin delivery was made possible by an analytical procedure developed as part of this 
PhD. Following in vitro application of the derivative to skin, the perfusate samples in 
PBS could be taken and injected directly onto the HPLC system. In addition to 
quantifying aspirin (ASA) and its metabolite salicylic acid (SAL), the introduction of a 
gradient after ASA and SAL had eluted allowed determination of the parent compounds.
In chapter 4, the quantitation of ASA and SAL in human plasma using column-switching 
HPLC with on-line solid-phase extraction is discussed. Following a simple dilution step, 
the plasma was injected directly onto the system. On switching the 10-port valve, the 
sample containing the extracted ASA and SAL was sent to the analytical column for 
quantitation. The protocol was successfully applied to the investigation of levels of these 
compounds in healthy volunteers following an oral dose of aspirin.
In chapter 5, identification and qualitative analysis of a cachectic factor and its albumin- 
bound complex in the urine of cancer patients with cachexia is presented. This work was 
carried out using capillary electrophoresis.
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Chapter 1
Introduction to Sample Preparation and 
Biopharmaceutical Analysis
i
1.1 SAMPLE PREPARATION IN BIOPHARMACEUTICAL 
ANALYSIS
In any analytical procedure, special attention must be given to the sample 
pretreatment protocol since this is an integral part of the overall process. About two 
thirds of the total analysis time is spent on sample preparation, and 30% of all errors 
generated during the entire analytical procedure are introduced at this stage’. 
Contamination can be minimised during sample preparation if sufficient care is given 
to collecting, storing, transporting and pretreating the sample. However, these 
procedures are an aspect of analytical practice that is often neglected in the literature, 
particularly for biological samples.
1.1.1 COLLECTION OF BIOSAMPLES
In drug analysis, the most commonly sampled matrices are blood and urine . Urine 
samples are usually collected in plastic containers and are often treated with a 
preservative such as boric acid; untreated urine will gradually lose carbon dioxide, 
thus becoming more alkaline with time. Calcium and phosphate precipitates may also 
form. Hence, any dipstick tests must be carried out on fresh urine in order to 
accurately record pH and other parameters that can change progressively. The most 
important factor to consider when collecting a urine sample is the volume of the 
sample, since often it is the amount of analyte excreted rather than its concentration 
that is required.
Blood is generally treated such that plasma or serum is the actual fluid 
analysed. Whole blood is not often analysed due to its higher viscosity and more 
complex nature when compared to serum or plasma. After a fresh blood sample has 
been taken and allowed to stand, a clot will form in about 20 to 30 minutes at room 
temperature (or longer at 4°C). The pale fluid which remains is serum and can be 
simply decanted from the clot which contains the cellular elements of blood i.e. 
erythrocytes, leukocytes and platelets. Alternatively, the tube can then be centrifuged 
to separate the clot and the serum from each other more definitively. Serum and 
plasma differ only in the fact that serum contains no fibrinogen, since this soluble 
element of blood is involved in the clotting process and is thus removed with the
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cellular components. Plasma is collected in a different way. An anticoagulant is added 
to the collecting tube, which means that centrifugation can take place immediately, an 
advantage if time is an important factor. From a given volume of blood, more plasma 
can be obtained than serum. Care should be taken when handling whole blood such 
that hemolysis does not occur since this would preclude the harvesting of plasma or 
serum.
There are many variables involved in the collection of biological samples. The 
temperature of centrifugation can affect recovery of the drug from the whole blood 
into the plasma as illustrated by the fact that phenytoin levels increase by 10% when 
centrifugation takes place at 4°C instead of 24° C3. The type of anticoagulant used can 
introduce extra contamination into the plasma or can even affect the concentration of 
drug extracted. This has been shown in a study comparing the effect of using different 
anticoagulants (and even different brands) on the number and level of interferences in 
blank plasma4. Also, plastic tubes used for collection can release plasticisers or other 
components of the tube material into the matrix, which may interfere with the assay. 
The type of syringe is another consideration since cells can be ruptured during blood- 
taking if the needle gauge is too small. This is illustrated by the fact that taurine, an 
amino acid which is present in high concentrations in platelets, will be released into 
plasma giving a falsely elevated concentration if the platelets are disturbed by a 
narrow bore needle. Thus, a large bore butterfly syringe was used for taking blood 
samples so that no hemolysis occurred and the whole blood could then be prepared as 
platelet-poor and/or platelet-rich plasmas5. Although plasma is a very complex matrix, 
its composition is remarkably stable from person to person with pH and protein and 
salt concentrations remaining well controlled. However, lipid content can vary 
considerably with the timing and nature of food intake and this can require extra 
clean-up of the sample2. The time of day can affect the quality of the biological 
sample. Early morning blood collection is favoured to avoid diurnal variation, 
postural effects, postprandial changes and exercise effects6. For example, the total 
protein level can increase by as much as 9% while standing as opposed to supine, and 
analytes that are protein bound also increase in concentration if the person is in the 
erect position6. With so many factors affecting sample collection, analysts should 
make every effort to be present during the sampling or liase closely with the person 
collecting the samples so that any information relevant to the sample is known before 
analysis takes place.
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1.1.2 STORAGE OF BIOSAMPLES
Another important factor in the sampling process is whether the samples are stable or 
not under the chosen storage conditions. Refrigeration of biological fluids is really 
only sufficient if the samples will be used in a matter of hours. If there is to be a 
significant time lapse between collection and analysis, and to ensure stability of 
biosamples generally, freezing is used to slow down degradation of the sample due to 
the action of organisms or enzymes. Freezing at -20°C or lower virtually eliminates 
microbial growth. Plastic containers are usually used since alterations in the 
concentration of the analyte can result due to adsorption onto glass. Jorgenson et al. 
circumvented the problem of adsorption of nitroglycerin and its metabolites onto 
glassware during the analysis of plasma by including triethylamine in the sample 
preparation step7. Adsorption onto glass was also a problem in the analysis of 
mitoxantrone in plasma, but when the glassware was silanised, the recovery from 
plasma increased from 50 to 85%8. However, adsorption onto denatured proteins or 
precipitated salts in stored samples can also occur.
Whether samples such as plasma or serum are treated to some extent (e.g. 
acidification) before freezing depends on the stability of the species of interest. For 
example, fluoride is often combined with an anticoagulant or added alone to blood 
samples to prevent the action of esterase enzymes4. If the analyte of interest is 
susceptible to breakdown by enzymes, preventing this action should be made a 
priority to ensure that the integrity of the sample is preserved. This is a factor that 
should be evaluated during validation of the method. Frozen blood samples should be 
carefully thawed just prior to analysis and the stability of the analyte through a 
number of freeze-thaw cycles should also be evaluated. The stability of the drug in the 
biofluid under different conditions of temperature, light and pH should also be 
assessed during development of a protocol for storage.
1.1.3 TRANSPORT OF BIOSAMPLES
Biological samples are generally packed on dry ice in well-insulated containers to 
protect from light, heat and other possible hazards.
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1.1.4 PRETREATMENT OF BIOSAMPLES
Not all biopharmaceutical determinations require sample pretreatment, especially the 
cleaner matrices such as bile, cerebrospinal fluid or even urine. Generally however, 
some clean-up steps will be needed. There are two main approaches to sample 
preparation. The first is complete removal of all interferences followed by a rather 
non-selective separation/reaction/detection system. The second approach is partial 
removal of interfering compounds and/or preconcentration of the analyte followed by 
a more selective separation/reaction/detection system. Usually a combination of these 
two approaches is used. The main objectives are to extract as much as possible of the 
intact analyte from the matrix to the exclusion of the other matrix components. In 
practice, this is rarely achieved totally. The choice of sample handling procedure(s) 
depends on the available instrumentation and expertise, the time available, the type of 
matrix, the amount of sample, the concentration of analyte in the sample, the stability 
of the analyte, the binding of the analyte and whether qualitative or quantitative 
analysis is to be performed.
Many important aspects of the analysis will be influenced by these initial 
sample preparation techniques. For example, careful selection of solvent during 
extraction can save time in subsequent liquid chromatography where samples should 
be dissolved in the mobile phase or similar solvent in order to minimise 
chromatographic artifacts. Choice of the correct pore size for a dialysis membrane 
during sample processing can ensure that most of the endogenous interferences from a 
matrix are eliminated, thereby increasing the selectivity of the method. The 
concentration of the samples is an important parameter and must be controlled so that 
overloading does not occur during quantitation of the species of interest, or at the 
other extreme, that the method is capable of detecting the low levels required. In 
short, the handling of biofluids at this stage should succeed in extracting, 
concentrating and isolating the species to be analysed while removing as much 
endogenous material as possible.
There are a number of sample preparation methods in use which can be 
classified into four types : a) protein precipitation, b) liquid extraction techniques, c) 
solid-phase extraction techniques and d) membrane techniques.
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1.1.4.1 Protein Precipitation
This is the simplest and oldest method for removing proteins from plasma and other 
biological media. It involves the addition of a water-miscible organic solvent, a 
solution of an inorganic salt or strong acid to a proteinaceous sample with a view to 
precipitating the proteins and isolating the supernatant. Following mixing and 
centrifugation, the supernatant containing the compound of interest is separated from 
the protein pellet and is analysed immediately or subjected to further clean-up.
The theory behind the use of water-miscible organic precipitating agents is 
that they lower the solubility of the proteins and hence the proteins precipitate out of 
the solution. As long as the analyte is very soluble in the organic precipitant, it will be 
released from the proteins into the supernatant. Sometimes a mixture of solvents is 
required to improve the recovery of the compound from the sample. The ratio of 
precipitant to sample is important since dilution at this stage will reduce the 
concentration of the analyte which may adversely affect the sensitivity of the analysis. 
Acetonitrile gives good recovery of most drugs in an efficient 1:1 or 1.5:1 ratio, while 
at least two volumes of ethanol are required to precipitate all plasma proteins9, and a 
less powerful agent such as methanol may need a ratio of 3:1 to effect quantitative 
precipitation. Acetonitrile is hence the most efficient10 and the most popular organic 
precipitant11. It is popular also because of its compatibility with subsequent 
chromatography eluents and also because it forms a loose floe which means that there 
is minimum coprecipitation of the analyte with the proteins.
The use of inorganic solutions in protein precipitation is advantageous because 
they can be added in small amounts causing less dilution of the sample and they 
generally give very clean extracts. Anionic précipitants such as strong acids e.g. 
perchloric and trichloroacetic acid, are commonly used at a concentration of 10 to 
20% w/v in a ratio of as little as 1:10 with the sample. They work by forming 
insoluble protein salts with the positively charged proteins at low pH. A disadvantage 
of their use is that unless acidic samples are required for the assay, the samples will 
subsequently need to be either adjusted to a more neutral pH or extracted into a 
different solvent prior to analysis. Cationic protein précipitants can also be used and 
these consist of a solution of a heavy metal dissolved in a strong base such as zinc 
sulphate in sodium hydroxide. Inorganic agents can be used in combination with an 
organic precipitant in order to optimise recovery of an analyte -  an example of this is 
the mixture of 10|J of 10% zinc sulphate and 100|J of methanol or acetonitrile used to 
extract drugs from a 100(a.l sample12.
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Some problems encountered when using protein precipitating agents are the 
possibility of further precipitation on standing (which can adversely affect the 
analytical instrument), and the fact that the supernatant usually still contains many 
interferences that are carried through the precipitation step i.e. this procedure is not 
very selective. These procedures are generally dilutional and hence are often not 
suitable for work requiring a low limit of detection.
1.1.4.2 Liquid Extraction Techniques
Liquid-Liquid Extraction
Liquid-liquid extraction is a classical method for separating a compound from a liquid 
matrix. It is a selective dissolution method that involves the transfer of the material of 
interest from the original solvent into a different immiscible solvent, leaving behind 
the rest of the sample. Usually an aqueous-based solution is extracted with an 
immiscible organic solvent e.g. dichloromethane or diethyl ether, although more 
unusual solvents are sometimes employed such as 1-chlorobutane, which was used to 
extract phenmetrazine from urine13. For liquid-liquid extraction, if the analyte is to be 
isolated in the non-polar phase, an organic solvent should be chosen that has less than 
10% solubility in water, that is volatile for easy removal after extraction and that is 
compatible with the analytical technique to follow. The amount of solute that is 
extracted depends on the relative distribution between the two phases which in turn 
depends on the relative solubilities in the two layers. Thus, for a solute A partitioning 
between an aqueous and an organic solvent,
[A]org/[A]aq = K
where square brackets denote concentrations and K is the distribution or partition 
coefficient. Constant temperature and pressure are assumed and A must exist in the 
same form in both solvents. Equilibrium is achieved after a few minutes of vigorous 
shaking. If the value of K is very large, the transfer of solute into the organic phase 
will be easier and is considered to be quantitative. If K < 1, very little of the solute has 
been extracted. Since K is influenced by the type of organic solvent employed and the 
pH and ionic strength of the aqueous solution14, these conditions must be optimised 
for maximum partition.
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More universally applicable is the value D, the distribution constant, which 
takes into account species of the analyte that may be in different chemical states, 
some of which may be extracted and some of which may not.
D = cA (org)/ cA (aq)
The value cA in the equation above refers to the total concentration of all analyte 
species present in that phase. Repeated extractions (>2) with small portions of organic 
solvent recovers more analyte than extraction with one large aliquot. Continuous 
liquid extraction techniques are used when the sample volume is large, the value of D 
is low or the rate of extraction is slow.
The polarity of the extraction solvent is very important, and generally the 
more non-polar it is, the more selective the extraction procedure. There is usually a 
trade-off between choosing a solvent that is non-polar, where co-extraction of 
interferences is minimised and a solvent that is polar, where recovery of the 
compound is high. Some typical solvents used for liquid-liquid extraction are shown 
in Table 1.1, along with some of their relevant properties. For an acidic compound 
with a single pK„, a pH of at least 1-2 units lower than the pKa value will maximise 
recovery by ensuring that it exists mainly in its unionised form. For a basic compound 
with a single pKb, a pH of at least 1 -2  units higher than the pKb value will maximise 
recovery by ensuring that it exists mainly in its unionised form.
Table 1.1 : Order of Polarity of some Solvents used in Liquid-Liquid Extractions
Solvent UV cut-off 
(nm)
Boiling Point 
(°C)
Viscosity 
(Cp @ 25° C)
n-Hexane 190 69 0.30 Least Polar
Cyclohexane 200 81 0.90
Carbon tetrachloride 265 77 0.90
Toluene 285 111 0.55
Benzene 280 80 0.60
Methylene chloride 233 40 0.41
Diethyl ether 220 35 0.24
Tetrahydrofuran 212 67 0.46
Chloroform 245 61 0.53
Ethyl acetate 256 77 0.43
Methanol 205 64 0.54
Acetonitrile 190 82 0.34 Most Polar
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‘Salting out’ is another solvent extraction technique. The addition of salts to 
an aqueous solution increases its ionic strength to such an extent that polar 
compounds can be isolated from the polar matrix. If a polar solvent e.g. n-propanol is 
added to an aqueous solution that has been saturated with salt, it will form a separate 
layer when they are mixed, although under normal circumstances n-propanol would 
be miscible with such a solution. ‘Salting out’ can also aid in the breaking up of an 
emulsion. Cimetidine was extracted from plasma into ethyl acetate using a salting out 
procedure with a saturated solution of potassium carbonate15. The extraction protocol 
resulted in recoveries of 79-81% and a limit of quantitation of 50ng/ml.
Microextraction is a form of liquid-liquid extraction where the volumes of 
organic solvents are greatly reduced and the analyte concentration in the organic 
phase is greatly increased. These extractions tend to take place in volumetric flasks 
using organic solvents with densities lower than that of water, so that the small 
volume of organic solvent accumulates in the narrow neck of the flask for easy 
withdrawal. However, this particular variation on liquid-liquid extraction is only 
suitable for analytes with high values of D.
Liquid-liquid extraction is a useful technique for extracting drugs from 
biological matrices such as plasma and urine. Table 1.2 lists some of the recent 
applications in the literature that use liquid-liquid extraction as a sample preparation 
procedure prior to analysis.
While liquid-liquid extractions are relatively easy to develop such that a high 
recovery of solute can be obtained, they are somewhat labour-intensive, difficult to 
automate and are susceptible to safety hazards due to the use of flammable and/or 
toxic solvents. Emulsions can sometimes be formed, evaporation can be slow and loss 
of analyte can occur at this stage. Disposal of solvents can be difficult, costly and can 
cause legal and environmental problems. Another drawback sometimes associated 
with solvent extraction is that of adsorption of the species of interest onto glassware. 
To overcome this, alkylsilylating agents have been used to treat the glass or amines 
have been included in the organic solvent. Addition of polyethylene glycol to 
dichloromethane prior to solvent evaporation was found to significantly improve the 
recovery of cortisol from urine and plasma16.
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Table 1.2 : Examples of Liquid-Liquid Extraction in Biopharmaceutical Analysis
Solvent used Compound and Matrix Comments Reference
Acetonitril e-butyl 
chloride (1:4)
Docetaxel from human 
plasma
Recovery was 84.3% 17
Methanol Irinotecan and its active 
metabolite from plasma
Recoveries of 87% and 
90%, respectively
18
Toluene Nisoldipine from plasma Recovery of 94%; octanol 
gave a recovery of 90%
19
Diethyl ether Fluoxetine from human 
plasma
Efficiency of extraction 
was 86 -  91%
20
Chloroform Cocaine and 3 metabolites 
from rat plasma
Extraction efficiencies 
were 57 -  79% for the 
four compounds
21
Ethanol containing 
1 mg/ml ascorbic 
acid
Flavone from human serum Recoveries over the range 
of the standard curve 
were 93 -  103%
22
Hexane Lignocaine and bupivacaine 
from human plasma
Recovery of each of the 
compounds was greater 
than 95%
23
Dichloromethane 
containing 10% 
v/v isopropanol
Midazolam and its major 
metabolites
Recoveries were > 70% 24
Liquid-Solid Extraction
Sometimes the solute is present in a solid rather than a liquid matrix. In this case, the 
weighed solid, such as a tissue sample, can be extracted by bringing it into contact 
with the extracting solvent. The mixture is then shaken or stirred, the length of time 
depending on the rate of the dissolution. Shake flask methods work well when the 
analyte is very soluble in the extracting solvent and when the solid is porous to some 
extent. Ultrasonic agitation allows more intimate solid-liquid contact, and the 
warming of the sample during sonication can also aid the extraction process. 
Following this procedure, the undissolved solid material is removed by filtration and 
the filtrate analysed. For example, Gonzalez et al. used a solid-liquid extraction
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protocol for the 99.3% extraction of clenbuterol from bovine liver25. The sample was 
first homogenised with barium hydroxide-barium chloride and then extracted by 
stirring at 37°C for 4 hours in t-butyl methyl ether before analysis.
An extension of the above process is when it is desirable to continually expose 
the sample to fresh extracting solvent so as to maximise the transfer of the solute to 
the liquid. In a soxhlet apparatus, this is made possible by placing the sample in a 
soxhlet thimble which receives the solvent after it has boiled, evaporated and 
condensed into it from above. Although a slow procedure, this type of extraction is 
very usefiil since fresh solvent is in continuous contact with the sample, the 
experiment can be left unattended and recoveries are very high.
Forced-flow leaching and homogenisation are two other established 
techniques that are now used to a lesser extent. Microwave-assisted solvent extraction 
is a more modem method which employs microwaves to heat solvents in contact with 
the solid sample.
Supercritical Fluid Extraction
Supercritical fluids combine the low densities and viscosities of gases with the 
solvating powers of liquids. The advantages of supercritical fluid extraction (SFE) as 
compared with other sample pretreatment techniques are due to the lower viscosities, 
(which makes for more rapid extractions), and the ability to manipulate the density 
(and hence polarity) by changing temperature or pressure.
SFE is more commonly used in an on-line mode, particularly in conjunction 
with supercritical fluid chromatography (SFC). SFE has also been coupled to gas 
chromatography (GC) by depressurising the supercritical fluid extract inside a 
conventional GC injector or by inserting the extract directly into the capillary column 
itself. It is technically a lot simpler than coupling SFE to high performance liquid 
chromatography (HPLC), due to the fact that supercritical fluids are more compatible 
with high temperature, non-polar, gaseous systems than high pressure, polar, liquid 
ones. Also, the types of compounds that are extracted well by SFE are the type of 
compounds that are best suited to GC analysis (volatile organic compounds), hence 
SFE is often used to extract non-polar analytes from solid samples. The most 
commonly used supercritical fluid, carbon dioxide (CO2), is usually too non-polar to 
extract the majority of polar biopharmaceuticals efficiently. This is because its 
solubilising power lies somewhere between hexane and benzene, depending on the 
density. To circumvent this problem, organic modifiers can be added to the
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supercritical fluid, but these modified solvents lose the advantages that make SFE an 
attractive alternative to other sample preparation procedures.
Temazepam has been successfully extracted from whole blood using SFE 
followed by HPLC26. Melengestrol acetate has been extracted from bovine fat tissue
27using a combination o f SFE and SPE, giving an overall recovery o f 99.4% . This 
new procedure used a total o f 12ml o f organic solvent per fat tissue sample versus 
more than 1700ml in previous extraction procedures.
1.1.4.3 Solid-Phase Extraction Techniques
Solid-Phase Extraction
In its simplest form, solid-phase extraction (SPE) can be carried out by bulk mixing 
the SPE sorbent with the analyte sample and then desorbing the analyte from the 
sorbent prior to analysis. The first SPE applications involved the use o f  columns 
based on diatomaceous earth (celite). These columns were really sophisticated liquid- 
liquid columns in which the buffered aqueous fraction o f a biological sample was 
adsorbed onto the diatomaceous earth particles forming a stationary liquid phase28. An 
organic solvent such as dichloromethane was passed through the column, which 
extracted the analyte from the immobilised liquid phase.
Conventional hydrophobic bonded phase extraction columns e.g. C l8, and 
macroreticular resins e.g. polystyrene divinylbenzene, began to be used for the 
extraction o f drugs o f abuse in the 1980’s. The strategy with these materials was to 
raise the pH to between 8 and 9 to deprotonate amines while attempting to extract the 
neutral and acidic compounds on the bonded hydrocarbon chains. However, there 
were a number o f problems with these phases such as the fact that these columns 
extracted many interferents from the biological matrix as well as the analyte. There 
were difficulties too with the degree o f ionisation o f the compounds being extracted. 
Newer ion-exchange columns began to tackle this problem for charged molecules, but 
they were not suitable for neutral substances. It was only with the development o f the 
phases available today that it has been possible to extract almost any molecule from 
almost any matrix, without necessarily requiring harsh pH conditions.
Both disposable and reusable precolumns filled with a variety o f bonded 
phases can be used in conjunction with liquid chromatography (LC) or gas 
chromatography (GC) techniques. SPE is a very important technique in conjunction 
with high performance liquid chromatography (HPLC), especially since it is 
particularly suitable for the extraction of clinical samples29,30. These bonded phases
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are mainly silica-based and Table 1.3 describes some o f the sorbent types available 
and the samples for which each one is most appropriate.
Table 1.3 : Silica-Based Bonded-Phase Sorbents and their Characteristics
Sample Type /Extraction Type Suitable Sorbent Type for SPE
Non-polar compounds e.g. drugs, steroids, 
and vitamins by reversed-phase extraction.
Octadecyl silane (C l8)
Moderately polar compounds e.g. drugs by 
reversed-phase extraction
Octyl (C8)
Non-polar compounds by reversed-phase 
extraction.
Phenyl
Polar compounds e.g. amines, vitamins and 
phenols by normal phase extraction.
Cyanopropyl (CN)
Polar compounds e.g. drugs, amino acids, 
steroids and vitamins by adsorption.
Silica gel
Polar compounds e.g. proteins and peptides 
by normal phase extraction.
Diol (OH)
Polar compounds e.g. peptides, steroids and 
vitamins by normal phase extraction.
Aminopropyl (NH2)
Amino acids by weak anion-exchange 
extraction.
Dimethylaminopropyl
Amino acids and catecholamines by strong 
cation-exchange extraction and reversed-phase 
extraction.
Sulphonic acid
Antibiotics and nucleotides by strong anion- 
exchange extraction.
Quaternary amines
Since the materials are similar to those used currently in LC techniques, 
except for the particle size, the same packing chemistries can be used to prepare any 
material in a form suitable for SPE. Sample pretreatment columns are extremely 
useful where large numbers o f samples require analysis, thereby making 
reproducibility and unattended operation possible.
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Although the most popular sorbent o f choice for SPE, modified silica does 
have disadvantages when used in certain SPE applications. The hydrophobic nature of 
C l8 and C8-bonded silicas requires a wetting step (usually with methanol) prior to 
use in order to condition the column. The column should not then be allowed to dry 
out to avoid the problem of low and/or variable recoveries. Silica is also limited to 
some extent by its sensitivity to pH. Very acidic solutions will hydrolyse the bonded 
phase while very basic solutions can dissolve the base silica. As an alternative to 
silica, some SPE methods employ polystyrene divinylbenzene phases. These sorbents 
are stable over a broader pH range. However, a wetting step is still required. Bouvier 
et al. used a new polymer-based sorbent o f N-vinylpyrrolidone and divinylbenzene 
which they found overcame all o f the limitations associated with silica sorbents when 
used for the SPE of a number of model compounds from serum31. The recoveries of 
the compounds were greater than 85% even when the cartridges were allowed to run 
dry for 10 minutes.
Residual surface silanols on silica-bonded phases can pose problems for basic 
or ionised compounds. Unreacted silanol groups that are ionised above pH 4 can 
interact with these compounds through an ion-exchange mechanism, which may 
prevent complete elution o f the analyte. Secondary electrostatic interactions were 
eliminated in the extraction o f basic drugs from cyanopropylsilica when a competing 
amine (2-aminoheptane) was added to the eluting solvent32. However, these secondary 
interactions due to the presence o f the silanol groups are often useful. In fact, in many 
extractions, the secondary ion-exchange reaction is a vital component in the retention 
mechanism. Some of the newer SPE columns specifically exploit mixed-mode 
interactions such as the hydrophobic/cation exchange resin “Clean Screen DAU” . 
This column has been used for the high recovery extraction o f a variety o f drug 
classes such as barbiturates and opiates from urine33. Patel et al. compared a 
polystyrene divinylbenzene sorbent that contained both C18 and sulphonic acid sites 
and a silica-based sorbent that also exhibited mixed-mode behaviour in a study where 
they investigated the isolation o f amphetamines and barbiturates from urine using 
both types o f SPE column34. They found the polymeric mixed-mode sorbents 
exhibited much higher reversed-phase and cation-exchange capabilities than the 
silica-based mixed-mode sorbents, making them more suitable for the isolation of 
compounds with high pKa values. More unusual SPE cartridges such as those packed 
with graphitised carbon black have also been used to extract compounds o f interest 
from biofluids. Kim et al. used 50mg carbon black columns (Carbopak B) to
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selectively extract chloramphenicol from serum35. Recovery of the antibiotic using 
this process was 90.8%. From the wide array o f columns and/or materials now 
available, a little method development usually yields a tailored extraction protocol 
that provides specific interactions for the analyte of interest. Applications o f the use o f 
SPE in biopharmaceutical analysis are shown in Table 1.4.
Table 1.4 : Examples of Solid-Phase Extraction in Biopharmaceutical Analysis
Sorbent Compound and Matrix Comments Reference
C18
C2
C18
NH2
C18
C18
CN
C18
C18
Ivermectin in bovine plasma Columns were dry-packed and
reusable. Limit of quantitation of 
2 ng/ml by HPLC. 76% recovery
Seven benzodiazepines in 
urine and plasma
Recoveries all greater than 90%. 
Recoveries also examined from 
C8, C l8, CN, phenyl and cyclo- 
hexyl
Amphetamine and metham- Detection limits of 4 and 2 ng/ml, 
phetamine in human urine respectively, by HPLC
Nisoldipine in plasma
Serotonin in whole blood 
and platelet-rich plasma
Doxorubicin and prochlor­
perazine in human plasma
Eight basic drugs from 
human plasma
Tilmicosin in bovine and 
porcine sera
Morphine and its metab­
olites in serum, blood, 
urine, cerebrospinal fluid 
and vitreous humor
36
37
Limit o f quantitation of 0.1 ng/ml 
by GC. Bond Elut® NH2 cartriges 
gave only 50% recovery. Baker® 
NH2 cartridges gave 100%
Linear from 0.5-3000 ng/ml by 
HPLC. Recovery was 100%
Limits of quantitation were 6.25 
and 10.0 ng/ml, respectively, by 
HPLC. Recoveries were 78% and 
89%, respectively
Absolute recoveries were found 
to range from 82-99%
Limit of detection 0.05 ng/ml by 
HPLC. Recoveries were 91-95% 
for bovine serum and 85-93% for 
porcine serum
Limit o f quantitation for morphine 
was 1 ng/ml by HPLC. Recovery 
ranged from 85 to 98% for each 
analyte
38
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39
40
41
42
43
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C8 Simvastatin and its active Limit o f quantitation was 0 . lng/ml 44 
metabolite in human plasma for both compounds by HPLC
Recently, as an alternative to precolumns, ultra-low mass sorbent bed 
cartridges and membrane extraction disks have been introduced which contain a 
suitable stationary phase e.g. silica-bonded C l8. These allow a significant reduction 
in solvent usage and extraction times. One interesting application o f membrane 
extraction disks incorporated 4mm size disks into the hub o f a syringe needle for the 
extraction o f organic compounds from human urine and serum45. Empore® disks have 
been used in the 96-well microtitre plate format for the extraction o f pharmaceuticals 
from biofluids, allowing elution volumes to be reduced to as low as 30jxl46.
Although traditionally an off-line procedure, SPE has been used on-line with 
HPLC. With on-line SPE-HPLC, a column-switching device is used which requires a 
valve and usually an extra pump. The analyte should be less retained by the 
concentration column than by the analytical column, and the flow rate through the 
precolumn should be less than or equal to that through the analytical column. The 
wash solvent for the first column should be a weakly eluting solvent for the analyte to 
ensure its retention on the SPE column, and must be miscible with the mobile phase 
for the second column. A diagram of such a system, which uses a 10-port valve for 
sample introduction, and switching o f the solvent flow between the columns, is shown 
in Figure 1.1.
The sample is loaded onto the loop with the valve in position 1. The valve is 
then turned to position 2, causing the sample to be swept onto the short SPE column, 
which will have been chosen to selectively retain the compound o f interest, ideally to 
the exclusion of most other components o f the matrix. The precolumn is flushed with 
a solvent that will wash any lingering interferents from the column, leaving the 
analyte unaffected. During this time, the mobile phase is equilibrating the analytical 
column. After a few minutes, the valve is switched back to position 1, whereupon the 
analyte(s) are desorbed and backflushed onto the analytical column for quantitation. 
In order to ensure that these three steps achieve their aim, it is necessary to optimise 
parameters such as pH, composition o f solvents, length of time for loading, flushing 
and eluting, amount o f sample etc.
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Figure 1.1 : Diagram of Column-Switching SPE-HPLC System
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The main advantages o f SPE include the facts that trace enrichment is often 
possible when large volumes are loaded, and the elution volume is small. This has an 
obvious positive impact on the levels o f sensitivity possible. The precolumns can be 
designed to suit any laboratory since they can be purchased commercially (and batch 
to batch reproducibility is continually improving) or prepared in-house (which allows 
rapid screening o f a number o f packings in a short time). There are now commercially 
available instruments that allow the use o f disposable precolumns for column- 
switching such as the ASPEC® system from Gilson and the Prospekt® system from 
Spark-Holland. The Prospekt system is a fully automated on-line sample clean-up and 
injection instrument which has a number o f advantages over conventional SPE. 
Firstly, the use o f a high pressure pump means that the flow rate through the
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cartridges is constant and the high back pressures do not alter this flow rate. Secondly, 
there is no carryover effect or contamination introduced because the entire process 
takes place in a closed system and the cartridges are only used once and are 
disposable. Thirdly, the entire analysis is considerably faster and less labour-intensive 
than manual manipulation of SPE cartridges. The Prospekt system has been used for 
the extraction o f serotonin from whole-blood samples and platelet-rich plasma using 
C l8 cartridges39. When compared to a previous method for serotonin, based on 
perchloric acid deproteinisation, good correlation was obtained. Reproducibility 
varied from 2-5%, depending on the matrix, and recovery was 100%.
Immunoaffirtity Extraction
Antibodies have been used for many years in immunoassays but have only been 
employed for sample pretreatment in the past two decades. Immunoaffinity 
chromatography (IAC) is an excellent way o f increasing the speed, sensitivity and 
selectivity o f  the clean-up process. It involves the binding o f antibodies to a short 
precolumn that precedes the analytical apparatus in a setup similar to on-line SPE. 
With on-line IAC-HPLC, the immuno-precolumn is connected in series with the 
HPLC column, sometimes linked by a second precolumn which allows efficient 
refocusing prior to analysis as well as relieving some of the pressure build-up in the 
system. Many o f the immunoaffinity matrices are preactivated and some are even 
prepackaged into columns or cartridges. This allows easy and efficient coupling of the 
antibodies. The use o f commercially available immunocolumns has also been reported 
e.g. anti-aflatoxin IAC cartridges from Biocode (U.K.)47. The most important 
hyphenated technique to emerge is IAC-HPLC, but IAC has been used in other 
configurations such as IAC-GC-mass spectrometry 48,49
There are also two very obvious advantages for using IAC in tandem with 
HPLC. The first reason is the specificity o f the antibody for the analyte, and although 
this specificity is not absolute, that exhibited by the antibody-analyte interaction is far 
greater than any physiochemical system available. The second reason is the possibility 
o f  creating antibodies against any particular analyte o f interest. There are other 
advantages such as the fact that due to selective preconcentration, there is a high 
probability o f excluding false positive results in screening, reusable immunocolumns 
are an economical option and modification o f existing HPLC instrumentation requires 
only a switching valve and an additional pump. Oestrogen has been extracted from 
plasma50 and propranolol has been extracted from urine51, both with reusable
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columns, in just two examples o f on-line IAC-HPLC. Alongside the advantages of 
immunoaffinity extraction, the increasing number o f applications documented in the 
literature is evidence o f its acceptance in the field o f analysis.
However, IAC has disadvantages too. There can be problems in the raising of 
suitable antibodies, which takes time and can be expensive. Immobilisation 
procedures can be inefficient and difficult to optimise. Most importantly, non-specific 
binding can occur which would render the extraction less selective. However, as with 
other extraction techniques, the few disadvantages it has can be overcome by careful 
consideration and understanding of all the criteria involved. The three most important 
parameters during IAC method development are the choice o f solid support, 
immobilisation procedure and desorption conditions.
Molecularly Imprinted Polymers
Molecular imprinting allows the creation of selective recognition sites in synthetic 
polymers, and as such these imprinted polymers are mimics o f antibodies. The 
imprints are made by polymerising functional momoners in the presence o f the ‘print’ 
molecule. Removal o f  the molecule from the polymer results in sites within the 
polymer network that are complementary to and have affinity for the original print 
molecule. These polymers can be incorporated into columns and used for the 
extraction o f analytes from biological matrices. A molecular imprinted polymer to 7- 
hydroxycoumarin (7-OHC) has been prepared and used as an SPE sorbent for the 
extraction o f 7-OHC from urine52. Extraction recovery was greater than 90%.
1.1.4.4 Membrane Techniques
Dialysis
With this sample preparation method, analytes are separated by their ability to diffuse 
through a membrane as a result o f a concentration gradient. It is usually employed to 
eliminate small-sized species from a sample matrix. The relative size o f the different 
molecules has the greatest effect on the permeation selectivity o f  the porous 
membrane. Dialysis is most often used for the desalting o f protein solutions and in 
separating small molecules from large ones in biofluids such as plasma and serum. It 
is also possible to use dialysis on-line and an example o f where this has been 
employed is for the enantioselective determination o f oxprenolol in human plasma53. 
A cellulose acetate membrane was used for the dialysis step that was coupled on-line 
with chiral chromatography.
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A recent development called the Minicon B15 (Figure 1.2) from Amicon is a 
static dialyser particularly suited to the isolation o f large molecular weight species 
from urine samples. The aliquot of urine is transferred by pasteur pipette into one of 
the eight 5ml cells in the Minicon unit. The back of the clear cell has a membrane 
with a chosen molecular weight cutoff e.g. 14 kDa. The sample is left standing in the 
unit for a period o f time, during which, solvent and small molecular weight species 
leave the cell through the dialysis membrane. This device allows dialysis and 
concentration (up to a 100-fold i.e. 50 ^1) to take place in about 2 hours. The resulting 
sample is very concentrated, contains few small molecules and can be directly 
analysed in many cases.
Figure 1.2 : Diagram of Minicon B15 Static Dialyser
Ultrafiltration
Like dialysis, ultrafiltration is a size-selective membrane-based method o f sample 
preparation. However, this method is usually employed to eliminate large-sized
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molecules from a sample matrix. The membrane pore size is chosen such that all 
molecules above a certain size will be retained on the surface o f the membrane while 
smaller molecules, such as the drug to be determined, can pass through into the 
filtrate. Another difference between this and dialysis is that force is used to push the 
smaller molecules through the membrane using pressure or centrifugation. However, 
if  the drug is protein-bound, recovery will not be quantitative since some will remain 
on the membrane with the proteins, though the extent o f the protein binding may be 
lowered depending on how vigorous the ultrafiltration process is. Hence, this sample 
pretreatment step is very useful when free (non protein-bound) drug is to be measured 
and less so when total drug is to be measured since losses may be incurred. Wilkins et 
al. evaluated the percentage o f protein-free and protein-bound methadone in the 
plasma o f patients on methadone treatment using an Amicon MPS-1 ultrafiltration 
device54. Two independent procedures demonstrated that, following the ultrafiltration 
process, no proteins were measurable in the filtrate. In addition, they found that the 
ultrafiltration process functioned independently o f the concentration of the methadone 
and o f the volume o f sample. Free L-tryptophan in plasma was also determined using 
this device55.
Advantages o f ultrafiltration include the fact that it is suitable for small 
volumes, and no dilution occurs during filtration. For example, Garcia-Capdevila et 
al. used ultrafiltration for sample preparation o f human plasma and required only 
250(j.l in order to determine imipenem with a limit o f detection o f 30 ng/ml and an 
inter-day precision o f 6.26%56. However, the disadvantages that must be taken into 
account with this process include the possibility o f non-specific binding of the drug to 
the membrane, which can be minimised or eliminated with some appropriate rinsing 
steps, and the previously mentioned problems if the analyte is protein-bound. Another 
consideration is the fact that if  high shear is not maintained throughout the procedure, 
an impermeable layer o f proteins will build up on the surface o f the membrane 
slowing down the rate o f filtration. Other conditions such as temperature and pressure 
require strict control for the method to be reproducible from sample to sample.
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1.2 ANALYTICAL TECHNIQUES IN BIOPHARMACEUTICAL 
ANALYSIS
Analysis is the science o f detection and determination, encompassing a large number 
of disciplines, techniques and species. There are many reasons why compounds need 
to be measured e.g. control of environmental pollutants, monitoring o f industrial 
waste, quality control o f drug substances in tablet formulations and flavourings in 
food to name but a few. Biopharmaceutical analysis is the determination o f chemicals 
(usually drug compounds) in biological matrices such as whole blood, plasma, urine, 
or solid tissues such as in the case of post-mortem samples.
There is a large degree of freedom in the decision about which approach to 
take or even which instrumentation to use within a chosen technique. Before starting 
any development work, it is necessary that certain key items o f information be 
available regarding the physiochemical properties o f the substance to be analysed i.e. 
solubility, molecular size, functional groups, spectral properties and stability to name 
just a few. This allows for a logical process o f deduction in order to arrive at the most 
suitable choice o f  technique. The method of taking the sample and the preparation of 
that sample prior to analysis is then chosen such that manual handling and 
manipulation time are minimised, while sensitivity and recovery o f the compound 
from the matrix are maximised (as discussed in section 1.1). In order to achieve these 
aims, knowledge o f the stability, metabolism and protein-binding (if applicable) o f the 
substance in the biosample is required. An understanding of the expected levels o f the 
compound and the nature o f any interferences present are also necessary if  the analyst 
is to develop the most suitable analytical protocols. After the preparation and 
analytical decisions have been made, further considerations include the extent of 
validation and the applications the assay will ultimately have.
The most commonly used instrumental techniques are those based on 
immunoassay, spectroscopy, electrochemistry and more importantly, chromatography 
and electrophoresis.
1.2.1 IMMUNOASSAY
The first competitive binding immunoassay was developed by Yalow and Berson in 
1959 for the diagnosis o f diabetes57. For their achievements in developing this new
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application o f analytical chemistry, they received the Nobel Prize for medicine in 
1977. In general, immunoassays are competitive binding techniques where an 
unknown concentration o f unlabelled analyte in a sample competes with a known 
concentration of labelled analyte for binding sites on an antibody raised against the 
analyte o f interest. Labelled analyte is the compound with a ‘tag’ or ‘label’ attached to 
it or incorporated into it. The label can be an enzyme, a radioactive atom or a 
molecule capable o f fluorescence. The importance o f the label is the fact that it allows 
a means o f specific detection. The basic principle of competitive immunoassays is 
shown below :
Ab + Ag + Ag* = AbAg + AbAg*
where Ab represents the antibody, Ag represents unlabelled analyte (antigen) and Ag* 
the labelled analyte. Antibodies, which are immunoglobulin proteins, are raised by 
introducing the analyte into a laboratory animal, which elicits an immune response. 
However, very small molecular weight species (haptens) may not be sufficiently 
immunogenic. In these cases a larger molecule - drug-antigen complex - is created by 
linking the drug to a large protein molecule such as bovine serum albumin (BSA) or 
human serum albumin (HSA). An appropriate animal such as a sheep or a rabbit is 
then innoculated with this complex whereupon the animal develops antibodies against 
the foreign drug-antigen. I f  serum is obtained from the blood of the animal, it will 
contain a high concentration o f the raised antibodies and is called antiserum. The 
antiserum may be further purified to isolate the antibodies or it may be used directly. 
The antibodies may be used as a solution or may be immobilised onto a solid phase 
e.g. they may be coated onto wells in microtiter plates or onto beads which will be 
subsequently used in immunoassays58,59.
In the original ‘heterogeneous’ immunoassays, the bound and unbound 
fractions are separated after the reaction between the labelled drug, unlabelled drug 
and the antibody. Precipitation, extraction, electrophoresis or centrifugation are 
usually used to accomplish this. The labelled drug in the bound or unbound fractions 
(or both) is measured using a detection method which depends on the label used. 
Thus, the amount o f drug present in the initial sample can be found by interpolation 
on a standard curve o f fraction bound labelled antigen versus unlabelled antigen 
concentration. Newer, ‘homogeneous’ assays do not require separation o f the bound
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and unbound fractions, since the reaction itself causes a loss in activity o f the 
measured entity and this can be related back to the concentration o f the analyte.
The advantages o f immunoassays are numerous. They are sensitive and 
selective (due to the specificity o f  the Ab-Ag interaction). They are inexpensive to 
execute once the antibody has been developed, they require only small amounts o f 
reagents and they are rapid. Detection is now easy, especially with commercially 
available kits and automated readers. However, there can be disadvantages such as 
non-specific binding, insufficient washing (for heterogeneous assays), labelling 
difficulties, cross-reactivity and stability problems. Furthermore, antibodies are 
difficult to develop. Polyclonal antibodies are inhomogeneous in their binding 
affinities, while being easier to handle due to better stability and lower costs in their 
production. Monoclonal antibodies are more homogeneous, all being from the same 
clone, but are less stable and more expensive to raise due to the specialised techniques 
required for their preparation.
1.2.1.1 Radioimmunoassay
Radioimmunoassay (RIA) combines the sensitivity o f radiochemistry with the 
specificity of immunology. This type o f immunoassay was originally developed for 
the determination o f hormones, and the first one to be applied was the insulin RIA 
developed by Yalow and Berson in 196260. This assay was based on competition 
between the human insulin (in the serum under test) and the radioactive iodine- 
labelled insulin for binding sites on the antibody. The insulin-antibody complex was 
separated by paper chromatography. Free (unbound) insulin remained at the point of 
origin while the complexed (bound) insulin migrated with the globulins. The ratio of 
‘bound’ to ‘unbound’ iodinated insulin decreased as the concentration o f insulin in the 
sample increased. The principle of RIA remains the same today and is shown 
diagrammatically in Figure 1.3.
In this diagram it can be seen that when there are 5 units o f compound in the 
sample, there are 3 units o f bound radioactive compound to be measured. When the 
concentration o f compound in the sample is doubled i.e. to 10 units, there are only 2 
units of bound radioactive compound to be measured. In short, increasing the amount 
of analyte in the sample decreases the radioactivity.
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Figure 1.3 : The Principles of Radioimmunoassay
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Figure 1.3 : In this diagram it can be seen that in radioimmunoassay, the concentration of 
analyte in the sample is inversely proportional to the measured radioactivity.
Radioisotopes, although they cause some difficulty with handling and 
disposal, are still used in immunoassay because they have the advantage o f allowing 
detection o f extremely low levels of analyte. RIA is classically used to determine 
hormones such as the thyroid-related hormones, digestive hormones, sex hormones 
and substances which require determination at very low concentrations such as 
vitamins and drugs. An example o f a compound classically determined by RIA is 
digoxin. Until recent years, the only way of obtaining the required low limits of 
detection of this drug in biological fluids was by using RIA. Some o f these RIA 
assays for digoxin are now available commercially e.g. the Ciba Corning Magic61. 
The emission o f beta and gamma radiation can be readily measured by a scintillation
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counter following separation o f the bound and unbound fractions. Some 
disadvantages include the fact that the scintillation equipment is relatively expensive, 
the radiolabels have shorter shelf lives when compared to fluorescent reagents and 
there is, o f course, the safety consideration when handling any radioactive substance.
1.2.1.2 Enzyme Immunoassay
With enzyme immunoassay (EIA), the binding o f the Ab to the Ag is detected using 
an enzyme label. The enzyme acts on the colourless substrate to give a coloured 
product which is readily measured. The two principal types o f EIA are enzyme-linked 
immunosorbent assay (ELISA) and enzyme multiplied immunoassay technique 
(EMIT). ELISA is a heterogeneous immunoassay while EMIT is a homogeneous 
immunoassay.
ELISA Immunoassays
An example of a competitive ELISA is where enzyme-labelled Ag competes with 
unlabelled Ag in a sample for binding to the immobilised Ab. The enzyme substrate is 
then added and after a suitable length o f time, the enzyme activity is measured. The 
enzyme activity is inversely proportional to the unlabelled Ag concentration in the 
sample. Alternatively, the Ag can be immobilised onto the solid phase. Then enzyme- 
labelled Ab and unlabelled Ab compete for binding to the Ag. Following addition of 
substrate, the enzyme activity is inversely proportional to the Ab concentration in the 
sample. There are also variations o f this type o f assay where a second Ab is 
employed.
An example o f a non-competitive ELISA is where the Ab is immobilised onto
the solid phase. The sample containing Ag is added, followed by enzyme-labelled Ab.
Because of the Ab-Ag-Ab effect, these assays are often called ‘sandwich assays’.
Enzyme substrate is then added and after a suitable length o f time, the enzyme
activity is measured. The enzyme activity is directly proportional to the unlabelled A g
concentration in the sample. Alternatively, the Ag can be immobilised and then Ab in
the sample is added followed by a second Ab. The enzyme activity in this case is
directly proportional to the Ab concentration in the sample.
ELISA techniques are very useful diagnostic indicators in certain disease
* * 62states, for example ELISA can be used to confirm suspected cases of meningitis . 
There is also a commercially available ELISA kit for assessing exocrine pancreatic 
function in children with cystic fibrosis63. An ELISA has been developed by Laurie et
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al. for the determination of benzodiazepines in human urine64. Using only 10^1 o f 
urine, a limit o f detection o f  0.3^ig/ml was obtained.
EM IT Immunoassays
In a competitive EMIT, the activity o f the enzyme is modified upon immunochemical 
reaction and hence the change in activity can be related directly to the concentration 
o f the Ag. Enzymes commonly used include isocitrate dehydrogenase and glucose-6- 
phosphate dehydrogenase. These systems can be designed to enhance or diminish the 
enzyme activity. A number o f non-competitive EMIT immunoassays are now 
available and these assays employ two different types o f Ab, which react with 
different sites on the Ag, each labelled with a different enzyme. One enzyme produces 
the substrate for the other and significant enzyme activity is only detected when both 
enzymes are in close proximity to each other i.e. both o f  the Abs are bound close 
together to the Ag. EMIT is used mainly for the determination o f drugs and 
metabolites in biofliuds, for example the quantitation o f benzoylecgonine in serum 
without any sample preparation65, cocaine in human urine66 and vancomycin in 
human serum67.
1.2.1.3 Fluorescence Immunoassays
The Ab or Ag can be labelled with fluorescent dyes such as fluorescein isothiocyanate 
or lissamine rhodamine B. These fluorescent agents are easier to handle than 
radioactive compounds. A fluorescence immunoassay (FIA) can be homogeneous or 
heterogeneous. The protein to be conjugated to the dye is usually a mixture of 
immunoglobulins which should be free of other serum protein fractions because 
albumin and other globulins label more readily than gamma globulins, and they would 
render the method non-specific. After labelling, unreacted dye is removed and the 
labelled protein is purified. As with the EIA technique, the activity (fluorescence) is 
often quenched upon reaction with the Ab and the decrease in fluorescence can be 
related to the concentration o f the analyte. This immunoassay technique has many 
medical applications. For example, FIA can be used to rapidly diagnose oleander 
poisoning, using a serum digitoxin assay68 and also to determine digoxin 
pharmacokinetics in patients with renal dysfunction69. The FIA for digoxin has been 
compared to EMIT, RIA and chemiluminescence immunoassay for digoxin in terms 
o f cross-reactivity, accuracy and precision61’70.
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1.2.1.4 Chemiluminescence Immunoassays
The chemiluminescence immunoassay (CIA) is used mainly for the determination of 
steroids, steroid conjugates, hormones and certain drugs. One application of the use of 
an automated CIA is the determination o f theophylline in serum and plasma71. The 
assay had a limit o f quantitation o f 0.2(ig/ml and a range up to 40p.g/ml. Two digitoxin 
immunoassays were compared in terms o f their susceptability to cross reactivity with 
oleandrin72. The FIA exhibited high cross reactivity, while the CIA showed minimal 
cross reactivity.
1.2.1.5 Molecular Imprinting Assays
Although not an immunoassay, a molecular imprint assay (MIA) is worth mentioning 
in this section since these assays are in direct competition with immunoassays. In the 
same way as antibodies can be raised to any analyte, so too can molecular imprints be 
raised to any analyte. The main advantages o f MIA are the greater speed and lower 
cost with which the imprints can be prepared. However, MIAs also display excellent 
stability when stored dry at ambient temperature for several years, showing no loss of 
recognition. Also important to note is that, unlike many immunoassays, no laboratory 
animals are used during the production o f imprints. An MIA was developed for the 
quantitation of theophylline in serum and the assay yielded results comparable 
(correlation coefficient of 0.98) to those obtained using a well-established EMIT, 
during the analysis o f 32 patient samples73.
1.2.2 SPECTROMETRY
Both absorption and emission may be observed in each region o f the electromagnetic 
spectrum but in practice, only absorption spectra are studied extensively. Some o f the 
oldest and most popular o f  instrumental analysis techniques include ultraviolet and 
visible (UV-Vis) spectrometry, which is based on electronic energy changes, 
fluorescence spectrometry (a related technique), infrared (IR) spectrometry, which is 
based on vibrational and rotational energy changes and nuclear magnetic resonance 
(NMR) spectrometry, which is based on nuclear spin energy changes. Mass 
spectrometry (MS) is included in this section because it gives similar structural 
information to that o f the other techniques even though the principle upon which it is
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based is entirely different. Spectrometric methods do not involve a separation step and 
they are generally quick and easy to use. Certain drugs can be determined in this way 
especially if  they are present in high concentrations in the sample. The type of 
spectrometric technique used depends on a number o f factors such as whether the 
analyte is coloured or can be converted into a coloured derivative (see examples in 
Table 1.5), whether it contains functional groups that absorb in the appropriate region 
o f the spectrum, and the sensitivity required. All o f these spectrometric techniques can 
be adapted for use as detectors following LC or GC, and their application in this field 
will be discussed in section 1.2.4 (Chromatography).
1.2.2.1 UV-Vis and Fluorescence Spectrometry
The reason that UV-Vis absorption is useful is that no two molecular absorption 
spectra are exactly alike. The absorbance versus wavelength plot is a simple but 
characteristic spectrum of the molecule. The wavelength at which absorbance is 
maximum is called the X a^x, and this wavelength is the one at which the spectrometer 
is set when absorbance readings are taken for quantitative analysis. The usual 
procedure is to construct a plot of absorbance versus concentration; a straight line is 
obtained within the limits o f  the Beer-Lambert Law, and from this, the unknown 
concentrations can be calculated by interpolation. Benzene absorbs strongly at 200nm 
with a weaker band at 255nm. As conjugation and substitution onto the benzene 
molecule increase, the wavelengths o f absorption are shifted (usually to longer 
wavelengths). Most inorganic, organic and biochemical substances can therefore be 
determined either directly or after formation of an absorbing derivative or complex.
A spectrometer consists o f a) a source o f continuous radiation, b) a 
monochromator for selecting a narrow band of wavelengths from the source spectrum, 
c) a detector and d) a recorder for data output. A typical UV-Vis spectrometer will 
have both a tungsten lamp and a deuterium lamp for the visible region and the UV 
region, respectively. A photomultiplier tube (PMT) is the most common detector for 
the UV-Vis region. It consists o f a series of electrodes, each amplifying the signal o f 
the previous one. The final amplification factor is at least 106. Spectrometers that use 
PMTs are generally called spectrophotometers. Although not a suitable technique for 
all compounds, UV-Vis is useful in certain cases, some o f which are described in 
Table 1.5. The use o f the UV-Vis spectrophotometer as a detector following HPLC 
separation is discussed in section 1.2 .4.4.3.
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Table 1.5 : Examples of UV-Vis Spectrometry and Fluorimetry in
Biopharmaceutical Analysis
Analyte Method Detection Reference
Uric acid in serum Proteins precipitated with tungstic 
acid. Supernatant oxidised with 
alkaline phosphotungstate
Measure absorbance 
@ 680nm (blue red­
uction product)
74
Creatinine in serum Proteins precipitated with trichloro­
acetic acid and supernatant reacted 
with alkaline picrate solution
Measure absorbance 
@ 490nm (coloured 
product)
74
Proteins in serum Alkaline copper (11) tartrate (biuret 
reagent) formed complex with 
proteins in 30 mins.
Measure absorbance 
@ 550nm
74
Barbiturates in 
serum
Serum sample extracted with 
chloroform and back extracted into 
NaOH
Measure UV absorb­
ance of the alkaline 
solution @ 252nm
74
Salicylate in serum Complex formed with acidic ferric 
nitrate
Measure absorbance 
@ 540nm
75
P-aminophenol in 
human urine
After enzymatic hydrolysis, free 
compound was reacted with 
resorcinol in presence of mang­
anese ions
Measure absorbance 
@ 550nm (indophenol 
dye)
76
Paracetamol in 
plasma
Proteins precipitated with methanol 
and the supernatant incubated with 
aryl acrylamidase for 2 min. Then 
o-cresol and ammoniacal copper 
sulphate were added
Measure absorbance 
@ 615nm
77
Glucose in serum l,F-dimethylferricinium (DMFe+) 
is reduced to DMFe in presence 
o f glucose in maleate buffer pH 6.5
Measure absorbance 
@ 650nm
78
Norfloxacin in urine Aluminium (IE) ion Measure fluorescence 79
Fluorescence spectrometry (fluorimetry) is also a spectrophotometric 
technique and it utilises the ability o f some substances to exhibit fluorescence. This 
phenomenon occurs when a compound is irradiated with light (such as UV) and 
following the absorption process, emits light of a longer wavelength. Only those 
molecules that absorb radiation, usually UV radiation, can fluoresce, and of those that
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do absorb, only 5-10% will fluoresce. The molecular requirements for fluorescence 
are not clearly defined but many fluorescent molecules contain rigid, planar, 
conjugated systems. The emitted radiation may be in the UV region o f the spectrum 
(especially if  the compound absorbs at less than 300nm) but it is more often in the Vis 
region. This emitted radiation is measured and is related to the concentration. Samples 
that are not naturally fluorescent can be labelled with a fluorescing agent, and this 
considerably expands the applications base for this measurement technique. The use 
o f the fluorimeter as a detector in HPLC separations is discussed in section 1.2 .4.4.3.
With the spectrofluorimeter, it is necessary to separate the emitted radiation 
from the incident radiation and this is most easily done by measuring fluorescence at 
right angles to the incident radiation. A usual source of radiation is a mercury vapour 
lamp. Two monochromators are used -  one to select the wavelength o f excitation and 
one to select the wavelength o f fluorescence. Commercial instruments usually adjust 
the spectra to correct for variations in the source intensity with wavelength and for 
variations in detector response. When compared to absorption spectrometry, 
fluorescence has advantages, it suffers much less from interferences and it is more 
sensitive. This is because in absorption spectrometry, the difference between two 
finite signals is measured and the sensitivity is governed by the ability o f the 
instrument to distinguish between these two. In fluorescence, the difference between 
zero and a finite number is measured, so the sensitivity is governed by the intensity of 
the source and the sensitivity and stability o f  the detector. Fluorescence has a third 
advantage and that is the fact that this technique has a greater linear range for 
concentration (103-fold would not be uncommon). However, disadvantages with 
fluorescence include the problem o f quenching and the fact that the numbers of 
chemical species that exhibit native fluorescence are limited.
1.2.2.2 Infrared Spectrometry
IR spectrometry is based on the measurement o f energy changes due to the rotational 
and vibrational energy transitions o f the molecules. The absorbance versus 
wavelength plot is a molecular fingerprint o f  the molecule. However, unlike UV-Vis, 
IR spectra give more qualitative than quantitative information. Hence, this technique 
is a very important identification test for a known compound as well as a method that 
yields valuable structural information about a new compound. Quantitative analysis in 
IR spectrometry uses the Beer-Lambert Law but reading the spectrum can pose 
difficulties if  the peak is not fully resolved from neighbouring peaks and if  the
31
baseline is not adequately defined. Finding a suitable, transparent solvent for use in 
quantitative IR can also be difficult. The slit width must be kept constant if 
quantitative measurements are to be made, as band intensities are highly sensitive to 
changes.
Newer infrared spectrometers which employ an interferometer and have no 
monochromator are called Fourier-Transform (FT) spectrometers. These instruments 
can record IR spectra with much greater speed and sensitivity than before. This is 
because instead o f scanning a spectrum over a range of wavenumbers, an 
interferometer allows simultaneous collection o f all data points in the form of an 
interferogram. This interferogram is then mathematically transformed into a 
conventional spectrum. A full-range FT-IR spectrum can now be recorded in less than 
one second and by accumulating multiple scans, greater sensitivity is also obtained. 
Quantitative analysis o f  FT-IR interferograms is discussed in an article by Mattu et 
al.so. Due to its relative imprecision and insensitivity when compared to UV-Vis, 
there are few applications of its use in the literature for biopharmaceutical analysis. 
However, like UV-Vis, this technique has bioanalytical applications as a detector for 
chromatographic separations.
1.2.2.3 Nuclear Magnetic Resonance Spectrometry
NMR uses electromagnetic radiation in the radio wave region o f the spectrum 
involving nuclear spin energy transitions, which occur in a magnetic field. Absorption 
o f radiation in this technique can be observed for those nuclei which spin about their 
own axes. The instrumentation is expensive and complex, with moderate to poor 
sensitivity. There is a limited range of solvents available since they must be 
deuterated or tritiated. Most o f the applications o f this spectrometric technique are in 
fact qualitative or as a detector for chromatographic separations.
1.2.2.4 Mass Spectrometry
MS uses a high-energy beam o f electrons to cause destruction and/or fragmentation of 
the molecules in a sample. The fragments (ions) pass through a magnetic field which 
separates them according to their mass and charge. A detector determines the mass-to- 
charge ratio for each ion and plots this parameter versus the quantity o f that particular 
ion. The essential components o f a mass spectrometer include a sample inlet system, 
an ionisation source, an acceleration chamber, an analyser, a detector and a recorder. 
Numerous methods o f sample ionisation are available o f which the most important are
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a) electron impact, b) chemical ionisation and c) fast atom bombardment. Depending 
on the type o f ionisation method used, the extent o f ionisation o f the compound will 
be lesser or greater which will correspond to a less or more complicated 
fragmentation pattern. As well as being a very important qualitative tool, MS is used 
as a very sensitive quantitative instrument and finds special applications as a detector 
for LC, GC and CE.
1.2.3 ELECTROCHEMISTRY
If a solution forms part of an electrochemical cell, the voltage, current and resistance 
o f that system are all determined by the chemical composition o f the solution. By 
measuring one or more o f these electrical properties under controlled conditions, both 
qualitative and quantitative information can be obtained. This section includes 
analytical techniques which are based on electrical measurements o f such solutions. 
One o f these parameters is quantified and related to the concentration o f the species 
under analysis. Electrolytic methods include some of the most accurate, as well as 
most sensitive, instrumental techniques.
1.2.3.1 Potentiometry
This is the most widely used electroanalytical mode o f detection and it utilises the 
galvanic cell concept. There is no net current flow. Potentiometric techniques include 
pH measurement, ion-selective electrode (ISE) measurement and potentiometric 
titrations. The Nernst equation forms the basis for measuring the potential (voltage) of 
one o f a pair of immersed electrodes. The unchanging reference is a portable electrode 
designed to give a constant potential e.g. the saturated calomel electrode or the silver- 
silver chloride electrode. The working electrode is the electrode of analytical 
significance and examples o f  such electrodes include the pH glass electrode and the 
fluoride-selective electrode.
An ISE responds quickly and logarithmically to the activity of an ion. The 
errors associated with ISEs, which can be large, are however independent of 
concentration. ISEs are most useful when the concentration of an ion is required at the 
point o f sample collection, due to their portability. They are also very important in 
cases where the solution to be measured is cloudy or coloured i.e. where 
spectrometric techniques may fail, and in flowing systems or kinetic studies where
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constant monitoring is needed. A number of sensors incorporating potentiometric 
detection have been developed for the determination o f drugs and biomolecules in 
biological matrices. For example, Hassan et al. determined uric acid in human urine 
and serum samples using a miniaturised graphite sensor81. Response times were 5-10 
seconds, the minimum detectable concentration was 8p.g/ml and recovery was > 97%.
Potentiometric titrations can also be carried out using such electrodes but these 
have no real applications in biopharmaceutical analysis.
1.2.3.2 Voltammetry/Polarography
Voltammetry and polarography are current-voltage techniques and are essentially 
electrolysis on a microscale. The principle o f these techniques is based on applying a 
voltage (or current) to an electrode and measuring the resultant current flow (or 
change in potential) through the system. The current is directly proportional to the 
concentration o f the electroactive species. The resultant waveforms can be quite 
complex.
Voltammetry
In voltammetric techniques, current-versus-voltage curves are recorded as a gradually 
changing voltage is applied to the cell. To obtain diffusion-controlled currents, the 
solution is unstirred and the temperature kept constant. A high concentration of 
electrochemically inert background electrolyte is added to suppress migration of the 
analyte o f interest towards the electrodes by electrostatic attraction. The cell typically 
comprises o f a working micro-electrode e.g. carbon or platinum (readily polarisable) 
and a reference electrode e.g. calomel (non-polarisable). The potential o f the working 
electrode is slowly scanned and the resulting current is recorded as a function of the 
applied potential.
The voltammogram produced has a number of key parameters such as 
diffusion current, the background current and the half-wave potential. The diffusion 
current is the current due directly to the presence o f the analyte of interest, the 
background current is the current that would be observed if there was no analyte 
present in solution and the half-wave potential is the potential at which the increase in 
current is at half its full value. Measurement o f the limiting current (iL) forms the basis 
o f quantitative analysis. This value iL is calculated by subtracting the background 
current (A) from the diffusion current (B), as can be seen in the typical
34
voltammogram in Figure 1.4 below. Reproducibility can be a problem with this 
technique due to a build-up o f contamination on the electrodes.
Figure 1.4 : Diagram of a Typical Voltammogram
Applied Potential, Volts
Variations on voltammetric methods include linear sweep voltammetry which 
is carried out on an electrode with a constant and unchanging surface e.g. a mercury 
pool, or on an electrode with a periodically renewed surface. The rate o f scanning 
must be fast. Stripping voltammetry is suitable for materials that can be accumulated 
within the electrode (as an amalgam) or on the electrode (surface). This technique is 
essentially an electrochemical preconcentration step wherein the analyte o f interest is 
concentrated from a larger volume into a suitable electrode volume, hence it can have 
a very sensitive limit o f detection o f 10'9 M. Applications o f voltammetry include the 
analysis o f thyroxine in urine (with a detection limit o f 2.7 ng/ml)82, clenbuterol in 
bovine urine (with a detection limit o f 1.02 x 10"9 M )83 and doxazosin in urine84.
Polarography
When the working electrode used is the dropping mercury electrode (DME), the 
technique is called polarography. All the above voltammetric methods can be carried
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out using the DME or hanging DME. This non-stationary electrode gives more 
reproducible waveforms due to the constantly renewed electrode surface i.e. a new 
drop each time. As the mercury drop forms and falls, the current increases and 
decreases. The current-versus-voltage curves are now called polarograms. A typical 
limit o f detection would be o f the order o f 10'6 M.
Modern polarographic techniques include sampled DC polarography, pulse 
polarography and differential pulse polarography. These are more sensitive than 
classical polarography because o f the nature o f the potential-time characteristic or the 
mode of current measurement (or both). Pulse polarography, instead of a continuously 
changing voltage, applies a single rectangular voltage pulse to the electrode during the 
last quarter o f its life. In this way, the period at the beginning o f the drop life, when 
changes in charging current are greatest, is avoided. The current is also measured in a 
very short time. Differential pulse polarography limits the contribution from the 
charging current even further. It does so by applying a 40-60 milliseconds duration of 
pulses during the last quarter o f the drop life, but these pulses have constant amplitude 
and are superimposed on a slowly increasing linear voltage ramp. There are two 
current-measuring periods. This method can have a detection limit o f 10'8 M. Two 
examples o f the bioanalytical applications o f polarography are the quantitation of 
cinnamic acid in urine (detection limit O.l|og/ml)85, nicardipine in blood and urine 
(with no sample clean-up) 86 and ceftriaxone in aqueous humour and serum (linear 
range 0.02 to 1300 ng/ml)87.
1.2.4 CHROMATOGRAPHY
1.2.4.1 Principles of Chromatography
During a chromatographic separation, components o f a mixture are continually 
moving back and forth between two phases. The nature o f the two phases and the kind 
o f  interaction the solute molecules have with them can be varied and this gives rise to 
the different types o f chromatography. One o f the phases is a moving phase (mobile 
phase) and the other is a non-moving phase (stationary phase). The mobile phase can 
be a gas or a liquid and the stationary phase can be a liquid or a solid. The separation 
is achieved because compounds differ in their distribution between the mobile and the 
stationary phases. The distribution varies because molecules have different polarities,
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charge and/or size Chromatography can be broadly divided into two categories - 
planar chromatography and column chromatography. The planar methods utilise a 
thin sheet of stationary phase material and the mobile phase moves across the sheet 
Column methods use a cylindrical tube to contain the stationary phase and the mobile 
phase moves through this tube either by gravity, with the use of a high-pressure pump 
or by gas pressure.
1.2.4.1.1 History of Chromatography
The word 'chromatography' was first used by Tswett in 1903 when he described the 
separation o f coloured plant pigments through a column filled with calcium 
carbonate88. Coloured bands were formed as the pigments migrated at different rates. 
The next milestone was in 1941 when Martin and Synge developed the theory of 
partition chromatography between a stationary liquid and a flowing liquid . Martin, 
along with A.T. James, was also responsible for the first application of GC in 195290. 
Soon afterwards, the first commercial GC instruments became available. It was 
Giddings who provided the ‘unifying theory’ in 1965 which allowed comparisons of 
all types of chromatography91 and this rejuvenated interest in LC which led to the 
design of the first commercially available LC instrument in 1969 Although LC was 
slower to be developed as a technique, it is now more popular and more widely 
applicable than GC.
Modern chromatographic techniques are more complex than those in the early 
part of the century and are often used to quantify substances such as drugs to very low 
levels. Chromatography allows greater versatility, speed and applicability than many 
other analytical techniques, particularly in view o f the possibilities offered by modern 
instrumentation.
1.2.4.1.2 Theory of Chromatography
Efficiency
The ideal chromatographic process is one where all components o f a mixture form 
narrow bands that are completely resolved from one another. The narrowness (width) 
of a band peak is a measure of the efficiency of the process The separation efficiency 
of a column can be expressed in terms of the number of theoretical plates in the 
column A theoretical plate can be thought of as representing a single equilibrium 
step. For high efficiency, a large number of theoretical plates is therefore necessary. 
Efficiency N, also called plate number, is related to retention time and peak width
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measured in terms o f the standard deviation, assuming an ideally shaped gaussian 
peak i.e.
N =  16
r
tr
2 or N = 5.54
r ~\
tr
\v
So >
W 1/2
N_ - /
where w is the baseline peak width and w1/2 is the peak width measured at half of the 
peak height and tr is the retention time for the compound. In order to compare 
efficiencies for different solutes on a column or different columns for a solute, the 
same formula for N must be used throughout.
An alternative means o f quoting efficiency is in terms of plate height H. This 
value is the length of the column divided by N, In order to avoid the use of long 
columns, the value H  should be as small (short) as possible. Values o f N  may be 
thousands with the corresponding values of H being very tiny (<lmm). N and H are 
inversely related by the following equation, where L is length o f the column
H = L/N
Ultimately, the width of a peak is determined by the total amount of diffusion 
occurring during movement o f the solute through the system and on the rate of mass 
transfer between the two phases. Both o f these effects are interdependent and 
complex because they consist of a number of contributions from different sources. 
Because they are kinetic effects, their influence on efficiency is determined by the rate 
at which the mobile phase travels through the system. Attempts to define efficiency in 
terms of diffusion and mass transfer effects are numerous but the most useful is that 
by van Deemter92, from which the following simplified equation can be derived for 
efficiency in terms o f plate height H
H = A + B ¡ ¡ j + C / j .
where ju is the mean linear flow rate o f the mobile phase, and A, B and C are terms 
involving diffusion and mass transfer. A is the 'eddy diffusion' term which accounts 
for the different portions o f the mobile phase (and hence the solute) travelling
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different total distances because o f the various routes taken around the particles of 
stationary phase. This effect is minimised by reducing particle size but increases with 
length o f column. B//i is the 'molecular diffusion' term and relates to diffusion of 
solute molecules within the mobile phase caused by local concentration gradients. 
Diffusion within the stationary phase also contributes to this term, which is significant 
only at low flow rates and increases with column length. Cju is the 'mass transfer' term 
and arises because o f the finite time taken for solute molecules to move between two 
phases. Consequently, a true equilibrium situation is never established as the solute 
moves through the system, and the concentration profiles spread out. This effect is 
minimised with small particle sizes and thin coatings of stationary phase but increases 
with flow rate and length o f column.
Experimental values o f H when plotted against the rate of flow of mobile 
phase for a given solute and set o f conditions, produces a hyperbolic curve (Figure 
1.5) showing an optimum flow rate for maximum efficiency.
Figure 1.5 : Illustration of the van Deemter Equation
Mobile phase velocity (//)
This position is dependent on the solute, and each solute in a mixture will have a 
different optimal flow rate. Hence, the most efficient flow rate for a particular sample 
is a matter of compromise. The equation also indicates that the highest efficiencies are 
achieved with stationary phases o f  small particle size (small values o f A and Cju) and
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thin coatings o f liquid (small value o f C/i). Although this equation applies strictly 
speaking to packed column GC, similar equations have been derived for capillary GC 
and HPLC.
Capacity Factor
A solute can be characterised by the length o f time required it takes for it to appear (as 
a peak) after injection onto the column. This is known as the retention time tr. The 
mobile phase solvent front will take a length o f time tm to appear, which is the time it 
would take an unretained solute to appear as a peak. The difference tr -  tm is the 
adjusted retention time tr\  The capacity factor k’ can be defined in terms of retention 
by
If k ’ = 0, then tr= tm and the solute is not retained by the column at all. A large value 
o f k ’ favours good separation o f a solute. However, large capacity factors also mean 
increased elution time, so there is a compromise between separation efficiency and 
separation time. Ideal values o f k ’ for most separations is between I and 10. A change 
in the value o f k’ over time indicates degradation o f the stationary phase.
Resolution
Resolution is the ability to resolve the peaks o f components with similar t. values. 
Resolution Rs is a measure o f the degree o f separation o f two solutes and is given by 
the expression
R s = N2. (a -1 ). k ’2 
4 a  1+ k ’2
N 2 is the plate number measured for the second solute, k ’2 is its capacity factor and a 
is the separation factor defined as k ’2 / k’,. An Rs value o f 0 indicates that the two 
solutes are completely unresolved, and this would occur if a  was 1 i.e. k ’2= k \  or if 
k ’2 = 0 i.e. if  solute two eluted in the solvent front. Improvement in the resolution of 
two solutes can be achieved by increasing the magnitude o f N, k ’ or a, A doubling in
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Rs would require a fourfold increase in the value o f N. Very significant improvements 
in Rs can also be achieved by changing one or both o f the stationary and mobile 
phases since this can have a large effect on a. The chromatographic effects that 
modification o f N, k3 and a would have under a typical set o f conditions are illustrated 
in Figure 1.6.
In practice, Rs is measured from a chromatogram by relating the peak-to-peak 
separation to the average peak width. This is expressed by the equation
R, = At, / lv
where Atris the separation of the peak maxima and w is the average width o f the peaks 
involved An Rs value o f 1.5 or more indicates less than 0.1% contamination.
Figure 1.6 : The Effects of Changing N, k’ and a on a Particular Set of 
Chromatographic Conditions
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1.2.4.1.3 Retention Mechanisms in Chromatography
The physiochemical processes that can occur during chromatography are based on 
one or some combination o f the following types o f retention: adsorption, partition,
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ion-exchange and size exclusion. A general classification of the various retention 
mechanisms of chromatography are given in Table 1.6.
Table 1.6 : General Classification of Retention Mechanisms
Property of Molecule Retention M echanism
Adsorption Adsorption
Solubility Partition
Ion-exchange Ion-exchange
Size and shape Size exclusion
Adsorption
In adsorption, there is competition between the solvent (liquid or gas) and the solid 
adsorbent for the solute molecules. The relative polarities o f solute and stationary 
phase determine the rate of movement of that solute through the column or across the 
surface. Separations where this is the predominant sorption process depend on 
polarity differences between solute molecules in a mixture. The more polar a 
molecule, the more tenaciously it will be adsorbed by a polar surface. During the 
process, there is competition for adsorption sites between solute molecules and those 
of the mobile phase. Solute and solvent molecules are continually adsorbed and 
desorbed as the mobile phase travels through the system. Solutes of low polarity 
spend proportionately more time in the mobile phase than those that are highly polar. 
Consequently, the components of a mixture are eluted in order o f increasing polarity. 
Silica gel or alumina are typical polar phases. In silica, the adsorption sites are the 
oxygen atoms and silanol groups (Si-OH) which readily form H bonds with polar 
molecules. Adsorption chromatography is often called normal-phase chromatography 
because its most common application involves the use o f polar stationary phases and 
non-polar mobile phases.
Partition
Partition is a process that occurs when there is a liquid coated or bonded onto the solid 
support (silica gel is the most common support). This coated or bonded liquid forms 
the stationary phase. The mobile phase is immiscible with this stationary phase.
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Movement of the solute is determined solely by its relative solubility in the two 
phases if the mobile phase is a liquid, and by its relative volatility if  the mobile phase 
is a gas. Solutes move through the system at rates dependent on their solubilities in 
the stationary versus the mobile phase. Coated liquid phase partition chromatography 
is rarely used since coated stationary phases are often unstable and are liable to bleed 
during the separation. The stationary phase is now typically composed o f long chain 
alkyl groups chemically bonded to the solid support. These chains behave like liquids.
Ion-Exchange
Ion-exchange interactions occur when the stationary phase is a support with fixed 
charged groups and mobile counter ions which can readily exchange with solute and 
other ions in the mobile phase. In cation exchange columns, cations in the sample are 
exchanged for cations on the resin. In anion exchange columns, anions in the sample 
are exchanged for anions on the resin. Hence, only charged components can be 
separated by this retention mechanism. Ion-exchange columns can be silica bonded 
phases with anionic (e.g. tetraalkylammonium) or cationic groups (e.g. sulphonic 
acid) attached, polymeric gels or ion-exchange resins.
Size-Exclusion
The size exclusion mechanism effects separation because o f variations in the extent to 
which the solute molecules can diffuse through an inert but porous stationary phase. 
The stationary phase is normally a gel-type structure which has a fixed pore size 
through which molecules greater than the predetermined size are excluded from 
accessing the gel network. Small molecules are trapped in the pores while the larger 
molecules cannot enter the pores and pass around the gel. Hence, large molecules 
elute first and the smallest ones elute last.
1.2.4.1.4 Identification and Quantitation in Chromatography
In chromatography, there are two main aims a) to determine the nature o f the analytes 
in a sample (qualitative analysis) and b) to determine the concentration of each 
analyte (quantitative analysis). Qualitative analysis of peaks can be aided by the use 
of retention data i.e. tr , tf’ or k ; values are generally used for this. Spiking (standard 
addition) experiments are used to further identify the components then thought to be 
present in the sample.
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The first step in quantitative analysis is measurement o f the peaks obtained 
(heights, areas or densities as appropriate). This is usually achieved by electronic 
devices which employ analog-to-digital conversion o f the signals. The next data 
manipulation step is calculation which can be carried out in a number of ways: 
normalisation, external standard method, internal standard method and standard 
addition method. The most commonly used o f these calculations are the external and 
internal standard methods.
In the external standard method, standard solutions containing the solutes o f 
interest are prepared at a number of different concentrations. These solutions are 
analysed and the peak response versus concentration plotted as a calibration curve. 
From this calibration plot, the unknown concentrations o f solutes in the sample can be 
determined. Standard solutions can be run just prior to the samples or can be used to 
‘bracket’ the samples so as to minimise any chromatographic effects that may have 
occurred over the course o f the run. Some researchers also use quality control 
standards which are interspersed with the samples for extra control compensation for 
any changes in the chromatographic separation.
Internal standards are used to correct for errors in sample preparation and 
handling, for variation in instrument response and to help determine solute recoveries. 
The internal standard is usually a compound chemically similar to the analyte, and in 
general, the more its chemical structure resembles that of the compound under test, 
the better the control of variation achieved. Both samples and standards have a 
particular concentration of the internal standard added to them. It is essential that the 
internal standard and the analyte have similar responses to in the detection scheme 
employed. All samples and standards receive the same treatment from addition o f the 
internal standard right through to detection. Internal standards must be carefully 
chosen to minimise the introduction o f further errors. Calibration curves are 
constructed using the standard solutions, by plotting the ‘ratio o f the detector response 
for each solute relative to that o f the internal standard’ against the ‘solute 
concentration’. The peak area ratio for each component in the sample is then 
calculated, and from these values, the amount of each constituent in the sample can be 
quantified.
1.2.4.2 Thin Layer Chromatography
Thin layer chromatography (TLC) is a planar chromatographic method since the 
stationary phase is a thin layer of material spread across a glass or metal plate. These
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plates can be purchased commercially or prepared in-house. The most common 
stationary phase used in TLC is silica gel. The mobile phase is always a liquid. The 
mixture to be separated and known substances (standards) are applied as spots near to 
one end of the plate (approx. 2cm from the bottom edge). Following application, the 
plate is placed in a developing chamber with the bottom edge down and the mobile 
phase level below the level o f the sample spots. A diagram of a TLC plate in a TLC 
tank is shown in Figure 1.7.
Figure 1.7 : TLC A pparatus
The solvent moves up the plate by capillaiy action. The samples are carried up the 
plate at different rates depending on their interaction with the stationary and mobile 
phases. This interaction is determined by any o f the four types o f retention processes, 
the most common mechanisms involved in TLC being adsorption and partition.
Two-dimensional chromatography can also be carried out by removing the 
plate and allowing it to dry after the first separation has occurred. A second edge of 
the plate, at right angles to the original line o f migration, is then dipped into a 
different solvent and chromatography occurs again. This second TLC can separate 
two or more components that coeluted in the first system.
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1.2.4.2.1 Detection in TLC
When chromatography has finished, the plate can be developed in a number of ways 
if  the spots are not visible i.e. coloured. The most common means o f developing the 
plate is by using special plates that have been impregnated with a fluorescent dye 
(Silica F-254 plates). Under UV light, the spots show up dark against the fluorescent 
green background. Fluorescence detection can also be used. If  the molecules of 
interest are not naturally fluorescent, they can be derivatised prior to examination 
under a spectrofluorometer. Cephalosporins have been determined in serum and urine 
using fluorescent detection93. Two derivatising agents were compared - fluorescamine 
and o-phthalaldehyde - in this work. Iodine staining, spray reagents e.g. ninhydrin, 
and ashing techniques are also used in order to visualise the chromatography. TLC is 
often used for drug screening in cases o f toxicity or poisoning because it is simple and 
rapid. A positive result is usually confirmed by another technique. TLC has important 
applications in the analysis o f metabolites in new compounds.
1.2.4.2.2 Identification and Quantitation in TLC
In TLC, retardation factors (Rf values), as opposed to tr , t /  or k’ values, can be 
calculated for each component on the plate in order to mathematically define their 
positions. Quantitative analysis can be carried out by using a scanning densitometer 
which measures the absorbance o f UV-Vis light at the spot location.
1.2.4.3 Gas Chromatography
Gas chromatography (GC) has very widespread use, especially for organic materials. 
The technique is rapid, simple and can handle very complex mixtures and very small 
sample sizes. GC is so-called because the mobile phase is a gas, typically purified 
helium or nitrogen. This gas flows from a compressed gas cylinder through the 
column containing the stationary phase where the separation takes place. The GC 
column is housed in the oven which is at elevated temperatures. Hence, the analytes 
should be volatile and thermally stable at the operating temperature. It is important to 
maintain a constant high temperature during the chromatographic run to prevent 
condensation o f the sample components in the system. The components in the sample 
migrate at different rates because o f differences in boiling point, solubility or 
adsorption. The continuous gas flow elutes the components from the column into the 
detector, where they are quantified. Samples are introduced into the gas flow via an
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injection port located at the top o f the column. The injection chamber is heated to a 
very high temperature, and a small volume o f injected liquid (typically 0.1 - 3.0^1) is 
flash vapourised and carried onto the column. To prevent overloading o f narrow 
capillary columns, split injectors have been developed where only a fraction o f the 
liquid from the syringe (2% or less) is passed to the column. The remaining portion is 
vented to air. As previously mentioned, precise control o f temperature is vital in GC, 
so the role o f the oven is crucial. This is because retention times are increased at 
lower temperatures, yielding improved separations, but at the expense o f increasing 
the analysis time. Both isothermal and gradient-controlled temperature programmes 
are possible.
1.2.4.3.1 Columns in GC
There are two types o f columns used for GC. The older, less widely used type are 
packed with the sorbent whereas the newer columns are o f an open tubular design 
where the sorbent is coated onto the walls o f the column. Packed columns in GC are 
usually no longer than 6-7 metres and are made from stainless steel or glass. The 
liquid stationary phase is adsorbed onto the surface o f an inert and finely divided 
support, such as diatomaceous earth or Teflon, before the phase is packed into the GC 
column. The open tubular columns can be a hundred metres in length and are 
composed o f fused silica, usually with an imide coating on the outside surface. These 
capillary columns have largely replaced packed columns due to their superior 
resolving power arising from increased length and decreased internal diameter. The 
actual stationary phase can be any o f hundreds o f  different liquids. The selection of an 
appropriate stationary phase depends largely on trial and error but some 
chromatographers refer to various tables o f constants and indices as a starting point. 
The Kovats retention index and the McReynolds constants94 are two examples where 
phases are grouped according to their retention properties.
1.2.4.3.2 Detectors in GC
Flame Ionisation Detector
There are many different detectors available for GC but the most commonly used one 
is the Flame Ionisation Detector (FID). It detects all flammable organic compounds, 
irrespective o f functional groups present. It is insensitive to inorganic gases and water. 
The lack of response to water is an asset since most bioanalytical samples will contain
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some amount o f water. It has high sensitivity and the widest linear range (10') o f any 
detector in common use, but it does destroy the sample
Thermal Conductivity Detector
The Thermal Conductivity Detector (TCD) is the most universal o f all GC detectors 
but it has only moderate sensitivity when compared to other detectors for GC. It 
works on the principle that gases eluting from the column have different 
conductivities from that o f the carrier gas. It does not destroy the sample.
Electron Capture Detector
The Electron Capture Detector (ECD) is especially useful for large halogenated 
hydrocarbon molecules for which it is extremely sensitive, selective and non­
destructive. Thus it finds special application in the analysis o f biomedical samples.
Nitrogen/Phosphorous Detector
The Nitrogen/Phosphorous Detector (NPD), which is a slight modification on the 
FID, is the most sensitive o f all GC detectors but is only selective for phosphorous 
and nitrogen-containing compounds.
Flame Photometric Detector
In the Flame Photometric Detector (FPD), a flame photometer aspirates the column 
effluent into a hydrogen flame. This detector is selective and sensitive for sulphur and 
phosphorous-containing compounds.
Electrolytic Conductivity Detector
The Electrolytic Conductivity Detector (Hall) has excellent selectivity and sensitivity, 
giving a peak only for the compounds that produce ions in the reaction chamber. The 
conversion to ions is effected by chemically oxidising or reducing the components 
with a reaction gas in a small reaction chamber made o f nickel which is positioned 
between the column and the cell.
Photoionisation Detector
The Photoionisation Detector (PID) is selective and sensitive for aromatic 
hydrocarbons and inorganics. It is a non-destructive detector that involves the 
ionisation o f the eluting components by UV light.
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1.2.4.3.3 GC-MS and GC-IR
Two very important analytical techniques employing GC are GC-MS and GC-IR. 
With complex mixtures or mixtures containing unknown compounds, both of these 
hyphenated techniques can give remarkable structural and molecular weight 
information. Commercially available instruments allow the direct transfer o f the gas 
effluent from the GC to the mass spectrometer. The MS is an extremely sensitive and 
selective, if somewhat costly, detector. Table 1.7 below gives some recent 
bioanalytical examples o f  GC-MS.
Table 1.7 : Examples of GC-MS in Biopharmaceutical Analysis
Compound & Matrix Comments Reference
Clenbuterol in bovine liver Trimethylsilyl derivatives were prepared. The 
quantitation limits were in the low ng/ml range
25
Phenmetrazine in urine Perfluorooctanoyl chloride derivatives were 
prepared. The linear range o f the assay was 1-100 
ng/ml with a detection limit o f 0.5|.ig/ml
13
Antiepileptics in serum i.e. 
lamotrigine, carbamazepine 
and carbamazepine epoxide
A reference spectrum for pure lamotrigine was 
published for the first time
95
Homocysteine in human 
plasma
The propoxycarbonyl propyl ester derivative was 
prepared and the ion selectively monitored
96
Metabolites o f pyrethroids 
in human urine
The calibration graphs for the five most important 
metabolites were linear from 0.5 to 200ng/ml and 
detection limits were 0.3 to 0.5ng/ml for each
97
Mandelic acids in human 
urine
The chlorodifluoromethyl-1,2-dioxolan-5 -one 
derivatives were prepared and the ions monitored 
selectively
98
The effluent gas from a GC can also be fed into a heated infrared gas cell as 
part o f a GC-IR configuration. The vapour phase FT-IR spectra of the components 
can then be recorded. These spectra are, however, slightly different from the 
corresponding liquid or solid phase spectra but with the availability o f spectral 
libraries, this no longer presents a real problem. Compared to GC-MS, GC-IR is much
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less sensitive. Also, if  sample size is a consideration, a mass spectrum can be recorded 
from as little as 10'10g o f sample while an IR spectrum requires at least lO^g.
1.2.4.3.4 Derivatisation in GC
Some non-volatile, polar or thermally sensitive compounds can be derivatised to 
enhance their volatility and stability prior to GC analysis. Compounds containing 
functional groups such as hydroxyl, carboxyl and amino can be readily reacted with 
appropriate reagents to convert these polar groups into less polar methyl, 
trimethylsilyl or trifluoroacetyl derivatives of greater volatility. Fatty acids, 
carbohydrates, phenols, amino acids and other compounds o f biological interest are 
the most frequently derivatised, although liquid chromatography is very often the 
preferred technique for these types o f compound. Some examples of the use of 
derivatising agents in GC can be seen in Table 1.7.
Alkylsilylaling Reagents
Alkylsilyl derivatives are easily prepared and are suitable for polar molecules 
containing protonic functional groups. Alkylsilylating agents are the most versatile 
and universally applicable GC derivatising agents since the reactions occur 
instantaneously at room temperature. No artifacts or byproducts are formed.
Haloalkylacylating Reagents
Haloalkylacyl derivatives are easily detected by ECD due to the presence o f the 
halogen atom(s). These derivatives are, however, just as suited to detection by FID. 
These compounds are volatile and produce carly-eluting peaks o f good shape.
Other Reagents
Estérification of acidic groups is another form of derivatisation, but these reactions 
can be slow. Straightforward alkylation replaces a H  atom with an alkyl or aryl group. 
There are also bifunctional derivatising agents which can be utilised in very specific 
situations.
1.2.4.3.5 Identification and Quantitation in GC
Identification and quantitation in chromatography in general has been discussed in 
section 1.2.4.1.4. However, particular to GC, retention time (tr) or adjusted retention 
time (tr’) is used to identify peaks for qualitative analysis. The hyphenated techniques
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GC-MS and GC-IR can also be used to give structural information on the compounds 
o f interest. Quantitative measurement in GC is possible in a number o f ways. Internal 
standards are often employed to compensate for variations in physical parameters, 
such as flow rate. The ratio o f the area or height o f the standard or analyte to that of 
the internal standard is used to prepare the calibration curve and hence determine the 
unknown concentration. An alternative method is to use standard additions, especially 
for occasional samples. External standards are not usually used in GC as the technique 
is quite susceptible to instrumental variations.
1.2.4.4 High Perform ance L iquid  C hrom atography
HPLC has its origins in classical column chromatography. Mixtures o f non-volatile 
components are separated by passage o f the sample through a column containing a 
stationary solid, by means o f the pressurised flow o f a liquid phase. The compounds 
migrate at different rates due to differences in solubility, adsorption, size or charge 
and they are detected as they elute from the column. Complex mixtures can be 
resolved in very short times if conditions are optimised. The layout of a typical HPLC 
system is shown in Figure 1,8.
The sample is most commonly introduced into an injector from which a fixed, 
accurate loop volume is injected into the high-pressure system. Autosamplers involve 
the use o f a loop injector coupled to a robotic needle which draws measured aliquots 
from the sample vials. Some automated systems allow extraction and/or derivatisation 
to take place prior to injection. The sample, after injection, is swept along the 
analytical column and thence into the detector and on to the recorder, (or integrator 
or computer). The choice o f  column for a particular analysis is the most important 
step in developing a suitable assay and there are many types of columns available 
with different dimensions, packings and hence characteristics. To prolong the life o f a 
HPLC column, the mobile phase is always o f analytical grade, is prefiltered and 
degassed before use, and in-line filters and a guard column are often employed to 
prevent build-up of contamination. With isocratic elution, the same mobile phase is 
used throughout the run whereas with gradient elution, the mobile phase composition 
can be changed during the run. A gradient programmer can draw from at least two 
solvent reservoirs at once and hence is capable o f altering the mobile phase that is 
delivered to the HPLC solvent delivery system. The very high pressures (often 4000 -  
6000 p.s.i.) are usually delivered by special pulsation-free pumps.
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Figure 1.8 : Layout of a Typical HPLC System
1.2.4.4.1 M odes of H PLC
HPLC may be classified into modes, which mainly involve one or more of the 
retention mechanisms shown in Table 1.6. These are normal-phase, reversed-phase, 
ion-exchange, affinity, size exclusion and chiral chromatography. Consideration of 
the properties o f the sample will aid in the choice o f a suitable HPLC mode. If  the 
compound is ionic or ionisable, ion-pair or ion-exchange chromatography should be 
tried. If  the sample is soluble only in non-polar solvents, normal phase 
chromatography is a likely candidate. Size exclusion chromatography is preferred if 
the compound has a molecular weight of greater than 2000 and if separation o f 
enantiomers is required, chiral LC should be used.
Normal-Phase Chromatography
The oldest type of chromatography is normal phase (based on adsorption retention 
mechanism) and it involves the use o f a non-polar mobile phase e.g. hexane, and a 
polar stationary phase e.g. silica. Normal phase HPLC is used mainly for water- 
insoluble samples, and it can be a powerful technique for isomer separation.
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Reversed-Phase Chromatography
In reversed-phase chromatography, the situation is the opposite to that in normal- 
phase chromatography; the stationary phases are non-polar and the mobile phases are 
polar. Solutes are usually eluted in order o f increasing hydrophobicity (decreasing 
polarity) and their elution can be speeded up by increasing the organic content of the 
mobile phase. Reversed-phase chromatography is more versatile and more generally 
applicable than any other type o f chromatography, and this is due in part to the readily 
available array o f suitable stationary phases. This technique is based heavily on the 
partition retention mechanism, but there are small contributions from adsorption and 
ion-exchange interactions. The stationary phase is usually a silica-bonded material 
(such as C8 or C18-modified silica and other examples previously described in Table 
1.3) or it may be a resin such as styrene divinylbenzene copolymer. The mobile phase 
for reversed phase HPLC is usually a mixture of polar organic solvent(s) and an 
aqueous buffer or water. This mode is preferred for neutral or non-ionised compounds 
that are soluble in organic solvent/water mixtures. Because o f the toxicity and 
environmental implications o f using organic solvents, such as are required in normal 
phase HPLC, reversed phase HPLC is favoured when at all possible.
Two subtypes of reversed phase HPLC are (i) ion-pair HPLC and (ii) ion- 
suppression HPLC. Ion-pair HPLC is used when the molecule o f interest is ionisable 
or ionic. It utilises reversed-phase sorbents. Ion-pair HPLC is especially suitable for 
the simultaneous separation o f acidic, basic and neutral components in a mixture e.g, 
by using a mobile phase containing an ion-pairing agent for cations at pH 2.5, the 
ionisation o f the acidic component is suppressed, the neutral component is unaffected 
and the basic component forms a neutral ion pair. Water/organic solvent mixtures that 
are pH buffered, and include an ion-pair reagent such as tetrabutyl ammonium 
hydroxide, are employed as mobile phases. The presence o f the ion-pair reagent 
increases retention and improves selectivity. However, ion-pair mechanisms are 
complex and hence, development o f ion-pair separations can be difficult. Method 
development using a step-wise approach for ion-pair HPLC has been discussed".
Ion-suppression HPLC is used for the separation of weak acids and weak 
bases. In this technique, a buffer o f appropriate pH is added to the mobile phase to 
render the analyte neutral. Acidic buffers are used to separate weak acids and alkaline 
buffers are used to separate weak bases100. As a result o f the added buffer, samples are 
eluted as sharper zones than they would have been in a similar mobile phase without 
the addition o f  a modifier101.
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Ion-Exchange Chromatography
Ion-exchange HPLC is usually used for mixtures of organic or inorganic ions, for 
example amino acids. The mobile phase is mainly pH-buffered water, and may 
contain additional neutral salts to adjust the ionic strength o f the mobile phase. The 
column has positive or negative binding sites on its surface at which ions are 
exchanged with the analyte molecules in the mobile phase. In order to change 
selectivity, two parameters are very important i.e. pH and salt type.
A ffinity Chromatography
Affinity chromatography is based on a special case of adsorption retention 
mechanism. This technique is based on the ‘lock and key’ mechanism prevalent in 
biological systems. It can be used to separate any molecule that is capable of 
recognising, binding to and forming a dissociable complex with another species e.g. 
antibody and antigen. When antibodies and antigens are involved, this technique is 
known as immunoaffinity chromatography (IAC). The use o f IAC in sample 
extraction has been discussed in section 1.1.4.3. The separation mechanism is very 
specific, but can be time-consuming and expensive when compared to other types of 
chromatography. An affinity ligand that is specific to one type o f biological molecule 
is covalently bonded to an inert support material. The sample mixture containing the 
biomolecule o f interest is applied to the column and washed through and only the 
molecule that can bind to the affinity ligand will be retained by the column. The 
adsorbed species is eluted after the rest o f the sample by changing the composition o f 
the mobile phase.
Size Exclusion Chromatography
Another mode of HPLC is size exclusion HPLC which is divided into two subtypes: 
gel permeation chromatography (GPC) and gel filtration chromatography (GFC). 
GPC uses non-polar organic solvents such as chloroform and toluene, and rigid gel 
stationary phases to analyse large organic molecules (often polymers). GFC uses 
water-based eluents as mobile phases and soft gels e.g. sephadex, as stationary phases 
to measure naturally occurring polymers such as proteins and nucleic acids.
Chiral Chromatography
Chiral chromatography is based on the separation of stereoisomers. This technique 
has developed because o f the importance o f enantiomeric purity o f certain drugs.
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Some molecules are chiral and as such can exist in one o f two 3-dimensional 
enantiomeric forms. Since enantiomers often have different bioavailability, 
pharmacological effects and rates of absorption and elimination102,101, the ability to 
discriminate between the R and S forms o f the molecule can be o f vital importance. 
There are three approaches to chiral discrimination in chromatography a) to form 
diastereomers from the enantiomers by derivatisation, b) to use a chiral stationary 
phase and c) to use a chiral mobile phase.
If  the first approach is used, diastereomers are structural isomers o f each 
other and can now be separated using normal techniques. The determination of 
warfarin enantiomers in the plasma o f stroke patients was made possible by their 
derivatisation to diastereoisomeric esters followed by HPLC104. The second method 
involves the use o f special chiral stationary phases which work by causing the 
transient formation o f diastereomeric complexes, which are then retained to different 
extents on the column. There are a number o f commercially available stationary 
phases for chiral chromatography such as ligand-exchange phases, protein phases, 
cycoldextrin phases and Pirkle phases. Ceccato et al. used a Chiralcel OD-R column 
which contained cellulose tris (3,5-dimethylphenylcarbamate) coated on silica as 
chiral selector for the enantioselective determination of oxprenolol in human 
plasma33. The third approach involves the incoiporation o f special reagents into the 
mobile phase. These chiral mobile phases may be used in normal or reversed phase 
HPLC and usually cause separation o f the enantiomers by the dynamic formation of 
diastereoisomers. Cyclodextrins are typical additives for this purpose and the 
chemical structures o f three cyclodextrins are shown in Figure 1.9.
1.2.4.4.2 Columns in HPLC
Silica in HPLC Columns
Silica is the basic starting material for the majority o f HPLC stationary phases. It is a 
very polar phase which has a large number o f silanol (Si-OH) and siloxane (Si-O-Si) 
groups on its surface. As discussed in section 1.1.4.3, these residual surface silanols, 
when ionised, can interact with basic or ionic compounds through a mixed retention 
mechanism which causes problems such as peak tailing. The presence o f this 
unknown variable in chromatography makes it difficult to obtain reproducible results. 
Since the pH range in which silica can be used is generally restricted to between 2 and 
7 (as silica dissolves in basic solvents), supression o f these interactions simply by 
raising the pH to greater than 7 or 8 is not feasible.
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Figure 1.9 : The Structures of a , P and y-Cydodextrins
Polymers in HPLC Columns
The pH stability considerations have led to the development o f polymeric reversed- 
phase columns. These columns are stable over the pH range 1-13 or 14. The base 
material is usually polystyrene divinylbenzene copolymers with C l8 functionality. 
Low flow rates and higher temperatures are usually required to achieve maximum 
efficiency on these phases. The retention characteristics o f these materials can be 
quite different to that o f silica-based reversed-phase materials because o f the 
extensive network o f tc-orbitals.
Bonded Phases
Because o f the inherent problems associated with pure silica, it has been modified in 
many ways to produce silica-bonded phases. This serves to reduce, though not 
eliminate, these undesirable secondary interactions that affect chromatographic 
separations. The greater the extent to which the silica surface is bonded, the lower the 
number o f  residual silanols. Further treatment o f the bonded phase with ‘end-capping’ 
agents such as trimethylchlorosilane can eliminate these silanols to an even greater
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extent. The one way to virtually remove silanol effects is to add an amine to the 
mobile phase or to use a buffer containing a silanol masking agent e.g. ammonium 
acetate. Base-deactivated columns are available and these columns have been 
exhaustively end-capped. To circumvent the limited pH range that silica columns 
have, some manufacturers have coated the silica surface with a polymer before 
bonding the alkyl chains to it. These columns are stable from pH 2 to 13.
The first bonded phases were produced in 1969 by Halasz et al. who reacted 
silica with alcohols105 and amines106. Subsequently, materials o f greater hydrolytic 
stability have been manufactured by reacting silica with alkylsilanes, some o f which 
are now described.
C l 8 columns are the most widely used of all silica-bonded phases and consist 
of -(CH2) 17-CH3 groups chemically bonded to silica, which renders the surface very 
hydrophobic. These C18 columns, also known as ODS columns, are the most 
commonly used in HPLC and are supplied by most manufacturers. They are used in 
reversed-phase separations. It is worth noting however that large differences can exist 
between different brands o f the same type o f  column, even if  the same type o f bonded 
phase chemistry has been used.
C8 columns consist o f -(CH2)7-CH3 groups chemically bonded to silica. Like 
ODS, it is hydrophobic in nature and hence non-polar. It is therefore used in reversed- 
phase chromatography. Generally, C8 packings show similar selectivity to C l8 but 
with reduced retention for many types o f compounds. It has been used for the 
separation o f low to medium polarity analytes and has been found to provide better 
selectivity than C l 8 for HPLC analysis o f the benzodiazepines24,107’108.
Phenyl columns consist o f -(CH2)3-C6H5 groups chemically bonded to silica. 
In general, phenyl columns exhibit similar retention characteristics to C8 columns but 
their selectivity, especially for aromatic compounds, may be different due to the 
possibility o f n-n  interactions. Phenyl columns have been used in HPLC for the 
separation o f polar aromatics and polycyclic aromatic hydrocarbons.
Cyano columns have -(CH2)3-CN groups chemically bonded to silica. It is a 
polar bonded phase and is used extensively in normal phase HPLC in addition to 
reversed phase. In the latter mode, it is less retentive than ODS and often shows 
different selectivity. It is usually used for the analysis o f medium polarity compounds. 
The cyano analytical column has been found to be very successful for the separation 
of the fi-blockcr class o f  drugs109.
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NH2 bonded phase consists o f -(CH2)3-NH2 groups chemically bonded to 
silica. It is a very polar material which is used extensively in normal phase HPLC as a 
replacement for silica. It has been used in this mode for the HPLC analysis o f a 
number o f drugs including vancomycin110. It is also used as a reversed phase material.
1.2.4.4.3 Detectors in HPLC
There is a wide selection o f detectors available for use in HPLC, the most common of 
which are compared and contrasted in terms of their typical specifications, relative to 
each other, in Table 1.8.
Table 1.8 : Typical Specifications for some Detectors used in HPLC
Detector type Limit of 
Determination 
(ng/ml)
Maximum linear 
range
Gradient
compatible?
UV-Vis 1(T 105 Yes
Fluorescence 10° 10J Yes
Refractive index 104 104 No
Conductivity 10'2 104 No
Amperometric IO'4 10b No
UV-Vis Detector
The most widely used of LC detectors is the UV-Vis spectrophotometer. A 
spectrophotometer measures the ratio o f the radiant power from two beams (generally, 
one that has passed through the sample and one that acts as a reference beam). The 
two beams can be measured separately or simultaneously in a single-beam or double­
beam instrument, respectively. The spectrophotometer contains a flow cell through 
which the absorbance o f the column effluent is monitored continually. Sensitivity 
depends on how strongly the sample absorbs light at a particular wavelength and the 
availability o f a mobile phase that is transparent at the monitoring wavelength. While 
UV-Vis is reasonably sensitive and universal, it is not suitable for all compounds such 
as those with poor or no chromophores.
Diode array UV-Vis spectrophotometers provide a means o f acquiring a full- 
range spectrum in usually less than one second. The optics are reversed in the sense
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that the monochromator disperses the radiation onto the array of photodiodes after it 
has passed through the sample, unlike ordinary spectrophotometers. This facilitates 
the continuous monitoring o f a wide spectral range. The diode array detector (DAD) 
optics yield detection limits and linear ranges that can equal or even exceed that of 
single or multiple wavelength detectors. The advantages o f the DAD are the 
possibility o f rapid spectral scanning of each component as it elutes from the column, 
thereby facilitating identification, 3-D images o f the peaks allowing detection of 
coeluting components, peak purity calculations, concurrent with quantitative analysis 
at the wavelength o f choice, for each species under assay.
Fluorescence Detector
Fluorescence detection is a very selective technique and hence interferences from 
other compounds in a mixture are less o f a problem than with other more universal 
detection methods. It is also more sensitive than UV-Vis detection by virtue o f the 
fact that the signal is measured against a dark background. There are many available 
reagents that can react with non-fluorescing compounds to form fluorescent 
derivatives that may then be detected using a fluorimeter.
Refractive Index Detector
Refractive index (RI) is another characteristic physical property that can be exploited 
in detection since it is rare to find two substances that have the same RI value. The RI 
detector is a ‘bulk property’ detector as opposed to UV-Vis and fluorescence 
detection which are ‘solute property’ detectors. A solute present in the mobile phase 
changes the RI o f the eluent and this is measured by a refractometer. The column 
effluent is passed through a flow cell in the refractometer and is compared to a 
reference flow cell containing only mobile phase. Although this detector is more 
universal than any other used in HPLC, it suffers from a lack of sensitivity, it cannot 
be used with gradient systems and it is strongly affected by temperature.
Conductivity Detector
The conductivity detector is a ‘bulk property’ electrochemical detector, reasonably 
universal in application but generally has a limited dynamic range. The conductivity 
detector is based on the principle o f  resistance and has a simple and robust design, 
consisting o f a small chamber containing two electrodes. A potential is applied and 
the resistance o f the low-volume cell is measured using a Wheatstone bridge circuit.
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These detectors have a means o f offsetting background conductivity signals. They are 
especially suitable when used in conjunction with ion-exchange chromatography. 
Solutions of ionic compounds have low electrical resistance and hence have high 
conductivity values, which makes this type o f detection measurement very feasible.
Amperometric Detector
A second type o f electrochemical detector is the amperometric ‘solute property’ 
detector. These detection systems can afford excellent selectivity since organic 
functional groups electrolyse only at specific values o f the applied potential. The 
amperometric detector has broad applicability for both ionic and molecular 
components as long as they can be oxidised or reduced at low voltages The two most 
popular designs are the thin-layer and wall-jet cell, with the three electrode 
configuration. The three electrodes (reference, auxiliary and working) are usually 
embedded in the wall o f  the flow stream. The chromatogram is recorded by measuring 
the detector cell current at a fixed potential as the sample is eluted from the column. 
The resulting current is directly proportional to the concentration o f electroactive 
species in accordance with Faraday’s Law. FtPLC with amperometric detection was 
the technique o f choice for the determination of polyglucose metabolites in plasma, 
which was linear in the range O.l-lOng/ml111. A carbon fibre flow-through 
amperometric detector cell has been developed and used to determine nifedipine, 
nicardipine and pindolol in plasma, with a limit o f detection of 15ng/ml for each 
compound112. Terbutaline and salbutamol have also been quantified in plasma using 
the same design o f cell, yielding the excellent limits o f  detection of 0.8 and 1.0 ng/ml, 
respectively113’114. The sensitivity is generally greater than with UV-Vis but is less 
than with fluorescence. A disadvantage is the fact that the indicator electrode requires 
frequent cleaning due to a build-up of products from the electrochemical reaction.
1.2.4.4.4 LC-MS and LC-IR
MS and IR can be employed in the hyphenated mode as detectors and/or spectral 
libraries to aid in structural elucidation as well as being capable o f quantitative 
analysis. It is easier to combine HPLC with IR since this mode of detection is 
normally used for liquids. LC-IR allows an IR spectrum to be taken of each 
component as it elutes from the column. This technique is especially suited for non- 
aqueous systems. The interfacing o f LC and MS is slightly more difficult since MS is 
normally operated under conditions o f low pressure and high vacuum. Interfacing is
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most commonly achieved using thermospray ionisation, where the column effluent is 
converted into a fine mist spray and the analyte molecules are ionised by a dissolved 
salt, before being introduced into the MS. Some recent LC-MS and LC-MS-MS 
applications in biopharmaceutical analysis are given in Table 1.9.
Table 1.9 : Recent Biopharmaceutical Applications of LC-MS and LC-MS-MS
Compound and Matrix Technique and Comments Reference
Tamsulosin hydrochloride in 
human plasma and urine
LC-MS-MS used. The method was validated 
in the range 0.5-50 ng/ml in plasma and 1-100 
ng/ml in urine
115
A series o f new AIDS drugs 
i.e. pronucleotides in cells
LC-MS used. The method was used to quantify 
levels and unambiguously determine structures 
o f the breakdown products. The use o f triethyl- 
ammonium acetate as an ion-pairing agent in 
the HPLC facilitated interfacing to the MS
116
Buspirone and identification 
of its metabolites in bile, 
liver and urine
Both LC-MS and LC-MS-MS used. The authors 
developed a metabolite structure database
117
Identification o f impurities 
in paclitaxel
Both LC-MS and LC-MS-MS used 117
MS is a universal but destructive detector. The MS bombards the substance under 
investigation with an electron beam and quantitatively records the result as a spectrum 
o f positive fragments. MS for HPLC can be performed using a single-quadrupole 
(LC-MS) or a triple-quadrupole (LC-MS-MS). LC-MS-MS allows selective ion 
monitoring for more accurate qualitative and quantitative work.
1.2.4.4.5 Derivatisation in HPLC
Derivatisation is sometimes used in HPLC to introduce a chromophore into a 
molecule, hence enabling its detection by UV-Vis or fluorescence. It can also be used 
to improve the response o f an analyte to other kinds o f detector. Samples can be 
derivatised before being separated on the analytical column (pre-column 
derivatisation) or after being separated on the analytical column and before reaching
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the detector (post-column derivatisation). However, derivatisation introduces an extra 
step into the protocol which can give rise to errors and should only be used if other 
detectors are not suitable and/or if  significant improvements in sensitivity and 
selectivity are to be gained. Table 1.10 gives some examples o f derivatising agents 
and the compounds for which they are most suitable.
Table 1.10 : Some Derivatising Agents used in HPLC
Type of Detection 
Required
Derivatising Reagent Type of Reference 
Compound
UV-Vis Benzoyl chloride Alcohols 118
3,5-dinitrobenzoyl chloride Amines 119
2,4-dinitrophenylhydrazine Aldehydes & ketones 120
Benzyl bromide Carboxylic acids 121
Fluorescence 1 -anthroylcy anide Primary and secondary 
alcohols
122
o-phthalaldehyde Primary amines & 
amino acids
123
Dansyl hydrazine Aldehydes & ketones 124
1 -bromoacetylpyrene Carboxylic acids 44
Electrochemical N-(4-anilinophenyl)maleimide Sulphahydryl
Compounds
125
o-phthalaldehyde Primary amines & 
amino acids
126
1.2.4.4.6 Identification and Quantitation in HPLC
This has been previously discussed in general terms in section 1.2.4.1.4 (Identification 
and Quantitation in Chromatography). However, particular to HPLC is the fact that tr, 
t /  or k ’ can be used for qualitative identification o f components, and external or 
internal standards are usually used for the purpose o f calibration and calculation. As 
in GC, the hyphenated techniques such as LC-MS and LC-IR can also be used to give 
structural information on the compounds o f interest. Quantitation in chromatography, 
particularly in HPLC, is further explored in section 1.3 on validation.
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1.2.4.5 Supercritical Fluid Chromatography
Supercritical Fluid Chromatography (SFC) is performed at pressures and temperatures 
above the critical values for the mobile phase. A supercritical fluid is neither a liquid 
or gas but has properties intermediate between the two. It can be formed from a 
conventional liquid by raising the temperature, or from a conventional gas by 
increasing the pressure. The density o f  supercritical fluids can be conveniently varied 
from gas-like to liquid-like by adjusting the temperature and pressure. In this way a 
compromise can be found between favourable chromatographic conditions and 
eluotropic strength. Supercritical carbon dioxide is a typical eluent for SFC with a 
critical temperature o f 304K and a critical pressure o f 72.8atm. It is safe, is 
compatible with a number o f detectors, it is readily available, relatively inert and 
inexpensive. Most importantly, however, it has favourable critical properties and can 
be stored and handled as a liquid. CO2, however, is not a good solvent for polar and 
high molecular weight solutes and it is not transparent in the mid-IR range. In these 
cases, alternative SFC mobile phases are ammonia, nitrogen oxide and alkanes. 
Ammonia however, is corrosive, which makes its use somewhat prohibitive. 
Sometimes modifiers such as methanol can be used to alter the base eluent properties 
o f supercritical CO2 to render it more polar, but care must be taken since this can 
interfere dramatically with detection, especially when using an FID.
The stationary phase, as in HPLC, determines the selectivity for the 
compound(s) o f interest. Both open tubular and packed columns can be used in SFC. 
Typical phases are polysiloxanes (which have high temperature stability and high 
diffusion coefficients for solutes) and carbowax. For packed column SFC, rapid, 
efficient analysis can be obtained on columns packed with 3 -  10 (im particles. 
Typical phases include modified silicas, porous-bonded phases and polymer-bonded 
phases. Simon et al. used a diol-bonded silica column, a mobile phase consisting of 
ethanol-water-methanesulphonic acid (97.5:2.4:0.1, v/v/v) to determine the urinary 
metabolites o f styrene127. Because o f the limited number o f supercritical fluids and the 
disadvantages associated with them such as those mentioned for ammonia, SFC has 
not expanded as much as would have been expected for a technique with so much to 
offer analytically. The technique is also limited to the analysis o f those compounds 
that are soluble in supercritical fluids. Hence SFC is not a widely used form of 
chromatography but for the analytes to which it is suited, it offers the benefits o f both 
HPLC and GC. This is because since both volatile and non-volatile solutes can be
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determined, rapid analysis is possible with high resolution, and a wider range of 
detection modes is available than in HPLC or GC alone.
1.2.5 CAPILLARY ELECTROPHORESIS
1.2.5.1 Principles of Capillary Electrophoresis
Capillary electrophoresis (CE) is a technique combining the separation principles of 
electrophoresis and the instrumentation and design concepts o f chromatography. 
Charged species are separated on the basis o f their different velocities in an electric 
field. Under the influence o f an external potential, each ion moves towards the 
electrode o f opposite charge. CE is performed in a system based on that shown in 
Figure 1.10.
Figure 1.10 : Layout of a Typical CE System
Capillary
Detector
Electrode uuwwk Electrode
A narrow-bore, fused silica capillary is used for the separation and the ends of which 
are placed in buffer reservoirs. These reservoirs o f electrolyte also usually contain the 
electrodes which are used to make contact between the high voltage (HV) power 
supply and capillary. The sample is introduced into the capillary by placing one end 
o f the capillary into the sample vial for just long enough so that a very small volume
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(usually a few nanolitres) can be introduced into the capillary, usually by 
hydrodynamic means. After replacing the capillary into the buffer reservoir, the high 
voltage is applied and the electrophoretic separation performed. After migrating from 
the injector some way into the capillary, the solutes are visualised by the detector 
through a window in the wall o f the capillary.
1.2.5.1.1 History of Capillary Electrophoresis
In the 1930s, it was discovered that by placing a mixture o f macromolecules between 
buffer solutions in a tube and applying an electric field, sample components migrated 
in a direction and at a rate determined by their charge and mobility. Electrophoresis 
has traditionally been performed in anti-convective media such as polyacrylamide gel, 
cellulose acetate or paper because o f thermal diffusion and convection limitations, and 
has been mainly applied to the size-dependant separation o f biological 
macromolecules such as nucleic acids and proteins. In 1967, Hjerten began to 
investigate the use o f narrow-bore capillaries rather than gel media128. These 
capillaries were only available as small as one millimetre in bore size. Later, 
capillaries o f  approximately 200p.m internal diameter composed o f glass and teflon 
were reported129. The capillaries used by Jorgenson and Lukács in the early 1980s 
were even more narrow (75fitn)130’131. The theory for CE was developed when the 
relationships between operational parameters and separation quality were described, 
and when the potential o f high performance capillary electrophoresis as a technique 
was demonstrated. Since the late 1980s, numerous books132’133 and reviews have been 
written, and commercial instruments are now in relatively widespread use.
1.2.5.1.2 Theory of Capillary Electrophoresis
Mobility
The migration of a solute in CE depends on the mobility (n) o f that species. 
Electrophoretic mobility (|ie) can be described in terms o f velocity (v) and applied 
electric field (E),
He = v / E
The electric field (in volts/cm) is a function o f the applied voltage and capillary 
length. Mobility is a constant for that ion in a particular medium under the
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electrophoretic conditions. Mobility can also be expressed in terms of physical 
parameters,
He= q
67rqr
where q is the charge on the ion, r\ is the viscosity o f the electrolyte and r is the radius 
of the ion. It is evident from this equation that small, highly charged species have high 
mobilities while large, minimally charged species have low mobilities. The 
electrophoretic mobility found in standard tables is usually different to that 
determined experimentally. The latter is called effective mobility (pes) and is often 
highly dependent on factors such as pH and composition o f the electrolyte buffer as 
well as temperature. In fact, mobility is found to increase by approximately 2% for 
each degree rise in temperature134. In the presence o f electroosmotic flow (discussed 
next), the effective mobility can be described as the sum of the electrophoretic 
mobility and the mobility o f the electroosmotic flow,
P e f f  =  P e  +  P E O F
Electroosmotic Flow
Another important parameter in CE operation is electroosmotic flow (EOF) which 
describes the ‘bulk flow’ o f liquid in the capillary and is a consequence o f the surface 
charge on the interior capillary wall. The EOF results from the dissociation o f acidic 
silanol groups at the capillary wall in contact with the electrolyte buffer. Hydrated 
cations in the electrolyte solution are attracted to the negatively charged silanol 
groups and become arranged into two layers (Figure 1.11). One layer is tightly bound 
to the wall by electrostatic forces (compact layer) and the other is more loosely bound 
(diffuse layer). When an electric field is applied, the predominantly negatively 
charged diffuse layer breaks away and moves towards the cathode, dragging with it 
the bulk solution o f the electrolyte as a result o f viscous drag.
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Figure 1.11 : Electrical Double-Layer at the Capillary Wall
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Thus, EOF can influence the mobility o f a solute in the capillary. It can accelerate the 
migration o f a solute if  flowing in the same direction, whereas it can increase the 
resolution o f a mixture o f solutes if  flowing in the opposite direction. Because the 
EOF arises from ionisation of acidic silanol groups at the surface o f the capillary wall, 
the magnitude o f the EOF will increase with increasing pH. It will also increase with 
increasing applied voltage. However, EOF is found to decrease with increasing ionic 
strength of the buffer.
Under normal conditions, the power supply is positively charged at the anode 
and the EOF flows from the anode via the detector to the cathode, such that cations in 
a mixture will migrate first, followed by neutral molecules followed by anions 
However, both the direction and magnitude o f the EOF can be controlled by varying 
parameters such as pH. To change the direction o f  the EOF, for example, if  a mixture 
of anions was to be separated, the polarity o f the electrodes can be reversed such that 
the cathode is at the injector end o f the capillary. To take advantage o f the EOF in this 
situation, the charge on the capillary wall must be reversed also. This is achieved by 
the addition o f cationic surfactants to the electrolyte solution which coat the capillary 
wall, thus giving it a positive charge. The charged diffuse layer now flows towards the 
detector from the cathode to the anode in the same direction as the analytes. To 
reduce or suppress the EOF in capillaries, the ionic strength o f the buffer may be 
increased or CE carried out at pH extremes. Alternatively, the surface o f the capillary 
may be chemically derivatised to eliminate charged attraction sites or a chemical
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reagent e.g. a surfactant, can be added to dynamically reduce solute-capillary 
interactions.
Efficiency and Resolution
Efficiency (N) in CE describes peak broadening as a function o f migration time. High 
voltages, fast migration times and species with low diffusion coefficients result in the 
most efficient separations. N  is also affected by injection length. For small injection 
lengths, the peak widths are determined by diffusion, while with large injection 
lengths, the peak widths are related to the variance o f the injection length. The shape 
of the peaks is determined by the concentration o f the analytes. Unless the 
concentrations o f the compounds are at least two orders o f magnitude lower than the 
ionic strength o f the buffer, slower moving analytes will exhibit tailing while faster 
moving analytes will exhibit fronting. N  can also be affected by a phenomenon called 
Joule heating which is the heat generation that occurs when analyte and buffer 
molecules collide as a result o f the conduction o f electric currents. It can cause non- 
uniform temperature gradients and local changes in viscosity, both o f which lead to 
zone broadening. It is minimised when capillaries are shorter than 90cm and the 
internal diameter is less than 80(j.m.
Resolution (R) is dependent primarily on the efficiency o f the system and to a 
certain extent on the differences in the migration times o f the analytes o f interest. This 
is in contrast to chromatography, where separation and resolution are primarily driven 
by selectivity. Resolution is affected by the speed and direction o f the EOF, the 
mobility o f the analytes o f interest and to a lesser degree, the applied voltage.
1.2.5.2 Modes of CE
As in HPLC, there are a number o f modes o f CE, which make it very versatile (see 
Figure 1.12). There are two main types of CE systems -  continuous and 
discontinuous. In the continuous CE modes, there is further subdivision into those 
modes that have a constant electrolyte composition throughout the analysis (kinetic 
process) and those modes where the composition o f the electrolyte is not constant 
over the length o f the capillary (steady-state process). The final array o f modes are 
capillary zone electrophoresis (CZE), micellar electrokinetic chromatography 
(MECC), capillary gel electrophoresis (CGE), capillary isoelectric focussing (CIEF) 
and capillary isotachophoresis (CITP), all exploiting different separation mechanisms.
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For the most part, the different modes are accessed simply by altering the electrolyte 
buffer composition.
Figure 1.12 : Modes of CE According to the Nature of the Electrolyte System
Capillary Electrophoresis
Continuous System Discontinuous System
Kinetic Process Steady-State Process
CZE MECC CGE CffiF C1TP
CZE
CZE is fundamentally the simplest form of CE, mainly because the capillary is filled 
only with buffer. The separation mechanism is based on the charge-to-mass ratio o f an 
analyte in an electric field. Because the composition o f the electrolyte buffer is 
constant, the electric field and the effective mobilities o f the solutes will remain 
constant, and the sample components will migrate with mutually different but 
constant velocities. Both anions and cations can be separated due to the EOF. Neutral 
species do not migrate and elute together with the EOF. In CZE, selectivity is easily 
altered by changing the composition o f the buffer or its pH, or by the use o f additives 
in the buffer. Many o f the applications o f  CZE are in the area o f bioscience, including
* * 133 * 136 137the analysis o f  glycoproteins such as erythropoietin , and peptides ’ , as well as
small molecular weight species such as cefixime or cefotaxime drugs138 and 
cephalosporin antibiotics.
Chiral CE is considered to be a variation o f CZE, with the additional 
separation mechanism based on chiral selectivity. When compared to chiral HPLC, 
chiral CE is less complex, not necessarily requiring specialised capillaries and it 
provides higher efficiencies, thereby allowing quantitation o f trace levels of 
enantiomers, which is difficult in HPLC. As with chiral HPLC, the same three
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approaches apply (see section 1.2 .4.4.1), the most commonly taken approach being 
the addition o f chiral agents to the buffer e.g. cyclodextrins.
MECC
MECC is widely used since it can separate mixtures containing both neutral and 
charged solutes. This is achieved by the use o f a surfactant in the running buffer. The 
individual surfactant molecules will aggregate to form micelles if  the concentration is 
above the critical micelle concentration, which for example is 8 to 9 mM for sodium 
dodecyl sulphate (SDS). Micelles are essentially spherical with the hydrophobic tails 
o f the surfactant molecules oriented towards the centre, and the charged heads 
oriented towards the buffer. It is this interaction between the charged micelle and the 
solutes (neutral or charged) that effects the separation. The presence o f micelles 
allows neutral components to be separated by a partitioning mechanism o f the solute 
between the micelles and the buffer. There are many applications o f MECC for the 
determination o f drugs such as cefotaxime138, amikacin139, paclitaxel140 and glipizide 
and glyburide141
CGE
CGE is principally employed for the separation o f larger biomolecules such as 
proteins, DNA and nucleotides. This technique operates using both electrostatic and 
size exclusion mechanisms. The ‘gel’ capillary contains either a real gel, such as 
crosslinked polyacrylamide or more commonly, a polymer network which acts as a 
molecular sieve. Thus, larger molecules are hindered to a greater extent than smaller 
ones as they migrate through the capillary.
CIEF
CIEF is a technique whereby a pH gradient is formed in the capillary (using 
ampholytes i.e. zwitterionic molecules) in order to separate peptides and proteins on 
the basis o f  their isoelectric points. This separation mechanism is quite different from 
the mechanisms encountered in the previous CE modes. A basic solution is added to 
the reservoir at the cathode and an acidic solution to the reservoir at the anode. The 
electric field is applied, and the mixture o f ampholytes and solute in the capillary 
migrate along the capillary until they reach a pH which coincides with their pi value. 
After this ‘focussing’ has taken place, the narrow zones are mobilised and passed 
through a detector. Larger sample volumes can be used when compared to other CE
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modes, but special coated capillaries are usually required to reduce the EOF, which 
otherwise would interfere with the focussing.
CITP
In CITP, a combination o f two buffers is used to create a state whereby all separated 
zones move at the same velocity. The zones remain sandwiched between leading and 
terminating buffers. I f  a group o f anions were to be separated, a leading buffer with a 
higher electrophoretic mobility and a terminating buffer with a lower electrophoretic 
mobility than that o f the solutes would be chosen. Either anions or cations, but not 
both, can be separated in one CITP experiment. Amiloride and P-blockers were 
separated by cationic CITP yielding quantitation limits o f 32-46ng/ml depending on 
the drug142.
1.2.5.3 Capillaries in CE
Fused silica is the most commonly used material for capillaries in CE. It is electrically 
inert, flexible and inexpensive. In a similar way to GC capillaries, the silica is coated 
with a protective layer o f polyimide to make it stronger. To create the optical window, 
a small section o f this polyimide material is removed, leaving only the silica glass 
which is UV-Vis transparent. Another material used for capillaries is teflon. However, 
teflon exhibits a number o f disadvantages including inhomogeneous inner diameters 
and significantly higher EOF values than silica. Short capillaries yield shorter analysis 
times, but longer capillaries yield superior resolution. Most commonly, 50 to 75cm 
effective lengths o f capillary are used. In order to maintain a high quality o f 
electrophoresis, conditioning o f the capillary must be carried out prior to starting CE 
and in between each injection thereafter. The precise procedure will depend on the 
nature o f the sample, but frequently a one or two minute wash is used to restore the 
characteristics o f the capillary wall and thus maintain the EOF. Temperature and 
voltage must also be carefully controlled.
1.2.5.4 Detectors in CE
Detectors that are suitable for HPLC are usually suitable for CE. The most widely 
used detection method, as with HPLC, is that o f UV-Vis.
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UV-Vis Detector
With fused silica capillaries, wavelengths as low as 190nm can be scanned. This has 
useful applications in the analysis o f compounds such as proteins that have no strong 
chromophores but which can be adequately detected at these wavelengths. At these 
low wavelengths, it is necessary to use buffers with low background absorbance such 
as phosphate or borate. It is important to note that since the detection window is in the 
capillary itself, there is no band broadening as a result o f dead-volume or mixing 
effects. However, the short pathlength is the factor that limits sensitivity in CE. 
Special capillaries have been developed to extend the optical pathway without 
increasing the overall capillary area. One such design is the ‘bubble cell’ which has an 
expanded region inside the capillary. Sensitivity is improved 3 to 5-fold without 
increasing the band broadening. Another design is called the Z-cell which offers an 
improvement of an order o f magnitude or more in the level o f sensitivity. A schematic 
diagram of such a cell is shown below in Figure 1.13.
Figure 1.13 : Diagram of a Z-Cell for CE
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The diode array detector (DAD) can greatly simplify the analysis o f 
electrophoretic data by making possible the rapid scanning of novel compounds so 
that the optimum wavelength for each analyte can be chosen rapidly. DAD then 
allows the monitoring o f different components o f a sample, at their different 
absorbance maxima simultaneously. Peak purity can be assessed, identities o f peaks 
can be confirmed and concentrations can be determined.
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Laser-Induced Fluorescence
The next most commonly used mode of detection is fluorescence. Fluorescence 
detectors have the great advantage over UV-Vis that sensitivity is comparatively 
independent o f pathlength. However, few commercial HPLC fluorescence detectors 
can be modified for efficient use with small capillaries. Consequently, most 
fluorescence detectors in CE are custom-built and because o f superior focusing 
capabilities and reduced stray light levels, lasers have been employed as the excitation 
source for fluorescence detectors used with CE. The use of laser-induced fluorescence 
(LEF) detectors is a relatively new technique with sensitivity so great (10' 14 -  10'16 M) 
that single molecule detection is now possible. Zolpidem was determined in urine 
without extraction using CE-LIF143. The separation took only 10 minutes and the limit 
of detection was 2 ng/ml.
As few molecules exhibit natural fluorescence, derivatisation is usually 
required prior to analysis. In the determination o f amikacin in human plasma by CE 
with fluorescent detection, the derivatisation reagent used was 1-methoxy- 
carbonylindolizine-3,5-dicarbaldehyde139. MECC was the mode o f choice, and the 
overall method yielded a limit o f detection o f 0.5|ig amikacin per ml o f  plasma.
Other Detectors
Other detection systems include electrochemical detection such as amperometry, 
conductivity and voltammetry as well as RI detection.
1.2.5.5 CE-MS
The use o f MS with CE is especially suitable since the liquid flow rate is compatible 
with conventional mass spectrometers. There are three main ways to interface CE 
with MS i.e. electrospray ionisation, ion spray and continuous-flow fast atom 
bombardment. The enantiomers o f terbutaline and ephedrine have been determined by 
CE coupled with ion spray MS detection144. A comparison o f this mode o f detection 
with UV detection was carried out to demonstrate the selectivity and sensitivity 
advantages o f the MS as a detector for CE.
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1.3 VALIDATION IN BIOPHARMACEUTICAL ANALYSIS
In sections 1.1 and 1.2, sample preparation and analytical procedures have been 
discussed. However, the choice o f techniques to use and the subsequent development 
of applicable methodology do not guarantee a reliable and effective assay. Just as 
important in the overall scheme of method development is validation o f the entire 
protocol. Before an analytical method can be routinely implemented, it must first be 
shown to fulfil certain performance criteria. When this has been documented, the 
method is said to be validated. However, controversy remains as to exactly what 
parameters should be measured, what the acceptable limits are for these parameters 
and what must be done to show that the parameters meet the performance criteria. 
Most regulatory bodies, such as the Food and Drug Administration, have mandated a 
code of Good Laboratory Practice for clinical and non-clinical laboratory studies. 
However, guidelines for validation are constantly in a state o f flux as methods and 
techniques change and improve.
The following twelve parameters, for assessing the validity o f a method, are 
discussed in the context o f chromatographic techniques, but in theory they can be 
applied to any analytical procedure. It should be noted that validation protocols are 
tailored for each individual assay, and hence criteria for validating one method may 
be different from those used to validate another method. Few validations will 
incorporate every parameter since each analytical technique will have different 
applications and hence different validation requirements. However, each parameter 
should be carefully considered even if  it is not to be evaluated in the final validation 
protocol.
1.3.1 CALIBRATION
The heart of a chromatographic method is the calibration procedure used to calculate 
the analyte(s) to be being measured. The calibration model should be described when 
reporting on a validation. There are a number o f options o f which the most common 
are linear regression148 (weighted and unweighted), average by amount and multilevel 
calibration; more obscure calibration routines such as quadratic and cubic have been 
reported145. Five to seven concentrations should be used to define the standard 
curve146.
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1.3.2 SELECTIVITY
Selectivity is a measure o f the extent to which the method can determine a particular 
compound in the matrix being analysed without interference from matrix components. 
It is recommended that the selectivity o f the method be established with respect to 
endogenous substances, metabolite(s) and known degradation products147. If a method 
is completely selective for a component or a group o f components, it can be 
considered to be specific. Specific methods are very rare.
1.3.3 RANGE
Quantitative analyses should have the working range o f the method stated. It is within 
this range that the precision and accuracy are calculated to be acceptable.
1.3.4 LINEARITY
Linearity is determined by analysing samples o f varying concentration and 
establishing the concentration-response relationship. It is very desirable that a method 
is linear over a substantial range, but it is not an absolute requirement. Linearity has 
been discussed in detail by Karnes et al. 148
1.3.5 LIMIT OF DETECTION
The limit o f detection (LOD) is determined experimentally for each analyte in a 
method. This is achieved by repeatedly analysing a blank matrix and one containing 
analyte at a concentration that produces a response equivalent to the mean blank 
response plus three standard deviations. The usefulness o f this parameter depends on 
whether the results close to this value are likely to be important.
1.3.6 LIMIT OF QUANTITATION
The limit o f quantitation (LOQ) is the lowest concentration o f an analyte that can be 
measured with an acceptable level o f  precision and accuracy. An acceptable level is in 
general considered to be 10-20% relative standard deviation145. The LOQ value must
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be determined by experiment and should be measured using at least five samples (of 
analyte in matrix)149. The LOQ is usually, but not always, the lowest point on the 
calibration curve.
1.3.7 RUGGEDNESS
Also known as robustness, this parameter attempts to measure variations that are 
introduced when a method is set up under other conditions, which may alter the 
performance of the method. Such influences can most easily be tested for by using 
experimental design to elucidate the factors that are most crucial for successful 
execution o f the method. In HPLC for example, such tests could comprise the 
influence o f type and concentration o f modifiers and additives in the mobile phase, 
pH of the mobile phase, temperature, concentration o f buffer etc.
1.3.8 ACCURACY
Accuracy, according to the Washington Conference Report on Bioanalytical Method 
Validation149, is the “closeness o f determined value to the true value. Generally, 
recovery of added analyte over an appropriate range o f concentrations is taken as an 
indication o f accuracy. Whenever possible, the concentration range chosen should 
bracket the concentration of interest”. Accuracy is probably the most difficult 
parameter to validate. The influences o f sampling and sample preparation must be 
considered, together with interferences in the separation and detection systems. 
Reference materials truly representing the unknown sample are not always available 
and complex biological matrices are difficult to mimic. The analyte can be added to 
liquid samples and recovery studies may give an indication o f method accuracy. The 
ideal situation is to compare the method with a totally independent method, even with 
respect to sample treatment. Accuracy should be evaluated at both high and low 
concentrations. Accuracy is affected by a combination o f two different kinds of 
experimental error -  systematic and random. These are discussed in detail in a 1994 
report150 which analysed the ‘Washington Conference Report on Bioanalytical 
Method Validation’.
76
1.3.9 PRECISION
Precision is “the closeness o f agreement between independent test results obtained 
under prescribed conditions”151. In other words, precision is a measure of the degree 
to which independent test results agree with each other, and is expressed in terms of 
standard deviation. According to the Eurachem/WELAC document on Accreditation 
for Chemical laboratories152, when measurements have been performed on the same 
material under the same experimental conditions, with the same analyst, using the 
same instrumentation (in the same laboratory) within a reasonable time frame (usually 
the same 24-hour period), this is described as repeatability or intra-assay. When 
measurements have been performed on the same material under the same 
experimental conditions, but with a different analyst or different instrumentation or 
during a time frame o f days or weeks, this is described as reproducibility or inter­
assay. The same definitions o f repeatability and reproducibility are given by ISO151. 
At a minimum, three concentrations representing the entire range o f the calibration 
curve should be studied -  one near the LOQ, one near the centre and one near the 
upper boundary o f the standard curve149.
1.3.10 SENSITIVITY
Sensitivity is the difference in analyte concentration corresponding to the smallest 
difference in the response o f  the method that is discernable. This parameter can be 
determined from the slope o f the calibration curve or experimentally by measuring 
closely related analyte concentrations over the entire range of the assay.
1.3.11 STABILITY
The stability o f the analyte in the matrix during the collection process and the sample 
storage period should be assessed, preferably prior to sample analysis. Assessment of 
stability during storage can be accomplished by analysing spiked samples 
immediately and on subsequent days for the anticipated storage period146. The 
influence o f freeze/thaw cycles should also be studied149.
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High recovery o f analyte(s) from the matrix is desirable, but it may sometimes be 
necessary to intentionally sacrifice high recovery in order to achieve better 
selectivity147. Relative recovery is defined as the response o f the analyte measured 
from the matrix as a percentage o f that measured from pure solvent146. Absolute 
recovery is defined as the response o f a processed spiked matrix standard expressed as 
a percentage of the response o f pure standard which has not been subjected to sample
146pretreatment
1.3.12 RECOVERY
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Chapter 2
HPLC Analysis of Taurine in Human 
Plasma using Pre-Column Extraction and
Derivatisation
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2.1 INTRODUCTION
2.1.1 Biological Background
Although taurine was discovered more than 160 years ago, it is only in the past two 
decades that the biochemical importance o f this molecule has really been investigated. 
Initial interest in taurine was generated when it was found that during both World 
Wars, naval doctors had administered taurine to their soldiers to enhance their night 
vision and relieve fatigue. Taisho Pharmaceutical Company in Japan heard about this 
and began production and sale o f ‘taurine extract” in 1949. Taurine, believed to be an 
all-round medicine, was used to cure everything from pneumonia to bedsores. With 
research beginning to show that taurine was useful for general health, Lipovitan D, a 
mixture o f taurine and B vitamins, was developed and sold for the first time in 1962. 
Today there are many taurine products sold in all forms. Perhaps the most recent 
taurine products are the new high energy drinks which are generally a combination of 
taurine with caffeine and/or vitamins. A typical 250ml can contains lOOOmg of taurine 
and 80mg o f caffeine. Manufacturers claim that their drinks “stimulate and revitalise 
the body and brain, and enhance mental and physical performance”.
Taurine (NH2CH2CH2SO3H), which is a naturally-occurring fi-sulphonated 
amino acid, has many other important and beneficial effects on the human body. This 
molecule has been implicated in many physiological functions1, pharmacological 
actions and pathological conditions; it also has a role in bile salt metabolism and has 
bacteriocidal and anti-inflammatory properties. Among the physiological roles 
attributed to taurine are membrane stabilisation2, antioxidation3’4, neuromodulation5 
and regulation of calcium homeostasis6. Taurine has also recently been associated with 
blood thinning abilities -taurine was found to augment the anti-aggregative effect of 
aspirin on the blood7 and to actually reverse blood clotting when given as a supplement 
to diabetics8. Some o f these unique properties o f taurine may be explained by the fact 
that, unusually, it is a free circulating amino acid that is not incorporated into proteins9. 
It is also different from the more commonly known amino acids insofar as it is a 
sulphonic rather than a carboxylic amino acid, and it is a B-amino acid rather than an a- 
amino acid. Taurine, also known as 2-aminoethanesulphonic acid, has a molecular 
weight of 125.2 and has two pKa values (at 25°C) of 1.5 and 9.1. It is the most 
abundant amino acid in the human body, and a 70kg person can contain up to 70g of
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taurine10. Most o f our taurine supply comes directly or indirectly from animal protein 
in our diet, which is why vegetarians may have lower levels of taurine.
Taurine concentrations are extraordinarily high in the developing brain and fall 
sharply thereafter. Other amino acids present in the brain show an opposite 
developmental pattern being higher in adult brain than in growing brain. However, this 
demand for taurine is combined in humans with an apparent inability to synthesise it in 
sufficient quantities to fulfil our needs. The major, if not the sole, source o f taurine in 
infants is breast milk, hence babies weaned on milk formulae can be deprived o f this 
source o f taurine. This deprivation results in a number of biochemical abnormalities, 
but no obvious clinical ones. Research has shown that supplementing premature 
infant’s food intake with 0.05g taurine per kg body weight brings their taurine levels as 
high as those in breastfed babies11. Although there is no compelling evidence to show 
that taurine deficiency in humans does any real harm, such evidence does exist for 
other mammals including cats and monkeys. Insufficient taurine in cats is associated 
with retinal degeneration and blindness12 and with cardiomyopathy13, a condition that is 
reversible as soon as the diet is supplemented with taurine14. This is now so important 
that manufacturers o f catfood supplement their products with taurine. Monkeys fed a 
taurine-deficient diet experience suppressed growth and development15.
Although intracellular taurine concentration in humans is controlled within 
narrow limits16, concentrations in blood are altered in certain disease states, for 
example, plasma levels o f taurine alter in trauma17, sepsis18 and cancer19. There is also 
evidence to suggest that the level o f taurine in plasma may be a useful indicator of 
myocardial infarction20. Taurine levels are significantly raised in the bronchoalveolar 
lavage fluid of asthmatic patients21 and in the cerebrospinal fluid o f patients with 
migraine22. Changes in the concentration o f taurine in the plasma o f patients with major 
depression have also been found23,24. Taurine levels are decreased in the neutrophils of 
patients with chronic psoriasis25, in the cerebrospinal fluid of patients with Parkinson’s 
disease26 and Alzheimer’s disease27, in the plasma o f patients undergoing long-term
I  £- O S  O Q  7 A
parenteral nutrition , and in the plasma and muscle o f uremic patients » > . As the 
diagnostic role o f taurine in various disease states becomes more widely recognised, 
the need for simple, rapid assays for routine plasma taurine analysis has become 
increasingly important.
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2.1.2 Analytical Background
Amino acids o f interest can mainly be found in biological fluids such as blood and 
urine. The clinical interest is not focussed so much on the total amount o f free amino 
acids in these samples but in the changes in their concentration that can be of 
diagnostic significance. The typical concentrations o f some amino acids in human 
plasma are given in Table 2.1
Table 2.1 : Levels of Amino Acids in Human Plasma
Amino Acid
CONCENTRATION (^g/ml)
Ref. [31] Ref. [321 (n=8)* Ref. [32] (n=76)+
Range Mean Range Mean Range
Alanine 25 .7 - 53.7 30.7 22.2 -  44.7 29.9 18 .7 -58 .9
Arginine 11.0-35.8 14.3 8 .6 -2 6 .3 13.0 3 .7 -2 4 .0
Asparagine 5.7 5.8 5 .4 -6 .5
Aspartic acid 5.8 2.2 0 .0 - 7 .2 1.0 0 .0 -3 .2
Citrulline 3 .8 -5 .9 5.3 2 .1 - 9 .7 5.0
Cystine 8.9-20 .5 17.7 11.5 -  33.7 10.5 2 .0 - 20.2
Glutamine 26 .8- 88.8 83.0 60 .7 -101 .5 83.0
Glutamic acid 6 .3 -61 .9 8.6 2 .5 -1 7 .3 8.5 2 .1 -2 8 .2
Glycine 12.5 - 22.9 17.4 10 .8 -3 6 .6 17.8 9 .0 -4 1 .6
Histidine 10.6-17.8 12.4 9 .7 -1 4 .5 11.5 4 .9 -1 6 .6
Isoleucine 9 .8 -22 .2 7.1 4 .6 -1 1 .5 8.3 4 .8 -1 2 .8
Leucine 12.3-25.9 13.2 9 .3 -1 7 .8 14.5 9 .8 -2 3 .0
Lysine 21.1 -37.9 25.4 2 1 .1 -3 0 .9 22.4 12 .1 -34 .8
Methionine 4 .6 -  14.8 3.2 2.3 - 3 .9 3.4 0 .9 - 5 .9
Phenylalanine 7 .4 -20 .2 9.5 6 .3 -1 9 .2 8.8 6 .1 -1 4 .5
Proline 23.6 27.1 12 .8 -5 1 .4 21.2 11 .7-38 .7
Serine 11.8 6 .8 -2 0 .3 12.1 7 .7 -1 7 .6
Taurine 8.3 5 .7 -1 7 .3 7.9 3 .4 -2 1 .0
Threonine 11.2-29.2 19.4 12 .2 -29 .3 15.4 9 .4 -2 3 .0
Tryptophan 6 .6 -15 .0 9.8 5.1 -  14.9
Tyrosine 7.4 - 22.2 9.1 6 .5 -1 1 .3 9.4 3 .9 -1 5 .8
Valine 21.5-35.1 19.9 1 3 .6 -2 6 .6 25.0 16.5-37 .1
* Data from one laboratory.
+ Data from 9 laboratories.
The classic procedures for the separation and determination of amino acids 
have been ion-exchange chromatography using the ninhydrin reaction, and certain TLC 
systems which have worked most successfully as semi-quantitative methods. The
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answer to the quantitative analysis o f amino acids has been given by HPLC, which 
allows rapid and sensitive determinations to be made, even in difficult matrices such as 
blood. When HPLC results for taurine in human plasma have been compared with 
those from an Amino Acid Analyser, the concentrations correlate very well, which is 
not the case with some other amino acids33.
Most amino acids have low extinction coefficients and therefore they are 
usually derivatised before being determined by HPLC with fluorescence detection. 
Some of the derivatising agents that have been used to allow the quantitation o f taurine 
in biological matrices for HPLC analysis are given in Table 2.2.
Table 2.2 : Derivatising Agents used in the HPLC Analysis of Taurine
Derivatising Agent Reference
Ortho-phthalaldehyde Kisrakoi, 1988 [34] 
Patrizio, 1989 [35]
Ortho-phthalaldehyde / thiol Hirshberger, 1985 [36] 
Haller, 1987 [37] 
Eslami, 1987 [38] 
Hirai, 1987 [39] 
Anderson, 1988 [40] 
Porter, 1988 [41] 
Waterfield, 1994 [42]
Dansyl chloride Wiedmeier, 1982 [43] 
Biondi, 1987 [44] 
Sailer, 1989 [45] 
Amiss, 1990 [46]
Dabsyl chloride Stocchi, 1994 [47]
Phenylisothiocyanate Lippincott, 1988 [48]
9-fluorenylmethyl-chloroformate Mant, 1992 49]
3,5-dinitrobenzoyl chloride Masuoka, 1994 [50
1-naphthyl isocyanate Neidle, 1989 [51]
Thiamine Yokoyama? 1991 [52
Fluorescamine Shihabi, 1979 [53] 
Sakai, 1992 [54]
The most widely used derivatising agent for taurine has been ortho- 
phthalaldehyde (OPA), which usually requires the presence o f a thiol such as 2- 
mercaptoethanol to ensure that derivatisation occurs rapidly and in order to stabilise 
the derivatives. OPA is not fluorescent itself but it produces high yields o f highly 
fluorescent derivatives. Although the OPA derivative o f taurine has been determined in
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HPLC by both UV absorbance39,41 and fluorescence36’38’40, there are stability problems 
associated with the adducts formed55; within only a few minutes o f their formation, 
fluorescence begins to diminish. Hirschberger et al. documented this problem when 
they noticed that the fluorescence yield of their taurine derivative decreased 
dramatically when solutions were injected four minutes after derivatisation compared 
to one or two minutes after derivatisation36. Anderson et al. improved the half-life of 
OPA-derivatised taurine to 17 minutes, when the thiol used in the reaction was 3- 
mercaptopropionic acid40. Dansyl chloride has also been used to determine taurine by 
forming the fluorescent derivative43’45’46, but this derivatisation reaction typically 
suffers from many side products, requires quenching of the reaction and can have a 
long reaction time e.g. four hours43. Taurine has also been analysed by measuring the 
strong absorbance o f its dabsyl chloride derivative in the visible region47, which is very 
stable. However, this reaction requires high temperatures (70°C) and is sensitive to the 
presence of salts which can have detrimental effects on the reaction yield.
Other derivatising agents for amino acids include phenylisothiocyanate 
(Edman’s reagent) 48 which allows taurine to be monitored in the UV region (240- 
255nm). In this derivatisation, the pH needs to be carefully controlled to prevent 
conversion of the phenylthiocarbamyl derivatives to phenylthiohydantoin derivatives. 
This reaction is also markedly affected by the presence of salts, divalent cations and 
buffers. The reagent 9-fluorenylmethyl chloroformate (FMOC-C1) forms a very stable, 
fluorescent carbamate derivative with taurine49. Disadvantages o f the use o f this 
compound include the fact that it is itself fluorescent and it also forms hydrolysis 
products that in turn are fluorescent. Hence, an extraction step is usually required prior 
to HPLC analysis. The HPLC analysis o f taurine in biological samples has also been 
carried out using 3,5-dinitrobenzoyl chloride50, 1-naphthyl isocyanate51 and thiamine52.
The objectives o f this work were to develop an analytical HPLC procedure for 
the determination of taurine in human platelet-rich plasma. This was to be done using a 
derivatisation reaction so that taurine could be detected by its resultant absorbance in 
the UV-Vis region o f  the spectrum.
Two derivatising agents for taurine were investigated in this project. The first, 
hypochlorite, has been previously employed to quantify taurine in neutrophils56. The 
reason for using this reaction was based on the knowledge that taurine is known to 
undergo reaction with native HOC1 in vivo, during the respiratory burst, resulting in 
chlorinated derivatives3. When previously used, the derivatisation procedure was
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carried out at room temperature, and taurine was reacted with sodium hypochlorite to 
form the taurine derivative (monochlorotaurine) which has maximum absorbance at 
254nm. The (3-chloramine derivative, once formed, has been reported to be more stable 
than a-amino acid chloramines57, which is a clear analytical advantage and the reason it 
was selected as the preferred derivatising agent for investigation.
The second derivatising agent, fluorescamine (fluram), was first introduced for 
the determination of primary amines and amino acids in 197258. Fluorescamine and its 
hydrolysis products are not fluorescent and excess fluorescamine is concomitantly 
destroyed with a half-life o f milliseconds. The fluorophors have been found to be stable 
for several hours. This reagent has been used for the quantitation o f taurine using 
fluorescence detection53,54. Fluorescamine was selected for investigation because its 
reaction with primary amines proceeds instantaneously at ambient temperature in 
alkaline solution, the reagent and its major hydrolysis products do not interfere, and 
the derivatives are stable.
2.2 REAGENTS AND MATERIALS
2.2.1 Equipment
The high performance liquid chromatograph was equipped with a Waters (Milford, 
MA, USA) 510 dual-piston pump, a Waters 486 tunable absorbance detector and a 
Waters 746 data module. The Rheodyne (Cotati, CA, USA) injection port was fitted 
with a 20^1 loop. A C-8 guard column (10mm X 4.6mm) was fitted prior to the 
Bondclone® (Phenomenex, Torrance, CA, USA) C-18 10(im stainless steel analytical 
column (300mm X 3.9mm).
2.2.2 Reagents and Chemicals
Taurine (99%) and tetra-butyl ammonium hydroxide (TBAH), a 40% solution in 
water, were obtained from SIGMA (Poole, Dorset, UK). All other amino acids, 
sodium hypochlorite (NaOCl, a solution with 14% available chlorine), dipotassium 
hydrogen phosphate (K2HPO4), potassium dihydrogen phosphate (KH2P 0 4), perchloric 
acid (70%) and di-sodium tetraborate were obtained from BDH Chemicals (Poole, 
Dorset, UK). Acetonitrile, methanol, tetrahydrofuran and all other solvents were 
HPLC grade and were purchased from Labscan (Dublin, Ireland). Super purity
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acetonitrile from Romil Chemicals (Loughborough, UK) was used for the 
deproteinisation step. Trichloroacetic acid, phosphoric acid (85% wt., 99.999%) and 
fluorescamine (98%) were obtained from the Aldrich Chemical Company (Poole, 
Dorset, UK). Boric acid was from Merck (Darmstadt, Germany). Water was deionised 
using an Elgastat Purification system.
2.2.3 Other Materials
Hypersep® C18 cartridges (200mg, 3 ml) were received as a gift from Shandon 
Scientific (Runcorn, England). 1ST (Mid-Glamorgan, UK) kindly donated anion (SCX) 
and cation (PRS) exchange columns (200mg, 3ml). Microcon-3® (MW 3000 cutoff) 
concentrators and Micropure® (0.22|nn filter) separator inserts were purchased from 
Amicon Ltd. (Stonehouse, UK).
2.3 HYPOCHLORITE DERIVATISATION OF TAURINE
2.3.1 EXPERIMENTAL
2.3.1.1 Blood Collection
Blood samples were taken from fasting volunteers into glass tubes containing 10% 
sodium citrate as anti-coagulant. Large bore butterfly syringes were used so as to 
minimise cell damage, since this can result in platelet ruption and hence give rise to 
falsely elevated levels o f basal taurine present in the plasma. Platelet-rich plasma (PRP) 
was obtained by centrifugation for 5 min. @ 170g (lOOOrpm) at room temperature. 
Platelet-poor plasma (PPP) was obtained by centrifugation for 15 min. @ 1500g 
(3000rpm), also at room temperature. Care was taken during pipetting so as not to 
disturb the buffy coat layer.
2.3.1.2 Preparation of Reagents for HOCI Derivatisation
For the hypochlorite derivatisation reaction, a 1M stock solution of NaOCl was 
prepared on a weekly basis and it was stored at 4°C, away from sunlight when not in 
use. The required standard solutions were prepared daily by dilution o f the stock
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solution. The 50 or lOOmM phosphate buffer was prepared by making a solution of 
K 2H PO 4 in purified water and adjusting the pH to 6.5 with phosphoric acid. A 0.5M 
solution of tetra-butyl ammonium phosphate (TBAP) was prepared by mixing 8ml 
TBAH with 10ml water, adjusting the mixture to pH 6.5 with a few drops of 
phosphoric acid and making the volume to 25ml in a volumetric flask.
2.3.1.3 Procedure for Hypochlorite Derivatisation
This derivatisation reaction is shown in Figure 2.1. The sodium hypochlorite solution 
in water becomes a solution o f hypochlorous acid (HOC1). As the derivatisation of 
taurine by HOC1 is pH-dependent, the pH of the reacting mixture was maintained at > 
6.5, to ensure formation of the monochlorinated derivative and prevent formation o f  
the dichlorinated derivative57. The 0.01M taurine solution was mixed with 0.02M 
NaOCl solution in equal proportions by volume and was diluted as appropriate to the 
required concentrations in order to form the aqueous standard solutions of 
monochlorotaurine for investigation by spectrophotometry. In each case, the HOC1 
was in excess and the derivatisations were carried out in stoppered flasks to minimise 
evaporation of reagents.
Figure 2.1 : Derivatisation of Taurine by Hypochlorous Acid
SO3H CH2 +  HOC1  ► SO3H CH, +  H?0
\  / \  \  / ' s
CH2 NH2 CH2 NHC1
Taurine Hypochlorous acid Monochlorotaurine
The aqueous standard solutions o f monochlorotaurine for HPLC analysis were 
prepared by mixing 0 to 40 ng/ml solutions o f taurine (0 to 0.32 mM) with 1 mM 
NaOCl. This procedure was called Method 1 and was found to compare favourably to 
the preparation o f standards by two other methods (in terms of the linearity o f the 
standard curve). Method 2 involved the preparation of a stock solution o f  
monochlorotaurine using 0.001M taurine and 0.001M NaOCl, and subsequent dilution 
to obtain the correct concentrations o f the other standards. Method 3 involved the
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preparation o f a stock solution o f monochlorotaurine using 0.01M taurine and 0.01M 
NaOCl, and subsequent dilution to obtain the correct concentrations of the other 
standards. These results are displayed graphically in Figure 2.2, showing that for three 
different preparation methods for aqueous standards of monochlorotaurine, each gave 
similar peak height results by FIPLC and each were linear with concentration for the 
concentration range examined. Since normal levels o f taurine in human platelet-rich 
plasma are 7.7 to 19.1 ng/ml (from Table 2.3, references 24 and 40), this concentration 
range was expected to be suitable for the analysis o f samples.
Figure 2.2 : Standard Curves of Aqueous Standards of Monochlorotaurine 
Prepared in Three Different Ways
Concentration (ug/ml)
Fig. 2.2 : Method 1 monochlorotaurine standards were prepared by mixing 0 to 40 pig/ml 
solutions of taurine (0 to 0.32 mM) with 1 mM NaOCl. Methods 2 and 3 involved the preparation 
of a stock solution of monochlorotaurine using 0.001M reactants for Method 2 and 0.01M 
reactants for Method 3, respectively, and subsequent dilution of the stock solution to obtain the 
correct concentrations of the working standards.
The plasma standards were prepared by mixing 500^1 of platelet-poor plasma 
(PPP) and 10(il o f taurine solution on a vortex mixer for 10 seconds. Acetonitrile 
(500jil) was added to deproteinise the sample. Following centrifugation, the 
supernatant was added to 500nl o f ImM NaOCl solution for the derivatisation
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reaction. The taurine derivative is formed almost instantaneously at room temperature. 
Samples were usually analysed on the HPLC system within 2 hours.
2.3.1.4 HPLC Conditions for Monochlorotaurine
An ion-pair HPLC method was employed. The flow rate o f the eluent was lml/min, the 
system pressure was approximately 1100  p.s.i. and all measurements were made at 
ambient temperature. The chart speed was 0.5 cm/min and the attenuation was 2. 
Taurine was reacted with the hypochlorite (in excess) at room temperature to form the 
monochlorinated derivative. UV detection was carried out at 254nm, the maximum 
absorbance wavelength for the monochlorotaurine derivative (Figure 2.3). Taurine 
itself does not absorb in the UV region and hypochlorite absorbs at 295-302nm. The 
mobile phase consisted o f TBAP, acetonitrile and phosphate buffer (pH 6.5) in the 
proportions 1:5:94, v/v/v56. After mixing the phosphate buffer and the acetonitrile, the 
ion pair reagent, TBAP, was incorporated into the mobile phase and the mixture was 
adjusted to pH 6.5 with phosphoric acid. It was then filtered under vacuum through a 
0.45(im Millipore filter and sonicated for 20 minutes. Under these HPLC conditions, 
the peak for the derivative appeared at 9.0± 0.2 min.
Figure 2.3 : UV Absorbance Spectrum of Monochlorotaurine Derivative
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2.3.2 RESULTS AND DISCUSSION
2.3.2.1 Optimisation of Blood Collection Procedure
Blood levels o f taurine have been extensively determined and reported (see Tables 2.1 
and 2.3). However, the values obtained vary considerably depending on a number of 
factors. One of the major factors influencing the measurement o f taurine concentration 
is the type of blood analysed -  whole blood, serum, platelet-rich plasma (PRP) or 
platelet-poor plasma (PPP). The treatment o f blood to yield whole blood or serum is 
well established but the treatment o f blood to yield PRP or PPP is less well established. 
This is exemplified in Table 2.3 where certain criteria for the isolation o f PPP and PRP 
such as centrifugation speeds, temperatures and anticoagulants can vary dramatically 
from one report to the next, or details may be omitted entirely. The extent of 
centrifugation is probably the most important variable in the isolation o f PRP, since the 
more gentle the centrifugal force, the more platelets will remain in the plasma. And 
since platelets contain relatively high concentrations o f taurine, their number in plasma 
will affect the concentration of taurine in the PRP. Platelet count in blood can vary 
from 100,000 to 500,000 per ml o f plasma with factors such as sex, age59, diet60, 
health and sample treatment contributing to these numbers. Many reports do not state 
which type of plasma (PPP or PRP) was examined and simply use the term ‘plasma’. 
For some biomolecules, this lack o f distinction would make no differences to the final 
results, but taurine levels in PRP are o f the order o f 3-4 times higher than in PPP24, the 
primary reason for measuring taurine in PRP as opposed to PPP. Another reason for 
measuring taurine specifically in PRP is that any changes in concentration, due to 
various disease states, will be more dramatic than in PPP. Thus, this distinction 
between the two types o f plasma is important in the analysis o f taurine and should be 
documented in the preparation procedure.
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Table 2.3 : Comparison of Previous Methods for the Determination of Taurine in Blood
Reference Derivatising Agent 
and Detection Mode
Blood Collection and Preparation Taurine Results (jig/ml)
Tachiki, 
1977 [24]
OPA/mercaptoethanol
Fluorescence
Blood collected in EDTA vacutainer 7ml glass tubes from 
antecubital vein. Blood centrifuged @ 1000g at 4°C for 15min. 
to isolate PRP. PRP spun @ 12,100g at 4°C for 30min. to isolate 
PPP. Plasma proteins precipitated with trichloroacetic acid and 
kept on ice. Supernatant isolated by centrifugation and extracted 
with diethyl ether (3 times) before being subjected to cation- 
exchange. Extract dried and reconstituted.
Human PRP : 17 .7+1.4 
Human PPP : 5. 6±0.5
Hirschberger, 
1985 [36]
OPA/mercaptoethanol
Fluorescence
Blood collected in heparinised tubes. Blood centrifuged @ 2000g 
for 10min to isolate plasma. Plasma proteins precipitated with 
sulphosalicylic acid. Supernatant neutralised and diluted.
Human ‘plasma’ : 5.0±0.9
Eslami, 
1987 [38]
OP A/ ethanethiol 
Fluorescence
Blood collected in EDTA tubes. Blood centrifuged @ 1800rpm 
for 5min to isolate plasma. Plasma proteins precipitated with 
methanol. Sample mixed and centrifuged to isolate supernatant.
Human ‘plasma14.0±4.9
Hirai,
1987 [39]
OPA/mercaptoethanol 
UV (350nm)
No blood collection information. Proteins precipitated with 
perchloric acid. Supernatant subjected to cation-exchange and 
extract diluted with water.
Rat whole blood: 41.9+4.9
Anderson, 
1988 [40]
OPA/mercapto- 
propionic acid
Fluorescence
Blood collected in EDTA tubes Blood centrifuged @ 300g at 
10°C for 10min. to isolate PRP. PRP spun @ 800g at 10°C for 
15min. to isolate PPP. Plasma proteins precipitated with 
perchloric acid and kept on ice. Supernatant isolated by 
centrifugation and subjected to mixed-bed ion-exchange.
Human whole blood: 25.1+15.4 
Human PRP : 11.3+3.6 
Human PPP : 4.9+1.5
Porter, 
1988 [41]
OPA/mercaptoethanol 
UV (340nm)
Blood collected in heparinised syringes. Blood centrifuged @ 
1400g for 10min to isolate plasma. Plasma proteins precipitated 
with picric acid or by boiling for 15 min. (no recovery 
differences). Supernatant isolated by centrifugation and subjected
Rat ‘plasma’ : 12.6+1.6 
Chick ‘plasma’ : 13.5+0.04
to dual-bed ion-exchange. Extract dried and reconstituted.
Amiss, 
1990 [46]
Dansyl Chloride 
Fluorescence
Blood collected in chilled, heparinised syringes. Blood 
centrifuged @ 2677g to isolate plasma. Plasma mixed with 
organic solution, vortexed and ultrafiltered (Centricon-10) for 
15min. @ 2677g. Whole blood subjected to 2 freeze-thaw cycles 
to release taurine from cells.
Feline ‘plasma’ : 3.0±0.3 
Although whole blood preparation 
given, no results shown.
Quoted normal levels to be 10.3+4.2
[13]
Sakai, 
1992 [54]
Fluorescamine
Fluorescence
Blood collected in heparinised tubes. No isolation information. 
Plasma deproteinised with trichloroacetic acid, extracted with 
diethyl ether (3 times), evaporated to dryness and redissolved in 
water.
Yellowtailfish ‘plasma125+54 
Beef cattle ‘plasma’ . 5.6+1 .4 
Dairy cattle ‘plasma’ : 2 .2+0 .7 
Chicken ‘plasma’ : 20.0+9.6
Stocchi, 
1994 [47]
Dabsyl Chloride 
Visible (436nm)
Blood collected in heparinised tubes. Blood centrifuged @ 
3000rpm at 4°C for lOmin to isolate plasma. Plasma pretreated 
by (i) proteins precipitated with perchloric acid, and the 
supernatant obtained by centrifugation and nuetralisation or (ii) 
ultrafiltration (CF-50) (a)y 2500rpm for 10 min.
Human ‘plasma ’ :
4.8+0.7 by extraction (i) 
5.3+0.5 by extraction (ii)
Mosuoka, 
1994 [50]
3,5 -dinitrobenzoyl 
chloride 
UV (254nm)
No blood collection information. Blood deproteinised by Folin- 
Wu method61 and the supernatant was isolated by centrifugation.
Human blood: 19.9±2.4 
Rat blood: 49.4+5.6
Waterfield, 
1994 [42]
OPA/mercaptoethanol
Fluorescence/UV
Serum obtained directly from rats (abdominal aorta) and added to 
serum microtainers. Serum centrifuged @ 13,000g for 1 min., 
deproteinised with sulphosalicylic acid for 5 min. at 4°C, spun 
again and the supernatant subjected to dual-bed ion-exchange.
Although serum preparation method 
given, no results shown.
This work, 
1995
Fluorescamine 
UV (385nm)
Blood collected in sodium citrate glass tubes. Large bore 
butterfly syringes used to minimise cell rupture. Blood 
centrifuged @ 170g for 5 min. to isolate PRP. PRP was spun @ 
1500g for 15 min. to isolate PPP. Plasma deproteinised with 
acetonitrile, vortex-mixed and centrifuged to isolate supernatant.
Human PRP : 16.8±1.8
It was found in this study that the platelets could be removed from plasma with 
minimum rupture if the samples are collected with the large bore butterfly syringes. 
This procedure ensures that platelet taurine in PPP is minimised. However, it should 
be noted that there is always a basal level o f taurine present in human plasma. Other 
workers have circumvented this problem and obtained taurine-free plasma from kittens 
raised on a taurine-free diet. Feline plasma contains naturally low concentrations of 
taurine (see Table 2.3). In order to isolate PRP in this work, blood samples were taken 
and subjected to gentle centrifugation for 5 min. @ 170g  (lOOOrpm) at room 
temperature. If PPP was required, more vigorous centrifugation was necessary (15 
min. @ 1500# (3000rpm)).
2.3.2.2 Optimisation of Sample Preparation Procedure
As can be seen from Table 2.3, the manner in which blood has been treated prior to 
the determination of taurine therein are numerous. Hence, a number of sample 
preparation procedures were investigated in this work. The results o f these are 
summarised in Table 2.5 at the end o f this section. Each procedure was evaluated 
using plasma samples spiked with taurine, unless otherwise specified. Recovery and/or 
general performance of the different methods were assessed by comparing the results 
of the extracted, derivatised plasma sample with a derivatised, aqueous sample o f the 
same concentration that had not been subjected to the extraction procedure. HPLC 
was used to determine the quantitative results.
Protein Precipitation
The starting point for the plasma extraction was the boiling method used previously 
for neutrophils in conjunction with HOC1 derivatisation56. This procedure had been 
used to precipitate proteins present in the sample and was used because taurine is 
known to be stable to boiling. Boiling was carried out by mixing 300^1 o f plasma with 
700]il o f water and boiling the mixture for 20 min. in an open tube. Subsequent 
centrifugation allowed the separation of the (cloudy) supernatant. This method of 
sample preparation was found to give poor reproducibility and to introduce 
interferences.
Perchloric acid proved to be an efficient deproteinisation agent, especially since 
only 50jd were required to achieve removal o f most o f the proteinaceous material from
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a 500(il plasma sample. However, it was subsequently difficult to increase the pH 
reproducibly.
Methanol was required in a 3:1 ratio to sample in order to effect complete 
precipitation of proteins. This was found to have too great a dilutional effect and so 
was not employed.
Deproteinisation by acetonitrile proved to be the most reproducible method of 
sample preparation and was the easiest to execute. A ratio o f between 1 and 1.5 to 1 
of acetonitrile to sample was required.
Solid-Phase Extraction
Clean up with reversed-phase SPE C l8 cartridges was examined next. The Hypersep® 
cartridges (200mg, 3ml) were solvated with 2ml o f methanol, washed with 5ml of 
water and then the 300^ sample in 10% trichloroacetic acid (TCA) was applied to the 
column. It was allowed to equilibrate for 5 min. and then the cartridge was washed 
with 5% TCA. When an aqueous solution o f taurine was applied to the Cl 8 cartridges, 
the resulting extracts contained variable concentrations o f taurine and hence recovery 
was poor and irreproducible. When derivatised taurine was applied to the C18 
cartridges, various solvents were examined as to their ability to selectively elute 
monochlorotaurine from the cartridge. These varied in pH from phosphate buffer pH 
2.2, mobile phase o f pH 6.5, water and phosphate buffer pH 9.2. These results are 
listed in Table 2.4 overleaf, from which it was concluded that the phosphate buffer of 
pH 9.2 was the best eluting solvent for aqueous samples, giving a recovery o f the 
derivative o f 93%. However, when plasma samples were subjected to this procedure, 
the results were spurious and irreproducible.
Anion and cation exchange SPE columns were also investigated, the aim being 
to selectively retain or to selectively elute the taurine by exploiting its charged 
moieties. A general procedure for the extraction of amino acids from plasma using 
cation exchange (PRS columns) was used. This was unsuccessful, probably because 
buffering the sample to 2 pH units below the pKa o f the acidic group was required, 
which in the case o f taurine is impossible : with a pKa of 1.5, it was only possible to 
lower the pH to approximately 1 using 0.1M HC1.
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Table 2.4 : Extraction Recoveries of Monochlorotaurine from C18 Cartridges in
Different Eluents
Desorbing Eluent Recovery in 1ml
Phosphate buffer, pH 9.2 93%
Phosphate buffer, pH 2.2 13%
Mobile phase eluent* 86%
Water 75%
* The mobile phase consisted of TBAP, acetonitrile and phosphate buffer (pH 6.5) in the 
proportions 1:5:94, v/v/v. Sec experimental section.
The anion exchange procedure (on SAX columns) was easier to carry out for 
taurine in the plasma samples, with application o f the sample in pH 11 borate buifer, 
but there was still little or no retention o f the taurine on the extraction columns. 
Overall, it was not possible to retain the taurine on the columns, from aqueous 
samples, under any circumstances and in fact, extra impurities were introduced during 
this procedure. It has previously been reported that taurine is not well retained on 
either cation or anion exchange columns62.
Ultrafiltration
The next investigations centred on ultrafiltration as a method of sample preparation. 
Microcon-3® concentrators with a molecular cut-off o f 3000 were used with or 
without Micropure® separator inserts with a 0.22^m polysulfone membrane for 
removal o f macromolecules prior to derivatisation and analysis. An extraction recovery 
of approximately 70% was achieved when both eppendorf and insert were used 
together. The centrifugation time was found to be very long (approximately 140 min. 
@ 5800g) and although there was a concentrating effect, few of the smaller molecular 
weight interferents were removed. This method was found to be better than boiling, 
but not as efficient as precipitation with acetonitrile.
A combination of ultrafiltration and SPE was also investigated. Platelet-free 
plasma samples were spiked with taurine and each sample was centrifuged in a 
Microcon® eppendorf tube alone, or one containing a Micropure® 0.22nm separator. 
The filtrates were derivatised with NaOCl and applied to Hypersep® SPE cartridges.
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For desorption o f monochlorotaurine, phosphate buffer pH 9.2, which had given the 
highest recovery (93%), was used. The combination of Microcon®, Micropure® and 
SPE gave cleaner extracts than using SPE alone, but took an unreasonable length of 
time to complete. Also, the clean-up achieved using this procedure was still 
inadequate. The eluates were again compared to samples that did not undergo any 
extraction procedure.
Table 2.5 : Summary of Methods Investigated for Extraction of Taurine
Method of Extraction Results/Comments
Boiling deproteinisation Poor clean-up o f plasma. 
Interfering peaks introduced.
Perchloric acid deproteinisation Efficient agent for removal of proteins. 
Difficult to raise pH subsequently.
Methanol deproteinisation Required in a volume ratio o f 3:1 with 
plasma -  too dilutional.
Acetonitrile deproteinisation Required in a volume ratio of at least 1:1 
with plasma.
Satisfactory, reproducible clean-up
C l8 SPE Good recovery of monochlorotaurine 
from aqueous samples (up to 93%).
Poor and irreproducible recovery from 
plasma samples,
Anion and cation exchange Little or no retention of taurine on the 
ion-exchange columns.
Interferents introduced
Microcon concentrator® and Micropure® 
filter
Approx. 70% extraction recovery of 
taurine from plasma.
Long centrifugation time (140 min.)
2.3.2.3 Optimisation of HOC1 Derivatisation Procedure
HOC1 is well known for its potent oxidising abilities, and it also forms secondary 
chlorinating agents with amines. Chlorination o f amino acids by HOC1 is a pH- 
dependent reaction, and is first order with respect to both the amino acid and the 
HOC1. This reaction occurs naturally in the body and is suggested to act as a 
protective mechanism to remove the highly toxic endogenous hypochlorite10,63. The 
pH for the NaOCl derivatisation step was kept above 6.5 because above pH 6.5, 
amino acids form monochloroamines (the required derivative) and below pH 6.5, they 
form dichloramines57. The monochloroamines which are formed from a-amino acids at
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above pH 6.5 are reported to be unstable e.g. the monochloramines of lysine and 
leucine decompose within 5 minutes57, however the monochloramine o f taurine (a Ji- 
amino acid), has been reported to be more stable, rendering this method o f  
derivatisation quite selective. Stapleton et al. reported that monochlorotaurine was 
stable for 8 days in aqueous solution3. Taurine has even been seen to abstract chlorine 
from the monochloroamine o f another amino acid to form its own derivative. The only 
reported conditions under which monochlorotaurine was expected to be unstable were 
a) excessive heat (temperature is greater than 56°C), b) excessive light and c) 
excessive acid (pH <3.5), in which case the dichloroamine may be formed57.
Although the reaction between HOC1 and amines is believed to occur by a 
mechanism whereby OC1- is the attacking nucleophile in the reaction57, there is a more 
recent theory in circulation which puts forward Cl+ as an attacking electrophilic
• 64species .
Problems with the NaOCl derivatisation procedure arose when the method 
(which had been previously used for taurine in neutrophils50) was applied to both 
aqueous and plasma samples. While linearity could be shown in aqueous standards 
over the concentration range 0 - 4 0  jig/ml under general conditions, this was not 
consistently so. Under identical experimental conditions, following the same protocol, 
the monochloramine o f taurine would sometimes break down. Linearity was not 
obtained for samples in a plasma matrix. Even under strict reaction conditions, the 
procedure was very irreproducible. A number o f parameters were investigated in an 
effort to determine the reason for this lack of reproducibility :
(1) Was NaOCl in too high a concentration relative to taurine? The exact strength of 
the NaOCl was calculated by titration with thiosulphate so that molarities were 
accurate and various molar excesses o f NaOCl were reacted with taurine, but no 
differences were seen in the stability o f the reaction,
(2) Was the pH o f the reaction changing as it progressed? To examine the effect o f
pH, a buffer was added to maintain consistent pH values, but no differences were 
seen in the stability o f the reaction,
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(3) TLC was carried out on the taurine standards, the reagent and the reaction 
mixture to ensure that the reaction was occurring,
(4) All HPLC parameters were checked and the samples rerun to eliminate 
instrumental error.
However, investigation and optimisation o f these parameters failed to render 
the method more reproducible, so spectrophotometry was employed to examine the 
absorbance spectra o f the samples before, during and after derivatisation. It was found 
that although the monochloramine was being formed, on certain occasions its 
concentration decreased over time and this coincided with the increase in the 
absorbance of another interfering compound with maximum absorbance at 2 1 0 nm 
(Figure 2.4).
Although previous work on monochlorotaurine has shown it to be stable under 
aqueous conditions, it was found not to be stable in this work, and hence not suitable 
as a derivatisation reagent for taurine. The derivative was found to be even more 
unstable in the presence o f salts, buffers or solvents such as acetonitrile. Hence, even if 
the destabilising factor(s) could have been identified for the aqueous samples, there 
would have been further problems when the assay was attempted in plasma, where the 
use of salts, buffers and solvents would have been unavoidable.
It is postulated that in fact the monochlorotaurine was breaking down to give 
dichlorotaurine, even under non-acidic conditions (pH > 6.5). It was thought that two 
monochlorotaurine molecules were dismutating to give one dichlorotaurine and one 
original taurine molecule, or that the monochlorotaurine could be breaking down by 
deamination, decarboxylation and dechlorination to give its respective aldehyde, as this 
reaction is known to occur spontaneously for the unstable a-amino acid 
monochloroamines57. Thus, under the conditions o f this experiment, the 
monochloramine was unfortunately not as stable as expected.
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Figure 2.4 : Spectra of Monochlorotaurine Derivative taken over 24 hours
When this reagent had been employed previously for quantitation of taurine, 
the matrix was less complex and cleaner than plasma i.e. neutrophils. In neutrophils, 
the levels o f taurine are 22mM (2.75 nig/ml), which is a 1000-fold greater than the 
levels expected in platelet-free plasma of 10 - 100 nM (1.25 - 12.5 ng/ml)10. Hence, 
degradation of the derivative may not have been as noticeable in the neutrophil 
experiments.
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2.4 FLUORESCAMINE DERIVATISATION OF TAURINE
2.4.1 EXPERIMENTAL
2.4.1.1 Blood Collection
This was carried out in the same way as described in section 23.1.1.
2.4.1.2 Preparation of Reagents for Fluorescamine Derivatisation
For the fluorescamine derivatisation reaction, standard fluorescamine solutions were 
prepared in acetonitrile and kept at room temperature. Borate buffer was prepared by 
adjusting lOOmM disodium tetraborate solution to pH 9.2 with lOOmM boric acid. 
Fresh 15mM phosphate buffer was made weekly by dissolving potassium dihydrogen 
phosphate in water and adjusting to pH 3.5 with phosphoric acid.
2.4.1.3 Procedure for Fluorescamine Derivatisation
The derivatisation reaction is shown in Figure 2.5. The reaction mixture was adjusted 
to pH 9, the optimum pH for the reaction to take place. For preparation o f spiked 
samples, 5^ 1 o f taurine standard solution was added to 95 jji o f water or plasma to give 
standards with 0, 5, 10, 20 and 30 ng/ml added taurine. Again the standards were 
prepared in a range that was expected to be suitable for the analysis o f samples. Each 
sample ( 100 1^) was treated with 150^1 o f acetonitrile, vortex mixed and centrifuged for 
10 min. @ 5800#. The supernatant was added to 50 1^ o f borate buffer (lOOmM, pH
9.2) to adjust the pH to 9. Then 50(J of fluorescamine in acetonitrile (5mM) was 
added and the solution was immediately vortexed. Rapid addition and mixing was 
required for optimal results, as although the taurine derivative is formed almost 
instantaneously at room temperature, fluorescamine begins to break down in water 
within a few seconds. Samples were usually analysed on the HPLC system within 6 
hours.
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Figure 2.5 : Derivatisation of Taurine by Fluorescamine
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2.4.1.4 HPLC Conditions for Fluorescamine Derivative
The flow rate o f the eluent was lml/min; the system pressure was approximately 1100 
p.s.i. and all measurements were made at ambient temperature. UV detection was 
carried out at 385nm, the maximum absorbance wavelength for the taurine derivative 
(Fig. 2.6). The mobile phase eluent finally consisted o f tetrahydrofuran, acetonitrile 
and phosphate buffer (pH 3.5) in the proportions 4:24:72, v/v/v. After mixing, the 
mobile phase was filtered under vacuum through a 0.45nm Millipore filter and 
sonicated for 20 minutes. Under these HPLC conditions, the peak for the derivative 
eluted at 9.0± 0.3 min.
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Fig. 2.6 : UV Absorbance Spectrum of Taurine-FIuorescamine Derivative
2.4.2 RESULTS AND DISCUSSION
2.4.2.1 Optimisation of Blood Collection Procedure
This was previously discussed in section 2.3.2.1.
2.4.2.2 Optimisation of Sample Preparation Procedure
Although this was previously discussed in section 2.3.2 .2, some further investigations 
were carried out using SPE. Aqueous taurine was applied directly to the cartridge, 
eluted with solution A (acetonitrile-phosphate buffer (pH 2.5) 30:70 v/v), and 
subsequently derivatised with fluorescamine, which yielded a recovery o f 57-58%. 
When borate buffer pH 9.2 was used instead o f solution A  a recovery o f 56% was 
obtained. Recovery was raised to 71% when the eluting solution was comprised of 
acetonitrile-water, 35:65, v/v.
When taurine was derivatised wuh fiuorescamine prior to being applied to the 
cartridges and eluted with a volume o f 1.2 ml o f solution A  recovery was 53-57%.
114
3.000 
2.000 
1.000 
0
.0
0
0
With plasma samples, however, the above results could not be reproduced and 
recoveries were spurious.
2.4.2.3 Optimisation of Fluorescamine Derivatisation Procedure
The pH of the reaction between fluorescamine and primary amines must be > 8.5, and 
is optimum at pH 9 for amino acids. Fluorescamine was dissolved in acetonitrile 
because o f its compatibility with the deproteinised supernatant and its suitability as a 
non-hydroxylic but water-miscible solvent. Such a solution o f fluorescamine is stable 
for 12 weeks65. Immediate mixing was essential for maximum response because the 
reagent itself breaks down (by hydrolysis) in a matter o f seconds.
2.4.2.4 Development of HPLC Conditions for Fluorescamine Reaction
As a starting point, the mobile phase used in the work of Sakai et al. was tried i.e. 
23% acetonitrile in acidic 15mM phosphate buffer54. However, initial HPLC 
experiments with the taurine fluorescamine derivative in aqueous solution, using this 
mobile phase, resulted in very late elution o f the taurine peak. The acetonitrile content 
was therefore increased and the mobile phase was initially optimised with a 
composition o f acetonitrile:phosphate buffer (pH 2.5, 15mM) [35:65], While this gave 
good chromatography for aqueous standards, in plasma samples taurine was found to 
co-elute with other components. Methanol was used as an organic modifier at varying 
ratios instead o f acetonitrile to try to resolve the taurine derivatives from other closely- 
eluting peaks, but with little success. However, the use o f tetrahydrofuran altered the 
selectivity in a way that improved the resolution between taurine and other 
endogenous compounds. Only a small percentage was required and mobile phases 
containing 3, 3.5, 4 and 5% tetrahydrofuran were investigated. The optimal 
composition was tetrahydrofiiran:acetonitrile:phosphate buffer (15mM) [4:24:72].
A variety of pH's were examined - 1.6, 2.5, 2.8, 3.5 and 4.0, and at pH 3.5, 
taurine was adequately separated from other closely-eluting amino acid derivatives 
such as alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, 
serine, threonine and valine. Sakai et al. found that acidic conditions were required to 
separate the taurine fluorescamine derivative from other derivatives54. In fact, after 
trying three mobile phases o f different pH (2.7, 2.1 and 1.9), only the most acidic 
eluent allowed the derivatives to be resolved under their assay conditions.
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A number of absorbance wavelengths were investigated before it was found 
that 385nm was optimal (Figure 2.6). The concentrations and volumes o f the 
acetonitrile (for protein precipitation), borate buffer (for pH control during 
derivatisation) and sample (or standard) were modified a number of times before the 
optimum conditions for the analysis were identified.
2.4.2.5 Calibration and Calculation
The spiked samples o f PPP were quantified by external standardisation. The slope and 
intercept o f the calibration graphs were determined by unweighted linear regression of 
the taurine peak height versus the concentration of taurine added.
2.4.2.6 Precision
Precision was defined in terms of the variability between batches (reproducibility) and 
within batches (repeatability). Reproducibility was assessed in four replicate runs on 
four consecutive days, covering the concentration range 0-30 fxg/ml. Repeatability was 
assessed by running, in quadruplicate, standards at each concentration level in one day 
of the validation study in the same concentration range. The precision o f the method 
was described by the mean relative standard deviation (RSD), and this was found for 
taurine when the peak heights were interpolated as unknowns on the regression lines. 
For reproducibility, the interpolations were based on the four regression lines 
generated from the four replicate runs and for repeatability, the interpolations were 
based on a single regression line generated from the quadruplicate run. Because human 
plasma contains a basal level o f taurine, platelet-poor unspiked plasma shows a small 
peak in the chromatogram that corresponds to taurine. An unspiked platelet-poor 
sample was run with each calibration curve and the height o f the taurine peak was 
subtracted from the taurine peak in each o f the spiked samples. Precision data, 
calculated on the basis o f the subtracted results, are presented in Table 2.6, and they 
demonstrate that the reproducibility (mean RSD = 3.87%) and repeatability (mean 
RSD = 5.56%) o f the methods are within accepted values for clinical analyses. These 
results were compared with data from unsubtracted values (i.e. where the peak in the 
blank sample was not subtracted from the spiked standards) and it was found that the 
mean precision values were higher (4.08% and 6.75% for reproducibility and 
repeatability, respectively) and there was greater variability in precision amongst 
individual values.
2.4.2.7 Linearity and Accuracy
The correlation coefficient o f the regression line for the mean intra-assay values was 
0.9998 (subtracted data) and 0.9985 (unsubtracted data) for taurine. Accuracy 
(presented in Table 2.6), as defined as the percentage difference between the amount 
added and the amount found by back calculation, was usually less than 5% with mean 
values o f 4.38% and 2.75% for intra-day and inter-day analyses, respectively.
Table 2.6 : Precision and Accuracy Data
Inter-assay (reproducibility)
Amount added 
(fig/ml), n=4
Mean Amount 
found (ng/ml)
RSD (%) Accuracy(%)
5 4.82 ±0.26 5.33 3.56
10 10.22 ±0.58 5.69 2.21
2 0 20.00 ±0.69 3.43 0.02
30 29.95 ±0.31 1.05 0,15
y = 347.74 (±19.85)x - 179.11(±125.78) r = 0.9995 ± 0.0002
Intra-assay (repeatability)
Amount added Mean Amount RSD (%) Accuracy(%)
(jig/ml), n=4 found Gig/ml)
5(n=3) 4.56 ±0.41 9.01 8.87
10 10.30 ±0 .66 6.38 3.03
2 0 20.50 ±0.59 2.90 2.50
30 29.63 ± 1.17 3.95 1.21
y = 350.28x- 192.77 r = 0.9998
2.4.2.8 Recovery
Recovery may be calculated in absolute or relative terms. In the calculation o f absolute 
recovery, peak response of an extracted standard is compared with that o f unextracted 
standards that are prepared to the same theoretical concentration as the extracts.
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Relative recovery is calculated by comparing peak responses o f extracted matrix 
standards against those o f extracted aqueous standards. This procedure was used to 
account for the presence of acetonitrile in the sample to be injected. Using this 
method, the relative recovery of taurine from plasma was found to be 89.7%.
2.4.2.9 Limits of Detection and Quantitation
The limit o f quantitation was found to be 5ng/ml taurine in plasma samples. The limit 
of detection was found to be 1 ng/ml taurine in plasma samples.
2.4.2.10 Selectivity
A number o f amino acids are present in both platelet-poor and platelet-rich plasma and 
the ten amino acids thought most likely to interfere were subjected to the same 
extraction and separation conditions. Alanine, glutamine, threonine and valine were 
chosen because it can be seen from Table 2.1 that they are the amino acids with the 
highest concentration in human plasma. Proline (although o f high concentration) does 
not derivatise with fluorescamine because it is a secondary amine. Some o f the other 
amino acids with typically high concentrations in human plasma are arginine, glutamic 
acid, glycine and serine, so these too were investigated (Table 2.1). Asparagine and 
aspartic acid were subjected to derivatisation and HPLC analysis because other 
authors have investigated the presence o f one or both of these amino acids in the 
plasma o f humans, even though their concentrations in plasma tend to be low38,47’50. 
Hypotaurine, homotaurine and phosphoserine were not included in these experiments 
because it has been reported that these substances are not present in human plasma by 
Hirschberger et al.36, Eslami et a /.38 and Tachiki et al.24. By adjustment o f the mobile 
phase pH and aqueous-to-organic ratio, it was possible to resolve these compounds 
from the taurine peak. In fact, it is expected that the method described could be 
applied to the simultaneous determination o f taurine and other amino acids.
2.4.2.11 Stability
Stability o f the taurine fluorophor was assessed in aqueous solution initially. Three 
concentrations o f taurine (1, 10 and 50 ng/ml) were derivatised using the standard 
protocol i.e. 100^1 sample mixed with 150|j.l acetonitrile, 50fj.l lOOmM borate buffer 
and 50^1 5mM fluorescamine solution in acetonitrile. The final mixtures were injected 
onto the HPLC and the peak heights obtained. The samples were also run 60 hours
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later. The results are shown below in Table 2.7. This agrees with work carried out by 
Guzman et al. when they used fluorescamine as a derivatising agent for the 
determination o f amino acids and peptides by CE using UV detection66. They found 
the fluorescamine derivative of arginine to increase its UV response (by about 5%) 
when kept at ambient temperature for a period o f 24 hours. As can be seen from Table 
2.7, a small increase in absorbance can be seen to occur over time for the lower 
concentrations. However, when one considers that this small effect is over a time 
frame o f 2.5 days, the derivative can be considered to be relatively stable.
Table 2.7 : Stability Data for Aqueous Taurine Fluorescamine Derivative
Concentration (|ig/ml) Peak height within 1 hour Peak height after 60 hours
1 1051 1165 (111%)
10 9227 8805 (95%)
50 43411 43744 (101%)
When a 5^g/ml sample o f taurine in plasma was derivatised and left for 24 hours at 
room temperature, the absorbance was found to increase by 10%. In order to minimise 
any small changes in absorbance due to further reaction over time, all samples 
derivatised using fluorescamine were analysed by HPLC within 6 hours o f preparation.
2.4.2.12 Quantitative Determination of Taurine in Volunteer Samples
Table 2.3 highlights some o f the difficulties in taurine analysis in plasma, when the 
range of concentrations under seemingly similar experimental conditions are 
compared. It is obvious from Table 2.1 that the normal range o f concentration of 
taurine in plasma is quite wide. A more accurate ‘normal’ taurine concentration range 
in PPP can be obtained by averaging the specific taurine levels obtained in publications 
where the aim of the work was to determine taurine, and where the plasma was 
centrifuged to such an extent that most o f the platelets would have been eliminated. 
This yields a range 3.4 -  7.3 M-g/ml based on the PPP concentrations found in five 
different reports (references 24,40,67,68 and 69). A more accurate ‘normal’ taurine 
concentration range in PRP can be obtained by averaging the specific taurine levels 
obtained in publications where the plasma was very gently centrifuged such that most 
of the platelets will have remained in the plasma. This yields a range 7.7 -  19.1 ng/ml 
based on the concentrations from two different reports (references 24 and 40). Hence,
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looking at the results in Table 2.3 in light o f these ‘normal’ ranges for taurine 
concentration, it is probable that the plasma in the work of Eslami et al,38 is PRP, 
while the plasmas in the work o f Hirschberger et al,36 and Stocchi et a/.41 are likely to 
be PPP.
Samples o f PRP from three different sources were determined in this project by 
interpolation of the peak heights on a calibration curve (0-30 ng/ml). Results from the 
individual in Fig. 2.7 gave a value o f 15.0 ng/ml in PRP, while values from two pooled 
PRP samples were calculated to be 16.4 and 18.5ng/ml. All three results are within the 
expected range calculated above for PRP. It can be seen in Figure 2.7 that taurine is 
indeed at a higher concentration in PRP compared to PPP from the same volunteer.
Figure 2.7 : HPLC Chromatograms showing PPP and PRP from a Volunteer
Column : Bondclone C18,10pm (300 x 3.9 mm i.d.). Mobile phase THFrACN: Phosphate buffer 
(15mM, pH 3.5) [4:24:72]. Sample preparation as described in text
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2.5 CONCLUSIONS
Hypochlorite was investigated as a reagent for the pre-column derivatisation o f taurine 
prior to HPLC analysis o f the derivative. Although it had previously been used 
successfully for the quantitation o f taurine in neutrophils, it was found to be unsuitable 
for the quantitation o f taurine in this project. The successfully formed monochlorinated 
taurine derivative was unstable, breaking down to give what was thought to be the 
dichlorinated taurine derivative.
Fluorescamine was investigated and was found to be a useful reagent for the 
pre-column derivatisation o f taurine allowing the estimation o f taurine levels in 
platelet-rich plasma. Other analyses have difficult and labour-intensive sample 
preparation and some involve derivatisation procedures that require quenching and/or 
the presence o f co-solvents in order for the reaction to take place. Many are prone to 
interference from the derivatising agent itself and there are discrepancies in the stability 
of derivatives.
The method presented here, for the determination o f taurine in platelet-rich 
plasma, is simple, rapid and efficient, and a result is obtainable within one hour of  
taking blood from a patient. With the ever-increasing need for the quantitation o f  
taurine in human plasma for medical purposes, the simplicity o f this assay will be of 
benefit to clinical research. It could also aid in further elucidation of the complex 
biochemical roles and beneficial effects that taurine has in the human body.
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Chapter 3
Evaluation of Aspirin Derivatives as 
Prodrugs for Aspirin and Determination of 
Aspirin and Salicylic Acid in Transdermal
Perfusates
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3.1 INTRODUCTION
3.1.1 Historical Background
Acetylsalicylic acid (ASA), more commonly known as aspirin, is the commercially 
synthesized form of a naturally occurring compound called salicin, which is found in 
the bark of the willow tree. It was discovered about 200 B.C. by the Greek physician 
Hippocrates when he found that chewing on willow bark could relieve pain and fever. 
He gave it to women to ease their labour pains. It was not until 1897 that the ASA 
molecule was chemically synthesised (Figure 3.1). This was achieved by Felix 
Hoffmann, a chemist who had been seeking a pain-relieving medication for his 
father’s debilitating rheumatism. Not only did the drug powder ease his father’s pain 
and inflammation, but when it was marketed as ‘aspirin’ by Bayer two years later, it 
quickly became the world’s most popular pain reliever.
Figure 3.1 : Aspirin Molecule
In 1900, Bayer® aspirin was the first drug ever to be marketed in tablet form. During 
its first decade, ASA was found by physicians worldwide to be so effective as a 
medicine, it became popularly used for a range of ailments from headaches, fever, 
inflammation, pleurisy and tonsillitis to tuberculosis, gonorrhea and gout. Affordable 
for practically everyone, ASA quickly became a household necessity for safe and 
effective pain relief. Tens of thousands of people took ASA during several major 
influenza epidemics in the early 2 0th century.
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3.1.2 Pharmacological Background
Although ASA was a proven pain reliever, no one really knew how it worked until 
more than 70 years after Hoffmann’s discovery. In 1971, British pharmacologist John 
Vane discovered that the anti-inflammatory properties o f ASA result from its ability 
to inhibit the enzyme that produces prostaglandins which promote inflammation and 
therefore cause pain. Vane received the Nobel Prize for Medicine in 1982 for this 
medical research breakthrough1,2,3. More recent research has shown that the enzyme 
involved -  cyclooxygenase -  contains a very small tunnel into which arachidonate 
(the precursor) must go to be converted into prostaglandin4. ASA attaches its acetyl 
group inside the tunnel, where it acts like a gate, blocking the arachidonate from 
entering the ‘active site’ o f the enzyme.
3.1.3 Biological Background
Today, ASA is the most widely used oral medication in the world. In America alone, 
80 billion ASA tablets are taken each year5. It cures our headaches, reduces fever and 
alleviates muscle pain and inflammation. However, according to Bayer, the uses of 
ASA are for prevention o f heart disease (37.6%), arthritis (23.3%), headache (13.8%), 
body ache (12.2%) and other pain uses (13.1%). As can be seen from these statistics, 
the use o f ASA in cardiovascular disease is its most important medical application 
and this is discussed in more detail in section 3.1.4. However, ASA also has important 
potential in other medical conditions. Some researchers have reported that ASA may 
reduce the risk o f many common cancers e.g. colon and colorectal cancer6,7, 
oesophageal and stomach cancer8 and ovarian cancer9. Research is also ongoing to 
explore possible links between ASA and prevention o f other diseases including 
diabetes10,11,12, migraine headaches13,14,15 and Alzheimer’s disease16,17. The use of
ASA, in conjunction with heparin, has recently been shown to dramatically increase
* ■ 18the number of live births in pregnant women suffering from recurrent miscarriages .
The National Library o f Medicine in the US has logged more than 23,000 
scientific papers on ASA. Experts say yearly ASA consumption could rise even 
higher in its second century as researchers uncover new applications. "Aspirin now 
has a whole host o f  possibilities that were never envisioned," says Charles 
Hennekens, chief o f the Physicians Health Study, one o f the ongoing research projects 
that has examined ASA use closely. Unlike other pain relievers, many of which have
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been getting poor publicity due to their side-effects e.g. acetaminophen, ASA’s 
benefits continue to significantly outweigh any risks.
3.1.4 Aspirin and the Heart
Nearly five decades o f research now link ASA to the prevention of stroke and heart 
attacks. This is ironic when one considers Bayer advertisements from the 1920s where 
the slogan “aspirin does not affect the heart” was used to show how safe ASA was as 
a drug (Figure 3.2). Nowadays, ASA is used to save lives because o f its effect on the 
heart.
Figure 3.2 : Bayer Advertisement for Aspirin in the 1920s
No, 390 348 Lines
SAY “BAYER ASPIRIN”-
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In the UK, about 25,000 people die each year from acute myocardial 
infarction, other heart disease or stroke, events that are largely due to platelet 
activation and thrombosis19. In the United States, the number o f deaths due to these 
events is 900,OOO20 annually. Because aspirin (ASA) inhibits platelet aggregation in
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blood by blocking cyclooxygenase activity21’22, much research has focussed on the use 
o f ASA to protect the heart against cardiovascular disease, especially in ‘high risk’ 
groups20. Many clinical trials and collaborative studies have been undertaken in order 
to better understand the beneficial effects of taking ASA, the optimum doses o f ASA 
to administer and the possible side-effects o f such a regime.
The first experiment to examine the protective effect o f aspirin on the heart 
was conducted in 1948 by Dr. Lawrence Craven, a general practitioner from 
California. He noticed that aspirin increased bleeding in tonsillectomy patients, 
suggesting possible anti-clotting properties. At his suggestion, 400 o f his male 
patients took aspirin for two years and not one of them had a heart attack. By 1956, 
Dr. Craven reported that among 8,000 men who faithfully took one or two aspirin 
tablets daily, not one experienced a heart attack. Craven could only publicize his 
reports through interviews with the Los Angeles Times, because most medical 
journals refused to publish his findings.
Since then, there have been many trials carried out to investigate both primary 
and secondary prevention o f cardiovascular disease. The main clinical trial 
investigating ASA’s primary prevention of heart attack was The Physicians' Health 
Study who published their findings in 198923. This study had focused on 22,000 
healthy American male physicians aged 50 and older, who took either 325mg of ASA  
or a placebo. Regular aspirin administration reduced the incidence of heart attack by 
44%. The study only lasted for four versus its intended eight years in an effort to 
allow those taking the placebo to switch to aspirin therapy given its significant 
positive impact on heart attack prevention. After the trial, 99% of doctors on the 
aspirin regimen stated that they wished to continue taking the drug.
Some o f the main studies that have demonstrated the secondary benefits o f  
taking ASA include : The UK Transient Ischaemic Attack (UK-TIA)24 Aspirin Trial, 
The Dutch TIA Trial Study Group25, The 1994 Antiplatelet Trialists’ Collaboration26 
and The International Stroke Trial (1ST)27. In the UK-TIA Trial, two ASA doses were 
investigated (1200mg and 300mg) in the prevention o f major stroke, myocardial 
infarction (MI) or vascular death in patients with previous TIA24. Both doses reduced 
the incidence o f these events to a similar extent (15%). The incidence of  
gastrointestinal side effects was significantly lower in those patients receiving the 
lower dose of aspirin. The Dutch TIA Trial investigated lower doses o f ASA (30 mg 
and 283 mg) in patients after TIA or minor stroke with a view to preventing
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subsequent nonfatal stroke, nonfatal MI or death from vascular causes . The results 
showed that the reduction o f these events was similar in both low and medium dose 
groups (14.7% versus 15.2%). Minor bleeding complications and gastric discomfort 
occurred less often with the lower doses o f aspirin (30mg). The 1994 Antiplatelet 
Trialists’ Collaboration analysed results o f randomised trials o f  antiplatelet therapy 
among more than 54,000 high risk patients with prior evidence o f cardiovascular 
disease26. ASA therapy was found to reduce the risk of subsequent vascular events by 
one quarter. The largest ever trial carried out on acute stroke was the 1ST which 
reported its findings in 1997. 1ST examined the early use o f ASA, heparin or both 
following ischaemic stroke27. The absolute number o f recurrent ischeamic strokes 
within 14 days dropped by 1.1% and the combined endpoint o f death or non-fatal 
recurrent stroke was also reduced by 1.1%.
Intervention therapy has been reported by The Second International Study of 
Infarct Survival (ISIS-2) in 198 828. The results o f the study showed that in patients 
who took one-half tablet (162.5mg) o f ASA no later than 24 hours after the onset o f a 
heart attack, and for one month thereafter, there was a reduction in the risk o f death 
from a heart attack by 23%. The combination o f ASA and streptokinase (a clot- 
dissolving drug) reduced mortality from heart attack or stroke by up to 50 percent.
In the US alone, it is estimated that as many as 10,000 additional lives could 
be saved annually by broader use o f ASA in appropriate people who are at risk of 
heart attack and stroke29. Many of the USA’s 1.25 million heart attacks each year5 
could thus be prevented, providing additional years o f healthy, productive living. If 
ASA was regularly used after a transient ischaemic attack (TIA) or minor stroke, 
thousands of strokes could also be prevented. Overall, the potential cost savings for 
health care systems and economy are enormous, with a simple regimen of ASA likely 
to reduce lost work time and hospital-related costs. Worldwide, experts believe that as 
many as 100,000 deaths could be prevented each year through the regular use o f low- 
dose ASA in people at high risk of vascular disease.
3.1.5 The Skin as a Novel Route for Aspirin Delivery
As discussed in the previous sections, there is strong evidence to support the fact that 
a regime o f long term, low-dose ASA can reduce the occurrence, the reoccurrence and 
risk o f death from cardiovascular and cerebrovascular eventS’24’25’26’27’28’30’31’32’33 a  
typical daily dose of ASA for prevention o f heart disease would be 75mg (although
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doses that range from 30 -  325mg are prescribed). ASA is usually given orally but 
there are some problems associated with this route o f administration such as gastro­
intestinal bleeding and peptic ulceration25,34,35. Hence, the transdermal route has been 
investigated for continuous low-dose ASA administration.
The delivery o f compounds across the skin is not a new concept. There are
• 36 37 38established transdermal patches for drugs such as nicotine ’ ’ and hormones such as 
oestrodiol39,40, to name but a few. This means o f delivering a drug can allow many o f 
the problems o f oral absorption to be overcome. Since the stomach and intestine are 
essentially bypassed with transdermal therapy, pH changes, food intake and intestinal 
transit time are no longer important considerations. The constant and controlled 
delivery o f the drug eliminates pulse entry into the circulation, a phenomenon 
associated with its own side effects. Another advantage o f the topical approach is that 
in the event o f any allergic reaction, absorption o f the medication can be immediately 
terminated by simple removal o f the patch. This non-invasive therapy can also 
improve patient comfort and compliance, especially where a drug is to be taken long 
term i.e. decades.
Figure 3.3 : Diagram of a Cross-Section of the Skin
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The skin is the largest organ o f the human body, covering an area o f 
approximately 15-20 square feet and weighing several kilograms. Our skin protects us 
against becoming dehydrated and prevents us from being poisoned with toxic 
compounds from the environment. The skin is a very complex structure (see Figure
3.3) comprising of two main tissue layers, the epidermis (40-150|xm) and the dermis 
(2-5mm). The outermost layer o f the epidermis is the stratum comeum (SC), which is 
approximately 17^im thick in human skin41, and is considered to be essentially 
impermeable since it behaves like a passive diffusion barrier with no evidence o f 
metabolic transport processes. The SC consists o f approximately 40% proteins, 40% 
water and 20% lipids and a schematic diagram o f it is shown in Figure 3.4.
Figure 3.4 : A Diagrammatic Representation of the Stratum Corneum
Intracellular (protein) route 
for polar drugs
Intercellular (lipid) route 
for non-polar drugs
The biopharmaceutics o f topical preparations are very complex because of the 
many physiochemical principles involved in penetrating the SC. O f the many factors 
that can enhance or impede drug penetration through the SC, the most important are 
drug concentration (C) and drug partition coefficient (P), measured between skin and 
vehicle. P is more commonly expressed as log P, which can be approximated by 
experimentally determining the distribution o f a compound between oil and water. 
Substances that are very polar will have low values o f log P and hence poor 
permeation through skin, since the main pathway o f transport for water-soluble 
molecules is transcellular i.e. through cells, proteins and cell walls, which is difficult 
(see Figure 3 .4). Hence, the more non-polar drugs can penetrate the skin more readily
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since they have higher log P values and can travel intercellularly i.e. between the cells 
and proteins, which is less difficult.
Penetration of compounds through the skin can be predicted using a form of 
Fick’s law. The penetration flux (J, mol m'2 s '1) o f a low molecular weight, non­
electrolyte drug is directly proportional to C and P as shown below :
A 1
D = diffusion coefficient o f drug (m s' )
5 = thickness o f stratum comeum (m)
AC = difference in drug concentration between 
skin and vehicle (mol m'3)
The value o f D is determined by factors such as size, shape and charge of the 
molecule. The ideal drug for transdermal delivery should also be small (< 1000 Da) 
with a short biological half-life42. A parabolic relationship between log P and 
percentage absorption into skin for a series o f salicylates and other non-steroidal anti­
inflammatory drugs applied topically has been reported, with the optimum log P 
found to be 2.443. Log P values for homologous series o f compounds can also be 
correlated with their retention on a HPLC column.
The vehicle in which the drug is applied to the skin strongly influences the rate 
and extent o f absorption. There are a number o f types o f formulations used : aqueous 
lotions, ointments and aqueous creams are just a few. Some vehicles leave a greasy, 
occluding film on the skin which hydrates the surface o f the skin (occluded skin may 
absorb up to 5-6 times its dry weight o f water). These occlusive films can increase 
penetration o f low molecular weight species 2-5 fold44. I f  the vehicle is changed so 
that the drug is less soluble in it, P will increase and hence penetration will increase 
too. To aid dissolution o f the drug in the formulation, solubilisers or enhancers such 
as ethanol are often used. These also allow a higher concentration of drug to be 
applied to the skin at one time. There is a compromise between using a vehicle that is 
a good solvent for the drug, which allows a high concentration to be applied to the 
skin, which increases penetration flux, and a vehicle which is not a good solvent for 
the drug which promotes transfer o f the drug from the formulation to the skin, thereby 
increasing penetration flux. The optimum is often found at the level where the drug is 
ju s t dissolved in the vehicle.
J = PD . AC 
8
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The skin has previously been investigated as a route for continuous low-dose 
aspirin administration. ASA itself is a polar molecule and at first sight is not an 
attractive molecule for transdermal delivery. However, only 30-40mg/day ASA is 
required for >90% inhibition o f platelet cyclooxygenase45. Delivery o f small amounts 
o f ASA continuously is a more effective way o f inactivating cyclooxygenase46. ASA 
does cross the skin but in doing so, it is rapidly hydrolysed to its principal metabolite 
salicylic acid (SAL) during transport as seen in Figure 3.5. When the transdermal 
absorption o f a range o f drugs was examined by Beckett et al. in 1972, it was found 
that over a period o f 120 hours, only 22% of ASA was absorbed and 23% o f SAL was 
absorbed47. However, a more recent study showed that ASA applied to the skin 
surface in ethanol and propylene glycol selectively inhibited cyclooxygenase in 
platelets48. This work showed that even at a low rate o f transport, pharmacological 
effects are seen. Unfortunately, skin reactions were noted in 50% of the subjects at the 
750mg/day dose and this was thought to be due to the presence o f SAL on the skin 
surface, a known irritant. In 1996, Me Adam et al.49 reported that ASA in a 
transdermal patch, at a lower dose, was also found to induce marked suppression o f 
platelet cyclooxygenase in spite o f the fact that the bioavailability o f  ASA was again 
calculated to be low (only 20%). This was further evidence for the fact that the 
therapeutic effects o f ASA are present at very low doses.
Figure 3.5 : Hydrolysis of ASA to SAL
Aspirin (ASA) Salicylic Acid (SAL)
It was suggested by McAdam et al.49 in the conclusion o f their report on the 
transdermal patch that “it may be possible to improve the delivery o f aspirin through 
the skin using stable analogues o f aspirin.” Many researchers over the past two
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decades have prepared and evaluated prodrugs o f ASA with a view to improving the 
delivery o f  ASA across the skin50. Central to the prodrug design is in vivo 
reconversion to ASA. For ASA, most prodrug design has centred on masking the 
ionisable carboxylic group (which slows down its transdermal delivery). Hence, the 
ASA derivatives formed are more non-polar than ASA, aiding their transdermal 
permeability, and once in the top layers o f skin, they are hydrolysed to yield ASA.
3.1.6 Analytical Background
While much HPLC methodology has been reported in the literature which can 
determine ASA and SAL simultaneously, most o f the examples refer to analysis in 
biological fluids (such as plasma and whole blood)51’52’53, food54’55 or tablet 
formulations56’57. Many o f the reported methods involve protein precipitation and/or 
solvent extraction. However, this study required the development o f a number of 
HPLC methods, requiring analysis o f  ASA and SAL in different matrices, for 
different reasons in different experiments.
The aim of this study was to examine a number o f possible prodrugs for ASA. 
The compounds investigated in this study were to be derivatives o f ASA which were 
predicted to release the more polar ASA by their hydrolysis on or within the skin. The 
role o f the prodrug for ASA is to a) break down on or in the skin to give ASA, b) to 
do this at a continuous rate (after the lag time has passed) and c) not to pass into the 
systemic circulation itself. By doing this, small amounts o f ASA should be 
continually arriving into the circulation, thus achieving the desired pharmacological 
effect. Because there is less ASA on the surface o f the skin, however, there should be 
less SAL produced on the surface and this would serve to reduce or even eliminate 
skin reactions. It was also the objectives o f this work to develop analytical 
methodology that could reliably determine the concentrations o f ASA and SAL in the 
transdermal perfusates following the application o f the various derivatives to the skin 
surface.
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3.2 REAGENTS AND MATERIALS
3.2.1 Equipment
The high performance liquid chromatograph was equipped with Waters (Millford, 
MA, USA) models 501 single-piston and 510 dual-piston pumps, a Waters Model 486 
tunable absorbance detector, a Waters model 680 gradient controller and a Waters 
model 746 data module. The Rheodyne injection port (Cotati, CA, USA) was fitted 
with a 20(il loop. All experiments were carried out and all measurements were made 
at ambient temperature. The UV-Vis recording spectrophotometer was a UV-2100 
model from Shimadzu (Kyoto, Japan). The Franz cell apparatus for the transdermal 
experiments is described later in the text.
3.2.2 Reagents and Chemicals
Aspirin was supplied by SIGMA Chemical Co. (Dorset, England) and salicylic acid 
by BDH (Poole, England). ASA and the aspirin derivatives were prepared in-house 
and the protocols for their synthesis are given in Appendix A. The structures and full 
names o f the derivatives (ASA-Gly, ASA-Ala, ASA-PheAla, ASA-Phe, ASA-Phe- 
N 0 2, Dimer and ASA-Iso) are shown in Figure 3.9. Acetonitrile, tetrahydrofuran, 
methanol, diethyl ether and water were HPLC grade and were purchased from 
Labscan (Dublin, Ireland). Toluene was purchased from Romil Ltd. (Cambridge, 
England). Analytical grade orthophosphoric acid (OPA), sodium hydroxide and 
polyethylene glycol (MW 6000) came from BDH (Poole, England). High purity 
ethanol (>99.8%), sulphuric acid (selectipur 96%) and acetic acid (glacial 100%) were 
purchased from Merck (Darmstadt, Germany). Phosphate buffered saline (PBS) 
sachets were obtained from Sigma Diagnostics (St. Louis, MO, USA).
3.2.3 Other Materials
Two different HPLC analytical columns were used in this work : an Alphabond® C l 8 
column (10nm, 300 x 3.9mm) from Alltech (Lancashire, U.K.) and a Nucleosil® C8 
column (5|un, 250 x 4.6mm) from Hichrom (Berkshire, U.K.). Silica gel (F-254) TLC 
plates were purchased from Merck (Darmstadt, Germany).
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3.3 IDENTIFICATION OF AN IMPURITY IN ASPIRIN
3.3.1 EXPERIMENTAL
3.3.1.1 Preparation of Standards for TLC
The stock standard solutions were prepared in acetonitrile. For TLC analysis, the 
stock standard solutions were further diluted in acetonitrile.
3.3.1.2 Preparation of Standards for HPLC
The standard solutions were prepared in acetonitrile to 5mg/ml. For HPLC analysis, 
the stock standard solutions were further diluted in the mobile phase.
3.3.1.3 Preparation of Samples for TLC
All samples were dissolved in acetonitrile or tetrahydrofuran as appropriate.
3.3.1.4 Preparation of Samples for HPLC
All samples were prepared in mobile phase prior to injection.
3.3.1.5 TLC Conditions
The eluent was a mixture o f toluene-ether-acetic acid-methanol [120:60:18:1, 
v/v/v/v]. The TLC chamber was equilibrated for at least one hour with eluent before 
the plates were inserted. Unless otherwise stated, IOjJ  o f sample or standard was 
applied to the plate using a micropipette.
3.3.1.6 HPLC (Method 1) Conditions
The final HPLC conditions for this work were as follows: Alphabond® Cl 8 analytical 
column, mobile phase o f tetrahydrofuran-water-acetic acid [30:70:0.05, v/v/v, pH 
3.5*], flow rate o f lml/min, UV detection at 225nm. The injection volume was 20^1. 
The choice o f C18 column and the pH o f the mobile phase was based on the fact that 
almost all previous HPLC methods for the analysis o f ASA and/or SAL employed this 
type o f column and acidic working pH (2-3).
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3.3.2 RESULTS AND DISCUSSION
3.3.2.1 Development of HPLC Conditions for Method 1
A number o f eluents were investigated, using an Alphabond® C l8 analytical column 
(lOjim, 300 x 3.9mm) and a UV detection wavelength o f 230nm. At a flow rate of 
0.8ml/min, various combinations o f acetonitrile or tetrahydrofuran and water with 
acetic acid or phosphate buffer were equilibrated on the HPLC system and standard 
solutions o f ASA and SAL were injected. The mobile phase was maintained at an 
acidic pH (2.0 to 3.5) and this was achieved using acetic acid. Although ASA and 
SAL are weak acids with pKa values o f 3.5 and 3.058, respectively, their peak shapes 
were unaffected by having the pH at or close to these values, where the molecules 
would be ionised to some extent (by 50% at the pKa). It was found that ASA and SAL 
were not well resolved on the Alphabond® column when acetonitrile was the organic 
modifier used in the eluent, so tetrahydrofuran was used instead. Under the final 
conditions o f HPLC method 1, the retention times for ASA, SAL and dimer were 
6.4+0.1, 10.8+0.2 and 24.0+0.5 min., respectively. A typical example o f a 
chromatogram is shown in Figure 3.6.
3.3.2.2 Identification of the Impurity in ASA by TLC
The ASA was prepared in-house from salicylic acid and acetic anhydride. Some 
problems arose with regard to the purity o f this ASA, whereupon a number o f 
analytical procedures were carried out in order to ascertain the identity and quantity of 
the impurity. Hydrolysis o f ASA with sodium hydroxide and subsequent titration of 
the excess NaOH with sulphuric acid showed the in-house ASA to be 90% pure with 
respect to Sigma ASA. Samples for TLC were dissolved in acetonitrile to minimise 
any on-plate hydrolysis. The presence o f the impurity could be clearly seen in the 
ASA samples which were investigated by TLC, especially when compared to Sigma 
ASA (see Figure 3.7). This impurity was identified as being the dimer o f ASA 
(aspirin anhydride), the structure o f which is shown in Figure 3.9. This impurity 
hydrolyses to release ASA and SAL, and this can be seen to occur on the TLC plate 
shown in Figure 3.7. Other possible impurities such as acetylsalicylsalicylic acid and 
salicylsalicylic acid were not found to be present.
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Figure 3.6 : Typical Chromatogram using HPLC Method 1
acid
Figure 3.6 : HPLC Method 1 using Alphabond® C18 analytical column, mobile phase of 
tetrahydrofuran-water-acetic acid [30:70:0.05, v/v/v, pH  3.5*]. O ther experimental conditions 
described in te x t The vertical axis measures absorbance in mAU and horizontal axis measures 
time in minutes. This is the case fo r all chromatograms in this chapter.
3.3.2.3 Identification of the Impurity in ASA by HPLC
Further evidence for the identity o f the impurity was obtained when a standard o f the 
aspirin anhydride was found to have the same retention time as the impurity in the in- 
house ASA by HPLC. Figure 3.8 shows two chromatograms : a) Sigma ASA 
(100ng/ml) and b) In-house ASA (100ng/ml). The presence o f the dimer impurity can 
clearly be seen.
142
Figure 3.7 : Identification of Dimer Impurity in ASA by TLC
ASA ASA Dimer SAL ASA ASA Dimer SAL ASA
In-house Sigma In-house Sigma In-house
(500ug) (500ms) (50ng) (50ng) (400(ig) (400^g) (50ng) (50|ig) (400ng)
3.3.3 CONCLUSIONS
It was discovered that the dimer impurity found in the in-house ASA is a known 
condensation byproduct o f the synthesis o f ASA. Determination o f  this impurity is o f 
great importance since it has been established that allergic reactions can occur with 
ASA and that it is substances like the dimer that are thought to be responsible for 
‘aspirin allergy’. The in-house protocol for the preparation o f ASA was modified so 
as to minimise production o f the aspirin anhydride and subsequent batches of ASA 
were more than 99% pure.
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Figure 3.8 : Chromatograms of Sigma ASA versus ln-house ASA
Figure 3.8 : the two chromatograms are a) Sigma ASA (100ng/ml) and b) in-house ASA 
(lOOng/ml). The presence of the dim er impurity can clearly be seen. HPLC Method 1 was carried 
out using an Alphabond® C18 analytical column and mobile phase of tetrahydrofuran-w ater- 
acetic acid [30:70:0.05, v/v/v, pH 3.5*]. O ther experimental conditions described in te x t The 
vertical axis measures absorbance in mAU and horizontal axis measures time in minutes.
3.4 SCREENING OF DERIVATIVES BY HPLC AND TLC
3.4.1 EXPERIMENTAL
3.4.1.1 Synthesis of Aspirin Derivatives
The following compounds were prepared in-house by derivatising ASA with various 
amino acids and esters : aspirin glycine (ASA-Gly), aspirin alanine (ASA-Ala), 
aspirin phenylalanine (ASA-PheAla), aspirin phenyl ester (ASA-Phe), aspirin 
nitrophenyl ester (ASA-Phe-N02), aspirin anhydride (dimer) and aspirin isosorbide 
ester (ASA-Iso). Their structures are given in Figure 3.9.
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Figure 3.9 : Structures of the Derivatives for Screening
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3.4.1.2 Preparation of Standards for TLC
The stock standard solutions were prepared in tetrahydrofuran. For TLC analysis, the 
working standards were diluted from the stock standard solutions in tetrahydrofuran.
3.4.1.3 Preparation of Standards for HPLC
The stock standard solutions were prepared in acetonitrile. For HPLC analysis, the 
working standard solutions were diluted from the stock standard solutions in mobile 
phase.
3.4.1.4 Preparation of Samples for TLC
Sample solutions o f the derivatives were prepared by dissolving each o f them in 
tetrahydrofuran to a concentration o f 10 or 20mg/ml for TLC analysis.
3.4.1.5 Preparation of Samples for HPLC
For purity assessment, sample solutions were prepared by diluting the stock lOmg/ml 
TLC standard o f derivative in mobile phase, as required, to a concentration of 
100fig/ml for HPLC analysis. Preparation o f the platelet aggregation samples involved 
diluting the extracts in mobile phase. Preparation o f the derivative samples for 
stability in aqueous solution was carried out by dissolving both ASA-Gly and ASA- 
Ala in PBS.
3.4.1.6 TLC Conditions
The TLC chamber was equilibrated for at least one hour with eluent before the plates 
were inserted. Unless otherwise stated, 10|j1 (200(xg) o f sample or standard was 
applied to the plate using a micropipette. The plates were chromatographed in TLC 
eluent (toluene-ether-acetic acid-methanol [120:60:18:1, v/v/v/v]).
3.4.1.7 HPLC (Method 2) Conditions
The final HPLC conditions for this section o f the work were as follows : Alphabond® 
C18 analytical column, mobile phase o f tetrahydrofuran-water-acetic acid 
[25:75:0.05, v/v/v, pH 3.5*], flow rate o f lml/min, UV detection at 225nm. The 
injection volume was 20^1. The reasons for changing the method are explained in 
section 3.4.2.2.
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3.4.2 RESULTS AND DISCUSSION
3.4.2.1 Rationale for Synthesis of the Derivatives
The seven derivatives o f ASA synthesised in this part of the project were prepared 
because they are more non-polar structures than the ASA molecule alone. Also, they 
were predicted to release ASA on hydrolysis o f the derivatising bond (ester or amide). 
Being more non-polar than ASA, the partition coefficient o f the derivative would be 
higher than ASA, hence increasing penetration into the SC barrier layer o f the skin. 
Once in the top layer o f the skin, the derivatives should release ASA into the dermis 
o f the skin and thence into the circulation. However, it was required to investigate the 
suitability o f the prepared derivatives from two perspectives a) in terms of the 
derivative’s ability to inhibit platelet aggregation in vitro and b) in terms o f the 
derivative’s ability to actually break down to give ASA in vitro. Any derivative that 
did inhibit platelet aggregation via its production o f ASA on hydrolysis, that was also 
o f sufficient purity, was considered a suitable candidate for subsequent transdermal 
testing.
3.4.2.2 Development of HPLC Conditions for Method 2
Although the same column was used as in Method 1, the mobile phase composition 
was modified slightly to allow better separation o f the early-eluting amino acid 
derivatives and their hydrolysis products from ASA and SAL. Under the final 
conditions o f HPLC method 2, the retention times for ASA and SAL were 7.4±0.2 
and 13.6+0.3 min., respectively.
3.4.2.3 Platelet Aggregation Studies - Biological Results
An instrument called a Platelet Aggregation Profiler (model PAP-4) was used and 
these experiments carried out in the Department o f Pharmacology, The Royal College 
of Surgeons. A description o f how the PAP-4 works can be seen in Appendix B. 
Blank readings were made using plasma free o f platelets. All platelet-rich plasma 
(PRP) samples were maintained at 37°C while stirring. Negative and positive controls 
were run in conjunction with the derivative samples. The results o f  this work are 
given in Table 3 .1.
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3.4.2.4 Platelet Aggregation Studies -  HPLC
Derivatives that gave a positive result in the platelet aggregation studies i.e. they 
caused the desired pharmacological effect, were examined by HPLC to confirm the 
presence o f ASA. Samples at various time points : 30 and 60 min. (and sometimes 90 
min.) were extracted from plasma. The extraction was carried out based on a 
procedure from reference 59 and is described in Appendix C. Samples were then 
reconstituted in mobile phase prior to injection. ASA itself was subjected to the same 
tests for purposes o f comparison. The overall results are given in Table 3.1.
Table 3.1: Summary of Results from the Screening of Prodrug Candidates
Derivative TLC Results HPLC Results Biological Results
ASA-Ala Quite pure by 
TLC. Hydrolyses 
to SAL-Ala
Elutes at »4 min. 
Breaks down to give 
SAL-Ala
No inhibition o f platelet 
aggregation
ASA-Gly Quite pure by 
TLC. Hydrolyses 
to SAL-Gly
Elutes at 2.5 min. 
Breaks down to give 
SAL-Gly. >96% pure
No inhibition o f platelet
aggregation
ASA-PheAla Impure (many 
extra components)
Elutes at «33 min. 
Impure with many extra 
peaks, no ASA or SAL 
present
No results
ASA-Iso No results Poor chromophore but 
at high concentrations, 
could be seen to elute at 
«40 min. >95% pure
Inhibits platelet 
aggregation.
ASA seen in 
aggregation sample
ASA-Phe No results Elutes at «40 min. 
Appears not to break 
down. >99% pure
Inhibits platelet 
aggregation.
ASA seen in 
aggregation sample
ASA-Phe-N02 No results Elutes at «70 min. 
>99% pure
Inhibits platelet 
aggregation.
ASA seen in 
aggregation sample
Dimer No results Elutes at «37 min. 
Pure but unstable
Inhibits platelet 
aggregation.
ASA seen in 
aggregation sample
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3.4.2.5 Breakdown of Amino Acid Derivatives by TLC
From lOmg/ml solutions o f  AS A-Ala and ASA-Gly in tetrahydrofuran, aliquots were 
spotted onto TLC plates each day over seven days, and until the 7th day, no impurities 
were seen (under UV light at 254nm) to have formed in the tetrahydrofuran 
solution. On the 7th day, a degradation product was seen to appear just above the 
AS A-Ala spot, indicating that the new product was more polar than the precursor. On 
the 7th day, a few degradation products were seen above the ASA-Gly spot. In the 
case o f both derivatives, their degradation products (hydrolysis products) did not 
coincide with ASA or SAL standards. Samples left on the plate for a number o f hours 
prior to chromatography, and subsequently examined under UV light, also revealed 
the presence o f the degradation products.
The bond between ASA and the amino acid moiety in each o f the two 
derivatives did not cleave (as had been hoped) to give ASA and the associated amino 
acid, enhanced by the fact that no ASA was seen on hydrolysis o f  either compound by 
TLC. Using a different TLC procedure, no free alanine or glycine were seen. The 
principal hydrolysis product for each o f ASA-Ala and ASA-Gly was postulated to be 
due to straightforward hydrolysis of the ASA moiety on the compound to  SAL. In 
other words, the acetyl group on the ASA molecule was hydrolysed in preference to 
the amide bond. SAL-Ala and SAL-Gly standards were obtained and run by TLC to 
give further evidence for this finding, and these standards did, in fact, correspond to 
the hydrolysis products on the TLC plate.
TLC analysis was also carried out on ASA-PheAla but this derivative was 
found to be very impure. This may have resulted from problems during synthesis. A 
summary o f the TLC results for the three amino acid derivatives is given in Table 3.1.
3.4.2.6 Breakdown of Amino Acid Derivatives by HPLC
ASA-Gly and ASA-Ala standards were made to 100ng/ml in PBS, pH 7.2 and their 
stability monitored by HPLC over a number o f days by repeated injection. ASA-Ala 
in PBS, pH 7.2 broke down slowly to give the hydrolysis product SAL-Ala, as 
opposed to ASA. After 24 hours, this approximated to an overall breakdown of 10%. 
ASA-Gly in PBS, pH 7.2, gave a similar hydrolysis profile, degrading by 10% in 24 
hours to give SAL-Gly. These results agreed with those seen by TLC. The formation 
of SAL-Gly and SAL-Ala over time in PBS solutions, due to the hydrolysis o f ASA- 
Gly and ASA-Ala, respectively, is shown graphically in Figure 3.10.
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Although ASA-Gly (which elutes at 2.5 min. by HPLC) and AS A-Ala (which 
elutes at «4 min. by HPLC) were predicted to be more non-polar than ASA via the 
amide bond, in fact they were found to elute earlier on the chromatograms. This 
indicated that relative to the other four derivatives (ASA-Phe, ASA-Phe-NC>2, dimer 
and ASA-Iso), these amide derivatives were more polar and therefore less likely to 
cross the skin more efficiently than ASA alone.
Figure 3.10 : The Formation of SAL-Gly and SAL-Ala over Time in PBS 
Solution, due to the Hydrolysis of ASA-Gly and ASA-Ala, respectively
Time (hours)
F i g u r e  3 . 1 0  : t h e  m o l e c u l a r  w e i g h t  o f  t h e  c o m p o u n d s  h a s  b e e n  t a k e n  i n t o  a c c o u n t  w i t h  t h e  p e a k  
h e i g h t  i n  o r d e r  t o  c o m p e n s a t e  f o r  t h e  q u a n t i t y  b a l a n c e .
To investigate the effect o f pH on the hydrolysis o f ASA-Gly, the derivative was 
hydrolysed in PBS solutions with four different pH values. The results can be seen in 
Figure 3.11, and a HPLC chromatogram overlay showing the formation o f SAL-Gly 
with time is shown in Figure 3.12. It was apparent that over the pH range examined, 
the rate o f breakdown o f ASA-Gly to SAL-Gly remained relatively constant.
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HPLC analysis was also carried out on the ASA-PheAla derivative but it the 
derivative was found again to be very impure. This may have resulted from problems 
during synthesis. A summary o f the HPLC results for the three amino derivatives is 
given in Table 3.1.
Figure 3.11 : Breakdown of ASA-Gly to SAL-Gly over Time in Different pH
Solutions of PBS
3.4.2.7 HPLC Results for the Other Four Derivatives
The AS A-Iso derivative was found to have a poor UV response, but could be seen by 
HPLC (at high concentrations) to elute at approximately 40min. The ASA-Phe 
derivative had a similar retention time o f 40min. The ASA-Phe-N02 eluted very late 
by HPLC indicating that the molecule was very non-polar. The dimer, although pure 
(IR, NMR), was found to break down quickly in aqueous solution to  give ASA and 
thence, SAL.
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Figure 3.12 : HPLC Chromatogram showing Increase in SAL-Gly with Time
mAU ASA-Gly
SAL-Gly
26 hours
7 hours 
5 hours 
4 hours
Time (min.)
F i g u r e  3 . 1 2  : H P L C  M e t h o d  2  u s i n g  A l p h a b o n d ®  C 1 8  a n a l y t i c a l  c o l u m n ,  m o b i l e  p h a s e  o f  
t e t r a h y d r o f u r a n - w a t e r - a c e t i c  a c i d  [ 2 5 : 7 5 : 0 . 0 5 ,  v / v / v ,  p H  3 . 5 * ] .  O t h e r  e x p e r i m e n t a l  c o n d i t i o n s  
d e s c r i b e d  i n  t e x t
152
3.2.5 CONCLUSIONS
At the end o f this section, three o f the derivatives were eliminated from further 
investigation. These were ASA-Ala, ASA-Gly and ASA-PheAla. The first two did not 
have the required pharmacological effect i.e. did not prevent platelet aggregation. It 
was also shown by TLC and HPLC that these compounds were hydrolysing to give 
SAL-Ala and SAL-Gly, as opposed to ASA. This explained the inability o f  these 
derivatives to elicit the desired biological affects. The ASA-PheAla was eliminated 
due to problems during synthesis, which resulted in production of a very impure 
derivative. Due to these high levels o f impurities, further investigation was not carried 
out. The remaining four o f the derivatives were brought forward to the next stage of 
investigation since they had the desired biological effect via their production o f ASA 
and they were o f high purity.
3.5 EVALUATION OF DERIVATIVES AS PRODRUGS FOR 
ASPIRIN AND DETERMINATION OF ASA AND SAL IN 
TRANSDERMAL SAMPLES
3.5.1 EXPERIMENTAL
3.5.1.1 Preparation of Skin for Franz Cell Experiments
Sha/Sha hairless male mice aged 60±5 days were sacrificed in a carbon dioxide 
chamber. The skins were immediately removed and because they were to be used 
fresh, were not subjected to any pretreatment such as presoaking or chemical 
preservation.
3.5.1.2 Franz Cell Apparatus
The in vitro transdermal experiments were performed on the fresh sha/sha mouse 
skins directly in contact with a 22ml Franz cell reservoir o f PBS at physiological pH 
and 37°C. A diagram o f the Franz cell is shown in Figure 3.13 below.
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Figure 3.13 : Diagram of a Franz Cell for Transdermal Experiments
3.5.1.3 Preparation of Samples for Application to Skin
The prodrug being examined (20mg) was diluted in 250^1 ethanol, mixed with 250^1 
of 15% polyethylene glycol (PEG) and topically applied to a 5cm2 area o f skin.
3.5.1.4 Preparation of Standards for HPLC
Stock solutions o f ASA, SAL, ASA-Phe, ASA-Phe-N02, dimer and ASA-Iso were 
prepared by dissolving each of the compounds in acetonitrile to a concentration of 
lmg/ml. The structures o f the four derivatives can be seen in Figure 3.9. Working 
standards were prepared on a daily basis by dilution o f the stock solutions with PBS. 
The ASA and SAL standards were mixed together for the validation procedure and 
had final concentrations of 0.2, 0.5, 1.0, 2.0 and 5.0(ig/ml. The standard solutions of 
the derivatives were prepared individually in PBS to a concentration o f 2ng/ml as 
required.
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3.5.1.5 Preparation of Samples for HPLC
Aliquots were taken from the buffer vessel at 0, 2, 4 and 6 hours, injected directly 
onto the HPLC system and analysed by comparison with external standards, also in 
PBS (pH 7.35). Blank skin perfusates containing only the vehicle components i.e. 
ethanol and PEG, were run in parallel with the drug perfusates at all times to account 
for any formulation effects. At the end o f the transdermal experiment for each 
prodrug, a sample from the top o f the skin was taken by dissolving the remaining drug 
in 1ml o f acetonitrile. A 1 in 1000 dilution with PBS was usually required for these 
samples prior to analysis.
3.5.1.6 HPLC (Method 3) Conditions
The final HPLC conditions for this work were as follows : Nucleosil® C8 analytical 
column, flow rate o f lml/min, UV detection at 225nm and an injection volume of 
20ul. Eluent A was a mixture o f water-acetonitrile-OPA [650:350:2, v/v/v], the 
aqueous component o f which had a pH of 2.0. The entire mixture had a pH o f 2.5* 
when the acetonitrile was added. Eluent B was a mixture o f acetonitrile-OPA [1000:2, 
v/v]. Both eluents were filtered (0.45^m filter) under vacuum and sonicated for 20 to 
30 minutes to remove dissolved gases. The solvent program used was: time 0 to 
6.5min. - 100% A, time 10.5 to 19.0min. - 70% A/30% B, time 22.0 to 28.0min. - 
100% A  employing a linear gradient ramp.
3.5.2 RESULTS AND DISCUSSION
3.5.2.1 Rationale for Choice of Animal Model
Animal models are often used for in vitro dermal evaluation o f drugs since human 
skin is usually not readily available. Hairless mouse skin was used in this work since 
it is reported to be similar to human skin in the absorption o f  anti-inflammatory 
steroids60 and short chain alcohols61. Hairless mouse skin was found to be usefully 
predictive o f human skin in terms o f permeability o f compounds62. Some papers 
dispute the wisdom o f directly applying murine data to man63,64 but it has been shown 
that for a range o f drugs, even the most permeable o f animal skins such as rabbit and 
mouse are often well within an order o f magnitude o f values for human skin41.
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3.5.2.2 Rationale fo r Choice o f Form ulation
The derivatives ASA-Phe, ASA-Phe-NCh, dimer and ASA-Iso, shown in Figure 3.9 
were selected for this section o f the project because they were found to inhibit platelet 
cyclooxygenase in vitro in the platelet aggregation studies in section 3.4. Because of 
their hydrophobicity, special formulations are required to permit their application to 
the skin. A number of possible formulations were tried including the following : 
paraffin oil, aqueous cream BP (Uniphar® and ROW A®) and PEG, each with and 
without ethanol as an enhancer. There were a number o f interferences present in 
paraffin oil and aqueous cream, some that even coeluted with ASA by HPLC. Hence, 
it was necessary to change the formulation and the final vehicle was a mixture of 
250|il ethanol and 250^1 15% PEG. This formulation did not interfere with the HPLC 
analysis.
3.5.2.3 Development o f H P L C  Cond itions fo r M ethod 3
The HPLC method was again modified for this part o f the project. The reason for this 
was that it was required to run many samples and time was now a limiting factor. It 
was sought to reduce the retention times for ASA and SAL, and to sharpen the peaks 
for the late-eluting derivatives. This was achieved by using a Nucleosil® C8 column 
(5nm, 250 x 4.6mm) instead o f an Alphabond® C18 column. Eluent A was optimised 
to a final mixture o f water-acetonitrile-OPA [650:350:2, v/v/v]. The aqueous 
component o f eluent A had a pH o f 2.0 and the mixture was pH 2.5* when the 
acetonitrile was added (ASA is most stable at this pH value65). Eluent B was a 
mixture o f acetonitrile-OPA [1000:2, v/v]. Both eluents were filtered (0.45nm filter) 
under vacuum and sonicated for 20 to 30 minutes to remove dissolved gases. Under 
the final conditions o f HPLC method 3, the retention times for ASA and SAL were 
6.7±0.1 min. and 9.0+0.3 min., respectively. The solvent program developed was: time 
0 to 6.5 min. -100%  A  time 10-5 to 19.0 min. - 70% A/30% B, time 22.0 to 28.0 min. 
- 100% A  employing a linear gradient ramp. The retention times for the prodrugs 
using the gradient were as follows : dimer 18.4+0.2 min., ASA-Iso 19.1+0.3 min., 
ASA-Phe 20.2+0.3 min. and ASA-Phe-N02 20.6+0.3 min.
3.5.2.4 Ca lib ra tion  and Ca lcu lation
Calibration was based on regression analysis o f  peak areas versus concentration (peak 
areas were found to correlate better than peak heights with concentration). Calibration
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curves were constructed for 0.2, 0.5, 1.0, 2.0 and 5.0ng/ml ASA and SAL. This 
concentration range was suitable for the detection o f these compounds in the PBS 
buffer after transdermal experiments. Since the transdermal release o f ASA and/or 
SAL was the most important criterion and since none o f the intact parent drugs 
penetrated the skin intact, full validation was carried out only on the analysis o f ASA 
and SAL in the PBS.
3.5.2.5 Precision
Precision was defined in terms of the inter-day variability (reproducibility) and intra­
day variability (repeatability). Inter-assay reproducibility was assessed in four 
replicate runs on four consecutive days, on the concentration points in the range 0.2 to 
5.0ng/ml. Intra-assay repeatability was determined by running, in quadruplicate, 
standards at each concentration level on day two o f the validation study. The precision 
o f the method was described by the mean relative standard deviation (RSD) o f the 
recovered amounts, determined by interpolation o f the peak areas on the regression 
lines. Precision data are presented in Table 3.2, and they demonstrate that the 
reproducibility (mean RSDs = 1.51% and 1.30% for ASA and SAL, respectively) was 
slightly lower (better) than the repeatability (mean RSDs = 1.49% and 2.51% for ASA 
and SAL, respectively). However all o f the precision values are well within accepted 
values for bioanalyses.
3.5.2.6 L in ea r ity  and Accu racy
The correlation coefficient o f the regression line for the mean intra-assay values was
0.9999 for both ASA and SAL. Accuracy (presented in Table 3.2), as defined as the 
percentage difference between the nominal amount and the amount found, gave mean 
inter-day values o f 0.81% and 1.67% for ASA and SAL, respectively, and mean intra­
day values o f 0.28% and 1.87% for ASA and SAL, respectively.
3.5.2.7 L im it  o f Detection
The limit o f detection was found to be 0.05ng/ml for both compounds which 
corresponded to a peak which was three times the standard deviation o f the baseline 
noise.
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Table 3.2 : Precision and Accuracy Data
Inter-assay (reproducibility)
Am ount added Am ount found(fig/ml) R SD  (%) Accuracy(% )
(ng/ml) A S A S A L A S A S A L A S A S A L
n=4
0.200 0.194 0.212 3.46 2.60 3.00 6.00
0.500 0.499 0.503 2.20 1.24 0.20 0.60
1.000 1.004 0.994 1.18 0.89 0.40 0.60
2.000 2.008 1.979 0.62 1.67 0.40 1.05
5.000 4.997 5.006 0.11 0.12 0.06 0.12
Intra-assay (repeatability)
Am oun t added Am ount foundOig/ml) R S D  (%) Accuracy(% )
(ng/ml) A S A S A L A S A S A L A S A S A L
n=4
0.200 0.199 0.215 1.67 2.18 0.50 7.50
0.500 0.498 0.498 0.99 3.28 0.40 0.40
1.000 1.004 0.990 2.24 2.14 0.40 1.00
2.000 2.002 1.993 1.72 2.26 0.10 0.35
5.000 4.999 5.005 0.83 2.71 0.02 0.10
For ASA : y = 2711 + 121230x For SAL : y = -2574 + 109060x
3.5.2.8 Quantitative Determ ination o f A S A  and S A L  in  Perfusate Samples
No ASA was found in the perfusates for prodrugs ASA-Iso, ASA-Phe or ASA-Phe- 
NO2, but SAL was found in these samples. The presence o f SAL in the perfusates 
would appear to indicate that the prodrugs did in fact break down in the skin, and that 
the rate o f release o f ASA was less than the rate of its subsequent hydrolysis to SAL. 
The poor penetration o f the skin could have been due to the preferential solubility o f 
the prodrugs in the formulation as opposed to the skin.
The dimer (an anhydride) was significantly more susceptible to hydrolysis 
than the ester prodrugs, yielding ASA (and hence SAL) in the perfusate samples. This 
could be explained by the fact that anhydrides undergo hydrolysis more readily than
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esters. Figure 3.14 shows a chromatogram o f a) a blank perfusate and b) a perfusate 
sample taken two hours after application o f the dimer prodrug.
F igure 3.14 : Chrom atogram s o f Perfusate Samples
Figure 3.14 : Chromatograms of a) Blank perfusate sample and b) Perfusate sample taken two hours alter 
topical application of dimer prodrug to the skin. Concentrations of ASA and SAL in b) are 0.72ng/ml and 
2.99fig/ml, respectively. Chromatographic conditions as per test.
Figures 3.15 and 3.16 show the transdermal results for both A S A  and SAL in terms o f 
their flux i.e. ng o f compound that traversed the skin per square centimetre o f skin 
onto which the prodrug was applied. It can be seen that the dimer delivered double the 
flux o f ASA (Figure 3.15) and less SAL (Figure 3.16) when compared to the case 
where ASA was applied to the skin alone.
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Figure 3.15 : Transdermal Fluxes (fig/cm2) of ASA due to Prodrugs and ASA
So«
or1</}
'Bjd
3
Time (hours)
F igu re  3.16 : T ransderm al F luxes (jig/cm2) o f S A L  due to Prodrugs and A S A
Time (hours)
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3.5.2.9 Qualitative Analyses of Prodrug Transport and Breakdown on Skin 
Surface
At no time did any o f the intact prodrugs traverse the mouse skins. This was a 
promising result which was confirmed by gradient HPLC analysis o f the perfusates, 
by comparing the samples to external standards o f the prodrugs at a minimum 
concentration o f 2ng/ml. This concentration would correspond to less than 0.25% of 
the prodrug crossing the skin intact. The samples taken from the top o f the skin at the 
end o f the transdermal experiment for ASA-Iso, ASA-Phe and ASA-Phe-N02 
contained only the parent compound in each case. This indicated that these derivatives 
were not hydrolysed on the surface o f the skin. Only the dimer was hydrolysed on the 
surface o f the skin to yield ASA.
3.5.2.10 Correlation of Log P values and Retention Times by HPLC
The Log P values were calculated by a program called ACD Log P (Advanced 
Chemistry Development Inc., Toronto, Canada). The values obtained for these 
compounds correlated (with the exception o f the dimer) with their retention order on 
the reversed-phase HPLC system, as can be clearly seen in Table 3.3. According to 
the calculated log P values o f the test compounds, it was predicted that they would 
permeate the skin in the order ASA-Phe, ASA-Phe-N02, ASA-Iso, dimer and ASA.
Table 3.3 : Log P Values and Retention times for the Test Compounds
Compound Retention Time (mins) LogP
ASA 6.7+0.1 1.19
SAL 9.0+0.3 2.06
Dimer 18.4+0.2 1.33
ASA-Iso 19.1+0.3 2.19
ASA-Phe 20.2±0.3 2.74
ASA-Phe-N02 20.6+0.3 2.92
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However, no correlation was observed between Log P values and transdermal 
delivery o f ASA in the transdermal samples. Log P values are usually only found to 
correlate when homologous series o f compounds are used such as steroids, alcohols or 
a series o f salicylates, with only the substituent groups differing on the parent 
molecule. Also, when Fick’s law is taken into account (See section 3.1.5), P is only 
one o f a number o f important physiochemical factors that influence drug penetration 
through a membrane.
3.6 OVERALL CONCLUSIONS
In part one of this project, an impurity present in the in-house aspirin was identified 
using a combination o f HPLC and TLC, and as a result, it was possible to modify the 
protocol for the preparation o f aspirin such that formation o f dimer impurity during 
synthesis would be minimised.
Using the aspirin prepared in-house, a number o f derivatives were prepared 
and these were subjected to a general screening procedure in part two o f the project to 
assess their suitability as prodrugs for aspirin. Using HPLC and TLC, two o f the 
amino acid derivatives o f aspirin (ASA-Gly and ASA-Ala) were found to hydrolyse to 
salicylic acid derivatives rather than releasing aspirin as hoped. Because o f this, they 
did not have the desired pharmacological effect on platelets. A third amino acid 
derivative was found to be very impure and was not investigated further. The other 
four of the compounds investigated were found to have the desirable biological effects
i.e. inhibition of platelet aggregation. They were also o f sufficient purity to be 
investigated transdermally.
In part three o f the project, the four prodrugs with the desired inhibitive effect 
on platelet aggregation were subjected to transdermal assessment across mouse skin. 
They were compared to aspirin alone in terms o f their ability to undergo hydrolysis 
and release aspirin into the receptor fluid of the Franz Cell. Samples were removed 
periodically and analysed for the presence o f aspirin and salicylic acid using a HPLC 
method. Evidence o f hydrolysis o f  the ester compounds to aspirin was seen, but it was 
not at a level sufficient to warrant further investigation o f these compounds as aspirin 
prodrugs. Only the dimer prodrug released enough aspirin over time to warrant further 
investigation as a prodrug for an Aspirin Patch. In comparison to aspirin alone, this
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compound produced double the concentration of aspirin and less salicylic acid over a 
six hour time frame. Therefore, the dimer is considered a suitable candidate for 
further investigation, and is currently undergoing more transdermal studies. Log P 
values for the derivatives and aspirin and salicylic acid were found to have some 
correlation with their retention order by HPLC. However, there was no correlation 
between log P and transdermal penetration o f the derivatives.
This HPLC method was optimised and validated for the determination o f 
aspirin and salicylic acid produced by these prodrugs in transdermal samples. Samples 
could be directly injected and the analysis time was only ten minutes for 
determination o f aspirin and salicylic acid. The assay was reproducible with inter-day 
RSD values not exceeding 3.46% and 2.60% for aspirin and salicylic acid, 
respectively. The method was linear over the concentration range 0.2-5.0 jig/ml and 
had a limit o f detection o f 0.05 ng/ml for both analytes. The method could also be 
modified to run a gradient after salicylic acid had eluted to determine if  the non-polar 
derivatives were present.
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Chapter 4
Determination of Aspirin and Salicylic Acid 
in Human Plasma by Column-Switching 
Liquid Chromatography using on-line Solid
Phase Extraction
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4.1 INTRODUCTION
4.1.1 Biological Background
The history, pharmacology and biology of aspirin (ASA) have been discussed in the 
previous chapter. In summary, ASA has a myriad o f medical applications in diseases 
such as arthritis and cancer, but the most important application o f ASA is in heart 
disease. Recent studies have shown that ASA can a) prevent heart attacks and strokes 
among individuals who have previously suffered such events1’2’3’4, b) save lives o f heart 
attack victims if initiated in the hours just after the onset o f the attack5 and c) prevent 
an initial heart attack when taken regularly by apparently healthy people with no past 
history o f heart disease6.
4.1.2 Analytical Background
The plasma half-life o f aspirin is only about 20 minutes because it is so readily 
hydrolysed to salicylic acid (SAL)7’8, its principal metabolite. An analytical method that 
measures ASA in biological fluids should therefore be capable o f measuring SAL also. 
Such assays are required for many reasons - in cases o f aspirin poisoning, intolerance 
reactions, side-effects and for metabolic and pharmacokinetic studies. Low level 
determination of the compounds is usually achieved using HPLC methods, many of 
which have been described in a review by Kwong in 1987*. Some details o f these and 
more recent methods are listed in Table 4.3. The mobile phases usually contain 
methanol or acetonitrile and have a low pH (normally 2.5 - 3.0), and UV detection 
tends to be in the range 225 - 240nm.
Since 1980, HPLC methodology for ASA and SAL has only really changed in 
terms o f applications; room for improvement lies mainly with the sample preparation 
step, as always, the bottleneck in the protocol. Until now, assays have required sample 
clean-up procedures such as protein precipitation or solvent extraction. Usual methods 
of deproteinisation involve the addition o f an organic solvent such as acetonitrile9’10’11, 
ethanol12, or a strong acid such as perchloric acid13’14. Following centrifugation, the 
supernatant is usually dried and reconstituted in mobile phase before injection. The 
solvent extraction procedure is usually effected with ether15, dichloromethane16,17,18, 
chloroform19 or hexane20 and the organic extract evaporated and the residue 
reconstituted in mobile phase. Nieder et al.21 used a mixture o f hexane and ether to
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effect their extraction. Shen et al. 22 and Buskin el al. 23 also used a mixture o f hexane 
and ether but in order to avoid the evaporation step, the compounds were back- 
extracted into phosphate buffer before injection. This is because during evaporation, 
loss o f ASA and/or SAL are known to occur due to sublimation8’10’12’16’19 20 21 22 23. 
Another problem encountered in many of these methods is poor and/or variable 
recovery of the compounds because of losses during the protein precipitation 
procedure (which can be due to protein binding of the drug) or during the solvent 
extraction step. The use o f internal standards has gone some way towards reducing the 
variability o f recoveries, but it is worth remembering that their presence can also 
adversely affect the results o f analysis because of the added variability in the extraction 
recovery o f the internal standard itself24.
The aim o f this project was to develop an analytical method for the 
quantitation of ASA and its principal metabolite SAL in human plasma with an 
alternative sample preparation protocol to the manual methodologies used in previous 
assays (described above). It was hoped to achieve this using a column-switching 
HPLC system with on-line solid-phase extraction, since switching devices permit the 
off-line multistep methods for sample pretreatment to  be transformed into on-line 
single-step procedures. It was also noted that this technique had not been employed 
previously for these compounds in plasma.
Column-switching is just one of a number o f techniques encompassed by 
multidimensional liquid chromatography25. These methods are characterised by the use 
o f more than one column interfaced with each other by a valve which allows the 
‘switching’ o f fractions between the columns. The valve can be controlled manually or 
automatically but must possess two features i.e. it must be capable o f high pressure 
operation without deterioration and it must provide a low dead volume in order to 
avoid significant peak broadening. Column-switching has been commonly employed 
for trace enrichment and sample clean-up. In both cases, the compounds o f interest are 
retained on the precolumn while interferences flow to waste. The analytes are then 
transferred to the analytical column for separation and quantitation. Trace enrichment 
is used when the sample is too dilute to be detected. In this case, the precolumn is 
called a concentrator column. The concentrator column usually contains the same 
stationary phase as the analytical column and is often simply a guard column. Sample 
clean-up is used when separation o f the analytes o f interest from endogenous 
interferences in the matrix is required prior to analysis. In this case, the precolumn is
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usually referred to as a solid-phase extraction (SPE) column. The particle size o f  the 
SPE column is usually large (lCMO^im) compared to that in the analytical column in 
order to prevent clogging problems. The only previous work that had been reported 
employing column-switching HPLC for ASA and SAL was by Cockaerts et al. in 
1986. They analysed the compounds in a tablet formulation using two C8 columns 
(10cm and 25cm) in series.
On-line sample extraction on short precolumns is finding increasing use in the 
determination o f drugs in biological fluids ’ ’ . Some examples are described below 
in Table 4.1.
Table 4.1 : Examples of Column-Switching HPLC using on-line Solid-Phase 
Extraction in Biopharmaceutical Analysis
Matrix Compound Sorbent and Comments Reference
Plasma Ivermectin A 25 x 2.1mm SPE with Corasil C l8 
material. The LOQ was 2 ng/ml by HPLC. 
Recovery was 76% from plasma
29
Urine Diuretics and 
probenecid
20 x 2.1mm SPE was used. Hypersil ODS 
material (30^m) was found to give better 
retention than SynChropak material (30-70 
(j.m). Recoveries o f the 10 cited drugs 
were >92% from urine
30
Amphetamines 20 x 2.1mm SPE with Hypersil ODS(30fim) 
material. Following clean-up, in-line deriv- 
atisation was carried out. When the optimal 
conditions were found, recoveries o f the 2 
analytes from urine were 86 and 96%
31
Serum Pantoprazole
enantiomers
A 10 x 6mm SPE with Lichroprep RP-2, 
25-40(j,m particles was used. The LOQ for 
each enantiomer in 150 ,^1 serum was 0.1 
Hg/ml. Recoveries ranged from 93-117% 
and from 94-119% from serum for the (+) 
and (-) enantiomers, respectively
32
These SPE-HPLC column-switching systems allow circumvention o f the 
problems usually associated with direct injection o f untreated plasma, serum or urine
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onto reversed-phase columns i.e. adsorption o f proteins on the solid phase, 
precipitation o f the proteins by components o f the mobile phase and shortening o f the 
useful lifetime of the analytical column. The use o f the SPE precolumn serves the dual 
function o f acting as a guard column as well as effecting a preseparation o f the 
analytes from the biological matrix. This system, if developed, would allow the direct 
injection o f the plasma sample, sample clean-up and analysis to be performed on-line in 
the same closed system, and a result to be obtained quickly. This would improve 
therapeutic monitoring o f ASA and SAL following oral administration o f aspirin 
tablets, especially in cases o f intolerance reactions or unwanted side-effects.
4.2 REAGENTS AND MATERIALS
4.2.1 Equipment
The high performance liquid chromatograph was equipped with Waters (Millford, MA, 
USA) models 501 single-piston and 510 dual-piston pumps, a Waters Model 486 
tuneable absorbance detector, a Waters model 680 gradient controller and a Waters 
model 746 data module. The Rheodyne injection port (Cotati, CA, USA) was fitted 
with a 20nl loop. The V1CI AG 10-port switching valve (Valeo Europe, Schenkon, 
Switzerland) was fitted with a 200(¿1 loop. A Hypersil® C-8 guard column (30nm, 10 x 
4.0mm) was fitted prior to the Nucleosil® C-8 analytical column (5|im, 250 x 4.6mm). 
The solid-phase extraction (SPE) column was a biocompatible peek cartridge system 
(10 x 4.3mm) from Anachem (Luton, Bedfordshire, England). The cartridge was dry- 
packed with Hypersil® C-18 material (30jim) from Shandon HPLC (Runcorn, 
Cheshire, England).
4.2.2 Reagents and Chemicals
Aspirin was supplied by SIGMA Chemical Co. (Dorset, England), as were all the 
drugs used in the interference study. Aspirin tablets (300mg) for the volunteer study 
were from Bayer Ltd. (Dun Laoghaire, Dublin, Ireland). Salicylic acid was supplied by 
BDH (Poole, England). Acetonitrile, methanol and water were HPLC grade and were 
purchased from Labscan (Dublin, Ireland). Acetic acid (glacial 100%) was purchased
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from Merck (Darmstadt, Germany). High purity (99.999%) orthophosphoric acid 
(OPA) was obtained from Aldrich Chemical Co. (Milwaukee, WI, USA).
4.2.3 Other Materials
Plastic blood collection tubes (monovettes) were donated by Sarstedt Ltd. (Wexford, 
Ireland). Monovettes containing four types o f anticoagulant were obtained : Li- 
heparin, ED TA  fluoride/EDTA and citrate. Monovette needles and adapters, also 
from Sarstedt Ltd.,were used in conjunction with the above collection tubes.
4.3 EXPERIMENTAL
4.3.1 Blood Collection and Storage
Blood samples were collected into chilled plastic tubes containing a fluoride/EDTA 
mixture. The chilled blood samples were centrifuged @ 1500g for 10 min. to harvest 
the plasma. Samples were frozen at -30°C  until required if there was to be a time lapse 
before analysis. Both fresh and thawed plasma were kept on ice at all times.
4.3.2 Preparation of Standards for HPLC
Stock solutions o f ASA and SAL were prepared by dissolving each o f the compounds 
(50mg) in acetonitrile (50ml) to a concentration o f lmg/ml. In acetonitrile, the stock 
solutions were found to be stable for at least ten weeks when kept at room 
temperature. Aqueous working standards were made on a daily basis by dilution o f the 
stock solutions in eluent A (wash solvent, see section 4.3.4) to give the concentrations 
required. Eluent A was used for dilution because ASA and SAL, with pKa values o f
3.5 and 3.0, respectively33, are stable at this pH (2.5). Common ASA and SAL plasma 
standards were prepared by spiking blank plasma with working standard solutions, and 
had final concentrations of 0.1, 0.25, 0.8, 2.0 and 5.0|ig/ml for ASA and 0.25, 0.75, 
2.4, 6.0 and 15.0ng/ml for SAL. These concentrations were chosen because they 
covered the expected range o f the volunteer study samples. The drugs for the 
interference study were prepared individually as required and each had a final 
concentration o f approximately lug/ml.
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4.3.3 Preparation of Samples for HPLC
OPA (250^1 of 0.2M solution) was added to 250^1 o f the chilled plasma sample within 
10 minutes o f centrifugation (if fresh) or within 10 minutes o f thawing (if frozen) in 
order to minimise enzymatic hydrolysis o f ASA to  SAL. The samples were vortex- 
mixed for 20 seconds. Direct injection was usually possible at this stage but some of 
the volunteer's plasma samples, especially after eating, appeared cloudy after 
vortexing, so a short centrifugation step (5800g for 3 minutes) was required. In order 
to treat all samples equally, this centrifugation step was introduced as part o f the 
protocol. Following centrifugation, the sample was injected directly onto the HPLC. 
Samples that fell outside the standard curve concentration ranges were diluted 
appropriately and brought on scale for quantitation.
4.3.4 HPLC Conditions
Eluent B was a mixture o f water-methanol-acetonitrile-OPA [650:200:150:1, v/v/v/v] 
with a resultant pH of 2.6*. This mobile phase was based on the final HPLC method 
used in chapter 3. The same column (Nucleosil C8) was also employed. Eluent A was 
a mixture of water-OPA [1000:1, v/v] and had a pH o f 2.5 Both eluents were filtered 
(0.45nm filter) under vacuum and sonicated for 20 to 30 minutes to remove dissolved 
gases. The flow rates o f eluent A and eluent B through the columns were each 
lml/min, UV detection was at 225nm and all measurements were made at ambient 
temperature. Under these conditions, the retention times of ASA and SAL were 
11.5±0.2 and 15.6±0.3 minutes, respectively.
4.3.5 Column-Switching Conditions
The 200nl o f sample was loaded onto the loop with the valve in position 1 (Figure 
4.1). The valve was then turned to position 2, injecting the sample onto the extraction 
column (Figure 4.1). The wash solvent was eluent A and this was allowed to flow 
through the C l8 extraction column for two minutes. During this time, the analytes of 
interest would remain on the extraction column while endogenous components flowed 
to waste. After two minutes, the valve was switched back to position 1, whereupon 
the ASA and SAL were backflushed onto the analytical column by mobile phase 
(eluent B).
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Figure 4.1 : Diagram of Column-Switching Apparatus
Valve in 
Position 1
Valve in 
Position 2
Figure 4.1 : Sample is loaded onto loop with valve in position 1. The valve is then switched to 
position 2 so the sample is swept onto the SPE column while the analytical column is 
equilibrating. Finally, the valve is switched back to position 1 so the sample is desorbed from 
SPE column in backflush mode and carried onto analytical column for quantitation. Next 
sample is loaded onto loop.
4.4 RESULTS AND DISCUSSION
4.4.1 Optim isation  o f B lood Co llection
Since the nature o f the anticoagulant used in conjunction with the blood collection 
procedure can have a dramatic effect on the number o f interfering peaks, it was 
decided to investigate four different anticoagulant types. Previous work has shown 
that the levels o f plasma interferents following on-line SPE (using a C l8 precolumn)
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can be quite different when different anticoagulants and/or brands are used34. Hence, 
for this study, blood was taken from two volunteers using a butterfly syringe 
connected to each o f four types o f blood collection tube (Li-heparin, EDTA, 
fluoride/EDTA and citrate). All eight blank plasma samples were treated as per the 
protocol and analysed on the LC system. There was very little difference between the 
plasma profiles obtained, but the fluoride/EDTA mixture appeared to give a slightly 
cleaner baseline in the case o f both volunteers and so it was chosen as the 
anticoagulant for this method. A significant advantage o f the fluoride anticoagulant is 
that it inhibits the action o f esterases, and hence the in vitro hydrolysis o f ASA. A 
number o f workers have used fluoride (in the form of NaF or KF salts) in conjunction 
with blood collection for this reason12=13=14>16’17=ly=20=21’23. In fact, Rumble et al.u  
compared three commonly used esterase inhibitors ie. ecothiopate. physostigmine and 
fluoride and found that KF inhibited ASA hydrolysis to the greatest extent. Nieder et 
al.21 also found KF to be the most effective inhibitor when they conducted a similar 
study.
4.4.2 Optimisation of Sample Dilution
While the use o f acidic diluent or water made no difference to aqueous standards, it 
was critical to the recovery o f both ASA and SAL from plasma samples. It was 
especially important to use an acidic diluent for the recovery o f SAL. SAL is highly 
protein bound in plasma (80-90%)35’36 and the acid caused the liberation o f the SAL 
molecules from their binding sites. In determining the optimum concentration for the 
diluting acid, three concentrations were investigated : 0.02M, 0.2M and 2M OP A. The 
0.2M acid gave the highest recoveries (>90%) for both drugs. The lower 
concentration o f OPA gave low recoveries o f SAL (not strong enough to free SAL 
from proteins) while the higher concentration was high enough to cause a small 
amount o f protein precipitation, which was not a desirable effect.
The ratio in which the 0.2M OPA was added to the plasma sample also had an 
impact on recovery o f the analytes. Obviously, the lowest possible dilutional effect is 
always required so that sensitivity can be maximised. Three ratios o f OPA to plasma 
were examined i.e. 1:1, 2:1 and 3:1. When OPA was added in a ratio o f 2:1 or 1:1 to 
the plasma sample, the highest recoveries for both ASA and SAL were obtained. 
Hence, the 1:1 ratio o f OPA to plasma was used throughout the rest o f this work. 
These results are illustrated in Figure 4.2 below.
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Figure 4.2 : Effect of Ratio of OPA to Plasma on Recoveries of ASA and SAL
mAU
a)
u U
d )
; ASA
SAL
___I
I
Time (min.)
Figure 4.2 : Chromatogram a) blank plasma, b) plasma diluted 1:3 with OPA, yielding 
recoveries of ASA and SAL of 85% and 93% , respectively, c) plasma diluted 1:2 with OPA, 
yielding recoveries of ASA and SAL of 94% and 100%, respectively and d) plasma diluted 1:1 
with OPA, yielding recoveries of ASA and SAL of 94% and 100%, respectively. Each of the 
time axes represents 20 minutes from beginning (injection) to end of the arrow.
4.4.3 Development of HPLC Conditions
Initially, a mobile phase with the composition o f water-acetonitrile-acetic acid 
[700:300:0.5, v/v/v] was employed. The pH o f this eluent was 3.5*. However, under 
these conditions, the peak for SAL had a very poor shape and was not well resolved 
from the ASA peak. The first change made to the mobile phase was the substitution of 
acetic acid for OPA, and using 1ml o f the acid per 1000ml o f eluent to maintain the pH 
at 2.6*. This improved the baseline but not the chromatography. The presence of 
methanol in the mobile phase improved the peak shape o f SAL, which had been tailing 
badly. The presence o f 20% methanol was found to be the optimum amount with 
respect to its effect on the SAL peak. The amount o f acetonitrile was adjusted in order
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to elute both ASA and SAL in a reasonable time frame. The final mobile phase 
composition was a mixture o f water-methanol-acetonitrile-OPA [650:200:150:1, 
v/v/v/v] with a resultant pH o f 2.6*. This solution was referred to as eluent B. The 
flow rate o f eluent B through the analytical column was lml/min. UV detection was at 
225nm, although a number o f other wavelengths were investigated i.e. 210, 230, 235 
and 270nm. Under these conditions, the retention times o f ASA and SAL were 
11.5±0.2 and 15.6±0.3 minutes, respectively.
4.4.4 Development of Column-Switching Conditions
4.4.4.1 Choice of Packing Material for SPE Column
A number o f packing materials such as cyanopropyl, phenyl, C l, C8 and C18 (see 
section 1.1.4.3) were examined in terms o f their retention and selectivity for ASA and 
SAL on the extraction column. The C l8 phase was found to be the most retentive for 
the compounds.
4.4.4.2 Choice of Wash Solvent
When water alone was used as eluent for the SPE column, the subsequent recoveries 
o f ASA and SAL in aqueous solution were found to be very low (66-79% and 9-10%, 
respectively). When eluent A i.e. water-OPA [1000:1, v/v] was used for this step, the 
recoveries o f ASA and SAL improved to 99-100% and 98-100%, respectively (Figure
4.3). This is probably because both ASA and SAL, as weak acids, will interact with 
the hydrophobic SPE column to a greater extent in an acidic environment.
4.4.4.3 Choice of Dimensions of SPE Column
Two dimensions of cartridge were assessed : 10 x 4.3mm and 10 x 2.0mm. The 
smaller column had approximately 37% the capacity o f the larger column for a sample 
of ASA and SAL containing 0.2|ig/ml o f each (see Figure 4.4). This was not adequate 
for the column-switching SPE-HPLC system, so the larger of the two sizes was used 
for the remainder of the work.
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Figure 4.3 : Effect of Acidic Wash Solvent on Recovery of ASA and SAL
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Figure 4.3 : Chromatogram a) shows the poor recoveries of a 2ng/ml sample of ASA and SAL 
when a water wash was used during the 2 min. SPE step, and b) shows the same sample when an 
acidic wash solvent was used (water-OPA, 1000:1, v/v) with a pH of 2.5.
4.4.4.4 Choice o f Injection Loop  Size
Two sizes o f injection loop were investigated in this project. Initial experiments were 
carried out on the 20^1 loop but since a larger sample volume was required, for the 
purposes o f increasing sensitivity 10-fold (in theory), a 200^1 loop was evaluated 
under the same conditions. To investigate if there would in fact be a 10-fold increase 
in sensitivity, a 2(ig/ml aqueous sample o f ASA and SAL was injected onto the 20^1 
loop (chromatogram a) and the peak areas compared with those obtained by injection 
of a 0.2(ig/ml sample (chromatogram b) and a 2ng/ml sample onto a 200^1 loop 
(chromatogram c). The peak area results from Figure 4.5 showed that the recoveries 
o f ASA and SAL in chromatogram b were 93.6% and 84.5%, respectively when 
compared to chromatogram a. It was found from the peak areas in chromatogram c 
that the use of the 200^1 loop afforded sensitivity increases by a factor o f  8.85 for 
ASA and 8.20 for SAL, a little less than the theoretical increase expected. This can be
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explained due to a small amount o f band broadening evident in the peak shape, which 
would not be unexpected when changing from a small volume 20|il loop to a large 
volume 200|il loop.
Figure 4.4 : Effect of Type and Dimensions of SPE Column on Recovery of ASA
and SAL from Plasma
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F i g u r e  4 . 4  : C h r o m a t o g r a m  a )  s h o w s  t h e  g o o d  r e c o v e r i e s  o f  a  0 . 2 j i g / m l  s a m p l e  o f  A S A  a n d  S A L  
w h e n  t h e  s e l f - p a c k  C 1 8  c a r t r i d g e  w a s  u s e d  ( 1 0  x  4 . 3 m m )  f o r  t h e  2  m i n .  S P E  s t e p ,  b )  s h o w s  t h e  
s a m e  s a m p l e  w h e n  t h e  s e l f - p a c k  C 1 8  c a r t r i d g e  w a s  u s e d  ( 1 0  x  2 m m )  w i t h  3 7 %  r e c o v e r i e s  a n d  c )  
s h o w s  t h e  s a m e  s a m p l e  w h e n  a  c o m m e r c i a l  C 1 8  c a r t r i d g e  w a s  u s e d  ( 1 0  x  4 m m )  w i t h  6 5 %  
r e c o v e r i e s  o f  t h e  t w o  a n a l y t e s .  E a c h  o f  t h e  t i m e  a x e s  r e p r e s e n t s  2 0  m i n u t e s  f r o m  b e g i n n i n g  
( i n j e c t i o n )  t o  e n d  o f  t h e  a r r o w .
182
Figure 4.5 : Effect of Loop Volume on Sensitivity
Figure 4.5 : The chromatograms show injections of a) 2|ig/ml sample of ASA and SAL using a 
20fil loop, b) 0.2ng/ml sample using a 200jJ loop and c) 2fig/ml sample using a 200^1 loop. 
Results described in text.
4.4.5 Calibration and Calculation
Spiked plasma samples were used for calibration, validation and quantitation. 
Calibration was based on unweighted linear regression analysis o f concentration versus 
peak areas (which were found to correlate better than peak heights with 
concentration). Calibration curves were linear in the concentration ranges 0.10-5.00 
Hg/ml for ASA and 0.25-15.00 ng/ml for SAL with all r values > 0.999.
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4.4.6 Precision
Precision was defined in terms of the variability between batches (inter-assay) and 
within batches (intra-assay). Inter-assay variation (reproducibility) was assessed in four 
replicate runs on four consecutive days, covering the concentration range 0.1 to 
5.0(ig/ml for ASA and 0.25 to 15.0ng/ml for SAL. Intra-assay variability (repeatability) 
was determined in quadruplicate on the fourth day of the study. The precision o f the 
method was described by the mean RSD of the recovered amounts, determined by 
interpolation of the peak areas on the regression lines. For reproducibility, the 
interpolations were based on the four individual regression lines generated from the 
four replicate runs. For repeatability, the interpolations were based on a single 
regression line based on the mean peak areas o f the quadruplicate run. Precision data 
(Table 4.2) demonstrates that the reproducibility (mean RSDs = 3.83% and 4.76% for 
ASA and SAL, respectively) and repeatability (mean RSDs = 2.58% and 2.56% for 
ASA and SAL, respectively) are well within accepted values for clinical analyses.
4.4.7 Accuracy
Accuracy (presented in Table 4.2), as defined as the percentage difference between the 
nominal amount and the amount found, by back-calculation, gave mean between-batch 
values o f 2.21% and 1.27% for ASA and SAL, respectively and mean within-batch 
values o f 3.06% and 2.57% for ASA and SAL, respectively.
Table 4.2 : Precision and Accuracy Data
Intra-assay (repeatability) n=4 
For ASA: y = - l 1914 + 513530x
A m ount added 
ASA (pg/ml)
A m ount found 
ASA (jig/ml)
RSD
(% )
Accuracy
(% )
0.10 0.091+0.004 4.28 9.00
0.25 0.235±0.005 2.29 6.00
0.80 0.799+0.023 2.90 0.13
2.00 2.003+0.037 1.85 0.15
5.00 5.000+0.078 1.56 0.00
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For SAL : y = 69807 + 458990x
Am ount added
SAL (fig/ml)
Am ount found
SAL (ng/ml)
RSD
(% )
Accuracy
(% )
0.25 0.239±0.006 2.58 4.40
0.75 0.714±0.020 2.85 4.80
2.40 2.446±0.075 3.07 1.92
6.00 6.088±0.122 2.01 1.47
15.0 14.960±0.339 2.26 0.27
Inter-assay (reproducibility) n = 4 , * n=3
A m ount added Am ount found RSD Accuracy
ASA Oig/ml) ASA (pig/ml) (% ) (% )
0.10 0.093±0.006 6.74 7.00
0.25 0.254±0.018 7.11 1.60
0.80 0.789±0.025 3.18 1.38
2.00 1.982±0.036 1.80 0.90
5.00 5.009±0.016 0.31 0.18
A m ount added 
SAL (ftg/ml)
A m ount found 
SAL (fig/ml)
RSD
(% )
Accuracy
(% )
0.25 0.23 8±0.024 10.12* 4.80*
0.75 0.746±0.041 5.55* 0.53*
2.40 2.412±0.109 4.52 0.50
6.00 5.972±0.186 3.11 0.47
15.0 15.008±0.077 0.51 0.05
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4.4.8 Limits of Detection and Quantitation
The limit o f quantitation (LOQ) in plasma was found to  be lOOng/ml for each of the 
analytes. It can be seen in Table 4.3 that this LOQ for ASA is superior to the LOQs 
for previous assays in all but two cases. Brandon et al. obtained an LOQ of 25ng/ml 
for ASA but the LOQ for SAL in the assay was 0.5^.g/ml15. A similar situation arose 
for Buskin et al. with an LOQ of 50ng/ml reported for ASA and 0.5}ig/ml for SAL23. 
Certain validation parameters were carried out at the LOQ in the same way as for the 
calibration curve. The reproducibility at the LOQ (mean RSDs = 4.0% and 14.3% for 
ASA and SAL, respectively) and repeatability at the LOQ (mean RSDs = 18.4% and 
11.7% for ASA and SAL, respectively) were acceptable. Accuracy results were 
expressed as relative recovery values at this concentration i.e. against aqueous spiked 
samples at the same concentration. Inter-day recoveries at the LOQ were found to be 
99.3% and 84.4% for ASA and SAL, respectively, and intra-day recoveries were 
found to be 116.2% and 91.9% for ASA and SAL, respectively. The limit o f detection 
(LOD) in plasma was found to be 50ng/ml for each o f the analytes. In aqueous 
samples, the LOD values were 10 and 20ng/ml for ASA and SAL, respectively.
4.4.9 Recovery
Both absolute and relative recoveries were obtained for this method. Absolute 
recovery is defined as the response o f a processed, spiked matrix standard expressed 
as a percentage o f the response of pure standard which had not been pretreated24. Two 
concentrations o f each compound were chosen for examination (0.5 and 5.0|ig/ml) and 
the absolute recoveries were calculated by comparing the response in the spiked 
plasma samples to the response in aqueous samples injected directly onto the analytical 
column i.e. without SPE and column-switching. Absolute recoveries for ASA were 
found to be 99 and 100% at 0.5^g/ml and 5.0ng/ml, respectively; for SAL these results 
were 104 and 101%, respectively. Relative recovery was defined as the response of 
extracted analyte measured from matrix i.e. plasma, as a percentage of analyte 
extracted from water24. The relative recovery for this study was calculated for both 
analytes at both concentrations in two different plasmas on two different days. Relative 
recoveries for ASA were calculated to be 101 and 94% at 0 5^g/ml and 5.0ng/ml, 
respectively; for SAL these results were 88 and 90%, respectively.
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Table 4.3 : HPLC Assays for Aspirin and/or Salicylic Acid in Plasma
Reference 
&  Yea r
Sample Preparation L in ea r range 
(jig/ml)
L O Q  or L O D  
(jig/ml)
Recovery Internal
Standard
This work 
1997
Direct injection 0 .1 0 -5  (ASA) 
0.25 - 15 (SAL)
0.1 (LOQ ASA) 
0.1 (LOQ SAL)
99-100% ASA 
101-104% SAL
No
[9] 1996 ACN deproteinisation 0.1 -200  (SAL) 0.2 (LOQ SAL) > 85% SAL Yes
[10] 1996 ACN deproteinisation
Aqueous fraction separated with NaCl
0.2 - 20 (ASA) 
0.5 - 50 (SAL)
0.1 (LOQ ASA) 
0.1 (LOQ SAL)
106.8% ASA 
121.7% SAL
Yes
[12] 1996 Ethanol deproteinisation 
Supernatant diluted in mobile phase
4 - 4000 (SAL) 0.5 (LOD SAL) 96.2% SAL Yes
[16] 1992 Dichloromethane extraction 20 - 400 (ASA) 
100 - 500 (SAL)
0.02 (LOD ASA) 
0.02 (LOD SAL)
100.7% ASA 
80.1% SAL
Yes
[22] 1990 Ethyl ether/hexane extraction 
Back extracted into phosphate buffer
0.05 - 200 (ASA) 
0 .10 -200  (SAL)
0.05 (LOD ASA) 
0.10 (LOD SAL)
92 - 100% Yes
[20] 1987 Hexane extraction 0 .1 -2 0  (ASA) 
0 .1 -2 0  (SAL)
0.1 (LOD ASA) 
0.1 (LOD SAL)
27±3% ASA 
54±2% SAL
Yes
[15] 1985 Ethyl ether extraction 0.025 - 10 (ASA) 
0 .5 -7 0  (SAL)
0.025 (LOQ ASA) 
0.5 (LOQ SAL)
96.4-100.3% ASA 
76 .7 -91 .2%  SAL
Yes
[17] 1984 Dichloromethane extraction 0.2 - 100 (ASA) 
0.2 - 100 (SAL)
0.2 (LOQ ASA) 
0.2 (LOQ SAL)
92% ASA 
85% SAL
Yes
[13] 1984 Perchloric acid-methanol 
deproteinisation
1 - 500 (ASA) 
1 - 500 (SAL)
0.3 (LOD ASA) 
0.2 (LOD SAL)
80-86% ASA 
80-86% SAL
Yes
[19] 1983 Ethyl ether/hexane extraction 0.1 - 10 (ASA) 
0 . 1 - 40  (SAL)
0.05 (LOD ASA) 
0.05 (LOD SAL)
93-95% ASA 
88-89% SAL
No
[19] 1982 Ethyl ether/hexane extraction 
Back extracted into phosphate buffer
0 . 05-10  (ASA) 
0 . 5 -100  (SAL)
0.05 (LOQ ASA) 
0.5 (LOQ SAL)
98.6-107.7% ASA
95.6-98% SAL
Yes
[14]1981 Perchloric acid-methanol 
deproteinisation
0.5 - 200 (ASA) 
0.5 -200 (SAL)
0.1 (LOD ASA) 
0.1 (LOD SAL)
Yes
[19] 1980 Chloroform extraction 0.5 - 20 (ASA) 
0 . 5-100  (SAL)
0.5 (LOD ASA) 
0.5 (LOD SAL)
> 95% ASA 
70% SAL
Yes
[11] 1980 ACN deproteinisation 
Supernatant used for injection
2 - 3 0  (ASA) 
5 - 1 0 0  (SAL)
2.0 (LOQ ASA)
5.0 (LOQ SAL)
98 - 107% ASA 
93 - 116% SAL
No
[18] 1980 Dichloromethane extraction 2 - 1 0 0  (ASA) 
1 -1 5 0  (SAL)
1.0 (LOD SAL) Yes
When looking at previous work in Table 4.3, it would appear that no one assay 
obtained recoveries that were as quantitative for both analytes as those reported in this 
work. This is probably best explained by the fact that there is little sample loss in the 
column-switching on-line SPE LC system since once the sample is injected and the 
SPE conditions have been optimised to retain the analytes, the entire sample volume 
remains in the closed system for extraction and analysis. This is in sharp contrast with 
manual extraction procedures where losses can occur in many areas e.g. liquids 
adsorbing onto glassware, sample lost during transfer from vessel to vessel, losses due 
to sublimation, losses during evaporation and reconstitution of the sample; losses are 
also possible during protein precipitation if coprecipitation o f any o f the analytes 
occurs.
4.4.10 Selectivity
According to Karnes et al.24 and Shah et al.37, the matrix should not interfere with the 
analysis o f the compounds and this should be demonstrated in six different sources. 
Hence, plasma from six different individuals was examined for endogenous 
interferences and in no case were any interferences found that coeluted with ASA. In 
some sources o f plasma, a small endogenous peak was found that had the same 
retention time as SAL. However, its response always corresponded to a concentration 
of less than the LOD of SAL. A number o f commonly coadministered and/or available 
drugs were also investigated for possible coelution with either ASA or SAL. These are 
listed in Table 4.4. Only xylazine (which has mainly veterinary uses) and prazosin were 
found to interfere.
4.4.11 Stability
Kees et al.10 found that a 1 mg/ml solution o f ASA in acetonitrile was stable for at least 
one month (at 4°C). This study found that the same concentration o f ASA in 
acetonitrile was stable for at least 10 weeks at room temperature or in the fridge.
Various aspects o f the sample handling procedures prior to extraction o f the 
plasma samples and standards were also investigated with a view to minimising 
degradation due to  in vitro hydrolysis o f ASA. Four plasma samples (each containing 
2^jg/ml ASA) were subjected to different treatments. Sample 1 was acidified 1:1 with 
0.2M OPA and held on ice prior to injection, sample 2 was acidified 1:1 with acid and 
maintained at room temperature, sample 3 was diluted 1:1 with water and held on ice,
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Table 4.4 : Interference Testing
Drugs Tested for Interference
Barbitone Imipramine
Butobarbitone Nitrazepam
Caffeine Phenytoin
8-chlorotheophylline Pindolol
Clonazepam Prazosin
Cocaine Propranolol
Diazepam Quinidine
Flurazepam Theophylline
Furosemide Xylazine
Hydralazine
sample 4 was diluted with water and held at room temperature. Upon analysis three 
hours later, it can be seen from the chromatograms in Figure 4.6 that sample 1 had the 
smallest peak for SAL, indicating the least hydrolysis. The amount o f degradation (as 
evidenced by the hydrolysis of ASA to SAL) increased from sample 1 to 4, showing 
that acidifying the sample enhances the stability to  a greater extent than cooling on ice. 
In conjunction with fluoride in the anticoagulant to inhibit enzymatic decomposition of 
ASA, all samples were acidified and kept chilled in order to minimise hydrolysis o f 
ASA, hence ensuring sample integrity. Stability o f ASA and SAL in the spiked, 
acidified samples was then investigated during storage. The results of this work 
concluded that the levels o f ASA and SAL in these samples remained constant when 
stored at room temperature for up to 24 hours, at 4°C for up to 48 hours and at -30°C 
through two freeze-thaw cycles. After these lengths of time, the levels o f endogenous 
interferences had increased to such an extent that quantitation o f the ASA and SAL 
peaks was not possible.
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Figure 4.6 : Effect of Handling Conditions on Stability of ASA in Plasma
Figure 4.6 : Chromatograms showing the effect of handling conditions on the level of hydrolysis 
of ASA to SAL. Sample 1 : plasm a acidified 1:1 with OPA and held on ice, Sample 2 : plasma 
acidified 1:1 with acid and held a t room tem perature, Sample 3 : plasma diluted 1:1 with w ater 
and held on ice, Sample 4 : plasma diluted 1:1 with w ater and left a t room tem perature. 
Chromatographic conditions as per text.
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4.4.12 Ruggedness
Using an aqueous solution containing 2ng/ml o f both analytes, a number o f parameters 
were examined to demonstrate the robustness o f the method. Normal retention times 
for ASA and SAL were 11.5±0.2 and 15.6±0.3 minutes, respectively. Changes o f 
±10% to the flow rate through the extraction column had no effect on the peak areas 
obtained. Increasing the flow rate by 10% through the analytical column had the effect 
of decreasing the peak areas by 10% as would be expected, and decreasing the flow 
rate by 10% had the effect o f increasing the peak areas by the same amount, also as 
expected. The washtime o f the sample through the SPE column was incremented by 
±5% and ±10% and this was shown not to affect the peak areas. Changes o f  ±5% of 
the acetonitrile content o f the mobile phase had more o f an effect on the retention 
times (±0.4 mins for ASA and ±0.6 mins for SAL) than the same changes in the 
methanol content. However, neither significantly affected the size o f the peak areas. 
To adjust the normal pH o f the mobile phase by 0.1 pH unit, it was necessary to 
increase or decrease the volume of OPA by 20%. The retention time for SAL, as it is 
more pH sensitive, moved slightly i.e. +0.1 mins at pH 2.5* and -0.3mins at pH 2.7*.
When the C l8 extraction column was changed after approximately 50 plasma 
injections, the new C l8 column yielded no difference in the recoveries o f both 
components. Guard column changeover also had no effect on the chromatography.
4.4.13 Quantitative Analyses of Samples
One healthy male volunteer was given 600mg aspirin (in the form of two tablets) 45 
minutes after he had eaten a meal. Blood samples were taken just before the 
administration of ASA and then at a number o f time points over seven hours, and 
subjected to extraction and analysis. Some o f the resultant chromatograms are shown 
in Figure 4.7.
The results were plotted on a concentration-time curve (Figure 4.8) and from 
this, the peak plasma concentrations o f ASA and SAL were determined to be 6.2 and
27.1 ng/ml, respectively. The times taken to reach these peak concentrations were 33 
and 60 min., respectively. These results are in general agreement with those found in 
the literature, as can be seen in Table 4.5, the only difference being that SAL reaches 
its peak concentration faster than would be expected. However, the fact that rates of 
metabolism vary widely among individuals probably accounts for this discrepancy.
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A dm inistration of 600mg ASA
Figure 4.7 : Chromatograms of Plasma from a Volunteer before and after
Time (min.)
Figure 4.7 : a) Plasma from volunteer immediately prior to adm inistration of ASA b) Plasma 
sample taken 13 mins after adm inistration of ASA, concentration of ASA = 2.55fig/ml and 
concentration of SAL = 3.43pg/ml c) Plasma sample taken 5 hours after administration of ASA, 
concentration of SAL = 13.98pg/ml. Chromatographic conditions as per tex t
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Table 4.5 : Results of Concentration-Time Curves from other Studies
Reference 
&  year
Am ount o f 
A S A  given
A S A  Peak 
Concentration 
Oig/ml)
S A L  Peak 
Concentration 
(fig/ml)
T im e to 
reach A S A  
Peak Cone, 
(mins)
T im e to 
reach S A L  
Peak Cone, 
(mins)
This work 600mg 6 27 33 60
[10] 1996 500mg 5 30 30 130
[15] 1985 600mg 8 40 30-40 90-100
[19] 1982 650mg 8 40 20 80
[19] 1980 600mg 14 45 22 80
F igure 4.8 : Concentration-T im e Cu rve  o f A S A  and S A L  in  a M a le  Vo lunteer 
fo llow ing O ra l Adm in is tra tion  o f 600mg A S A
W)
3^
C
C3
U-4->
c
<U
oso
U
C3s
5Z 3
0 3
0 100 200 300
Time (minutes)
400 500
194
4.5 CONCLUSIONS
A new column-switching method has been developed for the analysis of aspirin and 
salicylic acid in plasma by on-line SPE in conjunction with HPLC. Only 300^1 of 
plasma is required for analysis and the method could be easily automated via the 10- 
port switching valve. The procedure is easier to execute and requires less sample 
handling than methods currently described in the literature. The method is linear over 
the concentration range 0.10-5.00 ng/ml for aspirin and 0.25-15.00 ng/ml for salicylic 
acid. Both compounds have a limit of quantitation of 0.1 ng/ml and a limit of detection 
of 0.05 jig/ml. Total analysis time is less than 20 minutes. Extensive stability work has 
been carried out and precautions taken to minimise in vitro hydrolysis of aspirin to 
salicylic acid ensures the integrity of the plasma sample. Validation of the method 
shows it to be reproducible and repeatable. Excellent recoveries from plasma obviate 
the need for an internal standard. It has been successfully applied to the investigation 
of the levels of aspirin and salicylic acid in a healthy, non-fasting volunteer following a 
600mg oral dose of aspirin.
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Chapter 5
Identification and Qualitative Analysis of 
Protein-Mobilising Factors in the Urine of 
Cancer Patients with Cachexia
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5.1 INTRODUCTION
5.1.1 Biological Background
The term cachexia is derived from the Greek words kakos meaning ‘bad’ and hexis 
meaning ‘condition’. Cachexia is an important manifestation of clinical disease most 
commonly seen in patients with cancer and AIDS. In cancer patients, it is 
characterised by anorexia, weight loss, anaemia and muscle weakness. Although most 
commonly associated with the final stages of cancer, cachexia may present itself even 
before the other signs and symptoms of malignancy appear1. This condition is more 
prevalent in patients with certain types of tumours, especially solid tumours such as 
those of the pancreas, stomach, colon and lung.
Cachexia is a wasting condition in which the patient has a marked and 
progressive loss of body mass, especially cardiac and respiratory muscle2 and adipose 
tissue. The weight loss that occurs in cancer patients with cachexia is very different to 
the type of weight loss that occurs in cancer patients or otherwise healthy subjects 
with anorexia. In starvation or anorexia, more than three quarters of the weight loss 
arises from fat losses and only a small amount from muscle, due to the fact that the 
body tries to conserve its muscle mass3. However, in cancer cachexia, there is equal 
loss from both fat and muscle4. Although cancer patients typically have an elevated 
resting energy expenditure5,6 and a lower nutrient intake7, these reasons alone do not 
account for the extent of the weight loss8,9. In fact, loss of both muscle and adipose 
tissue has been reported to occur before the fall in food intake10. The fact that cancer 
patients have been reported to have increased resting expenditure even before the 
onset of weight loss5 suggests that this elevated metabolic rate may be a contributing 
factor rather than a consequence of the condition. Protein synthesis is also known to 
be reduced in cachexia11 but it is in fact, the accelerated protein breakdown which is 
largely responsible for the significant muscle wasting12.
Cachectic cancer patients exhibit a reduced response to chemotherapy13 and a 
decreased survival rate14. The degree of weight loss is inversely proportional to life 
span14; moreover, this progressive loss of host cell body mass may be the actual cause 
of death in up to two thirds of cancer patients15. Patients who do not lose weight 
survive approximately twice as long as patients with the same type of cancer who are
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not cachectic . A 30% loss of body mass is generally considered to be fatal but there 
have been rare cases where patients have survived with up to 50% weight loss14.
This wasting seems to be mediated by a circulatory catabolic factor (which in 
some respects is believed to act similarly to a hormone) produced by the tumour. 
Thus, in theory, reversal of cachexia should be achievable by blocking the action of 
this factor. Several candidate compounds have been proposed as the factor that 
triggers cachexia in cancer patients based on observations of the unusual metabolic 
occurrences before and during weight loss in cachexia.
One compound that has been implicated in signalling the onset of cancer 
cachexia is tumour necrosis factor-a16 (TNF-a), since it has been detected at high 
levels in certain groups of cancer patients17. However, several studies failed to detect 
any increase in TNF-a in cachectic cancer patients18. Also, in animal models, it was 
found that the weight loss was more likely to be due to toxic effects19. Interleukins 
one20 and six21 have also been suggested as the elusive cachectic factors but while 
evidence shows them to be involved, they are not believed to be causative. Several 
clinical studies have reported the increased mobilisation of fatty acids before weight 
loss begins, suggesting the production of lipid-mobilising factors (LMFs) by the 
tumour22. This mobilisation of fats may be an important factor contributing to tumour 
growth and some fatty acids have been found to directly stimulate tumour growth in 
vivo23 and in vitro24 The first indications that the LMF might cause cachexia were 
seen when serum from mice bearing a lymphoma was injected into healthy mice, 
producing massive fat loss25. Other studies showed that the level of LMF in the sera 
of cancer patients was proportional to the extent of weight loss26 and was then 
reduced in patients responding to chemotherapy27. Most studies provide evidence that 
the LMF is an acidic protein but there are many variations in its reported molecular 
weight (6kDa28 to 75kDa29).
Recently there has been a great deal of evidence to support the fact that the 
material is actually a protein-mobilising factor (PMF). This product was first seen in 
1991 in human serum when a study of cancer patients with weight loss displayed 
PMFs in vitro; the factor was not found in healthy subjects30. The PMF has also been 
found in the serum of animals bearing the MAC 16 tumour with weight loss31; the 
factor was not present in the serum of mice bearing the similar but non cachexia- 
inducing MACD tumour32. In 1996, splenocytes from mice bearing the MAC 16 
tumour were fused with mouse myeloma cells to produce hybridomas, which were
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used to produce monoclonal antibodies against the PMF33. The PMF material was 
purified from both murine tumour and human urine sources by use of affinity 
chromatography using the antibody, and appeared to be of identical composition in 
both cases (24kDa, acidic material). The conservation in structure of the PMF 
between murine and human sources suggests that production of a PMF may be 
important in the growth and survival of some tumours. Intravenous administration to 
mice of affinity-purified material from the tumour (30pg protein) or the 24kDa 
material (30ng) produced rapid weight loss, which could be prevented by prior 
administration of the monoclonal antibody34. Furthermore, it was reported by Todorov 
et al. that material of molecular weight (MW) 24kDa had been isolated from the urine 
of patients with cancer cachexia (if their weight loss was greater than 1.5kg per 
month), but not from the urine of healthy subjects, patients with weight loss due to 
trauma, or patients with cancer but no cachexia34. Thus, the evidence that the 
cachectic factor is a PMF has been compelling.
The structural features of this PMF as elucidated thus far are as follows. This 
factor is believed to have a total mass of 24kDa and consists of a central polypeptide 
chain (~2kDa) of unique amino acid sequence34. The polypeptide chain is 
phosphorylated, and is also extensively glycosylated at both asparagine and serine 
residues35, giving it a total MW of 4kDa. There are two sulphated oligosaccharide 
chains attached to the central polypeptide, one is O-linked (MW 6kDa) and one is N- 
linked (MW lOkDa). These carbohydrate chains are also sulphated. It was also shown 
that the N- and O-linked sulphated oligosaccharide chains were both the antigenic and 
the biological determinants. The PMF also binds strongly to albumin producing a 
species of ~ 69kDa33. Because the PMF did not appear to contain glycosaminoglycan 
chains attached to either serine or asparagine residues, it was therefore deemed to be a 
sulphated glycoprotein rather than a proteoglycan. The fact that the cachectic factor is 
a glycoprotein is quite significant because these proteins are known to play a role in 
cellular adhesion and contact inhibition of cell growth in culture. They are also 
responsible for cellular recognition of foreign tissue and may be involved in tumour- 
specific antigenic activity.
As distinct from anorexia, attempts to halt or reverse cachexia by nutritional 
repletion have not been very successful. It has been found that it is not possible to 
reverse the physical composition changes seen in patients with cancer cachexia by the 
provision of extra calories or by dietary counselling36. Limited benefits have been
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seen with the use of two groups of agents a) those stimulating food intake e.g. 
megestrol acetate37 or hydrazine sulphate38, and b) those directly inhibiting the PMF 
e.g. eicosapentaenoic acid (EPA)39. However, while megestrol acetate has been shown 
to improve appetite and food intake leading to weight gain in some cancer patients, 
studies have also shown that host weight gain has been associated with a doubling of 
the weight of the tumour40. Hence there is optimism that the second approach may 
have better success41, and EPA has recently been initiated in clinical trials for patients 
with pancreatic cancer.
Weight loss in cachexia is not only associated with psychological distress and 
a lower quality of life, but through its serious effects on the cardiac and respiratory 
muscle, it can be the direct cause of death of the patient. Hence, any treatment 
regimen for the cachectic patient will have enormous benefits in terms of their general 
well-being, their response to chemotherapy and their overall survival time. In 
addition, since some tumours may depend on the products from host tissue catabolism 
for survival, such therapies may also have anti-tumour effects. However, more 
information about its structure, the circulating levels of it in the body and its exact 
role in mediating cachexia is required.
The aim of this project was to determine the presence of the PMF in the urine 
of cancer patients with cachexia using capillary electrophoresis (CE). The 
examination of human urine by CE for changes in levels of certain proteins is used as 
a diagnostic indicator for many disease states. Some of these assays include the 
monitoring of oestrogens for pregnancy and reproductive disease42, glycosidase 
enzymes for renal disorders43 and imidodipeptides in prolidase deficiency44.
5.1.2 Analytical Background
Analysis of glycoproteins in biological matrices can be achieved by CE, which lends 
itself more favourably to this task when compared to the technique of HPLC. This is 
because proteins have many charged moieties enabling their separation in the electric 
field provided by CE. However, because proteins tend to adhere to a variety of 
surfaces, especially silica, this is an important consideration when using CE for 
protein analysis. If precautions are not taken, proteins can build up on the capillary 
wall causing rapid degradation of the CE separation. There are two approaches to 
avoiding this problem.
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The first approach involves surface modification of capillaries for the 
prevention of these interactions. Chemically coating the surface converts it to a more 
neutral and less adsorptive one. Strege el al. resolved five model proteins with a wide 
range of ionic and hydrophobic character with high migration time reproducibility in 
C18-derivatised capillaries45. The coated capillaries were found to exhibit greater 
precision than bare silica capillaries in this work. Polymeric coatings generally 
demonstrate greater stability than non-polymeric coatings, hence many of the 
chemical derivatisation reactions of capillaries for CE over the past few years 
incorporate polymer chemistry46. Poly(acrylamide)-coated capillaries were used to 
simultaneously separate acidic and basic proteins with high resolution47. Gilges et al. 
used poly(vinylalcohol) to both permanently and dynamically coat silica capillaries in 
their analysis of highly charged proteins. They used a thermal immobilisation process 
for the permanent coating48. Other types of polymer coatings employed in the 
determination of proteins by CE are hydrogels which swell in aqueous environments, 
eliminating the interaction of large molecules with the surface49, and hydrophilic 
polymers e.g. dextran, which are reported to have excellent stability in the presence of 
detergents and at extremes of pH50. However, there are disadvantages associated with 
the use of coated capillaries such as batch-to-batch variability50,51 and poor stability 
over wide pH ranges. Irreproducibility of coated capillaries is thought to be due to the 
differences among silanisation reagents, the presence of water in the reagents which 
can facilitate unwanted polymerisation, and undesirable polymerisations taking place, 
catalysed by the byproducts of silanisation51.
The second approach in minimising protein interactions with the silica surface 
involves using particular buffers and/or the addition of a modifier to the run buffer for 
CE analysis. CZE was used for the separation of insulin and its deamidation products 
in an untreated capillary by using zwitterions and acetonitrile in the migration 
buffer52. Under these conditions, reproducibility of the runs was high and rinsing of 
the capillary with base between runs was unnecessary. Hydroxypropylmethyl 
cellulose was incorporated into an acidic phosphate buffer for the determination of 
histone variants and their derivatives on a fused silica capillary53. The presence of the 
additive eliminated interactions of the basic proteins with the capillary wall. Some 
examples of relevant protocols that employed ordinary fused silica specifically for 
glycoproteins are given in Table 5.1 below. In these cases, borate buffer is usually 
used for glycoproteins since it can dynamically interact with the diols of the
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carbohydrate groups, affording improved separating ability54’55’56 The presence of 
carbohydrate groups on the PMF being investigated in this project meant that the use 
of borate buffer would aid in its detection by CE methods.
Table 5.1 : Some Methods for the Analysis of Glycoproteins by CE using 
Uncoated Fused Silica Capillaries
Analyte & Matrix Run Buffer Comments Reference
Glycoproteins in 
ovalbumin mixture
Borate buffer with 
lmM putrescine
5 major protein peaks 
resolved in 30 min.
Landers, 1992 [55]
Ribonuclease B 
glycoforms
Borate buffer 5 glycoform 
populations found
Rudd, 1992 [56]
Plasminogen 
activator, fetuin and 
a 1 -acid-gly coprotein
Tricine buffer (pH 
8.2) with 1.25mM 
putrescine
High resolution of the 
glycoforms was 
obtained within 20 
min.
Taverna, 1992 [58]
Glycoforms of
recombinant
erythropoietin
Putrescine and 
urea added to run 
buffer
The additives caused 
the EOF to decrease 
and the resolution to 
increase
Watson, 1993 [59]
Peptide map of 
erythropoietin
Phosphate buffer 
(pH 2.5) with 
lOOmM heptane- 
sulphonic acid
The heptane-sulphonic 
acid also functioned as 
an ion-pair reagent
Rush, 1993 [57]
Sometimes a modifier is added to the buffer to enhance separation of 
glycoproteins, the most popular of which is putrescine (1,4-diaminobutane). 
Putrescine has been used in the run buffer to improve the resolution of a mixture of 
glycoproteins in ovalbumin55, the carbohydrate moieties of glycoproteins58 and the 
glycoforms of recombinant erythropoietin59. In between injections, rinsing of the 
uncoated capillary with strong base and/or water is carried out to ensure that there is 
no build-up of adsorbing protein. Some of the advantages of the use of bare silica 
capillaries includes the fact that batch-to-batch reproducibility is excellent, the surface 
is stable over a wide pH range and if blockage of the capillary does occur, aggressive 
cleaning with strong acids and bases is possible, while this is not the case with coated 
capillaries.
The objectives of this project were to identify and qualitatively determine the 
presence of a the PMF (and potentially its albumin-bound complex) in the urine of
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cachectic cancer patients and to show it not to be present in the urine samples of 
healthy subjects or cancer patients who were not cachectic. This was to be achieved 
using the technique of CE.
5.2 REAGENTS AND MATERIALS
5.2.1 Equipment
Two capillary electrophoresis instruments were used in the course of this work. The 
first was from Applied Biosystems (Foster City, CA, USA), model 270A-HT and the 
second was from Hewlett-Packard (Palo Alto, CA USA), model HPCE 3D with built- 
in diode-array detector. The high sensitivity optical cell assembly (Z-cell) for the ABI 
CE system was obtained from LC Packings Inc. (San Francisco, CA, USA) and the 
extended light path capillary (bubble cell capillary) for the HPCE was purchased from 
Hewlett-Packard as above.
5.2.2 Reagents and Chemicals
All chemicals, unless otherwise stated, were analytical grade and were obtained from 
the manufacturer at the highest available purity. Sodium hydroxide (NaOH), sodium 
tetraborate and boric acid were purchased from Sigma (St. Louis, MO, USA). 
Ammonium sulphate ((NH^SO^, analytical grade, was purchased from Mallinckrodt 
(Holland). The model protein a 1-acid-glycoprotein (AGP) of MW 44kDa and pi 2.7 
was obtained at 99% purity from Sigma (cat. no. G3643, 25mg bovine AGP). All 
other chemicals were of analytical reagent grade. Distilled water was used throughout 
this work.
5.2.3 Other Materials
Uncoated fiised silica was purchased from Polymicro Technologies (Phoenix, AZ, 
USA). The detection window was created by burning off a small section of the 
polyimide coating, and the excess residue was then gently wiped away with methanol. 
Minicon® B15 concentrators were obtained from Ami con (Beverly, MA, USA). 
Dialysis tubing with 12-14kDa exclusion size, % inch diameter, cat. no. 15961-022, 
was obtained from GIBCO BRL (Life Technologies, MD, USA). The urine dipsticks
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used were Bayer Multistix SG from Bayer Corporation, Diagnostics Division 
(Elkhart, IN, USA).
5.3 EXPERIMENTAL
5.3.1 Urine Collection
Spot urine samples were collected from patients who were on a routine check-up at 
the Lombardi Cancer Centre in Georgetown University, Washington DC. This study 
was endorsed by the Bioethics Committee. Under conditions of informed consent, 
urine samples were collected in 200ml plastic urine cups, labelled with relevant 
patient details (time of collection was referred to simply as ‘morning’ or ‘afternoon’) 
and were immediately placed on ice. No preservatives were used.
5.3.2 Preparation of Reagents
Stock borate buffer (lOOmM, pH 9.2) was prepared on a twice-weekly basis by 
dissolving sodium tetraborate in distilled water. It was diluted as appropriate for use. 
The borate buffer solution and all other aqueous solutions were filtered under vacuum 
through a 0.22(j.m filter and subjected to sonication for 20 minutes before use. The 
80% w/v (NH4)2 S0 4  was prepared by dissolving 8g in 10ml of aqueous sample unless 
otherwise stated. Solutions were stored at 4°C when not in use.
5.3.3 Preparation of Urine Samples
Within one hour of collection, the urine samples were subjected to dipstick analysis to 
qualitatively examine levels of various compounds in the urine i.e. glucose, ketone, 
blood, protein, urobilinogen, bilirubin, specific gravity, pH and nitrite. The most 
relevant of these measurements to this project were protein, blood and bilirubin. All 
results were recorded on the patient ‘chart information’ form (see Figure 5.1). Each of 
the samples were divided into two portions and labelled accordingly. One was kept at 
4°C (to be used on the same day) and one was frozen at -30°C. Each urine sample 
(fresh or thawed from frozen) was centrifuged for 10 min. @ 2000rpm at 4°C to 
sediment any particulate matter, although fresh samples were usually free of such 
sediment. For the concentration and dialysis step, 5ml of urine was transferred into
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the rinsed cell of a minicon® B15 unit using a 9 inch pasteur pipette. The cell was 
tapped gently to remove any air bubbles. The 5ml sample was left standing until it had 
been concentrated 50 times to 100|il (this usually took 1 to 2 hours), whereupon it was 
removed by pasteur pipette and transferred into a 1.5ml eppendorf tube. This sample 
could be frozen at -30°C if it was not to be used immediately, or diluted as 
appropriate with water whereupon it was now ready for CE analysis. The frozen 
extracts were stable for at least three weeks. The minicon® unit was stored at 2-4°C in 
the fridge until further required.
Figure 5.1 : Typical Chart Information Form
CHART INFORMATION
DETAILS TAKEN BY : 
PATIENT NAME :
•aA M e  D ATE. S / ( a / W „
ID NO : ■
DATE OF BIRTH : -------- ETHNIC ORIGIN :
W EIG H T: Jfcg .  .. HEIGHT : — ---------------B M I: ------- ------------
Diagnosis: (/AiSA Coach/- W hm  diagnosis was made: 1^14»
Uucr fAiU'S 
Doctor Attending: f i r ,
Treatment History: S’ FlA
PaM. 2.OYA0
CpirfntTherapy: frotordie- **9
£2u_pOJttU"
Adverse Reactions: fW lcdL K  C*M
Smoke/Drinlc: ^  IS uJtflA (WVm) . e W c
cd ooVurl
WEIGHT CHANGE! S 4 f f .  12. IIV »  3 ^ J |
I So JXo 111 Ho
U k rtH jA fl l  jSaiK  o A 10 Xlo
Glucoat ( 5  
Ketone 0  
Blood "T ract 
Protein "T ract 
Urobilinogen 0 .  'L
Bilirubin 0  
Specific Gravity I. OI 
pH 5 . 0
Nitrite Q )
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5.3.4 CE Conditions for A BI System
The final run conditions used a Z-cell extended light-path capillary (57cm fused 
silica, effective length 36cm). The other conditions were as follows: the electrolyte 
buffer was borate buffer (50mM, pH 9.2), the voltage was 13-15kV (current 60-85|oA) 
for 50 minutes, the injection was by pressure for 5 seconds, the UV wavelength 
monitored was 200nm, and the rinse schedule between injections consisted of 2 
minutes of NaOH (0.1M), 2 minutes of water and 2 minutes of electrolyte buffer. The 
capillary was conditioned each morning by flushing with air for 5 minutes, with 
NaOH (0.1M) for 10 minutes, with water for 10 minutes and with borate buffer for 10 
minutes. Each evening, the capillary was rinsed with water for 20 minutes and stored 
as such overnight.
5.3.5 CE Conditions for H P System
The final run conditions used a bubble cell extended light-path capillary (64.5cm 
fused silica, effective length 56cm) which is shown in Figure 5.2. The other 
conditions were as follows: the electrolyte buffer was borate buffer (60mM, pH 9.2), 
the voltage was set at 24kV for 35 minutes, injection was by pressure (50mbar) for 10 
seconds, the UV monitoring wavelength was 200nm and the rinse schedule consisted 
of 2 minutes of NaOH (0.2M) followed by 2 minutes of water and 2 minutes of 
electrolyte buffer. Conditioning of the capillary each morning was carried out by 
flushing for 5 minutes with air, for 10 minutes with NaOH (0.2M), for 10 minutes 
with water and finally for 10 minutes with borate buffer. Each evening, the capillary 
was rinsed with water for 20 minutes and stored as such overnight.
5.4 RESULTS AND DISCUSSION
5.4.1 Optimisation o f Urine Collection Procedure
In the early stages of the project, 24-hour urine collection was considered. However, 
owing to the difficulties associated with this protocol such as patient compliance and 
the handling and storage of large volumes of urine, it was decided to take spot urine 
samples. Also of importance at this stage was the fact that it was not known if any 
qualitative differences would be seen between the cachectic and non-cachectic urines,
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so no purpose would have been served by collecting large volumes of urine for 
analysis.
Figure 5.2 : Cross-sectional Diagram o f Bubble Cell for HP CE System
Extended 
light path
Because the urine samples were random specimens, there were many variables 
that could affect the nature of the urine sample. Some of these included times of day, 
void volume, age and sex of the patient, drug therapy and type of cancer. As much 
information as possible was obtained from the patients’ charts at the time of receiving 
the samples, so that it could be used later if required. As previously mentioned, the 
exact time of day was not recorded and samples were simply referred to as ‘morning’ 
or ‘afternoon’, depending on whether they were provided during morning or afternoon 
clinic, respectively.
Samples were kept on ice until analysis to conserve their integrity and in order 
to treat all samples in the same way and eliminate temperature differences.
5.4.2 Development o f CE Conditions for ABI System
The development of the analytical procedure were based on the analysis of the model 
protein AGP, since no standard PMF was available. AGP has a similar molecular 
weight, pi and general characteristics as the PMF structure reputedly has. Starting 
conditions were based on the typical conditions that other authors had used in their 
analysis of proteins or glycoproteins in urine. Since most CE analysis of glycoproteins 
has taken place successfully on bare silica capillaries, these were employed in this
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assay. The total length of the silica capillary (with Z-cell) was 57cm but the effective 
length was 36cm.
The background electrolyte was a borate buffer for the reason that it 
complexes with the diol groups of carbohydrates affording better separation. The 
other advantage of borate is its high pH (pH 9.2) which limits adsorption of the 
proteins to the wall of the capillary by keeping both the wall and the proteins 
negatively charged, thus limiting their mutual interaction because of charge repulsion. 
It has been used by many authors for the analysis of glycoproteins or proteins55,56,60,61. 
The borate buffer was prepared to 50mM concentration since the lower ionic strength 
(25 mM) gave very early-eluting peaks, which although sharp had low peak areas, 
while higher ionic strength buffer (75 or lOOmM) gave very late-eluting peaks, which 
were very broad in shape. The pH was maintained at 9.2 for a number of reasons. 
Lowering the pH of the borate buffer (by addition of boric acid, 50mM) reduced the 
current quite significantly causing an immediate and dramatic loss of resolution. 
Higher pH, with NaOH, did not result in any significant gain (or loss) of separating 
ability and hence was not used.
The UV wavelength used for most protein separations by CE is 200nm60’62, 
and proved to give optimum response for the urine samples in this work when 
compared to 214nm and 280nm. The 200nm wavelength was also found to give 
maximum response for the model protein AGP.
The voltage was set at 15kV initially but for later samples such as the 
minicon® extracts, it was necessary to lower the voltage to 13kV. This was because it 
was recommended that the current should not exceed lOOpA under the experimental 
conditions in use.
The rinse schedule was based on similar schedules seen in the literature60,62 
and it consisted of 2 minutes of NaOH (0.1M), 2 minutes of water and 2 minutes of 
run buffer. Injection was by pressure for 5 seconds.
5.4.3 Optimisation o f Sample Preparation Procedure
Generally for urine analysis, sample preparation may or may not be required, 
depending on the substance under test, though direct injection of urine has been 
possible in many applications where compounds in urine have been detected. Various 
metabolites in urine were determined by direct injection by Jellum et al. . The high 
ionic strength borate buffer (300mM) they used appeared to dissolve any precipitates
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present. Creatinine and calcium and other inorganic cations in urine were also 
determined following direct injection (after a simpie 1:50 dilution in buffer)63. Ideally, 
direct injection or injection following a simple dilution would have been the 
procedure of choice. However, it was not possible to inject untreated urine, or to 
inject a urine sample following â simple dilution step with water or run buffer. This 
was because, as it can be seen from Figure 5.3, there were too many compounds 
present in these samples. So it was decided that some clean-up of the sample was 
required. A number of sample preparation procedures were hence investigated in this 
work.
The first and simplest procedure investigated was to subject the urine samples 
to centrifugation for 10min. @ 3000g at 4°C to sediment any particulate matter. 
Capillary electrophoresis of the diluted supernatant yielded electropherograms very 
similar to those obtained in Figure 5.3.
Figure 5.3 : Electropherograms o f Urine Samples subjected to different Sample
Preparation Procedures
mV
r-»
La/ V
SO mil) « 50 min. 50 win.
Neat urine sample I Urine sample diluted f  Urine sample diluted I in
injected directly 4 1 in 20 with water 20 with borate buffer
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Precipitation with 80% w/v (NFL^SC^ was also tried. This is a common 
biological sample preparation step, and had been used by Todorov et al. when 
isolating the PMF from the urine of cancer patients34. This procedure was carried out 
by adding 8g of (NH^SC^ directly to 10ml of fresh urine (80% w/v solution) and 
stirring for 24 hours at 4°C. The precipitated protein was recovered and dissolved in 
lml of 25mM borate buffer and injected onto the CE system. However, the resulting 
electropherograms were very poor, possibly due to the very high ionic strength of the 
sample at this stage.
Dialysis of the urine samples was carried out with a view to removing small 
molecular weight species from the matrix. The urine sample (10ml) was placed into 
dialysis tubing with a MW cut-off of 12-14 kDa and stirred in a large water-filled 
container at 4°C for 4 days. The water in the container was changed every 6 hours 
where possible. Since the cachectic factor, if present, would have a MW of 24kDa, 
this meant that it should remain in the dialysis tubing. Samples were removed from 
the tubing after 1,2 and 4 days and injected directly onto the CE system. Results in 
Figure 5.4 shows that the extent of dialysis had a large effect on the removal of 
compounds from the urine. Although the procedure did clean up the samples, the 
length of time required meant that this procedure was prohibitively lengthy.
Also investigated was the combination of (NH^SC^ precipitation and 
dialysis. The protein pellet which remained after 24 hours of precipitation with 
(NH4)2 S0 4  was resuspended in lml of water and dialysed as described above. It was 
envisaged that the small molecular weight species in the pellet would be removed by 
dialysis, leaving only larger molecular weight molecules such as the PMF. The 
resultant electropherograms showed a conglomerate of peaks with very poor 
definition. It was realised that this technique would involve the introduction of large 
errors due to extensive manual handling of the sample and losses during the dialysis 
step.
The final sample preparation protocol examined was the use of minicon® B15 
static dialyser units. A diagram of such a unit is shown in Figure 5.5. These units had 
been used very successfully by Jenkins et al. for the quantitation of human urine 
proteins such as the Bence Jones protein60. When used, it was found to eliminate 
almost all of the small molecular weight species in the urine samples, simplifying the 
identification of the larger molecules present.
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Figure 5.4 : Electropherograms of Urine Samples following Dialysis
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Figure 5.4 : The units of the vertical axis in each case are millivolts (mV) and all 
electropherograms arc to the same scale.
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Figure 5.5 : Diagram of Minicon B15 Static Dialyser
The 5ml urine sample was centrifuged for 10 min. @ 3000g at 4°C to 
sediment any particulate matter and the supernatant was added to the minicon® B15 
cell using a pasteur pipette. Prior to this, the cell was rinsed with deionised water 
according to the manufacturer’s instructions. The 5ml sample was left standing until 
its level reached the 50x mark on the cell, where it was now of an approximate 
volume of 100(j.l (this usually took 1 to 2 hours). The extract was then removed by 
pasteur pipette and diluted as appropriate with water i.e. 40^1 in 200^ .1 (if concentrated 
urine) and 80^ 1 in 200^1 (if dilute urine).
The decision as to whether urine was ‘concentrated’ or ‘dilute’ was based on 
visual inspection of the colour and turbidity as well as taking into account the total 
void volume (if available). The darker, more opaque samples, which usually came 
from smaller void volumes were found to be more concentrated than the paler, clearer 
samples, which usually came from larger void volumes. Distinguishing between 
‘concentrated’ and ‘dilute’ samples by a dilution factor of two resulted in all 
electropherograms being comparable in terms of the five most important marker 
peaks.
The resulting electropherograms (Figure 5.6) obtained for the urine samples 
using the ABI CE, after employing the minicon® static dialyser unit, showed much
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improved peak profiles and there was a definite pattern seen in all the samples 
subjected to this procedure. Since this procedure could both dialyse and concentrate 
the urine in less than two hours of unattended operation, it proved to be the most 
efficient sample preparation procedure. It was also found, on investigation, that a 
minicon® cell could be used twice for the same sample i.e. two separate 5ml portions 
of a urine sample could be concentrated without any loss of efficiency (see section 
5.4.6).
5.4.4 Development of CE Conditions for HP System
During method development, the higher specification HP CE became available for use 
and so the ABI CE conditions were modified such that similar profiles of the urine 
samples could be obtained on the HP instrument. Initial run conditions used for this 
system were as follows : the capillary was bare fused silica with bubble cell (64.5cm x 
50pm i d.), the electrolyte was borate buffer (50mM, pH 9.2), the voltage was 24kV 
(65pA) with a 40 minute run time, the injection was by pressure (50mbar) for 5 
seconds, the UV monitoring wavelength was 200nm, and the rinse schedule consisted 
of 2 minutes of NaOH (0.1M), 2 minutes of water followed by 2 minutes of run 
buffer, also as before. The total length of the silica capillary was 64.5cm but the 
effective length was 56cm. The remaining parameters were as close as possible to 
those used with the ABI CE system (with Z-cell) and the conditions produced 
electropherogram profiles similar to those obtained with the other instrument (see 
Figure 5.6).
There was no Z-cell available for the HP CE instrument but there was a bubble 
cell capillary, so this was used instead. Although the Z-cell is reported to give 10-fold 
improvement in sensitivity, while the bubble cell is reported to give only 3 to 5-fold 
improvement, no major loss in response was noted in method transfer from the ABI 
CE to the HP CE. In fact, the peaks obtained were sharper, and resolution was 
improved.
After some initial experiments on patient samples, it was found that the 
migration times of the peaks were drifting quite significantly over the course of a 
sequence run. This was thought to be possibly due to buffer strength and/or buffer 
replenishment problems. Hence, the buffer vials were replenished periodically (every 
four hours during an overnight run) and borate buffer was prepared to the slightly 
higher ionic strength of 60mM, pH 9.2. The pressure injection was increased to 10
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BP C l Electropherograms
Figure 5.6 : Comparison of Urine Profiles from ABI CE and HP CE Instruments under similar Operating Conditions
seconds from 5 seconds and 0.2M NaOH was used instead of 0.1M, to ensure the 
capillary was cleared of any residual adsorbing protein in between injections. The 
combination of these changes to the method had the effect of increasing the retention 
times for the various peaks in the urine profiles under investigation. These conditions 
also served to improve separation between the peaks in the characteristic peak profile.
5.4.5 Identification of Cachectic Factors in Patient Samples by CE
5.4.5.1 Profiling of Urine Samples from Non-Cachectic Subjects
A number of urine samples from healthy subjects (n=7) and cancer patients with no 
cachexia (n=13) were run by CE. There were no apparent differences between the 
urine sample profiles of the two groups (Figure 5.7). Characteristic profiles resulted, 
with each sample containing the five expected peaks (in various proportions). Peaks
1,2,3,4 and 5 had migration times of 8±1,11+1,16+1,23+2 and 30±2 minutes, 
respectively. These peaks later became useful as markers because each of these 
components had a different UV spectrum which facilitated peak tracking when 
migration times drifted or if additional peaks were found to be present in samples. In 
samples where the later-eluting peaks were found to have drifting migration times, the 
time of their analysis usually corresponded to a change in temperature in the 
laboratory. For example, during the night, the temperature (on occasion) was found to 
drop by two or three degrees.
5.4.5.2 Rationale for Profiling Urine Samples from Cachectic Subjects
Although no pure standard of the PMF was available, it was decided to examine urine 
samples from cachectic cancer patients with the expectation that an extra compound, 
corresponding to the cachectic factor, would be found in the latter group of urine 
samples. The rationale for this was twofold. Firstly, there was the previous 
compelling evidence for the presence of the PMF in urine of cachectic cancer patients, 
hence there was a good possibility of resolving the factor in the urine of this group of 
cancer patients diagnosed to have cachexia34. Secondly, the small molecular weight 
species had been removed from the samples and there are few proteins eluted in urine, 
especially of MW > 15kDa, so it was expected that if the PMF (MW ~ 24kDa) was 
present, it would be clearly visible.
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Figure 5.7 : Electropherograms of Urine Samples from Healthy Subjects and
Non-Cachectic Cancer Patients
Figure 5.7 : Overlay of urine samples from healthy subjects and cancer patients with no cachexia. 
Peaks 1,2,3,4 and 5 appear to be characteristic to all urine samples from normal subjects and 
cancer patients with no cachexia. CE conditions as per text.
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5.4.5.3 Profiling of Urine Samples from Cachectic Subjects
First Time Analysis of Samples
The urine samples of eight cancer patients who had been diagnosed as cachectic were 
obtained and subjected to analysis by CE under the same conditions as were used for 
the urine from non-cachectic patients. Urine from healthy individuals was run in 
conjunction with the cachexia samples for the purposes of comparison. Relevant 
information from their chart information forms has been tabulated in Table 5.2. It is 
obvious that, in the case of each patient, there had been relatively recent weight loss 
prior to the taking of the urine specimens.
Table 5.2 : Information on the Cancer Patients Diagnosed with Cachexia
Patient
ID
Number
Age Ethnic
Origin
Height
(inches)
Weight 
Information 
(most recent weight taken)
Cancer
Type
1 64 Caucasian 68.25 186-1821b over previous 2 
months
(1821b in Sept. 97)
lost 10-151b since beginning
chemotherapy in April 97
Prostate 
and bone 
cancer
2 51 Caucasian 70 127.51b (had lost weight 
prior to visit)
Esophageal
cancer
3 45 Caucasian 69 202-1641b over previous 9 
months
(1641b in June 97)
Colon, 
liver and 
lymph 
nodes 
cancer
4 86 Caucasian 67 142-1301b over previous 7 
months
(1301b in Sept. 97)
Stomach 
and liver 
cancer
5 73 African 72 170-1591b over previous 6 
months
(1591b in Sept. 97)
(1531b in Oct. 97)
Pancreatic
cancer
6 77 Caucasian 67.5-68 160-13 lib over previous 11 
months
(1311b in Sept. 97)
Prostate
cancer
7 44 Caucasian 62 93-821b over previous 12 
months
(821b in Oct. 97)
Gastric and 
ovary 
cancer
8 63 Caucasian 64 148-1341b over previous 10 
months
(1401b in Sept. 97)
Pancreatic 
and liver 
cancer
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Of this particular group of individuals (patients 1-8 in Table 5.2), it was found that 
there were two extra peaks in the electropherograms of 6 of the 8 patients, thought to 
be the cachectic factor (PMF) and its albumin-bound complex. These were referred to 
as cachectic factors 1 and 2 and had migration times of 13±1 and 25±3 minutes, 
respectively. These cachectic factors were present in the urine of the patients 
highlighted in Table 5.2, and examples of these electropherograms can be seen in 
Figure 5.8. The factors were thus present in 75% of the cachectic cancer patients 
investigated and were never seen in the urine of healthy subjects or in the urine of 
patients with cancer but no cachexia. The positive samples were reanalysed a number 
of times to confirm these findings. In each case, the electropherograms were identical.
Repeat Analysis o f Samples
In order to check that these results were genuine in the patients who tested positive
i.e. cachectic patients 1,2,4,5,6 and 8, it was decided to take repeat urine samples 
where possible. Four of the patients (2,4,5 and 6) that had tested positive on the first 
occasion agreed to provide a second specimen two weeks later. These samples were 
obtained as before, prepared using the minicon® cells and run under the usual CE 
conditions. These new samples (referred to as sample B) were run in conjunction with 
the previous positive urine sample (sample A) that had been donated by the patient. In 
the case of patients 2 and 6, the urine profiles obtained were identical in almost every 
respect, with the cachectic factors appearing in both samples A and B. However, in 
the case of patients 4 and 5, although the profiles were identical in all other respects, 
the factors were absent from sample B. This is illustrated in Figure 5.9.
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Figure 5.8 : Electropherograms of Urine Samples from Healthy Subjects and
Cachectic Cancer Patients
Figure 5.8 : Overlay of urine samples from healthy subjects and cancer patients with cachexia. 
Peaks 1,2,3,4 and 5 appear to be characteristic to all urine samples from normal subjects and 
cancer patients with cachexia. However, the two peaks marked ‘Factor 1’ anti ‘Factor 2’ arc 
particular to the urine samples from cancer patients with cachcxia.
222
Figure 5.9 : Electropherograms of Repeat Urine Samples from Cachectic Cancer Patients
Figure 5.9 : Overlay of urine samples A and B from cachectic cancer patients. Sample A was taken two weeks prior to Sample B. 
Factor 1 and Factor 2 were evident in both samples for patient 6. However, the factors were only present in Sample A for patient 5.
5.4.6 Reusability of the Minicon@ B15 Cells
A urine sample (from cachectic patient 8) was subjected to the sample preparation 
procedure using the minicon® B15 cell to dialyse and concentrate the sample. A few 
days later, a second aliquot of the urine sample, which had been frozen during that 
time, was concentrated as before in the same minicon® cell that had been used for the 
sample on the first occasion and that had been stored at 4°C. When both samples were 
injected onto the HPCE instrument and run under the usual CE conditions, the results 
showed that interferences were removed to the same extent on both occasions. In 
addition, the peaks were usually of the same height and comparable area, showing 
that this sample preparation technique was very reproducible. Examples are shown in 
Figure 5.10.
5.4.7 Identification of Cachectic Factors in Patient Samples by their UV 
Spectra
The UV spectra of the cachectic factor and its albumin-bound complex were identical, 
but they differed from the other typical components of urine (see Figure 5.11). This 
allowed the cachectic factor peaks to be located on CE electropherograms (using the 
PDA detector) even when migration times had changed slightly due to external 
factors.
5.4.8 Identification of Cachectic Factors in Patient Samples by Immunoblotting
To confirm that the factors seen in these electropherograms were the same as those 
seen by Todorov el a/.34,35, a sample of antibody to the PMF was obtained from the 
UK. When Western Blotting of positive urine samples (patients 2 and 6) was carried 
out, the immunoblots of the samples revealed two bands as expected -  corresponding 
to the PMF and the albumin-bound PMF. When Western Blotting of negative urine 
samples (healthy subjects and non-cachectic cancer patients) was carried out, no 
bands appeared on the immunoblots. This evidence suggested that the two peaks seen 
in 75% of the cachectic cancer samples investigated were the PMF and its albumin- 
bound complex, as seen by Todorov et al. in the urine of cachectic cancer patients in 
199634.
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Figure 5.10 : Overlaid Electropherograms of the same Urine Sample prepared 
on two different days using the same Minicon® Cell
Figure 5.10 : Overlay of urine sample (from cachectic patient 8) prepared on different days using 
the same minicon® extraction ccll. Peaks 1,2,3,4 and 5 along with cachcctic factors 1 and 2 arc 
clearly visible.
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Figure 5.11 : UV Spectra of the Cachectic Factors
Figure 5.11 : Overlay of urine samples from a healthy subject and a cancer patient with cachexia. 
The inset diagram contains overlaid UV spectra from Factor 1 and Factor 2.
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5.4.9 Diagnosis and Prevention of Cachexia
Because there are no definitive clinical criteria for the diagnosis of cachexia, 
diagnosis by physicians of cachexia in cancer patients is still subject to error. This is 
due in part to the fact that the body weight of most cancer patients will rise and fall 
during their therapy. Some weight loss may have non-cachectic causative factors such 
as lack of appetite, nausea, apathy or changing body mass dynamics while on 
chemotherapy. However, cachexia is more certainly the cause if there is a continuous 
decline in body mass and an inability to replace lost weight.
There is, as yet, no cure for cachexia and current therapies, at best, serve only 
to slow the progress of the disease. However, diagnosis of cachexia is important in 
terms of treating the underlying cancer. Chemotherapy may be altered in light of the 
fact that a patient is diagnosed as being cachectic.
Should a real relationship be found between clinical cachexia and the presence 
of the cachectic factors in the urine, as is indicated in this work, there is potential for
a) a more objective method of diagnosing cancer cachexia (and possibly its severity),
b) prediction of onset of cachexia, c) elucidation of the structure of the PMF, and 
ultimately d) prevention of cachexia in cancer by inhibition of the PMF.
5.4.10 Further Work
This project is being continued in Georgetown University Medical Centre, 
Washington DC in order to develop a quantitative assay by CE for the measurement 
of these factors in urine. There is a proposal to carry out a large-scale clinical study in 
conjunction with the Lombardi Cancer Centre, Washington DC over two years. 
Analysis of the urine of healthy subjects, non-cachectic and cachectic cancer patients 
will be undertaken to prove an association between the presence of these factors in the 
urine and the presence of cachexia. The patients’ weights would be monitored 
carefully over time and the presence or absence of the cachectic factors in their urine, 
in addition to their concentrations would be followed. Immunoblotting techniques 
would be used to verify these results. There is hope that the levels may be correlated 
with the severity of the cachexia. This may prove to be an excellent approach for the 
prediction, objective diagnosis and monitoring of cachexia in cancer patients.
In parallel with this, CE-MS is also being carried out in Hewlett-Packard 
Laboratories in Palo Alto, California with a view to elucidating the full structure of 
this PMF. Once the structure is known, pure standards can be produced/isolated and
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research could begin into discovering more about this molecule’s exact role in 
mediating cachexia. Attempts to inhibit the action of this PMF in cancer patients may 
then be possible, and a therapy for treatment of cachexia could be developed.
5.5 CONCLUSIONS
A random urine sample was collected from normal subjects, cancer patients and 
cancer patients with cachexia at a general oncology clinic. These samples were 
concentrated (50x), dialysed to remove small molecular weight species (< 15kDa) and 
further diluted in water. HPCE analysis of the samples revealed the presence of two 
peaks in the electropherogram (in 75% of the samples) uniquely associated with the 
presence of carcinoma cachexia. These factors were not present in the urine of the 
healthy subjects or cancer patients who were not experiencing weight loss. The urine 
samples that gave positive results for the factor were from patients with different 
cancers, undergoing a range of therapies and who were of both sexes and all ages. The 
urine samples containing the cachectic factor peaks were subjected to immunoblot 
analysis using antibodies raised against PMF. Analysis of the immunoblots revealed 
the presence of the PMF factor and its albumin-bound complex by the presence of two 
bands of the correct molecular weight. Strong evidence is emerging to suggest that the 
factors reported by Todorov et a l 34 and the factors detected in this study by CE are 
identical. Ultimately, an assay would need to be developed to quantify PMF levels in 
the urine of patients and to correlate these levels with clinical status. Further 
investigation into the role and structure of the PMF may be one way to approach the 
difficult task of preventing cachexia.
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CONCLUSIONS AND SUM M ARY
Sample preparation is often the most time-consuming step in any analytical protocol 
since manual handling of the sample is usually involved. While advances in 
instrumentation continue to reduce analysis times, the proportional length of time 
required for sample pretreatment becomes relatively greater, especially if the analyte is 
to be determined in a biological fluid. The main aim of the work described in this thesis 
was to develop analytical methodologies involving HPLC and CE which would involve 
the minimum number of manipulations to be performed on small biological samples 
and which could be rapidly executed while taking into account the selectivity and 
sensitivity requirements of the method. The methods selected presented particular 
challenges in terms of the sampling, pretreatment, analysis and validation steps. Before 
embarking on the development of these biopharmaceutical protocols for biological 
samples, certain criteria were considered. These included the chemical behaviour and 
metabolism of the compound, the nature of any interferences which could be carried 
through sample preparation and which would thus have some bearing on the analytical 
techniques selected, and the extent of validation required.
Four discrete problem areas with medical applications were carefully chosen on the 
basis that they were complex in terms of their analytical requirements. The target 
analytes (drugs or amino acids) were usually in difficult matrices such as plasma and 
urine, and were quantified successfully by HPLC or CE. All aspects of the processing 
of the sample were investigated, from blood collection through injection, separation, 
detection and data handling. A variety of sample preparation techniques were tried in 
each case before electing the optimum for the analyte(s) in question, bearing in mind 
the chosen instrumental technique.
The general approach to analytical method development in each problem area was 
carried out based on the following key stages :
• A literature survey was carried out to identify previous work, and a proposed 
methodology was devised that would represent significant improvements over 
prior methods
• The procedures for taking the biological samples were established
The pretreatment of the samples was investigated with respect to reducing 
endogenous interferences, while ensuring the integrity and recovery of the 
analyte(s)
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• Derivatisation, if required for increased selectivity or sensitivity, was introduced at 
this stage
The analytical separation method for the determination of the compound(s) of 
interest was developed by varying one parameter at a time
• The overall method was subjected to statistical evaluation and validated according 
to conventional ICH parameters
In the first experimental work, which was based on the diagnostically important amino 
acid taurine, a method was required for its determination in human platelet-rich 
plasma. A number of sample pretreatment procedures were systematically investigated 
and these included ultrafiltration, ion-exchange extraction, and protein precipitation 
with strong acids such as perchloric acid. Ultimately, acetonitrile precipitation was 
shown to give the best recovery. Fluorescamine was shown to be a successful agent 
for the derivatisation of taurine whereas hypochlorite derivatisation (used in previous 
assays for amino acids) was found to yield an unstable derivative.
Novel aspirin derivatives were evaluated as prodrugs for transdermal aspirin (ASA) 
delivery using direct injection and reversed-phase HPLC. However, before the 
prodrugs were evaluated in terms of their ability to permeate the skin, a number of 
other tests were carried out on each compound. These were purity testing and 
degradation profiling (for which both TLC and HPLC were employed) as well as the 
effect that these prodrugs had on platelets. Of the initial seven derivatives, only four 
showed sufficient potential to warrant the final transdermal experiments. Following in 
vitro application of the derivative to mouse skins, samples from the PBS-filled wells 
of the Franz Cell apparatus could be injected directly onto the isocratic HPLC system. 
This allowed quantitation of ASA and its metabolite salicylic acid (SAL) and was 
followed by a gradient to elute the parent compounds in the same run. The validated 
method was used to examine levels of ASA and SAL released transdermally by the 
prodrugs, demonstrating that certain candidate compound(s) were appropriate for 
further pharmacological testing.
Sample pretreatment protocols in published methods for the determination of ASA and 
SAL in plasma are usually very labour-intensive involving solvent extraction and 
protein precipitation. In this work, column-switching HPLC with on-line solid-phase 
extraction (SPE) was for the first time shown to be a valuable approach for the 
determination of ASA and SAL in human plasma. It was shown to be essential to 
optimise the dimensions, the particle size and the type of material in the extraction
235
column for direct injection of plasma onto the system. This semi-automated method 
was extensively validated. Excellent recoveries of the analytes from the plasma (better 
than all previous HPLC methods for these compounds) obviated the need for an 
internal standard. The sampling procedure i.e. type of anticoagulant, addition of 
esterase inhibitor etc., was also optimised and stability testing was carried out to 
ensure the integrity of the sample. The method was found to be fast, reproducible and 
applicable to studies of aspirin metabolism in healthy volunteers.
The final area involved the identification of a glycoprotein, which is known to be a 
protein-mobilising factor (PMF), associated with cancer cachexia. Although previouly 
detected in serum and urine by immunoblotting, the structure of this cachectic factor 
has not been frilly elucidated (although its molecular weight has been reported to be 24 
kDa) and it had not been investigated by any separation techniques. A number of urine 
sample pretreatment procedures were investigated prior to analysis by CE e.g. dialysis, 
ammonium sulphate precipitation and simple dilution, before deciding on the use of a 
static dialyser unit. Although there was no standard PMF with which to carry out 
spiking experiments, the PMF (if present) would be easily detected as a molecule with 
molecular weight greater than 15 kDa (the filter cut-off point). In fact, few proteins 
normally appear in urine and when investigated by CE, the PMF (plus a compound 
believed to be its albumin-bound complex) were seen as two extra peaks in the urine 
samples of cancer patients with cachexia. These results were confirmed by 
immunoblotting. It was also shown that these factors were absent from the urine of 
healthy subjects and cancer patients who were not experiencing weight loss. The 
factor was found in patients of both sexes with different types of cancer, on a range of 
therapies. The results of this work have prompted further research into the screening 
of cancer patients with a view to predicting, monitoring and possibly preventing 
cachexia. In addition, research is ongoing to determine the structure of the PMF and 
to prepare a pure standard for use in a quantitative method for the cachectic factor(s).
This thesis has described the development of analytical methodology for a number of 
compounds which are diagnostically important. These ranged from the endogenous 
amino acid taurine to aspirin and prodrugs of aspirin. This research succeeded in 
finding ways of reducing the time required to prepare the biological samples by 
developing simple, rapid and reproducible sample preparation methods. All of these 
methods were applied to clinical samples, demonstrating that careful optimisation of 
the sample preparation process, followed by optimisation of the analytical 
measurement procedure, is necessary for high quality results in bioanalysis.
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Preparation of Aspirin
50g (0.36 mol) of dry salicylic acid and 70ml (0.74 mol, 2.03 eq) of acetic anhydride 
were mixed together in an Erlenmyer flask. To this was added 40 drops of 
concentrated sulphuric acid. The mixture was stirred with a spatula and at the same 
time warmed for 20 minutes at 50-60°C in a water bath. First, a solubilisation of the 
salicylic acid occurred, then a precipitate of aspirin appeared. The precipitate was 
filtered, dissolved in the minimum of boiling ethanol. Water was poured drop by drop 
into the solution until the precipitate of aspirin appeared. The mixture was filtered and 
recrystallised from a mixture of ethanol/water (30/70). The yield was 93%, the 
melting point was 132°C (literature value 134°C) and both NMR and IR showed the 
material to be pure aspirin.
Preparation of Aspirin Glycine
600mg (3.33 mmol) of aspirin were dissolved in 7 ml of dry tetrahydrofuran under 
nitrogen. The solution was cooled to -5°C, and 0.442 ml (3.33 mmol) of freshly 
distilled triethylamine was added. After 5 minutes, 0.323 ml of ethylchloroformate 
was added and a precipitate of triethylammonium chloride appeared. A solution of 
374.6mg (5 mmol) glycine in 2.5 ml of NaOH (2M) was added drop by drop to the 
mixture. After stirring for 15 minutes, the temperature rose slowly to 20°C. The 
tetrahydrofuran was removed under pressure and the aqueous solution was acidified 
with HC1 until it reached pH 2-3. The mixture was extracted with ethyl acetate (3x10 
ml), the organic layers were combined and washed with a saturated ammonium 
chloride solution. The organic layer was dried with Na2 SC>4 , filtered and the solvent 
removed under pressure. A very dense slightly yellow oil was obtained which 
precipitated overnight. The solid was filtered off and washed with chloroform (10 ml). 
173 mg of the compound was obtained as a white powder with a yield of 22% and a 
melting point of 151°C. IR and microanalysis proved the identity of the product and 
showed it to be pure.
Preparation of Aspirin Alanine
Aspirin (900 mg, 5 mmol) was dissolved in dry tetrahydrofuran (10 ml) under 
nitrogen and distilled triethylamine (0.7 ml, 5 mmol) was added to the solution. It was 
kept at 0°C and ethylchloroformate (0.5 ml, 5 mmol) was added. A precipitate 
appeared immediately. Alanine (623 mg, 7 mmol)was dissolved in a 0.63M NaOH 
solution and added drop by drop to the mixture which was stirred at 0°C for 1 hour 
and then left overnight at 20°C. The mixture was acidified with a solution of 5% HC1 
(20 ml) and extracted with ethyl acetate (20 ml). The organic layer was washed with 
brine (10 ml), dried over magnesium sulphate, filtered and the solvent was removed. 
The oil was purified by precipitation in petroleum ether and crystallised in a mixture 
of ethyl acetate and petroleum ether. The white crystals were washed with diethyl 
ether to eliminate any residual aspirin. 488 mg of white powder were obtained with a 
yield of 39% and a melting point of 115°C. IR and microanalysis showed that the 
product obtained was as expected and pure.
Preparation of Aspirin Phenylalanine
Aspirin (1.8 mg, 10 mmol) was dissolved in dry tetrahydrofuran (40 ml) under 
nitrogen and distilled triethylamine (1.4ml,10 mmol) was added to the solution. It was 
cold at 0°C and the ethylchloroformate (lml, 10 mmol) was added. A precipitate 
appeared immediately. Phenylalanine (1.81 g, 11 mmol) was dissolved in a 1M NaOH 
solution (10 ml) and added drop by drop to the mixture which was stirred at 0°C for 1 
hour and then left overnight at 20°C. The mixture was acidified with a solution of 5% 
HC1 (20 ml) and extracted with ethyl acetate (20 ml). The organic layer was washed 
with brine (10 ml), dried over magnesium sulphate, filtered and the solvent was 
removed. The oil was purified by chromatography on silica gel column using ethyl 
acetate/petroleum ether (75/25) as eluent. The product was not the phenylalanine 
amide of aspirin but the amide of salicylic acid. The derivative at this point (0.7 g) 
was dissolved in pyridine (2 ml) and ethyl acetate (0.5 ml) under nitrogen. The 
mixture was cold at 0°C and the acetylchloride (0.21 ml) was added drop by drop to 
the solution and stirred for 30 minutes at 0°C and 1 hour at room temperature. The
mixture was then poured into a solution of 5% HC1 (5 ml) and extracted with ethyl 
acetate (10 ml). The organic layer was washed with brine, dried over magnesium 
sulphate, filtered and the solvent was removed. The oil was purified by 
chromatography on an alumina (basic) gel using ethyl acetate/petroleum ether (3/1). 
The resultant oil gave the correct microanalysis.
Preparation of Aspirin Anhydride (Dimer)
Aspirin (1.8g, lOmmol) was dissolved in dry tetrahydrofuran (20ml) and 
dicyclohexylcarbodiimide (1.05g, 5mmol), 2:1 ratio was added at 0°C under nitrogen. 
The mixture became cloudy. After 3 hours at room temperature, the dicyclohexylurea 
was filtered off and the filtrate evaporated down in vacuo. The residue was taken up 
in ethyl acetate and filtered free of any further precipitated urea. The solvent was 
removed under reduced pressure. The product crystallised from diethyl ether. 38% of 
white crystals were obtained (MP 71-72°C )
Preparation of Aspirin Isosorbide Ester
Aspirin (3.6g, 20 mmol) and urea (0.06g) were dissolved in dry dichloromethane (10 
ml) under nitrogen. Thionyl chloride (2.9 ml, 40 mmol) was added and the mixture 
was refluxed for 4 hours at 30-40°C. Then the excess thionyl chloride was distilled 
off, giving the crude acetylsalicylchloride as an orange oil which was used 
immediately without further purification. This oil was added slowly to the isosorbide 
(2.92g, 20 mmol) dissolved in dry pyridine (15 ml) at 0°C under nitrogen. The 
mixture was refluxed for 3 hours, then acidified with 5% HC1 and extracted with 
dichloromethane. The organic phase was washed with brine, dried over magnesium 
sulphate, filtered and concentrated in vacuo. Crystallisation from ethyl acetate gave 
2.7g (42%) of white crystals mp 166-7°C.
Preparation of Aspirin Phenyl Ester
Polyphosphoric ester (PPE) was prepared by boiling phosphorous pentoxide (25g) in 
chloroform (25ml) containing diethyl ether (50ml) until the solution became clear (8 
hours). The solution was filtered to remove the phosphorous chloride which did not 
react and the solvents were evaporated. The viscous colourless syrup was used 
directly.
Aspirin (1.8g, 10 mmol) and phenol (0.94g, 10 mmol) were dissolved in dry 
chloroform (50 ml) and excess of PPE (24.9g, 150 mmol) was added under nitrogen. 
The mixture was stirred for 15 hours, then poured into a saturated sodium 
hydrogenocarbonate solution (60 ml) and extracted with dichloromethane (40 ml). 
The organic layer was washed with a saturated hydrogeno carbonate solution and then 
with water, dried over magnesium sulphate, filtered and the solvent was removed 
under reduced pressure. Column chromatography of the oil on silica gel with a 85/15 
cyclohexane/ethyl acetate solvent mixture yielded a clear liquid. Crystallisation from 
diethyl ether gave 0.74g (29%) of white crystals mp 99°C. Both IR and microanalysis 
showed the material to be the expected product and to be pure.
Preparation of Aspirin Nitrophenyl Ester
Aspirin (1.8g, 10 mmol) and 4-nitrophenol (1.39g, 10 mmol) were dissolved in dry 
chloroform (50ml) and excess of PPE (24.9g, 150 mmol) was added under nitrogen. 
The mixture was stirred for 24 hours, then poured into a saturated sodium 
hydrogenocarbonate solution (50 ml) and extracted with dichloromethane (50 ml). 
The organic layer was washed with a saturated hydrogeno carbonate solution and then 
with water, dried over magnesium sulphate, filtered and the solvent was removed 
under reduced pressure. The yellow oil was recrystallised from ethyl acetate yielding
0.95g (31%) of white crystals mp 136-8°C. IR and microanalysis were carried out.
Appendix B
Use of Platelet Aggregation Profiler
Sample Collection
Whole blood sample taken into sodium citrate anticoagulant (10%).
Sample Fretreatment
Sample centrifuged at 1000 rpm for 10 minutes to yield platelet-rich plasma (PRP). 
Platelet-poor plasma (PPP), which was to be used as a blank, was obtained by 
centrifuging at 3000 rpm for 10 minutes.
Background Correction Measurement
The platelet aggregation profiler (model 4, Biodata Corporation, Horseham, PA, 
USA) was first blanked. This was carried out by adding 500^1 PPP to a glass tube, 
and taking an absorbance scan while the sample was kept at 37°C. This sample was 
regarded as 100% aggregation for blanking purposes, equivalent to all platelets having 
clumped together and fallen out of solution, yielding an essentially clear sample. This 
blank measurement is used to account for the differences in plasma composition for 
each blood donor.
Standard Measurement
The PRP sample was then measured by placing 500^1 PRP in a glass tube, and 
allowing the sample to stir at 37°C. After two minutes, a platelet agonist such as 
arachidonic acid was added. Due to the presence of cyclooxygenase in platelets, 
clotting would occur within a few minutes and the clots would drop out of solution, 
leaving a clear solution behind. The extent of aggregation is measured on the vertical 
axis and is inversely proportional to absorbance of the sample. An example of such an 
absorbance profile is shown below in scan A where it can be seen that 60% 
aggregation of the sample has occurred within approximately one minute.
Sample Measurement
A sample of PRP containing the drug under investigation e.g. aspirin or prodrug of 
aspirin, was added to the glass tube, and was allowed to stir at 37°C. After two 
minutes, a platelet agonist such as arachidonic acid was added. If the drug under test 
was an inhibitor of platelet aggregation via its blocking of cyclooxygenase activity, 
clotting would not occur and a profile such as scan B below would result. In scan B, it 
can be seen that essentially no aggregation of the sample has occurred.
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Procedure for Extraction of ASA from Plasma
Taken from reference 59 at the end of Chapter 3 :
Japanese Pharmacology and Therapeutics, 16(1), 17-25 (1988).
lml plasma was placed in a stoppered test tube with 2ml water and 7ml 
dichloroethylene and shaken for 5 minutes.
0.5g sodium hydrogen carbonate was added and the mixture was again shaken for 10 
minutes and centrifuged at 3500 rpm for 10 minutes.
The organic layer was transferred to another test tube.
To 3ml of the aqueous layer was carefully added 0.5ml 6M HC1.
7ml dichloroethylene and 2g anhydrous sodium sulphate were added, the tube shaken 
for 15 minutes and centrifuged at 3500 rpm for 10 minutes.
3 ml of the organic layer was evaporated to dryness and combined with the previous 
organic layer, evaporated to dryness and reconstituted as required.
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A b s tra c t
Plasm a samples (100 //l) were treated w ith 150 p i  o f acetonitrile and centrifuged at 5800g for 10 m in and 50 p \  of 
10 m M  borate buffer (pH  9.2) were added to the supernatan t solution. This was followed by the addition  o f  a 50 p \ 
aliquot o f 5 mM  fluorescam ine in acetonitrile and  im m ediate vortex mixing. A  20 /¡I sam ple was injected on to  a 
reversed-phase H PL C  system using a Bondclone C-1B 10 //m  analytical colum n (300 m m  x 3.9 mm ). The m obile 
phase was te trah y d ro fu ran -ace to n itrile -p h o sp h a te  buffer (15 m M , pH  3.5) (4:24:72, v/v/v). The taurine derivative 
was detected by m easuring the UV absorbance o f 385 nm. P latelet-poor plasm a sam ples were spiked w ith know n 
am ounts o f taurine and inter- and intra-assay calib ration  curves were obtained. The m ethod  was applied to  the 
determ ination of taurine in platelet-rich plasm a.
Keywords: D erivatization; Fluorescam ine; H um an plasm a; Reversed-phase chrom atography; T aurine
1. Introduction
Taurine is a naturally occuring /?-sulphonated 
amino acid that is not incorporated into proteins, 
but found free or in some simple peptides [1], It 
has been implicated in m any physiological func­
tions, pharm acological actions [2] and pathologi­
cal conditions. Am ong the physiological roles
* C orresponding author.
1 Presented at the F ifth  In ternational Sym posium  on D rug 
Analysis, Septem ber 1995, Leuven, Belgium.
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attribu ted  to  taurine are m em brane stabilization 
[3], antioxidation [4,5], neurom odulation  [6] and 
regulation o f calcium hom eostasis [7]. A lthough 
intracellular taurine concentration is stringently 
controlled [8], plasm a levels are altered during 
traum a [9], sepsis [10] and cancer [11]. Recent 
evidence suggests that the level o f taurine in 
plasm a may be a useful indicator o f m yocardial 
infarction [12]. As the role o f taurine in various 
disease states becomes m ore widely recognized, 
the need for a simple, rapid assay for routine 
plasm a taurine estim ation becomes m ore im por­
tant.
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Recent H PLC  m ethods involving derivatization 
for the determ ination o f taurine have employed 
o/-?/(o-phthalaldehyde (OPA), which requires the 
presence of a thiol such as m ercaptoethanol to 
ensure that derivatization occurs instantaneously. 
A lthough taurine has been determ ined in this way 
with both ultraviolet (UV) absorbance [13] and 
fluorescence detection [14], there are stability 
problem s associated with this reagent. Dansyl 
chloride has also been used to  determine taurine 
[15], but this derivatization form s m any side p rod­
ucts, requires quenching and has a long reaction 
time. Taurine has been determ ined by derivatiza­
tion with dansyl chloride, forming a derivative 
that absorbs in the visible region [16], but the 
reaction requires high tem peratures and the pres­
ence of salts can have detrim ental effects on the 
reaction yield.
O ther available derivatizing agents for amino 
acids include phenyl isothiocyanate, but the yield 
can be adversely affected by the presence o f salts, 
divalent cations and buffers [17]. 9-Fluorenyl- 
m ethyl chloroform ate forms stable derivatives, 
but hydrolysis products o f the reagent interfere 
unless rem oved prior to  analysis [17],
Fluorescam ine was first introduced for the de­
term ination o f prim ary amines and amino acids in 
1972 [18] and has been used for the quantitation  
o f  taurine (Fig. 1) using fluorescence detection 
[19], In this work, UV absorption  at 385 nm was 
chosen because whereas the fluorescence intensity 
m ay decrease over a few hours, the absorbance 
rem ains unchanged for up to 1 week. F luo­
rescamine was selected because its reaction with 
prim ary amines proceeds instantaneously at am bi­
ent tem perature in alkaline medium, the reagent 
and its m ajor hydrolysis products do not interfere 
w ith UV detection and the derivatives are stable.
2. Experimental
2.1. Chemicals
Taurine (99%) and fluorescamine (98%) were 
obtained from  the Aldrich Chemical (Gillingham, 
D orset, U K ). All o ther am ino acids were obtained 
from  B D H  Chemicals (Poole, D orset, U K ), as
were perchloric acid (70%), disodium  tetraborate 
and potassium  dihydrogenphosphate. Boric acid 
was purchased from M erck (D arm stadt, G er­
many). Acetonitrile, m ethanol and tetrahydro- 
furan were o f H PLC grade and were purchased 
from Labscan (Dublin, Ireland). Super-purity ace­
tonitrile from  Rom il Chemicals (Loughborough, 
UK) was used for the deproteinization step. W a­
ter was deionized using an Elgastat purification 
system.
2.2. Materials
Hypersep C-18 cartridges (200 mg, 3 ml) were 
received as a gift from  Shandon Scientific (R un­
corn, UK). Anion- (SCX) and cation- (PRS) ex- 
hange columns (200 mg, 3 ml) were kindly 
donated by 1ST (M id-G lam organ, UK). Micro- 
con-3 concentrators and M icropure separator in­
serts were purchased from Amicon (Stonehouse, 
UK).
2.3. Preparation o f  reagents and standard 
solutions
Taurine standard  solutions were prepared daily 
from a stock aqueous solution of 1 mg ml ~ 1 that 
was prepared on a weekly basis. Fluorescamine 
solution (5 mM ) was prepared in acetonitrile and 
kept at room  tem perature. Such a solution is 
stable for 12 weeks [20]. Borate buffer was pre­
pared by adjusting 100 mM  disodium  tetraborate 
solution to  pH  9.2 with 10 m M  boric acid. The 15 
m M  phosphate buffer was made up  each week by 
dissolving potassium  dihydrogenphosphate in wa­
ter and adjusting the pH  to 3.5 w ith phosphoric 
acid. The mobile phase was te trahydrofu ran-ace- 
ton itrile -phosphate  buffer (pH 3.5) (4:24:72, v/v/ 
v). After mixing, the pH  o f the mobile phase was
s o 3h  c h ,
\  /  \  
c h 2 n h 2
T a u rine  Fluorescamine Fluorophor
Fig. 1. Derivatization of tanrine with fluorescamine.
I  ^^COOH
G.P. McMahon et a i  /  J. Pharm. Biomecl. Anal. 14 (1996) 1287-1294 1289
(nm)
Fig. 2. UV absorbance spectrum of taurine derivative.
assessed, then it was filtered under vacuum  
through a 0.45 /itn M illipore filter and sonicated 
for 20 min.
2.4. H P L C  system
The high-perform ance liquid chrom atograph 
was equipped with a W aters (M iliford, MA, 
USA) model 510 dual-piston pump, a W aters 
Model 486 tuneable absorbance detector and a 
W aters model 746 da ta  module. The Rheodyne 
injection port (Cotati, CA, USA) was fitted w ith a 
20 loop. A  C-8 guard colum n was fitted prior 
to  the Bondclone C-18 10 //m  stainless-steel ana­
lytical colum n (300 m m  x 3.9 mm i.d.). The flow 
rate o f  the eluent was 1 ml m in - 1 , the system 
pressure was approxim ately 1100 psi and all m ea­
surements were m ade at am bient tem perature. UV
detection was carried ou t a t 385 nm, the m axi­
m um  absorbance wavelength for the taurine 
derivative (Fig. 2).
2.5. Sample preparation
Blood samples were taken  from  fasting volun­
teers in glass tubes containing sodium  citrate as 
anti-coagulant. Large-bore butterfly syringes were 
used so as to  minimize cell dam age, since this can 
result in platelet rup tion  and hence give rise to 
falsely elevated levels o f  basal taurine present in 
the plasma. Platelet-rich plasm a (PR P) was o b ­
tained by centrifugation for 5 min at 170# at room 
tem perature. Platelet-poor plasm a (PPP) was o b ­
tained by centrifugation for 15 min at 1500,? at 
room tem perature. C are was taken during pipet­
ting so as not to disturb  the bufly coat layer.
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F or the p reparation  o f spiked platelet-poor 
samples, 5 /¿I o f the taurine standard solution 
were added to 95 ¡j. 1 o f plasm a to give standards 
with 0, 5, 10, 20 and 30 /¿g m l~ ‘ of taurine 
added. Each sample (100 / / I ) was treated with 150 
/¿I o f super-purity acetonitrile, vortex mixed and 
centrifuged for 10 min at 5800g. Borate buffer (50 
H1, 100 mM , pH  9.2) was added to  adjust the 
supernatan t to  approxim ately pH  9. Then 50 ^ 1 of 
fiuorescamine in acetonitrile (5 m M ) were added 
and the solution was immediately vortex mixed. 
Samples were analysed on the H PLC  system 
w ithin 6 h.
3. Results and discussion
3.1. Optimization o f  protocol
3.1.1. Optimization o f  sample preparation 
Initial experiments centred on ultrafiltration as
a m ethod o f sample preparation. M icrocon-3 con­
centrators with a m olecular m ass cut-off o f 3000 
were used in conjunction with M icropure separa­
to r inserts for removal o f large molecules prior to 
derivatization and analysis. The centrifugation 
time was found to  be very long (appproxim ately 
140 min) and, although there was a concentrating 
effect, few o f the lower m olecular mass interfer- 
ents were removed. C lean-up with reversed-phase 
solid-phase extraction cartridges resulted in a 
large dilution factor and poor clean-up and recov­
ery. W ith the anion- and cation-exchange 
colum ns, the aim was selectively to retain or 
selectively to elute the taurine. It was not possible 
to  retain  the taurine on the columns under any 
circumstances and, in fact, extra impurities were 
introduced. Perchloric acid proved to be an 
efficient deproteinization agent, but it was subse­
quently difficult to raise the pH  reproducibly prior 
to derivatization. Boiling was found to give poor 
reproducibility and m ethanol was required in a 
3:1 ra tio  to  the sam ple in o rder to effect complete 
precipitation o f proteins. D eproteinization by ace­
tonitrile proved to be the most facile and repro­
ducible m ethod o f sam ple preparation and was 
the easiest to execute.
3.1.2. Optimization o f  reaction conditions
The pH  at which the derivatization of taurine 
takes place is crucial to the reaction. The pH  must 
be ^  8.5, and the optimum is 9. Fiuorescamine 
was dissolved in acetonitrile because o f its com ­
patibility with the deproteinized supernatant and 
its suitability as a non-hydroxylic but water-mis- 
cible solvent. Im m ediate mixing is essential for 
maximum response.
3.1.3. Optimization o f  mobile phase
The original m obile phase consisted of acetoni­
trile and phosphate buffer. Originally, this was 
optimized with the com position acetonitrile- 
phosphate buffer (pH 2.5, 15 mM ) (35:65, v/v). 
A lthough this gave good chrom atography for 
aqueous standards, in plasm a samples taurine co­
eluted with other components. M ethanol was used 
as an organic modifier at various ratios with little 
success, but tetrahydrofuran changed the selectiv­
ity, which improved the resolution between tau ­
rine and other endogenous com pounds. Hence the 
final com position was tetrahydrofuran -aceton i- 
tr ile -phosphate  buffer (15 m M ) (4:24:72, v/v/v). 
A variety o f pH  values were examined, 1.6, 2.5, 
2.8, 3.5 and 4.0, and at pH  3.5 taurine was 
adequately separated from  other closely eluting 
am ino acid derivatives such as alanine, arginine, 
asparagine, aspartic acid, glutamic acid, glu­
tamine, glycine, serine, threonine and valine.
3.2. Quantitative analyses o f  standards
3.2.1. Calibration and calculation
The spiked samples of platelet-poor plasma 
were quantified by external standardization. The 
slope and intercept o f the calibration graphs were 
determ ined by unweighted linear regression o f the 
taurine peak height versus the concentration of 
taurine added.
3.2.2. Precision
Precision was defined in terms o f the variability 
between batches (inter-assay) and within batches 
(intra-assay). Inter-assay variation was assessed 
singly in four replicate runs covering the concen­
tration range 5 -3 0  n m  m l~  '. Intra-assay variabil­
ity was determined in quadruplicate in the same
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Table 1 
Precision data
Am ount added (/ig/ml) M ean am ount found ±  SD (,ug/ml) RSD (%) Difference between added and found (%)
Intra -assay (repeatability)
5 (n =  3) 4.56 ±0.41 9.01 — 8.87
10 10.30 ±0 .66 6,38 -3 .0 3
20 20.50 ±0 .59 2.90 -2 .5 0
30 29.63 ±1 .17 3.95 +  1.21
Mean: 5.56 Mean: 4.38
y =  350.28*—192.77
c =  0.9998
Inter-assay (reproducibility)
5 4.82 ± 0 .26 5.33 +  3.56
10 10.22 +  0.58 5.69 -2 .2 1
20 20.00 ±  0.69 3.43 -0 .0 2
30 29.95 +0.31 1.05 +  0.15
Mean: 3.87 Mean: 2.75
y  =  347.74 ( ±  19.85)*-179.11 ( ±  125.78)
/■ =  0.9995 +  0.0002
concentration range. The precision o f the m ethod 
was described by the m ean relative standard 
derivation (RSD), and this was found  for taurine 
when the peak heights were interpolated as un ­
knowns on the regression lines. F o r inter-assay 
variation (reproducibility), the in terpolations were 
based on the four regression lines generated from 
the four replicate runs, and for intra-assay varia­
tion (repeatability), the in terpolations were based 
on a single regression line generated from  the 
quadruplicate run. Because hum an plasm a con­
tains a basal level o f taurine, p latelet-poor un­
spiked plasm a shows a small peak in the 
chrom atogram  tha t was assum ed to  correspond to 
taurine. A n unspiked platelet-poor sample was 
run with each calibration and the height of the 
taurine peak was subtracted from  the taurine 
peak in each o f the spiked samples. Precision 
data, calculated on the basis o f  the subtracted 
results, are presented in Table 1, and  they dem on­
strate that the reproducibility (mean R SD  =  
3.87%) and repeatability (m ean RSD  =  5.56%) of 
the m ethods are within accepted values for clinical 
analyses. These results were com pared with data 
from  unsubtracted values (i.e. where the peak in 
the blank sample was no t subtracted  from  the 
spiked standards), and it was found tha t the over­
all precision values were higher (4.08% and 6.75%
for reproducibility and  repeatability, respectively) 
and there was greater variability in precision 
am ongst individual values.
Platelct-poor
Plasma
Fig, 3, Platelet-poor and platelet-rich plasma from one volun­
teer. Column. Bondclone C-18, 10 )im. 3 0 0 x 3 .9  mm i d.). 
Mobile phase, tetrahydrofuran aceioniirile phosphate buffer 
(15 inM. pH 3.5) (4:24:72). Sample preparation as described in 
text.
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Table 2
Comparison of previous methods and results
Ref. Derivatizating agent/ 
detection method
Method of collecting and treating blood Taurine levels found (/ig/ml ')
[21] OPA/fluorescence Human:
Antecubital vein, vacutainer 7 ml glass tubes PPP: 5.6 ± 0 .5  PRP: 16-19
with EDTA. PRP: lOOOg, 15 min, 4°C (PC: 200-450 000 per ml plasma)
PPP: 12 lOOg, 30 min. 4°C
[22] OPA/fluorescence Human:
Method not quoted Quoted: 7.4 ±  1.5
[23] OPA/fluorescence Human:
Heparinized tubes, 2000g, 10 min 5.0 ± 0 .9
[24] OPA/UV Rat:
Whole blood 41.9 ± 4 .9
[13] OPA/UV Rat:
Inferior vena cava using heparinized syringes 12.6 ±  1.6
Chick:
Cardiac puncture, 1400g, 10 min 13.5 ± 0  04
[25] Dansyl chloride/ Feline: Chilled heparinized syringes, 2677g 3.0 ± 0 .3
fluorescence
3.2.3. Linearity and accuracy
The correlation coefficient of the regression line 
for the m ean intra-assay values was 0.9998 (sub­
tracted  data) and 0.9985 (unsubtracted data). Ac­
curacy (presented in Table 1), as defined as the 
percentage difference between the am ount added 
and the am ount found by back-calculation, was 
usually less than 5% with mean values of 4.38% 
and 2.75% for within-batch and between-batch 
analyses, respectively.
3.2.4. Recovery
Recovery m ay be calculated in absolute or rela­
tive terms. In the calculation o f absolute recovery, 
the peak response o f an extracted standard is 
com pared with th a t o f unextracted standards that 
are prepared to  the same theoretical concentration 
as the extracts. Relative recovery is calculated by 
com paring peak responses o f extracted m atrix 
standards against those o f  extracted aqueous stan­
dards. This procedure was used to account for the 
presence of acetonitrile in the sample to be in­
jected. Using this m ethod, the relative recovery of 
taurine from  plasm a was found to be 89.7%.
3.2.5. L im it o f  quantitation
The limit o f quan tita tion  was found to be 5 /.tg 
m l-1 taurine in p lasm a samples.
3.2.6. Selectivity
Taurine is adequately separated from endoge­
nous plasma com ponents, as can be seen in Fig. 3. 
A num ber o f  am ino acids arc inherently present in 
both platelet-poor and platelet-rich plasma and 
the ten thought m ost probable to interfere (as 
mentioned in Section 3.1,3) were subjected lo the 
same extraction and separation conditions and, by 
adjustm ent o f the mobile phase pH  and aqueous- 
to-organic ratio, it was possible to resolve these 
com pounds from the taurine peak. In fact, it is 
expected tha t the m ethod described could be ap­
plied to the sim ultaneous determ ination o f taurine 
and other amino acids.
3.3. Quantitative analyses o f  samples
The main difference between platelet-poor and 
platelet-rich plasm a from  the same volunteer is 
the height o f the taurine peak (Fig. 3). The level 
o f taurine in PR P  is usually o f the order of four 
times greater than  in PPP [21], but this depends 
not only on the num ber o f platelets present but 
also on how the sample was taken and treated. 
The role o f platelets should be considered, since 
the platelet count can vary from  100000 to 
500 000 per ml o f plasm a with factors such as age, 
sex, health and sample treatm ent playing a part.
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In the literature, it is often unclear w hether or not 
platelets are present in plasm a samples being 
analysed for taurine because protocols for blood 
collection may not be described or may often omit 
certain procedural steps (Table 2). Different sy­
ringes and collecting vials for the blood samples 
are used, different ¿--forces and tem peratures are 
com m on during the centrifugation step and pipet­
ting of the supernatant can cause cell rup ture if 
sufficient care is not taken.
It was found tha t the platelets could be re­
moved from  plasma with m inim um  rupture if the 
samples are collected with the large-bore butterfly 
syringes. This procedure ensures th a t taurine in 
platelet-poor plasma is minimized. However, it 
should be noted that there is always a basal level 
o f taurine present in hum an plasm a. O ther w ork­
ers have circumvented this problem  and obtained 
taurine-free, platelet-free plasm a by using plasm a 
from kittens raised on a taurine-free diet. Feline 
plasm a naturally contains low concentrations of 
taurine (see Table 2).
Samples of PR P  from  three different sources 
were determined by interpolation o f the peak 
heights as on a calibration curve (5 -3 0  /xg ml ~ !). 
Results from  the individual in Fig. 3 gave a value 
o f 15.0 //g m l ~ \  while values from  two pooled 
PR P  samples were calculated to  be 16.4 and 18.5 
/¿g m l~ ’. All three results are w ithin the expected 
range according to literature values.
4. Conclusions
Fluorescam ine can be used for the pre-colum n 
derivatization of taurine and allows the estim ation 
of taurine levels in platelet-rich plasma. O ther 
analyses have difficult and labour-intensive sam ­
ple preparation and some involve derivatization 
procedures that require quenching and /o r the 
presence o f co-solvents in order for the reaction to 
take place. M any are prone to  interference from 
the derivatizing agent itself and  there are dis­
crepancies in the stability o f derivatives. The 
m ethod presented here offers a simple, efficient 
and rapid m ethod for the determ ination o f taurine 
in platelet-rich plasma, w ith com parable sensitiv­
ity to fluorescence m ethods, where a result is
feasible within 1 h o f taking blood from  a patient. 
W ith escalating w ork into the quan tita tion  o f 
taurine in hum an plasm a for medical purposes, 
the simplicity o f this assay will be o f great benefit 
to clinical research.
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investigated as a route for continuous low-dose ASA 
administration. ASA itself is polar and can cross the 
skin without difficulty, but it is rapidly hydrolysed to 
salicylic acid (SAL) during transport. A 1993 study 
showed that ASA applied directly to the skin surface 
selectively inhibited the activity of cyclooxygenase 
in platelets [6], ASA in a transdermal patch, at a 
lower dose, was also found to induce marked sup­
pression of platelet cyclooxygenase, but the bioavail­
ability of ASA was calculated to be only 20% [7]. 
Since ASA is rapidly hydrolysed to SAL, studies 
have focused on the synthesis of stable aspirin 
analogues and derivatives, the idea being that these 
molecules would traverse the skin efficiently, yield­
ing ASA subcutaneously. The structure and polarity
reserved.
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of the derivative are major determinants o f transder- 
mal permeability. The compounds investigated in 
this study were esters or anhydrides which were 
predicted to release the more polar ASA by their 
hydrolysis within the skin. While much HPLC meth­
odology has been reported in the literature which can 
determine both ASA and SAL. most of the samples 
are in biological fluids (such as plasma and whole 
blood) |8 -10), food |!I,12J or tablet formulations 
[13,14). Many of these involve protein precipitation 
and/or solvent extraction. However, this study re­
quired analysis of the compounds of interest in a 
different matrix and direct injection of the samples. 
It was also necessary to have a method which could 
be readily adapted to ensure that no transdermal 
leakage of intact prodrugs occurred. This paper 
reports the development and implementation o f such 
a HPLC method for the analysis o f ASA and SAL in 
transdermal perfusates.
2. Experimental
2.1. Equipment
III
Phenyl ester
Fig. 1. Structures and names of the four aspirin prodrugs.
orthophosphoric acid (OPA) and polyethylene glycol 
(Air 6000) came from BDH. Phosphate-buffered 
saline (PBS) sachets were obtained from Sigma 
Diagnostics (St. Louis, MO, USA). High purity 
ethanol (>99 .8% ) was purchased from Merck 
(Darmstadt, Germany).
The high-performance liquid chromatograph was 
equipped with Waters (M illford, MA, USA) Models 
501 single-piston and 510 dual-piston pumps, a 
Waters Model 486 tunable absorbance detector, a 
Waters Model 680 gradient controller and a Waters 
Model 746 data module. The Rheodyne injection 
port (Cotali, CA, USA) was fitted with a 20 p.1 loop. 
A Hypersil C8 guard column (30 (xm, 10X4.0 mm) 
was fitted prior to the Nucleosil C 8 analytical column 
(5 |xm, 250X4.6 mm). The (low-rate of the eluent 
was I ml/min, UV detection was at 225 nm, 
attenuation was set to 32, chart speed was 0.5 cm / 
min and all measurements were made at ambient 
temperature.
2.2. Reagents and chemicals
Aspirin was supplied by Sigma Chemical Co. 
(Dorset, UK) and salicylic acid by BDH (Poole, 
UK). The four aspirin derivatives (I, II, III and IV) 
were prepared in-house (see Fig. 1). Acetonilrile and 
water were both HPLC grade and were purchased 
from Labscan (Dublin, Ireland). Analytical grade
2.3. Mobile phase
Eluent A was a mixture of w ater-acetonitrile- 
OPA (650:350:2, v /v /v ). The aqueous component of 
eluent A had a pH of 2.0 and the mixture was pH 
2.5* when the acetonilrile was added (ASA is most 
stable at this pH value) [15], Eluent B was a mixture 
of acetonitrile-OPA (1000:2, v/v). Both eluents 
were filtered (0.45 |im  filter) under vacuum and 
sonicated for 20 to 30 min to remove dissolved 
gases. The solvent program used was: time 0 to 6.5 
min -  100% A, time 10.5 to 19.0 min -  70% 
A /30%  B, time 22.0 to 28.0 min -  100% A, 
employing a linear gradient ramp.
2.4. Standard preparation
Stock solutions of ASA, SAL, I, II, III and IV 
were prepared by dissolving each of the compounds 
in acetonitrile to a concentration of I m g/m l. 
Working standards were prepared on a daily basis by 
dilution of the slock solutions with PBS. The ASA
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and SA L  standards were mixed together for the 
validation procedure and had final concentrations of
0.2, 0.5, 1.0, 2.0 and 5.0 (xg/ml. The standard 
solutions of the derivatives were prepared individual­
ly in PB S down to a concentration of 2 |xg/ml as 
required.
2.5. Sample preparation
The in vitro transdermal experiments were per­
formed on fresh sha/sha mouse skins directly in 
contact with a 22 ml Franz cell reservoir of PBS at 
physiological pH and 37°C. Twenty mg of the 
prodrug being examined was diluted in 250 j j l I  
ethanol, mixed with 250 ( j l I  of 15% poly(ethylene 
glycol) (PEG) and topically applied to the 5 cm 2 
area of skin. Aliquots were taken from the buffer 
vessel at 0, 2, 4 and 6 h, injected directly onto the 
HPLC system and analysed by comparison with 
external standards of the same matrix composition. 
Blank skin perfusates containing only formulation 
components, i.e. ethanol and PEG were run in 
parallel with the drug perfusates at all times to 
eliminate any formulation effects. At the end of the 
transdermal experiment for each prodrug, a sample 
from the top of the skin was taken by dissolving the 
remaining drug in 1 ml of acetonitrile. A 1 in 1000 
dilution with PBS was usually required for these 
samples prior to analysis.
3. Results and discussion
3.1. Optimisation o f  protocol
The derivatives shown in Fig. 1 were selected for 
this study because they were found to inhibit platelet 
cyclooxygenase in vitro. Because of their hydro- 
phobicity, special formulations have to be used in 
order to apply them to the skin. A number of 
possible formulations were tried and tested before 
deciding on 250 p,l ethanol, mixed with 250 |xl 15% 
PEG. When this was used for dissolution of the 
compounds, there was no interference from the 
formulation on the HPLC.
3.2. Validation o f the method
3.2.1. Calibration
Calibration was based on regression analysis of 
concentration versus peak areas (which were found 
to correlate better than peak heights with concen­
tration). Calibration curves were linear in the con­
centration range necessary for the detection of the 
compounds in the PBS buffer, i.e. 0.2 to 5.0 fxg/ml. 
Since the release of ASA and/or SAL was the most 
important criterion and since none of the parent 
drugs permeated the skin intact, full validation was 
carried out only on the analysis of ASA and SAL in 
the PBS.
3.2.2. Precision
Precision was defined in terms of the inter-day 
variability (reproducibility) and intra-day variability 
(repeatability). Inter-assay reproducibility was as­
sessed in four replicate runs on four consecutive 
days, covering the concentration range 0.2 to 5.0 
(xg/ml. Intra-assay repeatability was determined in 
quadruplicate on day two of the study in the same 
concentration range. The precision o f the method 
was described by the mean relative standard devia­
tion (R.S.D.) of the recovered amounts, determined 
by interpolation of the peak areas on the regression 
lines. Precision data are presented in Table 1, and
Table 1
Precision and accuracy data“
Amount adc 
(Hg/ml)
led Amount found 
(M-g/ml)
R.S.D.
(%)
Accuracy
(%)
ASA SAL ASA SAL ASA SAL
Inter-assay (reproducibility)
0.200 0.194 0.212 3.46 2.60 3.00 6.00
0.500 0.499 0.503 2.20 1.24 0.20 0.60
1.000 1.004 0.994 1.18 0.89 0.40 0.60
2.000 2.008 1.979 0.62 1.67 0.40 1.05
5.000 4.997 5.006 0.11 0.12 0.06 0.12
Intra-assay (repeatability)
0.200 0.199 0.215 1.67 2.18 0.50 7.50
0.500 0.498 0.498 0.99 3.28 0.40 0.40
1.000 1.004 0.990 2.24 2.14 0.40 1.00
2.000 2.002 1.993 1.72 2.26 0.10 0.35
5.000 4.999 5.005 0.83 2.71 0.02 0.10
" n=4.
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they demonstrate that the reproducibility (mean 
R.S.D. =  1.51 and 1.30% for ASA and SAL, respec­
tively) and repeatability (mean R.S.D.= 1.49 and 
2.51% for ASA and SAL, respectively) are well 
within accepted values for bioanalyses.
3.2.3. Linearity and accuracy 
The correlation coefficient of the regression line 
for the mean intra-assay values was 0.9999 for both 
ASA and SAL. Accuracy (presented in Table 1), 
defined as the percentage difference between the 
nominal amount and the amount found, gave mean 
inter-day values of 0.81 and 1.67% for ASA and 
SAL, respectively, and mean intra-day values of 0.28 
and 1.87% for ASA and SAL, respectively.
3.2.4. Limit o f  detection
The limit of detection was found to be 0.05 |xg/ml 
for both compounds which corresponded to a peak
which was three times the standard deviation of the 
baseline noise.
3.3. Quantitative analyses o f ASA and SAL in 
perfusate samples
The retention times for ASA and SAL were 
6.7±0.1 and 9.0±0.3  min, respectively. No ASA 
was found in the perfusates for prodrugs II, I I I  or 
IV, but SAL was found in these samples. The 
presence of SAL in the perfusates would appear to 
indicate that the prodrugs did in fact break down in 
the skin, and that the rate of release of ASA was less 
than the rate of its subsequent hydrolysis to SAL. 
The poor permeation of the skin was probably due to 
the preferential solubility of the prodrugs in the 
formulation as opposed to the skin. Prodrug I (an 
anhydride) was significantly more susceptible to 
hydrolysis than the ester prodrugs, yielding ASA 
(and hence SAL) in the perfusate samples. Fig. 2 
shows a chromatogram of (a) a blank perfusate and
D
<
c
cinnn
©
3
Fig. 2. Chromatograms of perfusate samples.
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(b) a perfusate sample taken two hours after applica­
tion of prodrug I. Fig. 3a,b show the transdermal 
results for both ASA and SAL in terms of their flux,
i.e. micrograms of compound that traversed the skin 
per square centimetre of skin onto which the prodrug 
was applied. It can be seen that prodrug I  delivered 
double the flux of ASA (Fig. 3a) and less SAL (Fig. 
3b) when compared to the case where ASA was 
applied to the skin alone. The reason that prodrug I 
breaks down more readily than the other prodrugs
Eu
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Fig. 3. (a) Transdermal fluxes (|xg/cm 2) of ASA due to prodrug I 
and ASA itself, (b) Transdermal fluxes (p.g/cm ) of SAL due to 
prodrugs and ASA itself.
could be explained by the fact that anhydride struc­
tures undergo hydrolysis more readily than ester 
structures.
3.4. Qualitative analyses o f  prodrug transport and 
breakdown on skin surface
The retention times for the prodrugs using the 
gradient were as follows: prodrug I  18.4±0.2 min, 
prodrug II 19.1 ±0.3 min, prodrug III 20.2±0.3 min 
and prodrug IV 20.6±0.3 min. At no time did any of 
the prodrugs leak across the mouse skins intact. This 
was confirmed by gradient HPLC analysis of the 
perfusates by comparing the samples to external 
standards of the prodrugs down to a concentration of 
2 (xg/ml. This concentration would correspond to a 
transmembrane leakage of less than 0.25% of the 
prodrug. The top-of-skin samples for prodrugs II, III 
and IV contained only the corresponding parent 
compound. This indicated that these derivatives were 
not hydrolysed on the surface of the skin. Only 
prodrug I  was hydrolysed on the surface of the skin 
to yield ASA.
4. Conclusion
The HPLC method presented was optimised and 
validated for the determination of ASA and SAL 
produced by prodrugs in transdermal samples. Sam­
ples could be directly injected and the analysis time 
was only ten minutes for determination of ASA and 
SAL. The method was easily adapted to allow 
determination of the nonpolar parent compounds 
using gradient elution. Using the method, four 
prodrugs were compared in terms of their ability to 
deliver ASA percutaneously. Evidence of hydrolysis 
of the ester compounds to ASA was seen, but it was 
not at a level sufficient to warrant further inves­
tigation of these compounds as aspirin prodrugs. The 
anhydride, prodrug I, did release significant amounts 
of ASA over time. In comparison to ASA alone, this 
compound produced more ASA and less SAL over 
the six hour time frame. Prodrug I is considered a 
suitable candidate for further investigation, and is 
currently undergoing more transdermal studies.
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A column-switching liquid chromatographic method is 
described for the simultaneous determination of aspirin 
and salicylic acid in human plasma. Blood samples are 
taken into chilled tubes containing a fluoride anticoagu­
lant, and the plasma is isolated by centrifugation. Fol­
lowing a simple acidification step, a 200 /¿L aliquot of the 
sample is injected directly onto the HPLC system. The 
C-18 extraction column is washed with acidified water for 
2 min, after which time the compounds are removed by 
back-flushing directly onto the analytical column (C-8 
Nucleosil, 5 fim, 250 mm x 4.6 mm). The flow rate 
through both columns is 1 mL/min, and the analytes are 
quantified by measurement of their UV absorbance at 225 
nm. The mobile phase is a mixture of water—methanol— 
acetonitrile-orthophosphoric acid (650:200:150:1 v/v/ 
v/v). The method is linear in the concentration ranges 
0.10-5 .00 ^g/mLfor aspirin and 0.25-15.00 pg/mL 
for salicylic acid. Both compounds have a limit of quan­
titation of 0.10 f tg/mL and a limit of detection of 0.04 
//g/mL. Extensive stability tests have been carried out, 
and validation studies reveal the method to be reproduc­
ible and repeatable. Excellent recoveries from plasma 
obviate the need for an internal standard. The procedure 
is easier to execute and requires less sample handling 
than methods currently described in the literature. It has 
been successfully applied to the investigation of the levels 
of aspirin and salicylic acid in a healthy, nonfasting 
volunteer following a 600 mg oral dose of aspirin.
Aspirin (ASA) is the oldest known prescription drug, and each 
year in the United States alone, 80 billion aspirin tablets are taken.1 
ASA reduces pain, inflammation, and fever and also inhibits 
platelet aggregation in blood by blocking cyclooxygenase activ­
ity.2'3 The plasma half-life of aspirin is only about 20 min because 
it is readily hydrolyzed to salicylic acid (SAL),3'4 its principal 
metabolite. An analytical method that measures ASA in biological 
fluids should, therefore, be capable of measuring SAL also. Such 
assays are required for many reasons—in cases of aspirin poison-
(1) Flieger, K. FDA Consum, Mag. 1994, January-February, Publication no.
95-3212.
(2) Patrono, C. N. Engl. J. Med. 1994, 330 (18), 1287-94.
(3) Reilly, I. A G.; Fitzgerald, G. A  Drugs 1988, 35, 154-76.
(4) Kwong, T. C. J. Liq. Chromarogr. 1987, 10, 305-21.
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ing, intolerance reactions, and side-effects and for metabolic and 
pharmacokinetic studies. Low-level determination of these com­
pounds is usually carried out using HPLC methods, many of which 
have been described in a review by Kwong in 1987.4 The mobile 
phases usually contain methanol or acetonitrile and have a low 
pH (normally 2.5—3.0), with UV detection in the range 225—240 
nm. Small improvements in validation results (e.g., sensitivity) 
have been made over the years, but since 1980, HPLC methodol­
ogy for ASA and SAL has only really changed in terms of 
applications. Scope for improvement lies mainly in the sample 
preparation step, the bottleneck in most analytical protocols. 
Assays for ASA and SAL have required sample cleanup procedures 
such as protein precipitation5-11 or solvent extraction.12-20 Usual 
methods of deproteinization involve the addition of an organic 
solvent such as acetonitrile,5’7’u ethanol,8 or a strong acid such 
as perchloric acid.6'9'10 Following centrifugation, the supernatant 
is usually dried and the residue reconstituted in mobile phase 
before injection. The solvent extraction procedure is usually 
effected with diethyl ether,15 dichloromethane,12'16'20 chloroform,19 
or hexane,14 thè organic extract evaporated, and the residue
(5) Iiu, J. H.; Smith, P. C.J. Chromatogr. B. 1996, 675 (1), 61—70.
(6) Krivosikova, Z.; Spustova, V.; Dzurik, R. Methods Find. Exp. Clin. Pharmacol. 
1996, 18 (8), 527-32.
(7) Kees, F.; Jehnich, D.; Grobecker, H ./ Chromatogr. B 1996, 677 (1), 172— 
7.
(8) Coudray, C.; Mangoumet, C.; Bouhadjeb, S.; Faure, H.; Favier, A /. 
Chromatogr. Sei. 1996, 34 (4), 166-73.
(9) O’Kruk, R. J.; Adams, M. A; Philp, R. B./. Chromatogr. B 1984 ,310,343— 
52.
(10) Rumble, R, H.; Roberts, M. S.; Wanwimolruk, S.J. Chromatogr. 1981 ,225, 
252-60.
(11) Cham, B. E.; Ross-Lee, L.; Bochner, F.; Imhoff, D. M. Ther. Drug. Monit. 
1980, 2 (4), 365-72.
(12) Klimes, J.; Sochor, J.; Zahradnicek, M.; Sedlacek, J./. Chromatogr. B 1992, 
584, 221-8.
(13) Shen, J.; Wanwimolruk, S.; Clark, C. R.; Roberts, M. S Liq. Chromarogr. 
1990, 13 (4), 751-61.
(14) Gaspari, F.; Locatelli, M. Ther. Drug. Monit. 1987, 9 (2), 243-7.
(15) Brandon, R. A.; Eadie, M. J.; Smith, M. T. Ther. Drug. Monit. 1985, 7 (2), 
216-21.
(16) Mays, D. C.; Sharp, D. E.; Beach, C. A.; Kershaw, R. A.; Blanchine, J. R.; 
Gerber, N ./. Chromatogr. B 1984, 311, 301-9.
(17) Nieder, M.; Jaeger, H High Resolut. Chromatogr. Chromatogr. Commun. 
1983, 6 (12), 655-60.
(18) Buskin, J. N.; Upton, R A.; Wiliams, R. L. Clin. Chem. 1982, 28, 1200—3.
(19) Lo, L. Y.; Bye, A. J. Chromatogr. 1 9 8 0 ,181, 473—7.
(20) Harrison, L. I.; Funk, M. L.; Ober, R. E.J. Pharm. Sei. 1980, 69 (11), 1268- 
71.
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reconstituted in mobile phase. Nieder and Jaeger17 used a mixture 
of hexane and ether to effect the extraction. Shen et a l13 and 
Buskin et al.18 also used a mixture of hexane and ether, but in 
order to avoid the evaporation step, they back-extracted the 
compounds into phosphate buffer before injection. This is 
because, during evaporation, loss of ASA and/or SAL is known 
to occur due to sublimation.4'7'8'12^ 14'17-19 Another problem en­
countered in many of these methods is poor and/or variable 
recovery of the compounds because of losses during the protein 
precipitation procedure (which can be due to protein binding of 
the drug) or during the solvent extraction step. The use of 
internal standards can reduce the variability of recoveries, but it 
can also adversely affect results of analysis because of the added 
variability in the extraction recovery of the internal standard 
itself.21 When column-switching is used in conjunction with HPLC, 
on-line cleanup of the biological sample is possible. A number of 
drugs have been analyzed in plasma employing this technique, 
such as bupivacaine,22 finasteride,23 dimiracetam,24 carbapenem 
antibiotics,25 midazolam,26 fluconazole,27 and quinidine.28 However, 
ASA and SAI, have not previously been quantified in plasma using 
column-switching. The method presented in this paper involves 
a simple, one-step, on-line solid-phase extraction system which 
gives good precision, accuracy, and recovery without the use of 
an internal standard. The method is economical, lends itself to 
automation, and also ensures the integrity of the plasma sample 
by taking precautions to minimize in vitro hydrolysis of ASA to 
SAL.
EXPERIMENTAL SECTION
Apparatus and Chromatography. The high-performance 
liquid chromatograph was equipped with Waters (Milford, MA) 
Models 501 single-piston and 510 dual-piston pumps, a Waters 
Model 486 tunable absorbance detector, a Waters Model 680 
gradient controller, and a Waters Model 746 data module. The 
VICI AG 10-port switching valve (Valeo Europe, Schenkon, 
Switzerland) was fitted with a 200 ¡i L loop. A Hypersil C-8 guard 
column (30 fim, 10 mm x 4.0 mm) was fitted prior to the Nucleosil 
C-8 analytical column (5/im, 250 mm x 4.6 mm). The solid-phase 
extraction (SPE) column was a biocompatible PEEK cartridge 
system (10 mm x 4.3 mm) from Anachem (Luton, Bedfordshire, 
England). The cartridge was dry-packed with Hypersil C-18 
material (30 /xm) from Shandon HPLC (Runcorn, Cheshire, 
England). Eluent A was a mixture of water—OPA (1000:1 v/v) 
and had a pH of 2.5. Eluent B was a mixture of water-methanol- 
acetonitrile—OPA (650:200:150:1 v/v/v/v) with a pH* of 2.6. Both 
eluents were filtered (0.45 fim  filter) under vacuum and sonicated 
for 20-30 min to remove dissolved gases. The flow rates of eluent 
A and eluent B through the columns were each 1 mL/min, UV 
detection was at 225 nm, and all measurements were made at
(21) Karnes, H. T.; Shui, G.; Shah, V. P. Pharm. Res. 1991, 8 (4), 421-6.
(22) Yu, Z.; Westerlund, D Chromatogr. A 1996, 725 (1), 149-55.
(23) Takano, T.; Hata, S.J. Chromatogr. B 1996, 676 (1), 141-6.
(24) Torchio, L.; Lombardi, F.; Visconti, M.; Doyle, E./. Chromatogr. B 1995, 
666 (1), 169-77.
(25) Takano, T.; Kagami, Y.; Kuwabara, Y.; Hata, S.J. Chromatogr. B 1994, 
656 (2), 353-8.
(26) Lauber, R.; Mosimann, M.; Buhrer, M.; Zbinden, A. M. J. Chromatogr. B 
1994, 654 (1), 69-75.
(27) Li, Z. W.; Guo, P.; Ye, L  M.; Hong, Z.; Wang, Y. S. Yao Hseuh Hseuh Po 
1994, 29 (10), 773-7.
(28) Huang, J. L.; Morgan, D. J .J. Chromatogr. 1993, 620 (2), 278-80.
ambient temperature. Under these conditions, the retention times 
of ASA and SAL were 11.5 ±  0.2 and 15.6 ±  0.3 min (n = 40), 
respectively.
Reagents and Chemicals. Aspirin was supplied by Sigma 
Chemical Co. (Dorset, England), as were all the drugs used in 
the interference study. Aspirin tablets (300 mg) for the volunteer 
study were from Bayer Ltd. (Dun Laoghaire, Dublin, Ireland). 
Salicylic acid was supplied by BDH (Poole, England). Acetonitrile, 
methanol, and water were HPLC grade and were purchased from 
Labscan (Dublin, Ireland). High-purity (99.999%) orthophosphoric 
acid (OPA) was obtained from Aldrich Chemical Co. (Milwaukee, 
W I ) .
Standards Preparation. Stock solutions of ASA and SAL 
were prepared by dissolving each of the compounds in acetonitrile 
to a concentration of 1 mg/mL. In acetonitrile, the stock solutions 
were found to be stable for at least 10 weeks when kept at room 
temperature. Working standards were prepared on a daily basis 
by dilution of the stock solutions with eluent A. This is because 
ASA and SAL, having pA'a values of 3.5 and 3.0, respectively,29 
are stable at this pH. The ASA and SAL plasma standards were 
prepared together by spiking blank plasma with working standard 
solutions and had final concentrations of 0.1, 0.25, 0.8, 2.0, and 
5.0 |Ug/mL for ASA and 0.25, 0.75, 2.4, 6.0, and 15.0 /<g/mL for 
SAL. These concentrations were chosen because they covered 
the expected range of the volunteer study samples. The drugs 
for the interference study were prepared individually as required, 
and each had a final concentration of approximately 1 ¿¡g/mL
Sample Collection and Storage. Blood samples were col­
lected into chilled plastic collection tubes containing a mixture of 
fluoride and EDTA salts (2.7 mL Monovette Catalog No. 
05.1073.100, Sarstedt Ltd., Wexford, Ireland). The chilled blood 
samples were centrifuged at 1500^ for 10 min to harvest the 
plasma. If there was to be a time interval of more than a few 
minutes before analysis, the samples were frozen at -30  °C until 
required. Both fresh and thawed plasma were kept on ice at all 
times.
Sample Preparation. Two hundred fifty microliters of 0.2 
M OPA was added to 250 /<L of the chilled plasma sample within 
10 min of centrifugation (if fresh) or within 10 min of thawing (if 
frozen) in order to minimize enzymatic hydrolysis of ASA to SAL. 
The mixture was vortexed for 20 s. Direct injection was usually 
possible at this stage, but some of the volunteer plasma samples, 
especially those obtained after the volunteer had eaten, appeared 
cloudy after vortex mixing, so a short centrifugation step (5800g 
for 3 min) was required. In order to treat all samples equally, 
this centrifugation step was introduced as part of the protocol for 
all samples.
Column-Switching. Two hundred microliters of the sample 
was loaded onto the loop with the valve in position 2 (Figure lb ). 
The valve was then turned to position 1, injecting the sample onto 
the extraction column (Figure la). During this time, the analytes 
of interest were retained on the extraction column, while endog­
enous components were removed to waste by the wash solvent. 
After 2 min, the valve was switched back to position 2, whereupon 
the ASA and SAL were back-flushed onto the analytical column 
for final separation and quantitation (Figure lb).
(29) Albert, A.; Sergeant, E. P. The Determination of Ionisation Constants—a 
Laboratory Manual, 3rd ed.; Chapman and Hall: London, 1984; pp 148,167.
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F igure  1. D iagram  of colum n-switching apparatus, (a) Sam ple is 
loaded onto the S P E  colum n for analytical column equilibrating, (b) 
Sam ple Is desorbed from S P E  column In back-flush mode and carried 
onto the analytical colum n for quantitation. Next sam ple is loaded  
onto loop.
RESULTS AND DISCUSSION
Optimization o f  B lood  C ollection and Sam ple Treatment.
Since the nature of the anticoagulant used in conjunction with 
the blood collection procedure can have a dramatic effect on the 
number of interfering peaks in chromatograms of plasma extracts, 
it was decided to investigate four different anticoagulant types. 
Previous work has shown that the levels of plasma interferences 
following on-line SPE (using a C-18 precolumn) can be quite 
different when different anticoagulants and/or brands are used.30 
Hence, for this study, blood was taken from two volunteers using 
a butterfly syringe connected to each of four types of blood 
collection tubes (Li-heparin, EDTA, fluoride/EDTA and citrate), 
and all eight blank plasma samples were subjected to the on-line 
SPE method and LC analysis. There was very little difference 
between the plasma profiles obtained, but the fluoride/EDTA 
mixture appeared to give a slightly cleaner baseline in the blank 
plasma chromatograms of both volunteers, and so it was chosen 
as the anticoagulant for this method. A significant advantage of 
the fluoride anticoagulant is that it inhibits the action of esterases, 
which catalyse in vitro hydrolysis of ASA, and for this reason a 
number of workers have used fluoride (in the form of NaF or KF 
salts) during the blood collection procedure.6'8-10'12'14'16-19 In fact, 
Rumble et al.10 compared three commonly used esterase inhibi­
tors, i.e., ecothiopate, physostigmine, and fluoride, and found that 
KF inhibited the hydrolysis of ASA to the greatest extent. Nieder
(30) Kelly, M. T. In Chemical Analysis in Co?nplex Matrices 1st ed.; Smyth, M., 
E<i; Ellis Horwood and Prentice Hall: West Sussex, 1992; pp 80—4,
and Jaeger17 also found KF to be the most effective inhibitor when 
they conducted a similar study.
In determining the optimum concentration for the diluting acid, 
three concentrations were investigated: 0.02, 0.2, and 2 M OPA. 
The 0.2 M acid gave the highest recoveries (90%) for both drugs 
when added in a ratio of 1:1 to the plasma sample.
Optimization of Analytical System. A number of packing 
materials, such as cyano, phenyl, C-l, C-8 and C-18, were examined 
in terms of their retentivities for ASA and SAL on the extraction 
column. The C-18 phase was found to be the most retentive for 
the compounds. Once this type of packing had been chosen, two 
dimensions of the cartridge were examined: 10 mm x 4.3 mm 
and 10 mm x 2.0 mm. The smaller column had approximately 
37% the capacity of the larger column for an aqueous sample 
containing 0.2 f i g / mL of both ASA and SAL, and a commercially 
available prepacked C-18 column (10 mm x 4.0 mm) gave 
recoveries of only 65% when compared to the larger extraction 
column. Therefore, a 10 mm x 4.3 mm PEEK cartridge packed 
with C-18 material was used throughout this work.
Stability. Kees et al.7 found that a 1 mg/mL solution of ASA 
in acetonitrile was stable for at least 1 month (at 4 °C). In this 
study, it was found that the same concentration of ASA in 
acetonitrile was stable for at least 10 weeks either at room 
temperature (~20 °C) or under refrigeration (4 °C). Various 
aspects of the handling of the plasma samples and standards were 
also investigated in terms of minimizing degradation due to in 
vitro hydrolysis of ASA. Four plasma samples (each containing 
2 ng/mL  ASA) were subjected to different treatments. Sample 1 
was acidified 1:1 with 0.2 M OPA and held on ice prior to injection; 
sample 2 was acidified 1:1 with acid and left at room temperature; 
sample 3 was diluted 1:1 with water and held on ice; sample 4 
was diluted with water and maintained at room temperature. Upon 
analysis 3 h later, it can be seen from the chromatograms in Figure 
2 that the amount of degradation (as evidenced by the hydrolysis 
of ASA to SAL) increased from sample 1 to 4, showing that acidity 
the sample is more important than temperature in terms of the 
stability of ASA. As a result of these findings, all samples were 
acidified and kept chilled to minimize hydrolysis of ASA. The 
effect of prolonged storage on the stability of spiked, acidified 
samples of ASA and SAL was then determined. The results of 
this experiment showed that the levels of ASA and SAL in these 
samples remained constant when the samples were stored at room 
temperature for up to 24 h, at 4 °C for up to 48 h, and at -30  °C 
through two freeze-thaw cycles. After these periods of time, and 
after more than two freeze-thaw cycles, the levels of endogenous 
interferences had increased to such an extent that quantitation 
of the ASA and SAL was adversely affected.
Quantitative Analyses of Standards. Calibration. Aliquots 
of drug-free plasma spiked to known concentrations of ASA and 
SAL were used for calibration, validation, and quantitation. 
Calibration was based on unweighted linear regression analysis 
of concentration versus peak areas (which were found to correlate 
better than peak heights with concentration). Calibration curves 
were linear in the concentration ranges 0.10-5.00 «g/ml. for ASA 
and 0.25-15.00 /tg/mL for SAL, with all values of correlation 
coefficient (r) greater than 0.999.
Precision. Precision was determined from measurements of 
the variability in results between batches (interassay) and within
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F ig u re  2 . Effect of handling conditions on stability of A SA  in plasm a. 
C hrom atogram s showing the effect of handling conditions on the level 
of hydrolysis of A SA  to SAL. Sam ple 1, p lasm a acidilied 1:1 with O P A  
and held on ice; sam ple 2 , p lasm a acidified 1:1 with acid and left at 
room tem perature; sam ple 3, p lasm a diluted 1 :1 with w ate r and held  
on ice; sam ple 4, p lasm a diluted 1:1 with w ater and left at room  
tem perature. Chrom atographic conditions a re  as  per text.
batches (intraassay) of spiked plasma calibration standards. It 
was measured as the mean relative standard deviation (RSD) of 
recovered concentrations (amounts found), determined by inter­
polation of the response values as unknowns on the regression 
lines. Interassay variation (reproducibility) was assessed in four 
replicate runs on four consecutive days in the concentration range 
0.1-5.0 fig/mL for ASA and 0.25—15.0 /<g/mL for SAL. The 
amounts found were calculated from the four individual regression 
lines generated from the four replicate runs. Intraassay variability 
(repeatability) was determined in quadruplicate on the fourth day 
of the study in the same concentration range, hi this case, the 
amounts found were calculated from a single regression line based 
on the mean peak areas of the quadruplicate run.
Precision data are presented in Table 1, and they demonstrate 
that the reproducibility (mean RSD =  3.83% and 4.76% for ASA 
and SAI,, respectively) and repeatability (mean RSI) =  2.58% and 
2.56% for ASA and SAL, respectively) are well within accepted 
values for clinical analyses.
Accuracy. Accuracy (presented in Table 1) was defined as the 
percentage difference between the nominal amounts and the 
amounts found and was calculated as described above. The mean 
between-batch accuracy values were 2.21% and 1.27% for ASA and 
SAL, respectively, while the corresponding mean within-batch 
values were 3.06% and 2.57%.
Recovery. Both absolute and relative recoveries were obtained 
for this method. Absolute recovery was defined as the response 
of a processed, spiked matrix standard expressed as a percentage 
of the response of a pure standard in mobile phase which had 
not been pretreated.21 T\vo concentrations of each compound 
were chosen for examination (0.5 and 5.0 ftg/mh), and the 
absolute recoveries were calculated by comparing the response 
in the spiked plasma samples to the response in aqueous samples
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T a b le  1. P re c is io n  and  A c c u ra c y  Data
Intra assay (Repeatability), n =  4 
amount added am ount found (±SD)
(wg/mL) (ug/m L) RSD (%) accuracy (%)
Aspirin (ASA)
0.10 0.091 ±  0.004 4.28 9.00
0.25 0.235 ±  0.005 2.29 6.00
0.80 0.799 ±  0.023 2.90 0.13
2.00 2.003 ±  0.037 1.85 0.15
5.00 5.000 ±  0.078 1.56 0.00
Salicylic Acid (SAL)
0.25 0.239 ±  0.006 2.58 4.40
0.75 0.714 ±  0.020 2.85 4.80
2.40 2.446 ± 0.075 0.07 1.92
6.00 6.088 ±  0.122 2.01 1.47
15.0 14.960 ±  0.339 2.26 0.27
Interassay (Reproducibility) , n = 4“
lount added am ount found (±SD)
(fig/mL) (fig/mL) RSD (%) accuracy (%)
Aspirin (ASA)
0.10 0.093 ±  0.006 6.74 7.00
0.25 0.254 ±  0.018 7.11 1.60
0.80 0.789 ±  0.025 3.18 1.38
2.00 1.982 ±  0.036 1.80 0.90
5.00 5.009 ±0.016 0.31 0.18
Salicylic Acid (SAL)
0.25 0.238 ±  0.024 10.12* 4.80*
0.75 0.746 ±  0.041 5.55* 0.53*
2.40 2.412 ±  0.109 4.52 0.50
6.00 5.972 ±  0.186 3.11 0.47
15.0 15.008 ±  0.077 0.51 0.05
0 Asterisk indicates n =  3.
injected directly onto the analytical column, i.e., without SPE and 
column-switching. Absolute recoveries for ASA were found to be 
99% and 100% at 0.5 and 5.0 wg/mL, respectively; for SAL these 
results were 104% and 101%, respectively.
Relative recovery was defined as the analyte response mea­
sured from matrix, i.e., plasma, as a percentage of that measured 
in water.21 The relative recovery for this study was calculated 
for both analytes at the two concentrations in two different plasma 
sources on two different days, and for ASA these were determined 
to be 101% and 94% at 0.5 and 5.0 ¿¡g/mL, respectively; for SAL 
these results were 88% and 90%, respectively. The fact that the 
absolute recovery values appear to be slightly greater that the 
relative recovery values may be accounted for by the fact that, 
with direct injection, the compounds are loaded onto the column 
in the mobile phase, whereas with column switching, the com­
pounds are loaded in 100% aqueous solution. For relative 
recovery, by comparing aqueous and plasma standards, differ­
ences arising from variation in the method of sample introduction 
are eliminated, and what is demonstrated is the extent to which 
the matrix affects recovery. Examination of the relative recovery 
values reveals that the recovery of SAL from the matrix is less 
than that for ASA which may be accounted for by the fact that 
SAL is highly protein bound.
Sensitivity. The limit of quantitation (LOQ) was taken as the 
lowest point on the calibration curve and was, therefore, 100 ng / 
mL for both ASA and SAL. Certain validation parameters were 
carried out at this concentration in the same manner as for the 
calibration curve. The mean interday RSDs at the LOQ were 4.0%
T a b le  2. D rugs U se d  in Interference Study
barbitone
butobarbitone
caffeine
8-chlorotheophylline
clonazepam
cocaine
diazepam
flurazepam
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F igure  3. C hrom atogram s of plasm a from a vo lunteer before and 
after adm inistration of 6 0 0  mg of A SA . (a ) P lasm a from volunteer 
im m ediately prior to adm inistration of A SA . (b) P lasm a sam ple taken  
13 min after adm inistration of A SA . concentration of A S A  -  2 .5 5  /tgl 
mL and concentration of SA L =  3.43/<g /m L. (c) P lasm a sam ple taken  
5 h after adm inistration of ASA, concentration of SA L =  13 .98  f i g /  
m L. C hrom atographic conditions a re  as per text.
and 14.3% for ASA and SAL, respectively; the corresponding 
intraday values were 18.4% and 11.7%. These values are within 
accepted limits for biopharmaceutical analyses. Interday relative 
recovery values (against aqueous spiked standards) were found 
to be 99.3% and 84.4% for ASA and SAL, respectively, and the 
corresponding intraday values were 116.2% and 91.9%. The limit 
of detection (LOD) in plasma was found to be 40 ng/mL for each 
of the analytes. In aqueous samples, the LOD values were 10 
and 20 ng/mL for ASA and SAL, respectively.
Selectivity. According to Karnes et al.21 and Shah et al.,31 the 
matrix should not interfere with the analysis of the compounds, 
and this should be demonstrated in six different sources. Hence, 
drug-free plasma from six different individuals was examined for 
endogenous interferences, and in no case were any peaks found 
that coeluted with ASA. In some sources of plasma, a small
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Figure 4- C o n ce n tra tio n -tim e  curve of A SA  and SA L in a m ale  
volunteer following oral administration of 6 0 0  mg of ASA.
endogenous peak was found that had the same retention time as 
SAL, but its response always corresponded to a concentration of 
less than the LOD of SAL. A number of commonly coadminis­
tered and/or available drugs—listed in Table 2—were also inves­
tigated for possible coelution with either ASA or SAL, and of these, 
only xylazine (which has mainly veterinary uses) and prazosin 
were found to interfere.
Ruggedness. Using a solution containing 2 //g/mL of both 
analytes, a number of parameters were examined to demonstrate 
the robustness of the method. Normal retention times for ASA 
and SAL were 11.5 ±  0.2 and 15.6 ±  0.3 min, respectively. 
Changes of ±10% in the flow rate of the wash solvent through 
the extraction column had no effect on the peak areas, whereas 
by increasing the flow rate by 10% through the analytical column, 
peak areas were decreased by 10%, and decreasing the flow rate 
by 10% increased the peak areas by Ihe same amount. The wash 
time of the sample through the SPE column was incremented by 
±5% and ±10%, but this was found not to affect the peak areas. 
Changes of ±5% of the acetonitrile content of the mobile phase 
had more of an effect on the retention times (±0.4 min for ASA 
and ±0.6 min for SAL) than the same changes in the methanol 
content. However, neither affected the size of the peak areas. 
The pH* of the mobile phase following the addition of the organic 
components was 2.6. By changing the pH* by ±0.1, the retention 
lime for SAL, being more pH-sensitive, was more strongly affected 
than that of ASA (+0,1 min at pH* 2.5 and -0.3 min at pH* 2.7).
When the C-18 extraction column was changed after ap­
proximately 50 plasma injections, the new C-18 column yielded 
no difference in the recoveries of both components, Changing 
the guard column also had no effect on the chromatography.
Quantitative Analyses of Samples. A healthy male volunteer 
was given 600 mg of aspirin (in the form of two tablets) 45 min 
after he had eaten a meal. Blood samples taken immediately prior 
to the administration of ASA and at a number of time points over
T a b le  3. R e su lts  of C o ncen tratio n-T im e C u rve s  from  O ther S tud ies
amount time to time to
of ASA ASA peak SAL peak reach ASA reach SAL
given concentration concentration peak concn peak concn
ref, year (mg) {fi g/m L) («g/mL) (min) (min)
this paper, 1997 600 6 27 33 60
ref 7,1996 500 5 30 30 130
ref 15,1985 600 8 40 30 -4 0 90-100
ref 18, 1982 650 8 40 20 80
ref 19,1980 600 14 45 22 80
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7 h were subjected to extraction and analysis. A sample chro­
matogram is shown in Figure 3. The results were plotted on a 
concentration-time curve (Figure 4), and from this, the peak 
plasma concentrations were determined to be 6.2 (after 33 min) 
and 27.1 /¿g/mL (after 60 min) for ASA and SAL, respectively. 
The times taken to reach these peak concentrations were 33 and 
60 min, respectively. These results are in general agreement with 
those found in the literature, and the only difference was that, in 
this study, SAL reaches its peak concentration faster than would 
be expected from previously published results, examples of which 
may be seen in Table 3. It is expected, however, that this 
discrepancy arises from the fact that rates of metabolism vary 
widely among individuals.
CONCLUSION
A new column-switching method has been developed for the 
analysis of ASA and SAL in plasma by on-line SPE in conjunction
(31) Shah, V. P.; Midha, K K; Dighe, S.; et al. Pharm. Res. 1992, 9 (4), 588- 
92.
with HPLC. Only 300 fiL of plasma is required for analysis, and 
the method could be easily automated via the 10-port switching 
valve. The HPLC method presented employs a simple and 
economical method of sample preparation, requiring little handling 
by the analyst, and is sufficiently reproducible not to require an 
internal standard. The assay is easier and more rapid, more 
stable, and more robust than current methodology.
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